(19) World Intellectual Property Organization International Bureau





(43) International Publication Date 4 October 2001 (04.10.2001)

PCT

(10) International Publication Number WO 01/72781 A2

(51) International Patent Classification⁷: C07K 14/00

(21) International Application Number: PCT/US01/09952

(22) International Filing Date: 27 March 2001 (27.03.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

60/192,583 28 March 2000 (28.03.2000) US

(71) Applicants (for all designated States except US):
CHIRON CORPORATION [US/US]; 4560 Horton
Street-R440, Emeryville, CA 04608 (US). HYSEQ INC.
[US/US]; 675 Almanor Avenue, Sunnyvale, CA 94086
(US).


(72) Inventors; and

(75) Inventors/Applicants (for US only): WILLIAMS,

Lewis, T. [US/US]; 3 Miroflores, Tiburon, CA 94920 (US). ESCOBEDO, Jaime [CL/US]; 1470 Lavorna Road, Alamo, CA 94507 (US). INNIS, Michael, A. [US/US]; 315 Constance Place, Moraga, CA 94556 (US). GARCIA, Pablo, Dominguez [CL/US]; 882 Chenery Street, San Francisco, CA 94131 (US). SUDDUTH-KLINGER, Julie [US/US]; 280 Lexington Road, Kensington, CA 94707 (US). REINHARD, Christoph [DE/US]; 1633 Clinton Avenue, Alameda, CA 94501 (US). HE, Zhijun [US/US]; Union City, CA (US). RANDAZZO, Filippo [US/US]: 690 Chestnut Street, Apt. 403, San Francisco, CA 94133 (US). KENNEDY, Giulia, C. [US/US]; 360 Castaneda Avenue, San Francisco, CA 94116 (US). POT, David [CA/US]; 1565 5th Avenue #102, San Francisco, CA 94112 (US). KASSAM, Altaf [US/US]; 2659 Harold Street, Oakland, CA 94602 (US). LAMSON, George [US/US]; 232 Sandringham Drive, Moraga, CA 94556 (US). DRMANAC, Radoje [YU/US]; 850 East Greenwich Place, Palo Alto, CA 94303 (US). CRKVENJAKOV,

[Continued on next page]

(54) Title: HUMAN GENES AND GENE EXPRESSION PRODUCTS XVI



(57) Abstract: This invention relates to novel human polynucleotides and variants thereof, their encoded polypeptides and variant thereof, to genes corresponding to theses polynucleotides and to proteins expressed by the genes. This invention also relates to diagnostic and therapeutic agents employing such novel polynucleotides, their corresponding genes or gene products, *e.g.*, these genes and proteins, including probes, antisense constructs, and antibodies.

WO 01/72781 A2



Radomir [YU/US]; 762 Haverhill Drive, Sunnyvale, CA 94068 (US). DICKSON, Mark [US/US]; 1411 Gabilan Drive #B, Hollister, CA 95025 (US). DRMANAC, Snezana [YU/US]; 850 East Greenwich Place, Palo Alto, CA 94303 (US). LABAT, Ivan [YU/US]; 140 Acalanes Drive, Sunnyvale, CA 94086 (US). LESHKOWITZ, Dena [US/US]; 678 Durshire Way, Sunnyvale, CA 94087 (US). KITA, David [US/US]; 899 Bounty Drive, Foster City, CA 94404 (US). GARCIA, Veronica [ES/US]; 396 Ano Nuevo, Apt. 412, Sunnyvale, CA 94086 (US). JONES, Lee, William [US/US]; 396 Ano Nuevo #412, Sunnyvale, CA 94086 (US). STACHE-CRAIN, Birgit [DE/US]; 345 South Mary Avenue, Sunnyvale, CA 94086 (US).

- (74) Agent: BLACKBURN, Robert, P.; Chief Patent Counsel, Chiron Corporation, P.O. Box 8097, Emeryville, CA 94662-8097 (US).
- (81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,

- CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.
- (84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:

 without international search report and to be republished upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

HUMAN GENES AND GENE EXPRESSION PRODUCTS XVI

Field of the Invention

5

10

15

20

25

30

35

The present invention relates to polynucleotides of human origin and the encoded gene products.

Background of the Invention

Identification of novel polynucleotides, particularly those that encode an expressed gene product, is important in the advancement of drug discovery, diagnostic technologies, and the understanding of the progression and nature of complex diseases such as cancer. Identification of genes expressed in different cell types isolated from sources that differ in disease state or stage, developmental stage, exposure to various environmental factors, the tissue of origin, the species from which the tissue was isolated, and the like is key to identifying the genetic factors that are responsible for the phenotypes associated with these various differences.

This invention provides novel human polynucleotides, the polypeptides encoded by these polynucleotides, and the genes and proteins corresponding to these novel polynucleotides.

Summary of the Invention

This invention relates to novel human polynucleotides and variants thereof, their encoded polypeptides and variants thereof, to genes corresponding to these polynucleotides and to proteins expressed by the genes. The invention also relates to diagnostics and therapeutics comprising such novel human polynucleotides, their corresponding genes or gene products, including probes, antisense nucleotides, and antibodies. The polynucleotides of the invention correspond to a polynucleotide comprising the sequence information of at least one of SEQ ID NOS:1-316.

Various aspects and embodiments of the invention will be readily apparent to the ordinarily skilled artisan upon reading the description provided herein.

Brief Description of the Figures

Figures 1A-1B is a comparison of SEQ ID NO:315 and clone H72034 (SEQ ID NO:317). Figure 2 is a comparison of SEQ ID NO:316 and clone AA707002 (SEQ ID NO:318).

Detailed Description of the Invention

The invention relates to polynucleotides comprising the disclosed nucleotide sequences, to full length cDNA, mRNA genomic sequences, and genes corresponding to these sequences and degenerate variants thereof, and to polypeptides encoded by the polynucleotides of the invention and polypeptide variants. The following detailed description describes the polynucleotide compositions encompassed by the invention, methods for obtaining cDNA or genomic DNA

encoding a full-length gene product, expression of these polynucleotides and genes, identification of structural motifs of the polynucleotides and genes, identification of the function of a gene product encoded by a gene corresponding to a polynucleotide of the invention, use of the provided polynucleotides as probes and in mapping and in tissue profiling, use of the corresponding polypeptides and other gene products to raise antibodies, and use of the polynucleotides and their encoded gene products for therapeutic and diagnostic purposes.

Polynucleotide Compositions

5

10

15

20

25

30

35

The scope of the invention with respect to polynucleotide compositions includes, but is not necessarily limited to, polynucleotides having a sequence set forth in any one of SEQ ID NOS:1-316; polynucleotides obtained from the biological materials described herein or other biological sources (particularly human sources) by hybridization under stringent conditions (particularly conditions of high stringency); genes corresponding to the provided polynucleotides; variants of the provided polynucleotides and their corresponding genes, particularly those variants that retain a biological activity of the encoded gene product (e.g., a biological activity ascribed to a gene product corresponding to the provided polynucleotides as a result of the assignment of the gene product to a protein family(ies) and/or identification of a functional domain present in the gene product). Other nucleic acid compositions contemplated by and within the scope of the present invention will be readily apparent to one of ordinary skill in the art when provided with the disclosure here. "Polynucleotide" and "nucleic acid" as used herein with reference to nucleic acids of the composition is not intended to be limiting as to the length or structure of the nucleic acid unless specifically indicted.

The invention features polynucleotides that are expressed in human tissue, specifically human colon, breast, and/or lung tissue. Novel nucleic acid compositions of the invention of particular interest comprise a sequence set forth in any one of SEQ ID NOS:1-316 or an identifying sequence thereof. An "identifying sequence" is a contiguous sequence of residues at least about 10 nt to about 20 nt in length, usually at least about 50 nt to about 100 nt in length, that uniquely identifies a polynucleotide sequence, *e.g.*, exhibits less than 90%, usually less than about 80% to about 85% sequence identity to any contiguous nucleotide sequence of more than about 20 nt. Thus, the subject novel nucleic acid compositions include full length cDNAs or mRNAs that encompass an identifying sequence of contiguous nucleotides from any one of SEQ ID NOS: 1-316.

The polynucleotides of the invention also include polynucleotides having sequence similarity or sequence identity. Nucleic acids having sequence similarity are detected by hybridization under low stringency conditions, for example, at 50°C and 10XSSC (0.9 M saline/0.09 M sodium citrate) and remain bound when subjected to washing at 55°C in 1XSSC.

Sequence identity can be determined by hybridization under stringent conditions, for example, at 50°C or higher and 0.1XSSC (9 mM saline/0.9 mM sodium citrate). Hybridization methods and conditions are well known in the art, see, e.g., USPN 5,707,829. Nucleic acids that are substantially identical to the provided polynucleotide sequences, e.g. allelic variants, genetically altered versions of the gene, etc., bind to the provided polynucleotide sequences (SEQ ID NOS:1-316) under stringent hybridization conditions. By using probes, particularly labeled probes of DNA sequences, one can isolate homologous or related genes. The source of homologous genes can be any species, e.g. primate species, particularly human; rodents, such as rats and mice; canines, felines, bovines, ovines, equines, yeast, nematodes, etc.

Preferably, hybridization is performed using at least 15 contiguous nucleotides (nt) of at least one of SEQ ID NOS:1-316. That is, when at least 15 contiguous nt of one of the disclosed SEQ ID NOS. is used as a probe, the probe will preferentially hybridize with a nucleic acid comprising the complementary sequence, allowing the identification and retrieval of the nucleic acids that uniquely hybridize to the selected probe. Probes from more than one SEQ ID NO. can hybridize with the same nucleic acid if the cDNA from which they were derived corresponds to one mRNA. Probes of more than 15 nt can be used, e.g., probes of from about 18 nt to about 100 nt, but 15 nt represents sufficient sequence for unique identification.

The polynucleotides of the invention also include naturally occurring variants of the nucleotide sequences (e.g., degenerate variants, allelic variants, etc.). Variants of the polynucleotides of the invention are identified by hybridization of putative variants with nucleotide sequences disclosed herein, preferably by hybridization under stringent conditions. For example, by using appropriate wash conditions, variants of the polynucleotides of the invention can be identified where the allelic variant exhibits at most about 25-30% base pair (bp) mismatches relative to the selected polynucleotide probe. In general, allelic variants contain 15-25% bp mismatches, and can contain as little as even 5-15%, or 2-5%, or 1-2% bp mismatches, as well as a single bp mismatch.

The invention also encompasses homologs corresponding to the polynucleotides of SEQ ID NOS:1-316, where the source of homologous genes can be any mammalian species, e.g., primate species, particularly human; rodents, such as rats; canines, felines, bovines, ovines, equines, yeast, nematodes, etc. Between mammalian species, e.g., human and mouse, homologs generally have substantial sequence similarity, e.g., at least 75% sequence identity, usually at least 90%, more usually at least 95% between nucleotide sequences. Sequence similarity is calculated based on a reference sequence, which may be a subset of a larger sequence, such as a conserved motif, coding region, flanking region, etc. A reference sequence will usually be at least about 18 contiguous nt long, more usually at least about 30 nt long, and may extend to the complete

sequence that is being compared. Algorithms for sequence analysis are known in the art, such as gapped BLAST, described in Altschul, et al. *Nucleic Acids Res.* (1997) 25:3389-3402.

In general, variants of the invention have a sequence identity greater than at least about 65%, preferably at least about 75%, more preferably at least about 85%, and can be greater than at least about 90% or more as determined by the Smith-Waterman homology search algorithm as implemented in MPSRCH program (Oxford Molecular). For the purposes of this invention, a preferred method of calculating percent identity is the Smith-Waterman algorithm, using the following. Global DNA sequence identity must be greater than 65% as determined by the Smith-Waterman homology search algorithm as implemented in MPSRCH program (Oxford Molecular) using an affine gap search with the following search parameters: gap open penalty, 12; and gap extension penalty, 1.

5

10

15

20

25

30

35

The subject nucleic acids can be cDNAs or genomic DNAs, as well as fragments thereof, particularly fragments that encode a biologically active gene product and/or are useful in the methods disclosed herein (e.g., in diagnosis, as a unique identifier of a differentially expressed gene of interest, etc.). The term "cDNA" as used herein is intended to include all nucleic acids that share the arrangement of sequence elements found in native mature mRNA species, where sequence elements are exons and 3' and 5' non-coding regions. Normally mRNA species have contiguous exons, with the intervening introns, when present, being removed by nuclear RNA splicing, to create a continuous open reading frame encoding a polypeptide of the invention.

A genomic sequence of interest comprises the nucleic acid present between the initiation codon and the stop codon, as defined in the listed sequences, including all of the introns that are normally present in a native chromosome. It can further include the 3' and 5' untranslated regions found in the mature mRNA. It can further include specific transcriptional and translational regulatory sequences, such as promoters, enhancers, etc., including about 1 kb, but possibly more, of flanking genomic DNA at either the 5' and 3' end of the transcribed region. The genomic DNA can be isolated as a fragment of 100 kbp or smaller; and substantially free of flanking chromosomal sequence. The genomic DNA flanking the coding region, either 3' and 5', or internal regulatory sequences as sometimes found in introns, contains sequences required for proper tissue, stage-specific, or disease-state specific expression.

The nucleic acid compositions of the subject invention can encode all or a part of the subject polypeptides. Double or single stranded fragments can be obtained from the DNA sequence by chemically synthesizing oligonucleotides in accordance with conventional methods, by restriction enzyme digestion, by PCR amplification, *etc*. Isolated polynucleotides and polynucleotide fragments of the invention comprise at least about 10, about 15, about 20, about 35, about 50, about 100, about 150 to about 200, about 250 to about 300, or about 350 contiguous nt selected from the polynucleotide sequences as shown in SEQ ID NOS:1-316. For the most part,

fragments will be of at least 15 nt, usually at least 18 nt or 25 nt, and up to at least about 50 contiguous nt in length or more. In a preferred embodiment, the polynucleotide molecules comprise a contiguous sequence of at least 12 nt selected from the group consisting of the polynucleotides shown in SEQ ID NOS:1-316.

5

10

15

20

25

30

35

Probes specific to the polynucleotides of the invention can be generated using the polynucleotide sequences disclosed in SEQ ID NOS:1-316. The probes are preferably at least about a 12, 15, 16, 18, 20, 22, 24, or 25 nt fragment of a corresponding contiguous sequence of SEQ ID NOS:1-316, and can be less than 2, 1, 0.5, 0.1, or 0.05 kb in length. The probes can be synthesized chemically or can be generated from longer polynucleotides using restriction enzymes. The probes can be labeled, for example, with a radioactive, biotinylated, or fluorescent tag. Preferably, probes are designed based upon an identifying sequence of a polynucleotide of one of SEQ ID NOS:1-316. More preferably, probes are designed based on a contiguous sequence of one of the subject polynucleotides that remain unmasked following application of a masking program for masking low complexity (e.g., XBLAST) to the sequence., i.e., one would select an unmasked region, as indicated by the polynucleotides outside the poly-n stretches of the masked sequence produced by the masking program.

The polynucleotides of the subject invention are isolated and obtained in substantial purity, generally as other than an intact chromosome. Usually, the polynucleotides, either as DNA or RNA, will be obtained substantially free of other naturally-occurring nucleic acid sequences, generally being at least about 50%, usually at least about 90% pure and are typically "recombinant", e.g., flanked by one or more nucleotides with which it is not normally associated on a naturally occurring chromosome.

The polynucleotides of the invention can be provided as a linear molecule or within a circular molecule, and can be provided within autonomously replicating molecules (vectors) or within molecules without replication sequences. Expression of the polynucleotides can be regulated by their own or by other regulatory sequences known in the art. The polynucleotides of the invention can be introduced into suitable host cells using a variety of techniques available in the art, such as transferrin polycation-mediated DNA transfer, transfection with naked or encapsulated nucleic acids, liposome-mediated DNA transfer, intracellular transportation of DNA-coated latex beads, protoplast fusion, viral infection, electroporation, gene gun, calcium phosphate-mediated transfection, and the like.

The subject nucleic acid compositions can be used to, for example, produce polypeptides, as probes for the detection of mRNA of the invention in biological samples (e.g., extracts of human cells) to generate additional copies of the polynucleotides, to generate ribozymes or antisense oligonucleotides, and as single stranded DNA probes or as triple-strand forming oligonucleotides. The probes described herein can be used to, for example, determine the presence or absence of the

polynucleotide sequences as shown in SEQ ID NOS:1-316 or variants thereof in a sample. These and other uses are described in more detail below.

Use of Polynucleotides to Obtain Full-Length cDNA, Gene, and Promoter Region

5

10

15

20

25

30

35

Full-length cDNA molecules comprising the disclosed polynucleotides are obtained as follows. A polynucleotide having a sequence of one of SEQ ID NOS:1-316, or a portion thereof comprising at least 12, 15, 18, or 20 nt, is used as a hybridization probe to detect hybridizing members of a cDNA library using probe design methods, cloning methods, and clone selection techniques such as those described in USPN 5,654,173. Libraries of cDNA are made from selected tissues, such as normal or tumor tissue, or from tissues of a mammal treated with, for example, a pharmaceutical agent. Preferably, the tissue is the same as the tissue from which the polynucleotides of the invention were isolated, as both the polynucleotides described herein and the cDNA represent expressed genes. Most preferably, the cDNA library is made from the biological material described herein in the Examples. The choice of cell type for library construction can be made after the identity of the protein encoded by the gene corresponding to the polynucleotide of the invention is known. This will indicate which tissue and cell types are likely to express the related gene, and thus represent a suitable source for the mRNA for generating the cDNA. Where the provided polynucleotides are isolated from cDNA libraries, the libraries are prepared from mRNA of human colon cells, more preferably, human colon cancer cells, even more preferably, from a highly metastatic colon cell, Km12L4-A.

Techniques for producing and probing nucleic acid sequence libraries are described, for example, in Sambrook *et al.*, *Molecular Cloning: A Laboratory Manual, 2nd Ed.*, (1989) Cold Spring Harbor Press, Cold Spring Harbor, NY. The cDNA can be prepared by using primers based on sequence from SEQ ID NOS:1-316. In one embodiment, the cDNA library can be made from only poly-adenylated mRNA. Thus, poly-T primers can be used to prepare cDNA from the mRNA.

Members of the library that are larger than the provided polynucleotides, and preferably that encompass the complete coding sequence of the native message, are obtained. In order to confirm that the entire cDNA has been obtained, RNA protection experiments are performed as follows. Hybridization of a full-length cDNA to an mRNA will protect the RNA from RNase degradation. If the cDNA is not full length, then the portions of the mRNA that are not hybridized will be subject to RNase degradation. This is assayed, as is known in the art, by changes in electrophoretic mobility on polyacrylamide gels, or by detection of released monoribonucleotides. Sambrook *et al.*, *Molecular Cloning: A Laboratory Manual, 2nd Ed.*, (1989) Cold Spring Harbor Press, Cold Spring Harbor, NY. In order to obtain additional sequences 5' to the end of a partial cDNA, 5' RACE (*PCR Protocols: A Guide to Methods and Applications*, (1990) Academic Press, Inc.) can be performed.

PCT/US01/09952 WO 01/72781

Genomic DNA is isolated using the provided polynucleotides in a manner similar to the isolation of full-length cDNAs. Briefly, the provided polynucleotides, or portions thereof, are used as probes to libraries of genomic DNA. Preferably, the library is obtained from the cell type that was used to generate the polynucleotides of the invention, but this is not essential. Most preferably, the genomic DNA is obtained from the biological material described herein in the Examples. Such libraries can be in vectors suitable for carrying large segments of a genome, such as P1 or YAC, as described in detail in Sambrook et al., 9.4-9.30. In addition, genomic sequences can be isolated from human BAC libraries, which are commercially available from Research Genetics, Inc., Huntsville, Alabama, USA, for example. In order to obtain additional 5' or 3' sequences, chromosome walking is performed, as described in Sambrook et al., such that adjacent and overlapping fragments of genomic DNA are isolated. These are mapped and pieced together, as is known in the art, using restriction digestion enzymes and DNA ligase.

5

10

15

20

25

35

Using the polynucleotide sequences of the invention, corresponding full-length genes can be isolated using both classical and PCR methods to construct and probe cDNA libraries. Using either method, Northern blots, preferably, are performed on a number of cell types to determine which cell lines express the gene of interest at the highest level. Classical methods of constructing cDNA libraries are taught in Sambrook et al., supra. With these methods, cDNA can be produced from mRNA and inserted into viral or expression vectors. Typically, libraries of mRNA comprising poly(A) tails can be produced with poly(T) primers. Similarly, cDNA libraries can be produced using the instant sequences as primers.

PCR methods are used to amplify the members of a cDNA library that comprise the desired insert. In this case, the desired insert will contain sequence from the full length cDNA that corresponds to the instant polynucleotides. Such PCR methods include gene trapping and RACE methods. Gene trapping entails inserting a member of a cDNA library into a vector. The vector then is denatured to produce single stranded molecules. Next, a substrate-bound probe, such a biotinylated oligo, is used to trap cDNA inserts of interest. Biotinylated probes can be linked to an avidin-bound solid substrate. PCR methods can be used to amplify the trapped cDNA. To trap sequences corresponding to the full length genes, the labeled probe sequence is based on the polynucleotide sequences of the invention. Random primers or primers specific to the library 30 vector can be used to amplify the trapped cDNA. Such gene trapping techniques are described in Gruber et al., WO 95/04745 and Gruber et al., USPN 5,500,356. Kits are commercially available to perform gene trapping experiments from, for example, Life Technologies, Gaithersburg, Maryland, USA.

"Rapid amplification of cDNA ends," or RACE, is a PCR method of amplifying cDNAs from a number of different RNAs. The cDNAs are ligated to an oligonucleotide linker, and amplified by PCR using two primers. One primer is based on sequence from the instant

polynucleotides, for which full length sequence is desired, and a second primer comprises sequence that hybridizes to the oligonucleotide linker to amplify the cDNA. A description of this methods is reported in WO 97/19110. In preferred embodiments of RACE, a common primer is designed to anneal to an arbitrary adaptor sequence ligated to cDNA ends (Apte and Siebert, *Biotechniques* (1993) 15:890-893; Edwards et al., Nuc. Acids Res. (1991) 19:5227-5232). When a single genespecific RACE primer is paired with the common primer, preferential amplification of sequences between the single gene specific primer and the common primer occurs. Commercial cDNA pools modified for use in RACE are available.

5

10

15

20

25

30

35

Another PCR-based method generates full-length cDNA library with anchored ends without needing specific knowledge of the cDNA sequence. The method uses lock-docking primers (I-VI), where one primer, poly TV (I-III) locks over the polyA tail of eukaryotic mRNA producing first strand synthesis and a second primer, polyGH (IV-VI) locks onto the polyC tail added by terminal deoxynucleotidyl transferase (TdT)(see, e.g., WO 96/40998).

The promoter region of a gene generally is located 5' to the initiation site for RNA polymerase II. Hundreds of promoter regions contain the "TATA" box, a sequence such as TATTA or TATAA, which is sensitive to mutations. The promoter region can be obtained by performing 5' RACE using a primer from the coding region of the gene. Alternatively, the cDNA can be used as a probe for the genomic sequence, and the region 5' to the coding region is identified by "walking up." If the gene is highly expressed or differentially expressed, the promoter from the gene can be of use in a regulatory construct for a heterologous gene.

Once the full-length cDNA or gene is obtained, DNA encoding variants can be prepared by site-directed mutagenesis, described in detail in Sambrook *et al.*, 15.3-15.63. The choice of codon or nucleotide to be replaced can be based on disclosure herein on optional changes in amino acids to achieve altered protein structure and/or function.

As an alternative method to obtaining DNA or RNA from a biological material, nucleic acid comprising nucleotides having the sequence of one or more polynucleotides of the invention can be synthesized. Thus, the invention encompasses nucleic acid molecules ranging in length from 15 nt (corresponding to at least 15 contiguous nt of one of SEQ ID NOS:1-316) up to a maximum length suitable for one or more biological manipulations, including replication and expression, of the nucleic acid molecule. The invention includes but is not limited to (a) nucleic acid having the size of a full gene, and comprising at least one of SEQ ID NOS:1-316; (b) the nucleic acid of (a) also comprising at least one additional gene, operably linked to permit expression of a fusion protein; (c) an expression vector comprising (a) or (b); (d) a plasmid comprising (a) or (b); and (e) a recombinant viral particle comprising (a) or (b). Once provided with the polynucleotides disclosed herein, construction or preparation of (a) - (e) are well within the skill in the art.

The sequence of a nucleic acid comprising at least 15 contiguous nt of at least any one of SEQ ID NOS:1-316, preferably the entire sequence of at least any one of SEQ ID NOS:1-316, is not limited and can be any sequence of A, T, G, and/or C (for DNA) and A, U, G, and/or C (for RNA) or modified bases thereof, including inosine and pseudouridine. The choice of sequence will depend on the desired function and can be dictated by coding regions desired, the intron-like regions desired, and the regulatory regions desired. Where the entire sequence of any one of SEQ ID NOS:1-316 is within the nucleic acid, the nucleic acid obtained is referred to herein as a polynucleotide comprising the sequence of any one of SEQ ID NOS:1-316.

Expression of Polypeptide Encoded by Full-Length cDNA or Full-Length Gene

The provided polynucleotides (e.g., a polynucleotide having a sequence of one of SEQ ID NOS:1-316), the corresponding cDNA, or the full-length gene is used to express a partial or complete gene product. Constructs of polynucleotides having sequences of SEQ ID NOS:1-316 can also be generated synthetically. Alternatively, single-step assembly of a gene and entire plasmid from large numbers of oligodeoxyribonucleotides is described by, e.g., Stemmer et al., Gene (Amsterdam) (1995) 164(1):49-53. In this method, assembly PCR (the synthesis of long DNA sequences from large numbers of oligodeoxyribonucleotides (oligos)) is described. The method is derived from DNA shuffling (Stemmer, Nature (1994) 370:389-391), and does not rely on DNA ligase, but instead relies on DNA polymerase to build increasingly longer DNA fragments during the assembly process.

Appropriate polynucleotide constructs are purified using standard recombinant DNA techniques as described in, for example, Sambrook *et al.*, *Molecular Cloning: A Laboratory Manual, 2nd Ed.*, (1989) Cold Spring Harbor Press, Cold Spring Harbor, NY, and under current regulations described in United States Dept. of HHS, National Institute of Health (NIH) Guidelines for Recombinant DNA Research. The gene product encoded by a polynucleotide of the invention is expressed in any expression system, including, for example, bacterial, yeast, insect, amphibian and mammalian systems. Vectors, host cells and methods for obtaining expression in same are well known in the art. Suitable vectors and host cells are described in USPN 5,654,173.

Polynucleotide molecules comprising a polynucleotide sequence provided herein are generally propagated by placing the molecule in a vector. Viral and non-viral vectors are used, including plasmids. The choice of plasmid will depend on the type of cell in which propagation is desired and the purpose of propagation. Certain vectors are useful for amplifying and making large amounts of the desired DNA sequence. Other vectors are suitable for expression in cells in culture. Still other vectors are suitable for transfer and expression in cells in a whole animal or person. The choice of appropriate vector is well within the skill of the art. Many such vectors are available commercially. Methods for preparation of vectors comprising a desired sequence are well known in the art.

PCT/US01/09952 WO 01/72781

The polynucleotides set forth in SEQ ID NOS:1-316 or their corresponding full-length polynucleotides are linked to regulatory sequences as appropriate to obtain the desired expression properties. These can include promoters (attached either at the 5' end of the sense strand or at the 3' end of the antisense strand), enhancers, terminators, operators, repressors, and inducers. The promoters can be regulated or constitutive. In some situations it may be desirable to use conditionally active promoters, such as tissue-specific or developmental stage-specific promoters. These are linked to the desired nucleotide sequence using the techniques described above for linkage to vectors. Any techniques known in the art can be used.

When any of the above host cells, or other appropriate host cells or organisms, are used to replicate and/or express the polynucleotides or nucleic acids of the invention, the resulting replicated nucleic acid, RNA, expressed protein or polypeptide, is within the scope of the invention as a product of the host cell or organism. The product is recovered by any appropriate means known in the art.

10

15

20

25

35

Once the gene corresponding to a selected polynucleotide is identified, its expression can be regulated in the cell to which the gene is native. For example, an endogenous gene of a cell can be regulated by an exogenous regulatory sequence as disclosed in USPN 5,641,670. Identification of Functional and Structural Motifs of Novel Genes Screening Against Publicly Available Databases

Translations of the nucleotide sequence of the provided polynucleotides, cDNAs or full genes can be aligned with individual known sequences. Similarity with individual sequences can be used to determine the activity of the polypeptides encoded by the polynucleotides of the invention. Also, sequences exhibiting similarity with more than one individual sequence can exhibit activities that are characteristic of either or both individual sequences.

The full length sequences and fragments of the polynucleotide sequences of the nearest neighbors can be used as probes and primers to identify and isolate the full length sequence corresponding to provided polynucleotides. The nearest neighbors can indicate a tissue or cell type to be used to construct a library for the full-length sequences corresponding to the provided polynucleotides.

Typically, a selected polynucleotide is translated in all six frames to determine the best 30 alignment with the individual sequences. The sequences disclosed herein in the Sequence Listing are in a 5' to 3' orientation and translation in three frames can be sufficient (with a few specific exceptions as described in the Examples). These amino acid sequences are referred to, generally, as query sequences, which will be aligned with the individual sequences. Databases with individual sequences are described in "Computer Methods for Macromolecular Sequence Analysis" Methods in Enzymology (1996) 266, Doolittle, Academic Press, Inc., a division of Harcourt Brace & Co.,

San Diego, California, USA. Databases include GenBank, EMBL, and DNA Database of Japan (DDBJ).

5

10

15

20

25

30

35

Query and individual sequences can be aligned using the methods and computer programs described above, and include BLAST 2.0, available over the world wide web at a site supported by the National Center for Biotechnology Information, which is supported by the National Library of Medicine and the National Institutes of Health. See also Altschul, et al. Nucleic Acids Res. (1997) 25:3389-3402. Another alignment algorithm is Fasta, available in the Genetics Computing Group (GCG) package, Madison, Wisconsin, USA, a wholly owned subsidiary of Oxford Molecular Group, Inc. Other techniques for alignment are described in Doolittle, supra. Preferably, an alignment program that permits gaps in the sequence is utilized to align the sequences. The Smith-Waterman is one type of algorithm that permits gaps in sequence alignments. See Meth. Mol. Biol. (1997) 70: 173-187. Also, the GAP program using the Needleman and Wunsch alignment method can be utilized to align sequences. An alternative search strategy uses MPSRCH software, which runs on a MASPAR computer. MPSRCH uses a Smith-Waterman algorithm to score sequences on a massively parallel computer. This approach improves ability to identify sequences that are distantly related matches, and is especially tolerant of small gaps and nucleotide sequence errors. Amino acid sequences encoded by the provided polynucleotides can be used to search both protein and DNA databases. Incorporated herein by reference are all sequences that have been made public as of the filing date of this application by any of the DNA or protein sequence databases, including the patent databases (e.g., GeneSeq). Also incorporated by reference are those sequences that have been submitted to these databases as of the filing date of the present application but not made public until after the filing date of the present application.

Results of individual and query sequence alignments can be divided into three categories: high similarity, weak similarity, and no similarity. Individual alignment results ranging from high similarity to weak similarity provide a basis for determining polypeptide activity and/or structure. Parameters for categorizing individual results include: percentage of the alignment region length where the strongest alignment is found, percent sequence identity, and p value. The percentage of the alignment region length is calculated by counting the number of residues of the individual sequence found in the region of strongest alignment, *e.g.*, contiguous region of the individual sequence that contains the greatest number of residues that are identical to the residues of the corresponding region of the aligned query sequence. This number is divided by the total residue length of the query sequence to calculate a percentage. For example, a query sequence of 20 amino acid residues might be aligned with a 20 amino acid region of an individual sequence. The individual sequence might be identical to amino acid residues 5, 9-15, and 17-19 of the query sequence. The region of strongest alignment is thus the region stretching from residue 9-19, an 11

amino acid stretch. The percentage of the alignment region length is: 11 (length of the region of strongest alignment) divided by (query sequence length) 20 or 55%.

Percent sequence identity is calculated by counting the number of amino acid matches between the query and individual sequence and dividing total number of matches by the number of residues of the individual sequences found in the region of strongest alignment. Thus, the percent identity in the example above would be 10 matches divided by 11 amino acids, or approximately, 90.9%

5

10

15

20

25

30

35

P value is the probability that the alignment was produced by chance. For a single alignment, the p value can be calculated according to Karlin *et al.*, *Proc. Natl. Acad. Sci.* (1990) 87:2264 and Karlin *et al.*, *Proc. Natl. Acad. Sci.* (1993) 90. The p value of multiple alignments using the same query sequence can be calculated using an heuristic approach described in Altschul *et al.*, *Nat. Genet.* (1994) 6:119. Alignment programs such as BLAST program can calculate the p value. See also Altschul *et al.*, *Nucleic Acids Res.* (1997) 25:3389-3402.

Another factor to consider for determining identity or similarity is the location of the similarity or identity. Strong local alignment can indicate similarity even if the length of alignment is short. Sequence identity scattered throughout the length of the query sequence also can indicate a similarity between the query and profile sequences. The boundaries of the region where the sequences align can be determined according to Doolittle, *supra*; BLAST 2.0 (see, *e.g.*, Altschul, et al. *Nucleic Acids Res.* (1997) 25:3389-3402) or FAST programs; or by determining the area where sequence identity is highest.

High Similarity. In general, in alignment results considered to be of high similarity, the percent of the alignment region length is typically at least about 55% of total length query sequence; more typically, at least about 58%; even more typically; at least about 60% of the total residue length of the query sequence. Usually, percent length of the alignment region can be as much as about 62%; more usually, as much as about 64%; even more usually, as much as about 66%. Further, for high similarity, the region of alignment, typically, exhibits at least about 75% of sequence identity; more typically, at least about 78%; even more typically; at least about 80% sequence identity. Usually, percent sequence identity can be as much as about 82%; more usually, as much as about 84%; even more usually, as much as about 86%.

The p value is used in conjunction with these methods. If high similarity is found, the query sequence is considered to have high similarity with a profile sequence when the p value is less than or equal to about 10^{-2} ; more usually; less than or equal to about 10^{-3} ; even more usually; less than or equal to about 10^{-4} . More typically, the p value is no more than about 10^{-5} ; more typically; no more than or equal to about 10^{-10} ; even more typically; no more than or equal to about 10^{-15} for the query sequence to be considered high similarity.

Weak Similarity. In general, where alignment results considered to be of weak similarity, there is no minimum percent length of the alignment region nor minimum length of alignment. A better showing of weak similarity is considered when the region of alignment is, typically, at least about 15 amino acid residues in length; more typically, at least about 20; even more typically; at least about 25 amino acid residues in length. Usually, length of the alignment region can be as much as about 30 amino acid residues; more usually, as much as about 40; even more usually, as much as about 60 amino acid residues. Further, for weak similarity, the region of alignment, typically, exhibits at least about 35% of sequence identity; more typically, at least about 40%; even more typically; at least about 45% sequence identity. Usually, percent sequence identity can be as much as about 50%; more usually, as much as about 55%; even more usually, as much as about 60%.

If low similarity is found, the query sequence is considered to have weak similarity with a profile sequence when the p value is usually less than or equal to about 10^{-2} ; more usually; less than or equal to about 10^{-3} ; even more usually; less than or equal to about 10^{-4} . More typically, the p value is no more than about 10^{-5} ; more usually; no more than or equal to about 10^{-10} ; even more usually; no more than or equal to about 10^{-15} for the query sequence to be considered weak similarity.

Similarity Determined by Sequence Identity Alone. Sequence identity alone can be used to determine similarity of a query sequence to an individual sequence and can indicate the activity of the sequence. Such an alignment, preferably, permits gaps to align sequences. Typically, the query sequence is related to the profile sequence if the sequence identity over the entire query sequence is at least about 15%; more typically, at least about 20%; even more typically, at least about 25%; even more typically, at least about 50%. Sequence identity alone as a measure of similarity is most useful when the query sequence is usually, at least 80 residues in length; more usually, 90 residues; even more usually, at least 95 amino acid residues in length. More typically, similarity can be concluded based on sequence identity alone when the query sequence is preferably 100 residues in length; more preferably, 120 residues in length; even more preferably, 150 amino acid residues in length.

Alignments with Profile and Multiple Aligned Sequences. Translations of the provided polynucleotides can be aligned with amino acid profiles that define either protein families or common motifs. Also, translations of the provided polynucleotides can be aligned to multiple sequence alignments (MSA) comprising the polypeptide sequences of members of protein families or motifs. Similarity or identity with profile sequences or MSAs can be used to determine the activity of the gene products (e.g., polypeptides) encoded by the provided polynucleotides or corresponding cDNA or genes. For example, sequences that show an identity or similarity with a chemokine profile or MSA can exhibit chemokine activities.

Profiles can designed manually by (1) creating an MSA, which is an alignment of the amino acid sequence of members that belong to the family and (2) constructing a statistical representation of the alignment. Such methods are described, for example, in Birney et al., Nucl. Acid Res. (1996) 24(14): 2730-2739. MSAs of some protein families and motifs are publicly available. For example, the Genome Sequencing Center at thw Washington University School of Medicine provides a web set (Pfam) which includes MSAs of 547 different families and motifs. These MSAs are described also in Sonnhammer et al., Proteins (1997) 28: 405-420. Other sources over the world wide web include the site supported by the European Molecular Biology Laboratories in Heidelberg, Germany. A brief description of these MSAs is reported in Pascarella et al., Prot. Eng. (1996) 9(3):249-251. Techniques for building profiles from MSAs are described in Sonnhammer et al., supra; Birney et al., supra; and "Computer Methods for Macromolecular Sequence Analysis," Methods in Enzymology (1996) 266, Doolittle, Academic Press, Inc., San Diego, California, USA.

Similarity between a query sequence and a protein family or motif can be determined by (a) comparing the query sequence against the profile and/or (b) aligning the query sequence with the members of the family or motif. Typically, a program such as Searchwise is used to compare the query sequence to the statistical representation of the multiple alignment, also known as a profile (see Birney *et al.*, *supra*). Other techniques to compare the sequence and profile are described in Sonnhammer *et al.*, *supra* and Doolittle, *supra*.

Next, methods described by Feng et al., J. Mol. Evol. (1987) 25:351 and Higgins et al., CABIOS (1989) 5:151 can be used align the query sequence with the members of a family or motif, also known as a MSA. Sequence alignments can be generated using any of a variety of software tools. Examples include PileUp, which creates a multiple sequence alignment, and is described in Feng et al., J. Mol. Evol. (1987) 25:351. Another method, GAP, uses the alignment method of Needleman et al., J. Mol. Biol. (1970) 48:443. GAP is best suited for global alignment of sequences. A third method, BestFit, functions by inserting gaps to maximize the number of matches using the local homology algorithm of Smith et al., Adv. Appl. Math. (1981) 2:482. In general, the following factors are used to determine if a similarity between a query sequence and a profile or MSA exists: (1) number of conserved residues found in the query sequence, (2) percentage of conserved residues found in the query sequence, (3) number of frameshifts, and (4) spacing between conserved residues.

Some alignment programs that both translate and align sequences can make any number of frameshifts when translating the nucleotide sequence to produce the best alignment. The fewer frameshifts needed to produce an alignment, the stronger the similarity or identity between the query and profile or MSAs. For example, a weak similarity resulting from no frameshifts can be a better indication of activity or structure of a query sequence, than a strong similarity resulting from

two frameshifts. Preferably, three or fewer frameshifts are found in an alignment; more preferably two or fewer frameshifts; even more preferably, one or fewer frameshifts; even more preferably, no frameshifts are found in an alignment of query and profile or MSAs.

Conserved residues are those amino acids found at a particular position in all or some of the family or motif members. Alternatively, a position is considered conserved if only a certain class of amino acids is found in a particular position in all or some of the family members. For example, the N-terminal position can contain a positively charged amino acid, such as lysine, arginine, or histidine.

5

10

15

20

25

30

35

Typically, a residue of a polypeptide is conserved when a class of amino acids or a single amino acid is found at a particular position in at least about 40% of all class members; more typically, at least about 50%; even more typically, at least about 60% of the members. Usually, a residue is conserved when a class or single amino acid is found in at least about 70% of the members of a family or motif; more usually, at least about 80%; even more usually, at least about 90%; even more usually, at least about 95%.

A residue is considered conserved when three unrelated amino acids are found at a particular position in the some or all of the members; more usually, two unrelated amino acids. These residues are conserved when the unrelated amino acids are found at particular positions in at least about 40% of all class member; more typically, at least about 50%; even more typically, at least about 60% of the members. Usually, a residue is conserved when a class or single amino acid is found in at least about 70% of the members of a family or motif; more usually, at least about 80%; even more usually, at least about 90%; even more usually, at least about 95%.

A query sequence has similarity to a profile or MSA when the query sequence comprises at least about 25% of the conserved residues of the profile or MSA; more usually, at least about 30%; even more usually; at least about 40%. Typically, the query sequence has a stronger similarity to a profile sequence or MSA when the query sequence comprises at least about 45% of the conserved residues of the profile or MSA; more typically, at least about 50%; even more typically; at least about 55%.

Identification of Secreted & Membrane-Bound Polypeptides

Both secreted and membrane-bound polypeptides of the present invention are of particular interest. For example, levels of secreted polypeptides can be assayed in body fluids that are convenient, such as blood, plasma, serum, and other body fluids such as urine, prostatic fluid and semen. Membrane-bound polypeptides are useful for constructing vaccine antigens or inducing an immune response. Such antigens would comprise all or part of the extracellular region of the membrane-bound polypeptides. Because both secreted and membrane-bound polypeptides comprise a fragment of contiguous hydrophobic amino acids, hydrophobicity predicting algorithms can be used to identify such polypeptides.

A signal sequence is usually encoded by both secreted and membrane-bound polypeptide genes to direct a polypeptide to the surface of the cell. The signal sequence usually comprises a stretch of hydrophobic residues. Such signal sequences can fold into helical structures. Membrane-bound polypeptides typically comprise at least one transmembrane region that possesses a stretch of hydrophobic amino acids that can transverse the membrane. Some transmembrane regions also exhibit a helical structure. Hydrophobic fragments within a polypeptide can be identified by using computer algorithms. Such algorithms include Hopp & Woods, *Proc. Natl. Acad. Sci. USA* (1981) 78:3824-3828; Kyte & Doolittle, *J. Mol. Biol.* (1982) 157: 105-132; and RAOAR algorithm, Degli Esposti *et al.*, *Eur. J. Biochem.* (1990) 190: 207-219.

5

10

15

20

25

30

35

Another method of identifying secreted and membrane-bound polypeptides is to translate the polynucleotides of the invention in all six frames and determine if at least 8 contiguous hydrophobic amino acids are present. Those translated polypeptides with at least 8; more typically, 10; even more typically, 12 contiguous hydrophobic amino acids are considered to be either a putative secreted or membrane bound polypeptide. Hydrophobic amino acids include alanine, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, proline, threonine, tryptophan, tyrosine, and valine.

Identification of the Function of an Expression Product of a Full-Length Gene

Ribozymes, antisense constructs, and dominant negative mutants can be used to determine function of the expression product of a gene corresponding to a polynucleotide provided herein. These methods and compositions are particularly useful where the provided novel polynucleotide exhibits no significant or substantial homology to a sequence encoding a gene of known function. Antisense molecules and ribozymes can be constructed from synthetic polynucleotides. Typically, the phosphoramidite method of oligonucleotide synthesis is used. See Beaucage *et al.*, *Tet. Lett.* (1981) 22:1859 and USPN 4,668,777. Automated devices for synthesis are available to create oligonucleotides using this chemistry. Examples of such devices include Biosearch 8600, Models 392 and 394 by Applied Biosystems, a division of Perkin-Elmer Corp., Foster City, California, USA; and Expedite by Perceptive Biosystems, Framingham, Massachusetts, USA. Synthetic RNA, phosphate analog oligonucleotides, and chemically derivatized oligonucleotides can also be produced, and can be covalently attached to other molecules. RNA oligonucleotides can be synthesized, for example, using RNA phosphoramidites. This method can be performed on an automated synthesizer, such as Applied Biosystems, Models 392 and 394, Foster City, California, USA.

Phosphorothioate oligonucleotides can also be synthesized for antisense construction. A sulfurizing reagent, such as tetraethylthiruam disulfide (TETD) in acetonitrile can be used to convert the internucleotide cyanoethyl phosphite to the phosphorothioate triester within 15 minutes at room temperature. TETD replaces the iodine reagent, while all other reagents used for standard

phosphoramidite chemistry remain the same. Such a synthesis method can be automated using Models 392 and 394 by Applied Biosystems, for example.

5

10

15

20

25

30

35

Oligonucleotides of up to 200 nt can be synthesized, more typically, 100 nt, more typically 50 nt; even more typically 30 to 40 nt. These synthetic fragments can be annealed and ligated together to construct larger fragments. See, for example, Sambrook *et al.*, *supra*. Trans-cleaving catalytic RNAs (ribozymes) are RNA molecules possessing endoribonuclease activity. Ribozymes are specifically designed for a particular target, and the target message must contain a specific nucleotide sequence. They are engineered to cleave any RNA species site-specifically in the background of cellular RNA. The cleavage event renders the mRNA unstable and prevents protein expression. Importantly, ribozymes can be used to inhibit expression of a gene of unknown function for the purpose of determining its function in an in vitro or in vivo context, by detecting the phenotypic effect. One commonly used ribozyme motif is the hammerhead, for which the substrate sequence requirements are minimal. Design of the hammerhead ribozyme, as well as therapeutic uses of ribozymes, are disclosed in Usman *et al.*, *Current Opin. Struct. Biol.* (1996) 6:527. Methods for production of ribozymes, including hairpin structure ribozyme fragments, methods of increasing ribozyme specificity, and the like are known in the art.

The hybridizing region of the ribozyme can be modified or can be prepared as a branched structure as described in Horn and Urdea, *Nucleic Acids Res.* (1989) 17:6959. The basic structure of the ribozymes can also be chemically altered in ways familiar to those skilled in the art, and chemically synthesized ribozymes can be administered as synthetic oligonucleotide derivatives modified by monomeric units. In a therapeutic context, liposome mediated delivery of ribozymes improves cellular uptake, as described in Birikh *et al.*, *Eur. J. Biochem.* (1997) 245:1.

Antisense nucleic acids are designed to specifically bind to RNA, resulting in the formation of RNA-DNA or RNA-RNA hybrids, with an arrest of DNA replication, reverse transcription or messenger RNA translation. Antisense polynucleotides based on a selected polynucleotide sequence can interfere with expression of the corresponding gene. Antisense polynucleotides are typically generated within the cell by expression from antisense constructs that contain the antisense strand as the transcribed strand. Antisense polynucleotides based on the disclosed polynucleotides will bind and/or interfere with the translation of mRNA comprising a sequence complementary to the antisense polynucleotide. The expression products of control cells and cells treated with the antisense construct are compared to detect the protein product of the gene corresponding to the polynucleotide upon which the antisense construct is based. The protein is isolated and identified using routine biochemical methods.

Given the extensive background literature and clinical experience in antisense therapy, one skilled in the art can use selected polynucleotides of the invention as additional potential therapeutics. The choice of polynucleotide can be narrowed by first testing them for binding to

"hot spot" regions of the genome of cancerous cells. If a polynucleotide is identified as binding to a "hot spot", testing the polynucleotide as an antisense compound in the corresponding cancer cells is warranted.

As an alternative method for identifying function of the gene corresponding to a polynucleotide disclosed herein, dominant negative mutations are readily generated for corresponding proteins that are active as homomultimers. A mutant polypeptide will interact with wild-type polypeptides (made from the other allele) and form a non-functional multimer. Thus, a mutation is in a substrate-binding domain, a catalytic domain, or a cellular localization domain. Preferably, the mutant polypeptide will be overproduced. Point mutations are made that have such an effect. In addition, fusion of different polypeptides of various lengths to the terminus of a protein can yield dominant negative mutants. General strategies are available for making dominant negative mutants (see, e.g., Herskowitz, *Nature* (1987) 329:219). Such techniques can be used to create loss of function mutations, which are useful for determining protein function.

Polypeptides and Variants Thereof

5

10

15

20

25

30

35

The polypeptides of the invention include those encoded by the disclosed polynucleotides, as well as nucleic acids that, by virtue of the degeneracy of the genetic code, are not identical in sequence to the disclosed polynucleotides. Thus, the invention includes within its scope a polypeptide encoded by a polynucleotide having the sequence of any one of SEQ ID NOS:1-316 or a variant thereof.

In general, the term "polypeptide" as used herein refers to both the full length polypeptide encoded by the recited polynucleotide, the polypeptide encoded by the gene represented by the recited polynucleotide, as well as portions or fragments thereof. "Polypeptides" also includes variants of the naturally occurring proteins, where such variants are homologous or substantially similar to the naturally occurring protein, and can be of an origin of the same or different species as the naturally occurring protein (e.g., human, murine, or some other species that naturally expresses the recited polypeptide, usually a mammalian species). In general, variant polypeptides have a sequence that has at least about 80%, usually at least about 90%, and more usually at least about 98% sequence identity with a differentially expressed polypeptide of the invention, as measured by BLAST 2.0 using the parameters described above. The variant polypeptides can be naturally or non-naturally glycosylated, i.e., the polypeptide has a glycosylation pattern that differs from the glycosylation pattern found in the corresponding naturally occurring protein.

The invention also encompasses homologs of the disclosed polypeptides (or fragments thereof) where the homologs are isolated from other species, *i.e.* other animal or plant species, where such homologs, usually mammalian species, *e.g.* rodents, such as mice, rats; domestic animals, *e.g.*, horse, cow, dog, cat; and humans. By "homolog" is meant a polypeptide having at least about 35%, usually at least about 40% and more usually at least about 60% amino acid

sequence identity to a particular differentially expressed protein as identified above, where sequence identity is determined using the BLAST 2.0 algorithm, with the parameters described *supra*.

5

10

15

20

25

30

35

In general, the polypeptides of the subject invention are provided in a non-naturally occurring environment, *e.g.* are separated from their naturally occurring environment. In certain embodiments, the subject protein is present in a composition that is enriched for the protein as compared to a control. As such, purified polypeptide is provided, where by purified is meant that the protein is present in a composition that is substantially free of non-differentially expressed polypeptides, where by substantially free is meant that less than 90%, usually less than 60% and more usually less than 50% of the composition is made up of non-differentially expressed polypeptides.

Also within the scope of the invention are variants; variants of polypeptides include mutants, fragments, and fusions. Mutants can include amino acid substitutions, additions or deletions. The amino acid substitutions can be conservative amino acid substitutions or substitutions to eliminate non-essential amino acids, such as to alter a glycosylation site, a phosphorylation site or an acetylation site, or to minimize misfolding by substitution or deletion of one or more cysteine residues that are not necessary for function. Conservative amino acid substitutions are those that preserve the general charge, hydrophobicity/ hydrophilicity, and/or steric bulk of the amino acid substituted. Variants can be designed so as to retain or have enhanced biological activity of a particular region of the protein (e.g., a functional domain and/or, where the polypeptide is a member of a protein family, a region associated with a consensus sequence). Selection of amino acid alterations for production of variants can be based upon the accessibility (interior vs. exterior) of the amino acid (see, e.g., Go et al, Int. J. Peptide Protein Res. (1980) 15:211), the thermostability of the variant polypeptide (see, e.g., Querol et al., Prot. Eng. (1996) 9:265), desired glycosylation sites (see, e.g., Olsen and Thomsen, J. Gen. Microbiol. (1991) 137:579), desired disulfide bridges (see, e.g., Clarke et al., Biochemistry (1993) 32:4322; and Wakarchuk et al., Protein Eng. (1994) 7:1379), desired metal binding sites (see, e.g., Toma et al., Biochemistry (1991) 30:97, and Haezerbrouck et al., Protein Eng. (1993) 6:643), and desired substitutions with in proline loops (see, e.g., Masul et al., Appl. Env. Microbiol. (1994) 60:3579). Cysteine-depleted muteins can be produced as disclosed in USPN 4,959,314.

Variants also include fragments of the polypeptides disclosed herein, particularly biologically active fragments and/or fragments corresponding to functional domains. Fragments of interest will typically be at least about 10 aa to at least about 15 aa in length, usually at least about 50 aa in length, and can be as long as 300 aa in length or longer, but will usually not exceed about 1000 aa in length, where the fragment will have a stretch of amino acids that is identical to a polypeptide encoded by a polynucleotide having a sequence of any SEQ ID NOS:1-316, or a

homolog thereof. The protein variants described herein are encoded by polynucleotides that are within the scope of the invention. The genetic code can be used to select the appropriate codons to construct the corresponding variants.

Computer-Related Embodiments

5

10

15

20

25

30

35

In general, a library of polynucleotides is a collection of sequence information, which information is provided in either biochemical form (e.g., as a collection of polynucleotide molecules), or in electronic form (e.g., as a collection of polynucleotide sequences stored in a computer-readable form, as in a computer system and/or as part of a computer program). The sequence information of the polynucleotides can be used in a variety of ways, e.g., as a resource for gene discovery, as a representation of sequences expressed in a selected cell type (e.g., cell type markers), and/or as markers of a given disease or disease state. In general, a disease marker is a representation of a gene product that is present in all cells affected by disease either at an increased or decreased level relative to a normal cell (e.g., a cell of the same or similar type that is not substantially affected by disease). For example, a polynucleotide sequence in a library can be a polynucleotide that represents an mRNA, polypeptide, or other gene product encoded by the polynucleotide, that is either overexpressed or underexpressed in a breast ductal cell affected by cancer relative to a normal (i.e., substantially disease-free) breast cell.

The nucleotide sequence information of the library can be embodied in any suitable form, e.g., electronic or biochemical forms. For example, a library of sequence information embodied in electronic form comprises an accessible computer data file (or, in biochemical form, a collection of nucleic acid molecules) that contains the representative nucleotide sequences of genes that are differentially expressed (e.g., overexpressed or underexpressed) as between, for example, i) a cancerous cell and a normal cell; ii) a cancerous cell and a dysplastic cell; iii) a cancerous cell and a cell affected by a disease or condition other than cancer; iv) a metastatic cancerous cell and a normal cell and/or non-metastatic cancerous cell; v) a malignant cancerous cell and a normal ginant cancerous cell (or a normal cell) and/or vi) a dysplastic cell relative to a normal cell. Other combinations and comparisons of cells affected by various diseases or stages of disease will be readily apparent to the ordinarily skilled artisan. Biochemical embodiments of the library include a collection of nucleic acids that have the sequences of the genes in the library, where the nucleic acids can correspond to the entire gene in the library or to a fragment thereof, as described in greater detail below.

The polynucleotide libraries of the subject invention generally comprise sequence information of a plurality of polynucleotide sequences, where at least one of the polynucleotides has a sequence of any of SEQ ID NOS:1-316. By plurality is meant at least 2, usually at least 3 and can include up to all of SEQ ID NOS:1-316. The length and number of polynucleotides in the

library will vary with the nature of the library, e.g., if the library is an oligonucleotide array, a cDNA array, a computer database of the sequence information, etc.

5

10

15

20

25

30

35

Where the library is an electronic library, the nucleic acid sequence information can be present in a variety of media. "Media" refers to a manufacture, other than an isolated nucleic acid molecule, that contains the sequence information of the present invention. Such a manufacture provides the genome sequence or a subset thereof in a form that can be examined by means not directly applicable to the sequence as it exists in a nucleic acid. For example, the nucleotide sequence of the present invention, e.g. the nucleic acid sequences of any of the polynucleotides of SEQ ID NOS:1-316, can be recorded on computer readable media, e.g. any medium that can be read and accessed directly by a computer. Such media include, but are not limited to: magnetic storage media, such as a floppy disc, a hard disc storage medium, and a magnetic tape; optical storage media such as CD-ROM; electrical storage media such as RAM and ROM; and hybrids of these categories such as magnetic/optical storage media. One of skill in the art can readily appreciate how any of the presently known computer readable mediums can be used to create a manufacture comprising a recording of the present sequence information. "Recorded" refers to a process for storing information on computer readable medium, using any such methods as known in the art. Any convenient data storage structure can be chosen, based on the means used to access the stored information. A variety of data processor programs and formats can be used for storage, e.g. word processing text file, database format, etc. In addition to the sequence information, electronic versions of the libraries of the invention can be provided in conjunction or connection with other computer-readable information and/or other types of computer-readable files (e.g., searchable files, executable files, etc, including, but not limited to, for example, search program software, etc.).

By providing the nucleotide sequence in computer readable form, the information can be accessed for a variety of purposes. Computer software to access sequence information is publicly available. For example, the gapped BLAST (Altschul *et al. Nucleic Acids Res.* (1997) 25:3389-3402) and BLAZE (Brutlag *et al. Comp. Chem.* (1993) 17:203) search algorithms on a Sybase system can be used to identify open reading frames (ORFs) within the genome that contain homology to ORFs from other organisms.

As used herein, "a computer-based system" refers to the hardware means, software means, and data storage means used to analyze the nucleotide sequence information of the present invention. The minimum hardware of the computer-based systems of the present invention comprises a central processing unit (CPU), input means, output means, and data storage means. A skilled artisan can readily appreciate that any one of the currently available computer-based system are suitable for use in the present invention. The data storage means can comprise any manufacture comprising a recording of the present sequence information as described above, or a memory access means that can access such a manufacture.

"Search means" refers to one or more programs implemented on the computer-based system, to compare a target sequence or target structural motif, or expression levels of a polynucleotide in a sample, with the stored sequence information. Search means can be used to identify fragments or regions of the genome that match a particular target sequence or target motif. A variety of known algorithms are publicly known and commercially available, *e.g.* MacPattern (EMBL), BLASTN and BLASTX (NCBI). A "target sequence" can be any polynucleotide or amino acid sequence of six or more contiguous nucleotides or two or more amino acids, preferably from about 10 to 100 amino acids or from about 30 to 300 nt A variety of comparing means can be used to accomplish comparison of sequence information from a sample (e.g., to analyze target sequences, target motifs, or relative expression levels) with the data storage means. A skilled artisan can readily recognize that any one of the publicly available homology search programs can be used as the search means for the computer based systems of the present invention to accomplish comparison of target sequences and motifs. Computer programs to analyze expression levels in a sample and in controls are also known in the art.

A "target structural motif," or "target motif," refers to any rationally selected sequence or combination of sequences in which the sequence(s) are chosen based on a three-dimensional configuration that is formed upon the folding of the target motif, or on consensus sequences of regulatory or active sites. There are a variety of target motifs known in the art. Protein target motifs include, but are not limited to, enzyme active sites and signal sequences. Nucleic acid target motifs include, but are not limited to, hairpin structures, promoter sequences and other expression elements such as binding sites for transcription factors.

A variety of structural formats for the input and output means can be used to input and output the information in the computer-based systems of the present invention. One format for an output means ranks the relative expression levels of different polynucleotides. Such presentation provides a skilled artisan with a ranking of relative expression levels to determine a gene expression profile.

As discussed above, the "library" of the invention also encompasses biochemical libraries of the polynucleotides of SEQ ID NOS:1-316, e.g., collections of nucleic acids representing the provided polynucleotides. The biochemical libraries can take a variety of forms, e.g., a solution of cDNAs, a pattern of probe nucleic acids stably associated with a surface of a solid support (i.e., an array) and the like. Of particular interest are nucleic acid arrays in which one or more of SEQ ID NOS:1-316 is represented on the array. By array is meant a an article of manufacture that has at least a substrate with at least two distinct nucleic acid targets on one of its surfaces, where the number of distinct nucleic acids can be considerably higher, typically being at least 10 nt, usually at least 20 nt and often at least 25 nt. A variety of different array formats have been developed and are known to those of skill in the art. The arrays of the subject invention find use in a variety of

applications, including gene expression analysis, drug screening, mutation analysis and the like, as disclosed in the above-listed exemplary patent documents.

In addition to the above nucleic acid libraries, analogous libraries of polypeptides are also provided, where the where the polypeptides of the library will represent at least a portion of the polypeptides encoded by SEQ ID NOS:1-316.

Utilities

5

10

15

20

25

30

35

Use of Polynucleotide Probes in Mapping, and in Tissue Profiling

Polynucleotide probes, generally comprising at least 12 contiguous nt of a polynucleotide as shown in the Sequence Listing, are used for a variety of purposes, such as chromosome mapping of the polynucleotide and detection of transcription levels. Additional disclosure about preferred regions of the disclosed polynucleotide sequences is found in the Examples. A probe that hybridizes specifically to a polynucleotide disclosed herein should provide a detection signal at least 5-, 10-, or 20-fold higher than the background hybridization provided with other unrelated sequences.

Detection of Expression Levels. Nucleotide probes are used to detect expression of a gene corresponding to the provided polynucleotide. In Northern blots, mRNA is separated electrophoretically and contacted with a probe. A probe is detected as hybridizing to an mRNA species of a particular size. The amount of hybridization is quantitated to determine relative amounts of expression, for example under a particular condition. Probes are used for in situ hybridization to cells to detect expression. Probes can also be used *in vivo* for diagnostic detection of hybridizing sequences. Probes are typically labeled with a radioactive isotope. Other types of detectable labels can be used such as chromophores, fluors, and enzymes. Other examples of nucleotide hybridization assays are described in WO92/02526 and USPN 5,124,246.

Alternatively, the Polymerase Chain Reaction (PCR) is another means for detecting small amounts of target nucleic acids (see, e.g., Mullis et al., Meth. Enzymol. (1987) 155:335; USPN 4,683,195; and USPN 4,683,202). Two primer polynucleotides nucleotides that hybridize with the target nucleic acids are used to prime the reaction. The primers can be composed of sequence within or 3' and 5' to the polynucleotides of the Sequence Listing. Alternatively, if the primers are 3' and 5' to these polynucleotides, they need not hybridize to them or the complements. After amplification of the target with a thermostable polymerase, the amplified target nucleic acids can be detected by methods known in the art, e.g., Southern blot. mRNA or cDNA can also be detected by traditional blotting techniques (e.g., Southern blot, Northern blot, etc.) described in Sambrook et al., "Molecular Cloning: A Laboratory Manual" (New York, Cold Spring Harbor Laboratory, 1989) (e.g., without PCR amplification). In general, mRNA or cDNA generated from mRNA using a polymerase enzyme can be purified and separated using gel electrophoresis, and transferred to a

solid support, such as nitrocellulose. The solid support is exposed to a labeled probe, washed to remove any unhybridized probe, and duplexes containing the labeled probe are detected.

5

10

15

20

25

30

35

Mapping. Polynucleotides of the present invention can be used to identify a chromosome on which the corresponding gene resides. Such mapping can be useful in identifying the function of the polynucleotide-related gene by its proximity to other genes with known function. Function can also be assigned to the polynucleotide-related gene when particular syndromes or diseases map to the same chromosome. For example, use of polynucleotide probes in identification and quantification of nucleic acid sequence aberrations is described in USPN 5,783,387. An exemplary mapping method is fluorescence in situ hybridization (FISH), which facilitates comparative genomic hybridization to allow total genome assessment of changes in relative copy number of DNA sequences (see, e.g., Valdes et al., Methods in Molecular Biology (1997) 68:1). Polynucleotides can also be mapped to particular chromosomes using, for example, radiation hybrids or chromosome-specific hybrid panels. See Leach et al., Advances in Genetics, (1995) 33:63-99; Walter et al., Nature Genetics (1994) 7:22; Walter and Goodfellow, Trends in Genetics (1992) 9:352. Panels for radiation hybrid mapping are available from Research Genetics, Inc., Huntsville, Alabama, USA. Databases for markers using various panels are available via the world wide web at sites supported by the Stanford Human Genome Center (Stanford University) and the Whitehead Institute for Biomedical Research/MIT Center for Genome Research. The statistical program RHMAP can be used to construct a map based on the data from radiation hybridization with a measure of the relative likelihood of one order versus another. RHMAP is available via the world wide web at a site supported by the Center for Statistical Genetics at the University of Michigan School of Public Health. In addition, commercial programs are available for identifying regions of chromosomes commonly associated with disease, such as cancer.

<u>Tissue Typing or Profiling.</u> Expression of specific mRNA corresponding to the provided polynucleotides can vary in different cell types and can be tissue-specific. This variation of mRNA levels in different cell types can be exploited with nucleic acid probe assays to determine tissue types. For example, PCR, branched DNA probe assays, or blotting techniques utilizing nucleic acid probes substantially identical or complementary to polynucleotides listed in the Sequence Listing can determine the presence or absence of the corresponding cDNA or mRNA.

Tissue typing can be used to identify the developmental organ or tissue source of a metastatic lesion by identifying the expression of a particular marker of that organ or tissue. If a polynucleotide is expressed only in a specific tissue type, and a metastatic lesion is found to express that polynucleotide, then the developmental source of the lesion has been identified. Expression of a particular polynucleotide can be assayed by detection of either the corresponding mRNA or the protein product. As would be readily apparent to any forensic scientist, the sequences disclosed herein are useful in differentiating human tissue from non-human tissue. In particular, these

sequences are useful to differentiate human tissue from bird, reptile, and amphibian tissue, for example.

<u>Use of Polymorphisms.</u> A polynucleotide of the invention can be used in forensics, genetic analysis, mapping, and diagnostic applications where the corresponding region of a gene is polymorphic in the human population. Any means for detecting a polymorphism in a gene can be used, including, but not limited to electrophoresis of protein polymorphic variants, differential sensitivity to restriction enzyme cleavage, and hybridization to allele-specific probes.

Antibody Production

5

10

15

20

25

30

35

Expression products of a polynucleotide of the invention, as well as the corresponding mRNA, cDNA, or complete gene, can be prepared and used for raising antibodies for experimental, diagnostic, and therapeutic purposes. For polynucleotides to which a corresponding gene has not been assigned, this provides an additional method of identifying the corresponding gene. The polynucleotide or related cDNA is expressed as described above, and antibodies are prepared. These antibodies are specific to an epitope on the polypeptide encoded by the polynucleotide, and can precipitate or bind to the corresponding native protein in a cell or tissue preparation or in a cell-free extract of an in vitro expression system.

Methods for production of antibodies that specifically bind a selected antigen are well known in the art. Immunogens for raising antibodies can be prepared by mixing a polypeptide encoded by a polynucleotide of the invention with an adjuvant, and/or by making fusion proteins with larger immunogenic proteins. Polypeptides can also be covalently linked to other larger immunogenic proteins, such as keyhole limpet hemocyanin. Immunogens are typically administered intradermally, subcutaneously, or intramuscularly to experimental animals such as rabbits, sheep, and mice, to generate antibodies. Monoclonal antibodies can be Monoclonal antibodies can be generated by isolating spleen cells and fusing myeloma cells to form hybridomas. Alternatively, the selected polynucleotide is administered directly, such as by intramuscular injection, and expressed in vivo. The expressed protein generates a variety of protein-specific immune responses, including production of antibodies, comparable to administration of the protein.

Preparations of polyclonal and monoclonal antibodies specific for polypeptides encoded by a selected polynucleotide are made using standard methods known in the art. The antibodies specifically bind to epitopes present in the polypeptides encoded by polynucleotides disclosed in the Sequence Listing. Typically, at least 6, 8, 10, or 12 contiguous amino acids are required to form an epitope. Epitopes that involve non-contiguous amino acids may require a longer polypeptide, e.g., at least 15, 25, or 50 amino acids. Antibodies that specifically bind to human polypeptides encoded by the provided polypeptides should provide a detection signal at least 5-, 10-, or 20-fold higher than a detection signal provided with other proteins when used in Western blots or other immunochemical assays. Preferably, antibodies that specifically polypeptides of the

invention do not bind to other proteins in immunochemical assays at detectable levels and can immunoprecipitate the specific polypeptide from solution.

The invention also contemplates naturally occurring antibodies specific for a polypeptide of the invention. For example, serum antibodies to a polypeptide of the invention in a human population can be purified by methods well known in the art, e.g., by passing antiserum over a column to which the corresponding selected polypeptide or fusion protein is bound. The bound antibodies can then be eluted from the column, for example using a buffer with a high salt concentration.

In addition to the antibodies discussed above, the invention also contemplates genetically engineered antibodies, antibody derivatives (e.g., single chain antibodies, antibody fragments (e.g., Fab, etc.)), according to methods well known in the art.

Polynucleotides or Arrays for Diagnostics

5

10

15

20

25

30

35

Polynucleotide arrays provide a high throughput technique that can assay a large number of polynucleotide sequences in a sample. This technology can be used as a diagnostic and as a tool to test for differential expression, e.g., to determine function of an encoded protein. Arrays can be created by spotting polynucleotide probes onto a substrate (e.g., glass, nitrocelllose, etc.) in a twodimensional matrix or array having bound probes. The probes can be bound to the substrate by either covalent bonds or by non-specific interactions, such as hydrophobic interactions. Samples of polynucleotides can be detectably labeled (e.g., using radioactive or fluorescent labels) and then hybridized to the probes. Double stranded polynucleotides, comprising the labeled sample polynucleotides bound to probe polynucleotides, can be detected once the unbound portion of the sample is washed away. Techniques for constructing arrays and methods of using these arrays are described in EP 799 897; WO 97/29212; WO 97/27317; EP 785 280; WO 97/02357; USPN 5,593,839; USPN 5,578,832; EP 728 520; USPN 5,599,695; EP 721 016; USPN 5,556,752; WO 95/22058; and USPN 5,631,734. Arrays can be used to, for example, examine differential expression of genes and can be used to determine gene function. For example, arrays can be used to detect differential expression of a polynucleotide between a test cell and control cell (e.g., cancer cells and normal cells). For example, high expression of a particular message in a cancer cell, which is not observed in a corresponding normal cell, can indicate a cancer specific gene product. Exemplary uses of arrays are further described in, for example, Pappalarado et al., Sem. Radiation Oncol. (1998) 8:217; and Ramsay Nature Biotechnol. (1998) 16:40.

Differential Expression in Diagnosis

The polynucleotides of the invention can also be used to detect differences in expression levels between two cells, e.g., as a method to identify abnormal or diseased tissue in a human. For polynucleotides corresponding to profiles of protein families, the choice of tissue can be selected according to the putative biological function. In general, the expression of a gene corresponding to

a specific polynucleotide is compared between a first tissue that is suspected of being diseased and a second, normal tissue of the human. The tissue suspected of being abnormal or diseased can be derived from a different tissue type of the human, but preferably it is derived from the same tissue type; for example an intestinal polyp or other abnormal growth should be compared with normal intestinal tissue. The normal tissue can be the same tissue as that of the test sample, or any normal tissue of the patient, especially those that express the polynucleotide-related gene of interest (*e.g.*, brain, thymus, testis, heart, prostate, placenta, spleen, small intestine, skeletal muscle, pancreas, and the mucosal lining of the colon). A difference between the polynucleotide-related gene, mRNA, or protein in the two tissues which are compared, for example in molecular weight, amino acid or nucleotide sequence, or relative abundance, indicates a change in the gene, or a gene which regulates it, in the tissue of the human that was suspected of being diseased. Examples of detection of differential expression and its use in diagnosis of cancer are described in USPNs 5,688,641 and 5,677,125.

5

10

15

20

25

30

35

A genetic predisposition to disease in a human can also be detected by comparing expression levels of an mRNA or protein corresponding to a polynucleotide of the invention in a fetal tissue with levels associated in normal fetal tissue. Fetal tissues that are used for this purpose include, but are not limited to, amniotic fluid, chorionic villi, blood, and the blastomere of an in vitro-fertilized embryo. The comparable normal polynucleotide-related gene is obtained from any tissue. The mRNA or protein is obtained from a normal tissue of a human in which the polynucleotide-related gene is expressed. Differences such as alterations in the nucleotide sequence or size of the same product of the fetal polynucleotide-related gene or mRNA, or alterations in the molecular weight, amino acid sequence, or relative abundance of fetal protein, can indicate a germline mutation in the polynucleotide-related gene of the fetus, which indicates a genetic predisposition to disease. In general, diagnostic, prognostic, and other methods of the invention based on differential expression involve detection of a level or amount of a gene product, particularly a differentially expressed gene product, in a test sample obtained from a patient suspected of having or being susceptible to a disease (e.g., breast cancer, lung cancer, colon cancer and/or metastatic forms thereof), and comparing the detected levels to those levels found in normal cells (e.g., cells substantially unaffected by cancer) and/or other control cells (e.g., to differentiate a cancerous cell from a cell affected by dysplasia). Furthermore, the severity of the disease can be assessed by comparing the detected levels of a differentially expressed gene product with those levels detected in samples representing the levels of differentially gene product associated with varying degrees of severity of disease. It should be noted that use of the term "diagnostic" herein is not necessarily meant to exclude "prognostic" or "prognosis," but rather is used as a matter of convenience.

The term "differentially expressed gene" is generally intended to encompass a polynucleotide that can, for example, include an open reading frame encoding a gene product (e.g., a polypeptide), and/or introns of such genes and adjacent 5' and 3' non-coding nucleotide sequences involved in the regulation of expression, up to about 20 kb beyond the coding region, but possibly further in either direction. The gene can be introduced into an appropriate vector for extrachromosomal maintenance or for integration into a host genome. In general, a difference in expression level associated with a decrease in expression level of at least about 25%, usually at least about 50% to 75%, more usually at least about 90% or more is indicative of a differentially expressed gene of interest, i.e., a gene that is underexpressed or down-regulated in the test sample relative to a control sample. Furthermore, a difference in expression level associated with an increase in expression of at least about 25%, usually at least about 50% to 75%, more usually at least about 90% and can be at least about 1½-fold, usually at least about 2-fold to about 10-fold, and can be about 100-fold to about 1,000-fold increase relative to a control sample is indicative of a differentially expressed gene of interest, i.e., an overexpressed or up-regulated gene.

"Differentially expressed polynucleotide" as used herein means a nucleic acid molecule (RNA or DNA) comprising a sequence that represents a differentially expressed gene, e.g., the differentially expressed polynucleotide comprises a sequence (e.g., an open reading frame encoding a gene product) that uniquely identifies a differentially expressed gene so that detection of the differentially expressed polynucleotide in a sample is correlated with the presence of a differentially expressed gene in a sample. "Differentially expressed polynucleotides" is also meant to encompass fragments of the disclosed polynucleotides, e.g., fragments retaining biological activity, as well as nucleic acids homologous, substantially similar, or substantially identical (e.g., having about 90% sequence identity) to the disclosed polynucleotides.

"Diagnosis" as used herein generally includes determination of a subject's susceptibility to a disease or disorder, determination as to whether a subject is presently affected by a disease or disorder, as well as to the prognosis of a subject affected by a disease or disorder (e.g., identification of pre-metastatic or metastatic cancerous states, stages of cancer, or responsiveness of cancer to therapy). The present invention particularly encompasses diagnosis of subjects in the context of breast cancer (e.g., carcinoma in situ (e.g., ductal carcinoma in situ), estrogen receptor (ER)-positive breast cancer, ER-negative breast cancer, or other forms and/or stages of breast cancer), lung cancer (e.g., small cell carcinoma, non-small cell carcinoma, mesothelioma, and other forms and/or stages of lung cancer), and colon cancer (e.g., adenomatous polyp, colorectal carcinoma, and other forms and/or stages of colon cancer).

"Sample" or "biological sample" as used throughout here are generally meant to refer to samples of biological fluids or tissues, particularly samples obtained from tissues, especially from cells of the type associated with the disease for which the diagnostic application is designed (e.g.,

ductal adenocarcinoma), and the like. "Samples" is also meant to encompass derivatives and fractions of such samples (e.g., cell lysates). Where the sample is solid tissue, the cells of the tissue can be dissociated or tissue sections can be analyzed.

Methods of the subject invention useful in diagnosis or prognosis typically involve comparison of the abundance of a selected differentially expressed gene product in a sample of interest with that of a control to determine any relative differences in the expression of the gene product, where the difference can be measured qualitatively and/or quantitatively. Quantitation can be accomplished, for example, by comparing the level of expression product detected in the sample with the amounts of product present in a standard curve. A comparison can be made visually; by using a technique such as densitometry, with or without computerized assistance; by preparing a representative library of cDNA clones of mRNA isolated from a test sample, sequencing the clones in the library to determine that number of cDNA clones corresponding to the same gene product, and analyzing the number of clones corresponding to that same gene product relative to the number of clones of the same gene product in a control sample; or by using an array to detect relative levels of hybridization to a selected sequence or set of sequences, and comparing the hybridization pattern to that of a control. The differences in expression are then correlated with the presence or absence of an abnormal expression pattern. A variety of different methods for determining the nucleic acid abundance in a sample are known to those of skill in the art (see, e.g., WO 97/27317).

In general, diagnostic assays of the invention involve detection of a gene product of a the polynucleotide sequence (e.g., mRNA or polypeptide) that corresponds to a sequence of SEQ ID NOS:1-316 The patient from whom the sample is obtained can be apparently healthy, susceptible to disease (e.g., as determined by family history or exposure to certain environmental factors), or can already be identified as having a condition in which altered expression of a gene product of the invention is implicated.

Diagnosis can be determined based on detected gene product expression levels of a gene product encoded by at least one, preferably at least two or more, at least 3 or more, or at least 4 or more of the polynucleotides having a sequence set forth in SEQ ID NOS:1-316, and can involve detection of expression of genes corresponding to all of SEQ ID NOS:1-316 and/or additional sequences that can serve as additional diagnostic markers and/or reference sequences. Where the diagnostic method is designed to detect the presence or susceptibility of a patient to cancer, the assay preferably involves detection of a gene product encoded by a gene corresponding to a polynucleotide that is differentially expressed in cancer. Examples of such differentially expressed polynucleotides are described in the Examples below. Given the provided polynucleotides and information regarding their relative expression levels provided herein, assays using such polynucleotides and detection of their expression levels in diagnosis and prognosis will be readily apparent to the ordinarily skilled artisan.

Any of a variety of detectable labels can be used in connection with the various embodiments of the diagnostic methods of the invention. Suitable detectable labels include fluorochromes, (e.g. fluorescein isothiocyanate (FITC), rhodamine, Texas Red, phycoerythrin, allophycocyanin, 6-carboxyfluorescein (6-FAM), 2',7'-dimethoxy-4',5'-dichloro-6-carboxyfluorescein, 6-carboxy-X-rhodamine (ROX), 6-carboxy-2',4',7',4,7-hexachlorofluorescein (HEX), 5-carboxyfluorescein (5-FAM) or N,N,N',N'-tetramethyl-6-carboxyrhodamine (TAMRA)), radioactive labels, (e.g. ³²P, ³⁵S, ³H, etc.), and the like. The detectable label can involve a two stage systems (e.g., biotin-avidin, hapten-anti-hapten antibody, etc.)

5

10

15

20

25

30

35

Reagents specific for the polynucleotides and polypeptides of the invention, such as antibodies and nucleotide probes, can be supplied in a kit for detecting the presence of an expression product in a biological sample. The kit can also contain buffers or labeling components, as well as instructions for using the reagents to detect and quantify expression products in the biological sample. Exemplary embodiments of the diagnostic methods of the invention are described below in more detail.

Polypeptide detection in diagnosis. In one embodiment, the test sample is assayed for the level of a differentially expressed polypeptide. Diagnosis can be accomplished using any of a number of methods to determine the absence or presence or altered amounts of the differentially expressed polypeptide in the test sample. For example, detection can utilize staining of cells or histological sections with labeled antibodies, performed in accordance with conventional methods. Cells can be permeabilized to stain cytoplasmic molecules. In general, antibodies that specifically bind a differentially expressed polypeptide of the invention are added to a sample, and incubated for a period of time sufficient to allow binding to the epitope, usually at least about 10 minutes. The antibody can be detectably labeled for direct detection (e.g., using radioisotopes, enzymes, fluorescers, chemiluminescers, and the like), or can be used in conjunction with a second stage antibody or reagent to detect binding (e.g., biotin with horseradish peroxidase-conjugated avidin, a secondary antibody conjugated to a fluorescent compound, e.g. fluorescein, rhodamine, Texas red, etc.). The absence or presence of antibody binding can be determined by various methods, including flow cytometry of dissociated cells, microscopy, radiography, scintillation counting, etc. Any suitable alternative methods can of qualitative or quantitative detection of levels or amounts of differentially expressed polypeptide can be used, for example ELISA, western blot, immunoprecipitation, radioimmunoassay, etc.

mRNA detection. The diagnostic methods of the invention can also or alternatively involve detection of mRNA encoded by a gene corresponding to a differentially expressed polynucleotides of the invention. Any suitable qualitative or quantitative methods known in the art for detecting specific mRNAs can be used. mRNA can be detected by, for example, *in situ* hybridization in tissue sections, by reverse transcriptase-PCR, or in Northern blots containing poly A+ mRNA. One

of skill in the art can readily use these methods to determine differences in the size or amount of mRNA transcripts between two samples. mRNA expression levels in a sample can also be determined by generation of a library of expressed sequence tags (ESTs) from the sample, where the EST library is representative of sequences present in the sample (Adams, et al., (1991) *Science* 252:1651). Enumeration of the relative representation of ESTs within the library can be used to approximate the relative representation of the gene transcript within the starting sample. The results of EST analysis of a test sample can then be compared to EST analysis of a reference sample to determine the relative expression levels of a selected polynucleotide, particularly a polynucleotide corresponding to one or more of the differentially expressed genes described herein. Alternatively, gene expression in a test sample can be performed using serial analysis of gene expression (SAGE) methodology (e.g., Velculescu et al., *Science* (1995) 270:484) or differential display (DD) methodology (see, e.g., U.S. 5,776,683; and U.S. 5,807,680).

Alternatively, gene expression can be analyzed using hybridization analysis. Oligonucleotides or cDNA can be used to selectively identify or capture DNA or RNA of specific sequence composition, and the amount of RNA or cDNA hybridized to a known capture sequence determined qualitatively or quantitatively, to provide information about the relative representation of a particular message within the pool of cellular messages in a sample. Hybridization analysis can be designed to allow for concurrent screening of the relative expression of hundreds to thousands of genes by using, for example, array-based technologies having high density formats, including filters, microscope slides, or microchips, or solution-based technologies that use spectroscopic analysis (e.g., mass spectrometry). One exemplary use of arrays in the diagnostic methods of the invention is described below in more detail.

Use of a single gene in diagnostic applications. The diagnostic methods of the invention can focus on the expression of a single differentially expressed gene. For example, the diagnostic method can involve detecting a differentially expressed gene, or a polymorphism of such a gene (e.g., a polymorphism in an coding region or control region), that is associated with disease. Disease-associated polymorphisms can include deletion or truncation of the gene, mutations that alter expression level and/or affect activity of the encoded protein, etc.

A number of methods are available for analyzing nucleic acids for the presence of a specific sequence, *e.g.* a disease associated polymorphism. Where large amounts of DNA are available, genomic DNA is used directly. Alternatively, the region of interest is cloned into a suitable vector and grown in sufficient quantity for analysis. Cells that express a differentially expressed gene can be used as a source of mRNA, which can be assayed directly or reverse transcribed into cDNA for analysis. The nucleic acid can be amplified by conventional techniques, such as the polymerase chain reaction (PCR), to provide sufficient amounts for analysis, and a detectable label can be included in the amplification reaction (*e.g.*, using a detectably labeled

primer or detectably labeled oligonucleotides) to facilitate detection. Alternatively, various methods are also known in the art that utilize oligonucleotide ligation as a means of detecting polymorphisms, see e.g., Riley et al., Nucl. Acids Res. (1990) 18:2887; and Delahunty et al., Am. J. Hum. Genet. (1996) 58:1239.

5

10

15

20

25

30

35

The amplified or cloned sample nucleic acid can be analyzed by one of a number of methods known in the art. The nucleic acid can be sequenced by dideoxy or other methods, and the sequence of bases compared to a selected sequence, *e.g.*, to a wild-type sequence. Hybridization with the polymorphic or variant sequence can also be used to determine its presence in a sample (*e.g.*, by Southern blot, dot blot, *etc.*). The hybridization pattern of a polymorphic or variant sequence and a control sequence to an array of oligonucleotide probes immobilized on a solid support, as described in US 5,445,934, or in WO 95/35505, can also be used as a means of identifying polymorphic or variant sequences associated with disease. Single strand conformational polymorphism (SSCP) analysis, denaturing gradient gel electrophoresis (DGGE), and heteroduplex analysis in gel matrices are used to detect conformational changes created by DNA sequence variation as alterations in electrophoretic mobility. Alternatively, where a polymorphism creates or destroys a recognition site for a restriction endonuclease, the sample is digested with that endonuclease, and the products size fractionated to determine whether the fragment was digested. Fractionation is performed by gel or capillary electrophoresis, particularly acrylamide or agarose gels.

Screening for mutations in a gene can be based on the functional or antigenic characteristics of the protein. Protein truncation assays are useful in detecting deletions that can affect the biological activity of the protein. Various immunoassays designed to detect polymorphisms in proteins can be used in screening. Where many diverse genetic mutations lead to a particular disease phenotype, functional protein assays have proven to be effective screening tools. The activity of the encoded protein can be determined by comparison with the wild-type protein.

Pattern matching in diagnosis using arrays. In another embodiment, the diagnostic and/or prognostic methods of the invention involve detection of expression of a selected set of genes in a test sample to produce a test expression pattern (TEP). The TEP is compared to a reference expression pattern (REP), which is generated by detection of expression of the selected set of genes in a reference sample (e.g., a positive or negative control sample). The selected set of genes includes at least one of the genes of the invention, which genes correspond to the polynucleotide sequences of SEQ ID NOS:1-316. Of particular interest is a selected set of genes that includes gene differentially expressed in the disease for which the test sample is to be screened.

"Reference sequences" or "reference polynucleotides" as used herein in the context of differential gene expression analysis and diagnosis/prognosis refers to a selected set of

polynucleotides, which selected set includes at least one or more of the differentially expressed polynucleotides described herein. A plurality of reference sequences, preferably comprising positive and negative control sequences, can be included as reference sequences. Additional suitable reference sequences are found in GenBank, Unigene, and other nucleotide sequence databases (including, *e.g.*, expressed sequence tag (EST), partial, and full-length sequences).

5

10

15

20

25

30

35

"Reference array" means an array having reference sequences for use in hybridization with a sample, where the reference sequences include all, at least one of, or any subset of the differentially expressed polynucleotides described herein. Usually such an array will include at least 3 different reference sequences, and can include any one or all of the provided differentially expressed sequences. Arrays of interest can further comprise sequences, including polymorphisms, of other genetic sequences, particularly other sequences of interest for screening for a disease or disorder (e.g., cancer, dysplasia, or other related or unrelated diseases, disorders, or conditions). The oligonucleotide sequence on the array will usually be at least about 12 nt in length, and can be of about the length of the provided sequences, or can extend into the flanking regions to generate fragments of 100 nt to 200 nt in length or more. Reference arrays can be produced according to any suitable methods known in the art. For example, methods of producing large arrays of oligonucleotides are described in U.S. 5,134,854, and U.S. 5,445,934 using light-directed synthesis techniques. Using a computer controlled system, a heterogeneous array of monomers is converted, through simultaneous coupling at a number of reaction sites, into a heterogeneous array of polymers. Alternatively, microarrays are generated by deposition of pre-synthesized oligonucleotides onto a solid substrate, for example as described in PCT published application no. WO 95/35505.

A "reference expression pattern" or "REP" as used herein refers to the relative levels of expression of a selected set of genes, particularly of differentially expressed genes, that is associated with a selected cell type, e.g., a normal cell, a cancerous cell, a cell exposed to an environmental stimulus, and the like. A "test expression pattern" or "TEP" refers to relative levels of expression of a selected set of genes, particularly of differentially expressed genes, in a test sample (e.g., a cell of unknown or suspected disease state, from which mRNA is isolated).

REPs can be generated in a variety of ways according to methods well known in the art. For example, REPs can be generated by hybridizing a control sample to an array having a selected set of polynucleotides (particularly a selected set of differentially expressed polynucleotides), acquiring the hybridization data from the array, and storing the data in a format that allows for ready comparison of the REP with a TEP. Alternatively, all expressed sequences in a control sample can be isolated and sequenced, *e.g.*, by isolating mRNA from a control sample, converting the mRNA into cDNA, and sequencing the cDNA. The resulting sequence information roughly or precisely reflects the identity and relative number of expressed sequences in the sample. The

sequence information can then be stored in a format (e.g., a computer-readable format) that allows for ready comparison of the REP with a TEP. The REP can be normalized prior to or after data storage, and/or can be processed to selectively remove sequences of expressed genes that are of less interest or that might complicate analysis (e.g., some or all of the sequences associated with housekeeping genes can be eliminated from REP data).

5

10

15

20

25

30

35

TEPs can be generated in a manner similar to REPs, *e.g.*, by hybridizing a test sample to an array having a selected set of polynucleotides, particularly a selected set of differentially expressed polynucleotides, acquiring the hybridization data from the array, and storing the data in a format that allows for ready comparison of the TEP with a REP. The REP and TEP to be used in a comparison can be generated simultaneously, or the TEP can be compared to previously generated and stored REPs.

In one embodiment of the invention, comparison of a TEP with a REP involves hybridizing a test sample with a reference array, where the reference array has one or more reference sequences for use in hybridization with a sample. The reference sequences include all, at least one of, or any subset of the differentially expressed polynucleotides described herein. Hybridization data for the test sample is acquired, the data normalized, and the produced TEP compared with a REP generated using an array having the same or similar selected set of differentially expressed polynucleotides. Probes that correspond to sequences differentially expressed between the two samples will show decreased or increased hybridization efficiency for one of the samples relative to the other.

Methods for collection of data from hybridization of samples with a reference arrays are well known in the art. For example, the polynucleotides of the reference and test samples can be generated using a detectable fluorescent label, and hybridization of the polynucleotides in the samples detected by scanning the microarrays for the presence of the detectable label using, for example, a microscope and light source for directing light at a substrate. A photon counter detects fluorescence from the substrate, while an x-y translation stage varies the location of the substrate. A confocal detection device that can be used in the subject methods is described in USPN 5,631,734. A scanning laser microscope is described in Shalon et al., *Genome Res.* (1996) 6:639. A scan, using the appropriate excitation line, is performed for each fluorophore used. The digital images generated from the scan are then combined for subsequent analysis. For any particular array element, the ratio of the fluorescent signal from one sample (e.g., a test sample) is compared to the fluorescent signal from another sample (e.g., a reference sample), and the relative signal intensity determined.

Methods for analyzing the data collected from hybridization to arrays are well known in the art. For example, where detection of hybridization involves a fluorescent label, data analysis can include the steps of determining fluorescent intensity as a function of substrate position from the data collected, removing outliers, *i.e.* data deviating from a predetermined statistical distribution,

and calculating the relative binding affinity of the targets from the remaining data. The resulting data can be displayed as an image with the intensity in each region varying according to the binding affinity between targets and probes.

In general, the test sample is classified as having a gene expression profile corresponding to that associated with a disease or non-disease state by comparing the TEP generated from the test sample to one or more REPs generated from reference samples (e.g., from samples associated with cancer or specific stages of cancer, dysplasia, samples affected by a disease other than cancer, normal samples, etc.). The criteria for a match or a substantial match between a TEP and a REP include expression of the same or substantially the same set of reference genes, as well as expression of these reference genes at substantially the same levels (e.g., no significant difference between the samples for a signal associated with a selected reference sequence after normalization of the samples, or at least no greater than about 25% to about 40% difference in signal strength for a given reference sequence. In general, a pattern match between a TEP and a REP includes a match in expression, preferably a match in qualitative or quantitative expression level, of at least one of, all or any subset of the differentially expressed genes of the invention.

Pattern matching can be performed manually, or can be performed using a computer program. Methods for preparation of substrate matrices (*e.g.*, arrays), design of oligonucleotides for use with such matrices, labeling of probes, hybridization conditions, scanning of hybridized matrices, and analysis of patterns generated, including comparison analysis, are described in, for example, U.S. 5,800,992.

Diagnosis, Prognosis and Management of Cancer

5

10

15

20

25

30

35

The polynucleotides of the invention and their gene products are of particular interest as genetic or biochemical markers (e.g., in blood or tissues) that will detect the earliest changes along the carcinogenesis pathway and/or to monitor the efficacy of various therapies and preventive interventions. For example, the level of expression of certain polynucleotides can be indicative of a poorer prognosis, and therefore warrant more aggressive chemo- or radio-therapy for a patient or vice versa. The correlation of novel surrogate tumor specific features with response to treatment and outcome in patients can define prognostic indicators that allow the design of tailored therapy based on the molecular profile of the tumor. These therapies include antibody targeting and gene therapy. Determining expression of certain polynucleotides and comparison of a patients profile with known expression in normal tissue and variants of the disease allows a determination of the best possible treatment for a patient, both in terms of specificity of treatment and in terms of comfort level of the patient. Surrogate tumor markers, such as polynucleotide expression, can also be used to better classify, and thus diagnose and treat, different forms and disease states of cancer. Two classifications widely used in oncology that can benefit from identification of the expression

levels of the polynucleotides of the invention are staging of the cancerous disorder, and grading the nature of the cancerous tissue.

The polynucleotides of the invention can be useful to monitor patients having or susceptible to cancer to detect potentially malignant events at a molecular level before they are detectable at a gross morphological level. Furthermore, a polynucleotide of the invention identified as important for one type of cancer can also have implications for development or risk of development of other types of cancer, e.g., where a polynucleotide is differentially expressed across various cancer types. Thus, for example, expression of a polynucleotide that has clinical implications for metastatic colon cancer can also have clinical implications for stomach cancer or endometrial cancer.

5

10

15

20

25

30

35

Staging. Staging is a process used by physicians to describe how advanced the cancerous state is in a patient. Staging assists the physician in determining a prognosis, planning treatment and evaluating the results of such treatment. Staging systems vary with the types of cancer, but generally involve the following "TNM" system: the type of tumor, indicated by T; whether the cancer has metastasized to nearby lymph nodes, indicated by N; and whether the cancer has metastasized to more distant parts of the body, indicated by M. Generally, if a cancer is only detectable in the area of the primary lesion without having spread to any lymph nodes it is called Stage I. If it has spread only to the closest lymph nodes, it is called Stage II. In Stage III, the cancer has generally spread to the lymph nodes in near proximity to the site of the primary lesion. Cancers that have spread to a distant part of the body, such as the liver, bone, brain or other site, are Stage IV, the most advanced stage.

The polynucleotides of the invention can facilitate fine-tuning of the staging process by identifying markers for the aggresivity of a cancer, e.g. the metastatic potential, as well as the presence in different areas of the body. Thus, a Stage II cancer with a polynucleotide signifying a high metastatic potential cancer can be used to change a borderline Stage II tumor to a Stage III tumor, justifying more aggressive therapy. Conversely, the presence of a polynucleotide signifying a lower metastatic potential allows more conservative staging of a tumor.

Grading of cancers. Grade is a term used to describe how closely a tumor resembles normal tissue of its same type. The microscopic appearance of a tumor is used to identify tumor grade based on parameters such as cell morphology, cellular organization, and other markers of differentiation. As a general rule, the grade of a tumor corresponds to its rate of growth or aggressiveness, with undifferentiated or high-grade tumors being more aggressive than well differentiated or low-grade tumors. The following guidelines are generally used for grading tumors:

1) GX Grade cannot be assessed; 2) G1 Well differentiated; G2 Moderately well differentiated; 3) G3 Poorly differentiated; 4) G4 Undifferentiated. The polynucleotides of the invention can be especially valuable in determining the grade of the tumor, as they not only can aid in determining

the differentiation status of the cells of a tumor, they can also identify factors other than differentiation that are valuable in determining the aggressiveness of a tumor, such as metastatic potential.

5

10

15

20

25

30

35

Detection of lung cancer. The polynucleotides of the invention can be used to detect lung cancer in a subject. Although there are more than a dozen different kinds of lung cancer, the two main types of lung cancer are small cell and nonsmall cell, which encompass about 90% of all lung cancer cases. Small cell carcinoma (also called oat cell carcinoma) usually starts in one of the larger bronchial tubes, grows fairly rapidly, and is likely to be large by the time of diagnosis. Nonsmall cell lung cancer (NSCLC) is made up of three general subtypes of lung cancer. Epidermoid carcinoma (also called squamous cell carcinoma) usually starts in one of the larger bronchial tubes and grows relatively slowly. The size of these tumors can range from very small to quite large. Adenocarcinoma starts growing near the outside surface of the lung and can vary in both size and growth rate. Some slowly growing adenocarcinomas are described as alveolar cell cancer. Large cell carcinoma starts near the surface of the lung, grows rapidly, and the growth is usually fairly large when diagnosed. Other less common forms of lung cancer are carcinoid, cylindroma, mucoepidermoid, and malignant mesothelioma.

The polynucleotides of the invention, e.g., polynucleotides differentially expressed in normal cells versus cancerous lung cells (e.g., tumor cells of high or low metastatic potential) or between types of cancerous lung cells (e.g., high metastatic versus low metastatic), can be used to distinguish types of lung cancer as well as identifying traits specific to a certain patient's cancer and selecting an appropriate therapy. For example, if the patient's biopsy expresses a polynucleotide that is associated with a low metastatic potential, it may justify leaving a larger portion of the patient's lung in surgery to remove the lesion. Alternatively, a smaller lesion with expression of a polynucleotide that is associated with high metastatic potential may justify a more radical removal of lung tissue and/or the surrounding lymph nodes, even if no metastasis can be identified through pathological examination.

Detection of breast cancer. The majority of breast cancers are adenocarcinomas subtypes, which can be summarized as follows: 1) ductal carcinoma in situ (DCIS), including comedocarcinoma; 2) infiltrating (or invasive) ductal carcinoma (IDC); 3) lobular carcinoma in situ (LCIS); 4) infiltrating (or invasive) lobular carcinoma (ILC); 5) inflammatory breast cancer; 6) medullary carcinoma; 7) mucinous carcinoma; 8) Paget's disease of the nipple; 9) Phyllodes tumor; and 10) tubular carcinoma;

The expression of polynucleotides of the invention can be used in the diagnosis and management of breast cancer, as well as to distinguish between types of breast cancer. Detection of breast cancer can be determined using expression levels of any of the appropriate polynucleotides of the invention, either alone or in combination. Determination of the aggressive nature and/or the

metastatic potential of a breast cancer can also be determined by comparing levels of one or more polynucleotides of the invention and comparing levels of another sequence known to vary in cancerous tissue, e.g. ER expression. In addition, development of breast cancer can be detected by examining the ratio of expression of a differentially expressed polynucleotide to the levels of steroid hormones (e.g., testosterone or estrogen) or to other hormones (e.g., growth hormone, insulin). Thus expression of specific marker polynucleotides can be used to discriminate between normal and cancerous breast tissue, to discriminate between breast cancers with different cells of origin, to discriminate between breast cancers with different potential metastatic rates, etc.

10

15

20

25

30

35

Detection of colon cancer. The polynucleotides of the invention exhibiting the appropriate expression pattern can be used to detect colon cancer in a subject. Colorectal cancer is one of the most common neoplasms in humans and perhaps the most frequent form of hereditary neoplasia. Prevention and early detection are key factors in controlling and curing colorectal cancer. Colorectal cancer begins as polyps, which are small, benign growths of cells that form on the inner lining of the colon. Over a period of several years, some of these polyps accumulate additional mutations and become cancerous. Multiple familial colorectal cancer disorders have been identified, which are summarized as follows: 1) Familial adenomatous polyposis (FAP): 2) Gardner's syndrome; 3) Hereditary nonpolyposis colon cancer (HNPCC); and 4) Familial colorectal cancer in Ashkenazi Jews. The expression of appropriate polynucleotides of the invention can be used in the diagnosis, prognosis and management of colorectal cancer. Detection of colon cancer can be determined using expression levels of any of these sequences alone or in combination with the levels of expression. Determination of the aggressive nature and/or the metastatic potential of a colon cancer can be determined by comparing levels of one or more polynucleotides of the invention and comparing total levels of another sequence known to vary in cancerous tissue, e.g., expression of p53, DCC ras, lor FAP (see, e.g., Fearon ER, et al., Cell (1990) 61(5):759; Hamilton SR et al., Cancer (1993) 72:957; Bodmer W, et al., Nat Genet. (1994) 4(3):217; Fearon ER, Ann N YAcad Sci. (1995) 768:101). For example, development of colon cancer can be detected by examining the ratio of any of the polynucleotides of the invention to the levels of oncogenes (e.g. ras) or tumor suppressor genes (e.g. FAP or p53). Thus expression of specific marker polynucleotides can be used to discriminate between normal and cancerous colon tissue, to discriminate between colon cancers with different cells of origin, to discriminate between colon cancers with different potential metastatic rates, etc.

<u>Detection of prostate cancer.</u> The polynucleotides and their corresponding genes and gene products exhibiting the appropriate differential expression pattern can be used to detect prostate cancer in a subject. Over 95% of primary prostate cancers are adenocarcinomas. Signs and symptoms may include: frequent urination, especially at night, inability to urinate, trouble starting

or holding back urination, a weak or interrupted urine flow and frequent pain or stiffness in the lower back, hips or upper thighs.

Many of the signs and symptoms of prostate cancer can be caused by a variety of other non-cancerous conditions. For example, one common cause of many of these signs and symptoms is a condition called benign prostatic hypertrophy, or BPH. In BPH, the prostate gets bigger and may block the flow or urine or interfere with sexual function. The methods and compositions of the invention can be used to distinguish between prostate cancer and such non-cancerous conditions. The methods of the invention can be used in conjunction with conventional methods of diagnosis, e.g., digital rectal exam and/or detection of the level of prostate specific antigen (PSA), a substance produced and secreted by the prostate.

Use of Polynucleotides to Screen for Peptide Analogs and Antagonists

5

10

15

20

25

30

35

Polypeptides encoded by the instant polynucleotides and corresponding full length genes can be used to screen peptide libraries to identify binding partners, such as receptors, from among the encoded polypeptides. Peptide libraries can be synthesized according to methods known in the art (see, e.g., USPN 5,010,175, and WO 91/17823). Agonists or antagonists of the polypeptides if the invention can be screened using any available method known in the art, such as signal transduction, antibody binding, receptor binding, mitogenic assays, chemotaxis assays, etc. The assay conditions ideally should resemble the conditions under which the native activity is exhibited *in vivo*, that is, under physiologic pH, temperature, and ionic strength. Suitable agonists or antagonists will exhibit strong inhibition or enhancement of the native activity at concentrations that do not cause toxic side effects in the subject. Agonists or antagonists that compete for binding to the native polypeptide can require concentrations equal to or greater than the native concentration, while inhibitors capable of binding irreversibly to the polypeptide can be added in concentrations on the order of the native concentration.

Such screening and experimentation can lead to identification of a novel polypeptide binding partner, such as a receptor, encoded by a gene or a cDNA corresponding to a polynucleotide of the invention, and at least one peptide agonist or antagonist of the novel binding partner. Such agonists and antagonists can be used to modulate, enhance, or inhibit receptor function in cells to which the receptor is native, or in cells that possess the receptor as a result of genetic engineering. Further, if the novel receptor shares biologically important characteristics with a known receptor, information about agonist/antagonist binding can facilitate development of improved agonists/antagonists of the known receptor.

Pharmaceutical Compositions and Therapeutic Uses

Pharmaceutical compositions of the invention can comprise polypeptides, antibodies, or polynucleotides (including antisense nucleotides and ribozymes) of the claimed invention in a therapeutically effective amount. The term "therapeutically effective amount" as used herein refers

to an amount of a therapeutic agent to treat, ameliorate, or prevent a desired disease or condition, or to exhibit a detectable therapeutic or preventative effect. The effect can be detected by, for example, chemical markers or antigen levels. Therapeutic effects also include reduction in physical symptoms, such as decreased body temperature. The precise effective amount for a subject will depend upon the subject's size and health, the nature and extent of the condition, and the therapeutics or combination of therapeutics selected for administration. Thus, it is not useful to specify an exact effective amount in advance. However, the effective amount for a given situation is determined by routine experimentation and is within the judgment of the clinician. For purposes of the present invention, an effective dose will generally be from about 0.01 mg/kg to 50 mg/kg or 0.05 mg/kg to about 10 mg/kg of the DNA constructs in the individual to which it is administered.

5

10

15

20

25

30

35

A pharmaceutical composition can also contain a pharmaceutically acceptable carrier. The term "pharmaceutically acceptable carrier" refers to a carrier for administration of a therapeutic agent, such as antibodies or a polypeptide, genes, and other therapeutic agents. The term refers to any pharmaceutical carrier that does not itself induce the production of antibodies harmful to the individual receiving the composition, and which can be administered without undue toxicity. Suitable carriers can be large, slowly metabolized macromolecules such as proteins, polysaccharides, polylactic acids, polyglycolic acids, polymeric amino acids, amino acid copolymers, and inactive virus particles. Such carriers are well known to those of ordinary skill in the art. Pharmaceutically acceptable carriers in therapeutic compositions can include liquids such as water, saline, glycerol and ethanol. Auxiliary substances, such as wetting or emulsifying agents, pH buffering substances, and the like, can also be present in such vehicles. Typically, the therapeutic compositions are prepared as injectables, either as liquid solutions or suspensions; solid forms suitable for solution in, or suspension in, liquid vehicles prior to injection can also be prepared. Liposomes are included within the definition of a pharmaceutically acceptable carrier. Pharmaceutically acceptable salts can also be present in the pharmaceutical composition, e.g., mineral acid salts such as hydrochlorides, hydrobromides, phosphates, sulfates, and the like; and the salts of organic acids such as acetates, propionates, malonates, benzoates, and the like. A thorough discussion of pharmaceutically acceptable excipients is available in Remington's Pharmaceutical Sciences (Mack Pub. Co., N.J. 1991).

<u>Delivery Methods.</u> Once formulated, the compositions of the invention can be (1) administered directly to the subject (*e.g.*, as polynucleotide or polypeptides); or (2) delivered ex vivo, to cells derived from the subject (*e.g.*, as in *ex vivo* gene therapy). Direct delivery of the compositions will generally be accomplished by parenteral injection, e.g., subcutaneously, intraperitoneally, intravenously or intramuscularly, intratumoral or to the interstitial space of a tissue. Other modes of administration include oral and pulmonary administration, suppositories,

and transdermal applications, needles, and gene guns or hyposprays. Dosage treatment can be a single dose schedule or a multiple dose schedule.

Methods for the ex vivo delivery and reimplantation of transformed cells into a subject are known in the art and described in *e.g.*, International Publication No. WO 93/14778. Examples of cells useful in ex vivo applications include, for example, stem cells, particularly hematopoetic, lymph cells, macrophages, dendritic cells, or tumor cells. Generally, delivery of nucleic acids for both ex vivo and in vitro applications can be accomplished by, for example, dextran-mediated transfection, calcium phosphate precipitation, polybrene mediated transfection, protoplast fusion, electroporation, encapsulation of the polynucleotide(s) in liposomes, and direct microinjection of the DNA into nuclei, all well known in the art.

10

15

20

25 -

30

35

Once a gene corresponding to a polynucleotide of the invention has been found to correlate with a proliferative disorder, such as neoplasia, dysplasia, and hyperplasia, the disorder can be amenable to treatment by administration of a therapeutic agent based on the provided polynucleotide, corresponding polypeptide or other corresponding molecule (e.g., antisense, ribozyme, etc.).

The dose and the means of administration of the inventive pharmaceutical compositions are determined based on the specific qualities of the therapeutic composition, the condition, age, and weight of the patient, the progression of the disease, and other relevant factors. For example, administration of polynucleotide therapeutic compositions agents of the invention includes local or systemic administration, including injection, oral administration, particle gun or catheterized administration, and topical administration. Preferably, the therapeutic polynucleotide composition contains an expression construct comprising a promoter operably linked to a polynucleotide of at least 12, 22, 25, 30, or 35 contiguous nt of the polynucleotide disclosed herein. Various methods can be used to administer the therapeutic composition directly to a specific site in the body. For example, a small metastatic lesion is located and the therapeutic composition injected several times in several different locations within the body of tumor. Alternatively, arteries which serve a tumor are identified, and the therapeutic composition injected into such an artery, in order to deliver the composition directly into the tumor. A tumor that has a necrotic center is aspirated and the composition injected directly into the now empty center of the tumor. The antisense composition is directly administered to the surface of the tumor, for example, by topical application of the composition. X-ray imaging is used to assist in certain of the above delivery methods.

Receptor-mediated targeted delivery of therapeutic compositions containing an antisense polynucleotide, subgenomic polynucleotides, or antibodies to specific tissues can also be used. Receptor-mediated DNA delivery techniques are described in, for example, Findeis et al., Trends Biotechnol. (1993) 11:202; Chiou et al., Gene Therapeutics: Methods And Applications Of Direct Gene Transfer (J.A. Wolff, ed.) (1994); Wu et al., J. Biol. Chem. (1988) 263:621; Wu et al., J. Biol.

Chem. (1994) 269:542; Zenke et al., Proc. Natl. Acad. Sci. (USA) (1990) 87:3655; Wu et al., J. Biol. Chem. (1991) 266:338. Therapeutic compositions containing a polynucleotide are administered in a range of about 100 ng to about 200 mg of DNA for local administration in a gene therapy protocol. Concentration ranges of about 500 ng to about 50 mg, about 1 μg to about 2 mg, about 5 μg to about 500 μg, and about 20 μg to about 100 μg of DNA can also be used during a gene therapy protocol. Factors such as method of action (e.g., for enhancing or inhibiting levels of the encoded gene product) and efficacy of transformation and expression are considerations which will affect the dosage required for ultimate efficacy of the antisense subgenomic polynucleotides. Where greater expression is desired over a larger area of tissue, larger amounts of antisense subgenomic polynucleotides or the same amounts readministered in a successive protocol of administrations, or several administrations to different adjacent or close tissue portions of, for example, a tumor site, may be required to effect a positive therapeutic outcome. In all cases, routine experimentation in clinical trials will determine specific ranges for optimal therapeutic effect. For polynucleotide related genes encoding polypeptides or proteins with anti-inflammatory activity, suitable use, doses, and administration are described in USPN 5,654,173.

The therapeutic polynucleotides and polypeptides of the present invention can be delivered using gene delivery vehicles. The gene delivery vehicle can be of viral or non-viral origin (see generally, Jolly, Cancer Gene Therapy (1994) 1:51; Kimura, Human Gene Therapy (1994) 5:845; Connelly, Human Gene Therapy (1995) 1:185; and Kaplitt, Nature Genetics (1994) 6:148). Expression of such coding sequences can be induced using endogenous mammalian or heterologous promoters. Expression of the coding sequence can be either constitutive or regulated.

Viral-based vectors for delivery of a desired polynucleotide and expression in a desired cell are well known in the art. Exemplary viral-based vehicles include, but are not limited to, recombinant retroviruses (see, e.g., WO 90/07936; WO 94/03622; WO 93/25698; WO 93/25234; USPN 5, 219,740; WO 93/11230; WO 93/10218; USPN 4,777,127; GB Patent No. 2,200,651; EP 0 345 242; and WO 91/02805), alphavirus-based vectors (e.g., Sindbis virus vectors, Semliki forest virus (ATCC VR-67; ATCC VR-1247), Ross River virus (ATCC VR-373; ATCC VR-1246) and Venezuelan equine encephalitis virus (ATCC VR-923; ATCC VR-1250; ATCC VR 1249; ATCC VR-532), and adeno-associated virus (AAV) vectors (see, e.g., WO 94/12649, WO 93/03769; WO 93/19191; WO 94/28938; WO 95/11984 and WO 95/00655). Administration of DNA linked to killed adenovirus as described in Curiel, *Hum. Gene Ther.* (1992) 3:147 can also be employed.

Non-viral delivery vehicles and methods can also be employed, including, but not limited to, polycationic condensed DNA linked or unlinked to killed adenovirus alone (see, e.g., Curiel, *Hum. Gene Ther.* (1992) 3:147); ligand-linked DNA(see, e.g., Wu, *J. Biol. Chem.* (1989) 264:16985); eukaryotic cell delivery vehicles cells (see, e.g., USPN 5,814,482; WO 95/07994; WO 96/17072; WO 95/30763; and WO 97/42338) and nucleic charge neutralization or fusion with

cell membranes. Naked DNA can also be employed. Exemplary naked DNA introduction methods are described in WO 90/11092 and USPN 5,580,859. Liposomes that can act as gene delivery vehicles are described in USPN 5,422,120; WO 95/13796; WO 94/23697; WO 91/14445; and EP 0524968. Additional approaches are described in Philip, *Mol. Cell Biol.* (1994) 14:2411, and in Woffendin, *Proc. Natl. Acad. Sci.* (1994) 91:1581

Further non-viral delivery suitable for use includes mechanical delivery systems such as the approach described in Woffendin *et al.*, *Proc. Natl. Acad. Sci. USA* (1994) 91(24):11581. Moreover, the coding sequence and the product of expression of such can be delivered through deposition of photopolymerized hydrogel materials or use of ionizing radiation (see, e.g., USPN 5,206,152 and WO 92/11033). Other conventional methods for gene delivery that can be used for delivery of the coding sequence include, for example, use of hand-held gene transfer particle gun (see, e.g., USPN 5,149,655); use of ionizing radiation for activating transferred gene (see, e.g., USPN 5,206,152 and WO 92/11033).

The present invention will now be illustrated by reference to the following examples which set forth particularly advantageous embodiments. However, it should be noted that these embodiments are illustrative and are not to be construed as restricting the invention in any way.

EXAMPLES

5

10

15

20

30

35

The following examples are offered primarily for purposes of illustration. It will be readily apparent to those skilled in the art that the formulations, dosages, methods of administration, and other parameters of this invention may be further modified or substituted in various ways without departing from the spirit and scope of the invention.

Example 1: Source of Biological Materials and Overview of Novel Polynucleotides Expressed 25 by the Biological Materials

cDNA libraries were constructed from mRNA isolated from the GRRpz or and WOca cells, which were provided by Dr. Donna M. Peehl, Department of Medicine, Stanford University School of Medicine. GRRpz cells were primary cells derived from normal prostate epithelium. The WOca cells were prostate epithelial cells derived from prostate cancer Gleason Grade 4+4.

Polynucleotides expressed by these cells were isolated and analyzed; the sequences of these polynucleotides were about 275-300 nucleotides in length.

The sequences of the isolated polynucleotides were first masked to eliminate low complexity sequences using the XBLAST masking program (Claverie "Effective Large-Scale Sequence Similarity Searches," In: Computer Methods for Macromolecular Sequence Analysis, Doolittle, ed., Meth. Enzymol. 266:212-227 Academic Press, NY, NY (1996); see particularly Claverie, in "Automated DNA Sequencing and Analysis Techniques" Adams et al., eds., Chap. 36,

p. 267 Academic Press, San Diego, 1994 and Claverie *et al. Comput. Chem.* (1993) 17:191). Generally, masking does not influence the final search results, except to eliminate sequences of relative little interest due to their low complexity, and to eliminate multiple "hits" based on similarity to repetitive regions common to multiple sequences, e.g., Alu repeats. The remaining sequences were then used in a BLASTN vs. GenBank search; sequences that exhibited greater than 70% overlap, 99% identity, and a p value of less than 1 x 10⁻⁴⁰ were discarded. Sequences from this search also were discarded if the inclusive parameters were met, but the sequence was ribosomal or vector-derived.

5

10

15

20

25 -

30

35

The resulting sequences from the previous search were classified into three groups (1, 2 and 3 below) and searched in a BLASTX vs. NRP (non-redundant proteins) database search: (1) unknown (no hits in the GenBank search), (2) weak similarity (greater than 45% identity and p value of less than 1×10^{-5}), and (3) high similarity (greater than 60% overlap, greater than 80% identity, and p value less than 1×10^{-5}). Sequences having greater than 70% overlap, greater than 99% identity, and p value of less than 1×10^{-40} were discarded.

The remaining sequences were classified as unknown (no hits), weak similarity, and high similarity (parameters as above). Two searches were performed on these sequences. First, a BLAST vs. EST database search was performed and sequences with greater than 99% overlap, greater than 99% similarity and a p value of less than 1×10^{-40} were discarded. Sequences with a p value of less than 1×10^{-65} when compared to a database sequence of human origin were also excluded. Second, a BLASTN vs. Patent GeneSeq database was performed and sequences having greater than 99% identity, p value less than 1×10^{-40} , and greater than 99% overlap were discarded.

The remaining sequences were subjected to screening using other rules and redundancies in the dataset. Sequences with a p value of less than 1 x 10⁻¹¹¹ in relation to a database sequence of human origin were specifically excluded. The final result provided the 316 sequences listed as SEQ ID NOS:1-316 in the accompanying Sequence Listing and summarized in Table 1 (inserted prior to claims). Each identified polynucleotide represents sequence from at least a partial mRNA transcript. Many of the sequences include the sequence ggcacgag at the 5' end; this sequence is a sequencing artifact and not part of the sequence of the polynucleotides of the invention.

Table 1 provides: 1) the SEQ ID NO ("SEQ ID") assigned to each sequence for use in the present specification; 2) the Cluster Identification No. ("CLUSTER"); 3) the sequence name ("SEQ NAME") used as an internal identifier of the sequence; 4) the orientation of the sequence ("ORIENT"); 5) the name assigned to the clone from which the sequence was isolated ("CLONE ID"); and the name of the library from which the sequence was isolated ("LIBRARY"). CH22PRC indicates the sequence was isolated from Library 22; CH21PRN indicates the sequence was isolated from Library 21. A description of the libraries is provided in Table 3 below. Because the provided polynucleotides represent partial mRNA transcripts, two or more polynucleotides of the invention

may represent different regions of the same mRNA transcript and the same gene. Thus, if two or more SEQ ID NOS: are identified as belonging to the same clone, then either sequence can be used to obtain the full-length mRNA or gene.

Example 2: Results of Public Database Search to Identify Function of Gene Products

5

10

15

20

30

35

SEQ ID NOS:1-316 were translated in all three reading frames, and the nucleotide sequences and translated amino acid sequences used as query sequences to search for homologous sequences in either the GenBank (nucleotide sequences) or Non-Redundant Protein (amino acid sequences) databases. Query and individual sequences were aligned using the BLAST 2.0 programs, available over the world wide web at a saite sponsored by the National Center for Biotechnology Information, which is supported by the National Library of Medicine and the National Institutes of Health (see also Altschul, et al. *Nucleic Acids Res.* (1997) 25:3389-3402). The sequences were masked to various extents to prevent searching of repetitive sequences or poly-A sequences, using the XBLAST program for masking low complexity as described above in Example 1.

Table 2 (inserted before the claims) provide the alignment summaries having a p value of 1 x 10⁻² or less indicating substantial homology between the sequences of the present invention and those of the indicated public databases. Specifically, Table 2 provides the SEQ ID NO of the query sequence, the accession number of the GenBank database entry of the homologous sequence, and the p value of the alignment. Table 2 also provides the SEQ ID NO of the query sequence, the accession number of the Non-Redundant Protein database entry of the homologous sequence, and the p value of the alignment. The alignments provided in Table 2 are the best available alignment to a DNA or amino acid sequence at a time just prior to filing of the present specification. The activity of the polypeptide encoded by the SEQ ID NOS listed in Table 2 can be extrapolated to be substantially the same or substantially similar to the activity of the reported nearest neighbor or closely related sequence. The accession number of the nearest neighbor is reported, providing a publicly available reference to the activities and functions exhibited by the nearest neighbor. The public information regarding the activities and functions of each of the nearest neighbor sequences is incorporated by reference in this application. Also incorporated by reference is all publicly available information regarding the sequence, as well as the putative and actual activities and functions of the nearest neighbor sequences listed in Table 2 and their related sequences. The search program and database used for the alignment, as well as the calculation of the p value are also indicated.

Full length sequences or fragments of the polynucleotide sequences of the nearest neighbors can be used as probes and primers to identify and isolate the full length sequence of the corresponding polynucleotide. The nearest neighbors can indicate a tissue or cell type to be used to

construct a library for the full-length sequences of the corresponding polynucleotides.

Example 3: Differential Expression of Polynucleotides of the Invention: Description of Libraries and

5 Detection of Differential Expression

10

The relative expression levels of the polynucleotides of the invention was assessed in several libraries prepared from various sources, including primary cells, cell lines and patient tissue samples. Table 3 provides a summary of these libraries, including the shortened library name (used hereafter), the mRNA source used to prepared the cDNA library, the "nickname" of the library that is used in the tables below (in quotes), and the approximate number of clones in the library.

Table 3. Description of cDNA Libraries

Library	Description	Number of
(Lib#)		Clones in
		Library
1	Human Colon Cell Line Km12 L4: High Metastatic	308731
	Potential (derived from Km12C)	
2	Human Colon Cell Line Km12C: Low Metastatic Potential	284771
3	Human Breast Cancer Cell Line MDA-MB-231: High	326937
	Metastatic Potential; micro-mets in lung	
4	Human Breast Cancer Cell Line MCF7: Non Metastatic	318979
8	Human Lung Cancer Cell Line MV-522: High Metastatic	223620
	Potential	
9	Human Lung Cancer Cell Line UCP-3: Low Metastatic	312503
	Potential	
12	Human microvascular endothelial cells (HMVEC) -	41938
	UNTREATED (PCR (OligodT) cDNA library)	
13	Human microvascular endothelial cells (HMVEC) – bFGF	42100
	TREATED (PCR (OligodT) cDNA library)	
14	Human microvascular endothelial cells (HMVEC) –	42825
	VEGF TREATED (PCR (OligodT) cDNA library)	
15	Normal Colon - UC#2 Patient (MICRODISSECTED PCR	282722
	(OligodT) cDNA library)	
16	Colon Tumor - UC#2 Patient (MICRODISSECTED PCR	298831
	(OligodT) cDNA library)	
17	Liver Metastasis from Colon Tumor of UC#2 Patient	303467
	16	

Library	Description	Number of
(Lib#)		Clones in
		Library
	(MICRODISSECTED PCR (OligodT) cDNA library)	
18	Normal Colon - UC#3 Patient (MICRODISSECTED PCR	36216
	(OligodT) cDNA library)	
19	Colon Tumor - UC#3 Patient (MICRODISSECTED PCR	41388
	(OligodT) cDNA library)	
20	Liver Metastasis from Colon Tumor of UC#3 Patient	30956
	(MICRODISSECTED PCR (OligodT) cDNA library)	
21	GRRpz Cells derived from normal prostate epithelium	164801
22	WOca Cells derived from Gleason Grade 4 prostate cancer	162088
	epithelium	
23-	Normal Lung Epithelium of Patient #1006	306198
	(MICRODISSECTED PCR (OligodT) cDNA library)	
24	Primary tumor, Large Cell Carcinoma of Patient #1006	309349
	(MICRODISSECTED PCR (OligodT) cDNA library)	

The KM12L4 cell line is derived from the KM12C cell line (Morikawa, et al., Cancer Research (1988) 48:6863). The KM12C cell line, which is poorly metastatic (low metastatic) was established in culture from a Dukes' stage B₂ surgical specimen (Morikawa et al. Cancer Res. (1988) 48:6863). The KML4-A is a highly metastatic subline derived from KM12C (Yeatman et al. Nucl. Acids. Res. (1995) 23:4007; Bao-Ling et al. Proc. Annu. Meet. Am. Assoc. Cancer. Res. (1995) 21:3269). The KM12C and KM12C-derived cell lines (e.g., KM12L4, KM12L4-A, etc.) are well-recognized in the art as a model cell line for the study of colon cancer (see, e.g., Moriakawa et al., supra; Radinsky et al. Clin. Cancer Res. (1995) 1:19; Yeatman et al., (1995) supra; Yeatman et al. Clin. Exp. Metastasis (1996) 14:246). The MDA-MB-231 cell line (Brinkley et al. Cancer Res. (1980) 40:3118-3129) was originally isolated from pleural effusions (Cailleau, J. Natl. Cancer. Inst. (1974) 53:661), is of high metastatic potential, and forms poorly differentiated adenocarcinoma grade II in nude mice consistent with breast carcinoma.

5

10

.15

The MCF7 cell line was derived from a pleural effusion of a breast adenocarcinoma and is non-metastatic. The MV-522 cell line is derived from a human lung carcinoma and is of high metastatic potential. The UCP-3 cell line is a low metastatic human lung carcinoma cell line; the MV-522 is a high metastatic variant of UCP-3. These cell lines are well-recognized in the art as models for the study of human breast and lung cancer (see, *e.g.*, Chandrasekaran *et al.*, *Cancer Res.* (1979) 39:870 (MDA-MB-231 and MCF-7); Gastpar *et al.*, *J Med Chem* (1998) 41:4965 (MDA-

MB-231 and MCF-7); Ranson et al., Br J Cancer (1998) 77:1586 (MDA-MB-231 and MCF-7); Kuang et al., Nucleic Acids Res (1998) 26:1116 (MDA-MB-231 and MCF-7); Varki et al., Int J Cancer (1987) 40:46 (UCP-3); Varki et al., Tumour Biol. (1990) 11:327; (MV-522 and UCP-3); Varki et al., Anticancer Res. (1990) 10:637; (MV-522); Kelner et al., Anticancer Res (1995) 15:867 (MV-522); and Zhang et al., Anticancer Drugs (1997) 8:696 (MV522)). The samples of libraries 15-20 are derived from two different patients (UC#2, and UC#3). The bFGF-treated HMVEC were prepared by incubation with bFGF at 10ng/ml for 2 hrs; the VEGF-treated HMVEC were prepared by incubation with 20ng/ml VEGF for 2 hrs. Following incubation with the respective growth factor, the cells were washed and lysis buffer added for RNA preparation. The GRRpz and WOca cells were provided by Dr. Donna M. Peehl, Department of Medicine, Stanford University School of Medicine. GRRpz cells were derived from normal prostate epithelium. The WOca cells are Gleason Grade 4 cell line.

5

10

15

20

30

35

Each of the libraries is composed of a collection of cDNA clones that in turn are representative of the mRNAs expressed in the indicated mRNA source. In order to facilitate the analysis of the millions of sequences in each library, the sequences were assigned to clusters. The concept of "cluster of clones" is derived from a sorting/grouping of cDNA clones based on their hybridization pattern to a panel of roughly 300 7bp oligonucleotide probes (see Drmanac et al., Genomics (1996) 37(1):29). Random cDNA clones from a tissue library are hybridized at moderate stringency to 300 7bp oligonucleotides. Each oligonucleotide has some measure of specific hybridization to that specific clone. The combination of 300 of these measures of hybridization for 300 probes equals the "hybridization signature" for a specific clone. Clones with similar sequence will have similar hybridization signatures. By developing a sorting/grouping algorithm to analyze these signatures, groups of clones in a library can be identified and brought together computationally. These groups of clones are termed "clusters". Depending on the stringency of the selection in the algorithm (similar to the stringency of hybridization in a classic library cDNA screening protocol), the "purity" of each cluster can be controlled. For example, artifacts of clustering may occur in computational clustering just as artifacts can occur in "wet-lab" screening of a cDNA library with 400 bp cDNA fragments, at even the highest stringency. The stringency used in the implementation of cluster herein provides groups of clones that are in general from the same cDNA or closely related cDNAs. Closely related clones can be a result of different length clones of the same cDNA, closely related clones from highly related gene families, or splice variants of the same cDNA.

Differential expression for a selected cluster was assessed by first determining the number of cDNA clones corresponding to the selected cluster in the first library (Clones in 1st), and the determining the number of cDNA clones corresponding to the selected cluster in the second library (Clones in 2nd). Differential expression of the selected cluster in the first library relative to the

second library is expressed as a "ratio" of percent expression between the two libraries. In general, the "ratio" is calculated by: 1) calculating the percent expression of the selected cluster in the first library by dividing the number of clones corresponding to a selected cluster in the first library by the total number of clones analyzed from the first library; 2) calculating the percent expression of the selected cluster in the second library by dividing the number of clones corresponding to a selected cluster in a second library by the total number of clones analyzed from the second library; 3) dividing the calculated percent expression from the first library by the calculated percent expression from the second library. If the "number of clones" corresponding to a selected cluster in a library is zero, the value is set at 1 to aid in calculation. The formula used in calculating the ratio takes into account the "depth" of each of the libraries being compared, *i.e.*, the total number of clones analyzed in each library.

5

10

15

20

30

35

In general, a polynucleotide is said to be significantly differentially expressed between two samples when the ratio value is greater than at least about 2, preferably greater than at least about 3, more preferably greater than at least about 5, where the ratio value is calculated using the method described above. The significance of differential expression is determined using a z score test (Zar, Biostatistical Analysis, Prentice Hall, Inc., USA, "Differences between Proportions," pp 296-298 (1974).

Using this approach, a number of polynucleotide sequences were identified as being differentially expressed between, for example, cells derived from high metastatic potential cancer tissue and low metastatic cancer cells, and between cells derived from metastatic cancer tissue and normal tissue. Evaluation of the levels of expression of the genes corresponding to these sequences can be valuable in diagnosis, prognosis, and/or treatment (e.g., to facilitate rationale design of therapy, monitoring during and after therapy, etc.). Moreover, the genes corresponding to differentially expressed sequences described herein can be therapeutic targets due to their involvement in regulation (e.g., inhibition or promotion) of development of, for example, the metastatic phenotype. For example, sequences that correspond to genes that are increased in expression in high metastatic potential cells relative to normal or non-metastatic tumor cells may encode genes or regulatory sequences involved in processes such as angiogenesis, differentiation, cell replication, and metastasis.

Detection of the relative expression levels of differentially expressed polynucleotides described herein can provide valuable information to guide the clinician in the choice of therapy. For example, a patient sample exhibiting an expression level of one or more of these polynucleotides that corresponds to a gene that is increased in expression in metastatic or high metastatic potential cells may warrant more aggressive treatment for the patient. In contrast, detection of expression levels of a polynucleotide sequence that corresponds to expression levels associated with that of low metastatic potential cells may warrant a more positive prognosis than

the gross pathology would suggest.

5

10

15

25 -

30

35

The differential expression of the polynucleotides described herein can thus be used as, for example, diagnostic markers, prognostic markers, for risk assessment, patient treatment and the like. These polynucleotide sequences can also be used in combination with other known molecular and/or biochemical markers.

The differential expression data for polynucleotides of the invention that have been identified as being differentially expressed across various combinations of the libraries described above is summarized in Table 4 (inserted prior to the claims). Table 4 provides: 1) the Sequence Identification Number ("SEQ ID") assigned to the polynucleotide; 2) the cluster ("CLUST") to which the polynucleotide has been assigned as described above; 3) the library comparisons that resulted in identification of the polynucleotide as being differentially expressed ("PairAB-text"), with shorthand names of the compared libraries provided in parentheses following the library numbers; 4) the number of clones corresponding to the polynucleotide in the first library listed ("A"); 5) the number of clones corresponding to the polynucleotide in the second library listed ("B"); 6) the "RATIO PLUS" where the comparison resulted in a finding that the number of clones in library A is greater than the number of clones in library B; and 7) the "RATIO MINUS" where the comparison resulted in a finding that the number of clones in library B is greater than the number of clones in library B is greater than the number of clones in library B is greater than the

Example 4: Differential Expression of a Polynucleotides Associated with Metastatic Potential in Breast Cancer

Differential expression was examined in breast cancer cells having either high metastatic potential or low metastatic potential. A single cluster, Cluster Identification No. 10154, was identified as displaying low expression in the high metastatic potential breast cancer cells (Library 3), and significantly increased expression – approximately 100-fold higher — in the low metastatic potential cells (Library 4). Specifically, three clones were identified that were expressed in Library 3, the high metastatic potential breast cancer library, while 317 clones were expressed in Library 4, the low metastatic potential breast cancer library. The two sequences assigned to this particular cluster, SEQ ID NO:315 and SEQ ID NO:316, both displayed this differential expression, suggesting that the two sequences are likely associated with a single transcript.

SEQ ID NO:315 and SEQ ID NO:316 were then used as query sequences to search for homologous sequences in GenBank as described in Examples 1 and 2. SEQ ID NO: 315 displayed identity to the GenBank entry H72034 (SEQ ID NO:317) and SEQ ID NO:316 displayed identity to GenBank entry AA707002 (SEQ ID NO:318). SEQ ID NO:315 displays striking identity to the 3' end of SEQ ID NO:317 (See Figures 1A and 1B), while SEQ ID NO:316 displays striking identity to the 5' end of SEQ ID NO:318 (See Figure 2). Clones of H72034 and AA707002 were ordered

from the I.M.A.G.E. Consortium at the Lawrence Livermore National Laboratories (Livermore, California) for further studies.

Restriction Mapping of Clones H72034 and AA707002

The newly identified sequences were digested with a number of different restriction

5 endonucleases to construct a restriction map of each of the clones. An appropriate amount of each clone, SEQ ID NO:317 or SEQ ID NO:318, was digested with various enzymes, and the restriction fragments identified as follows:

	SEQ ID NO:31	17								
	Enzyme	7	#Cuts	Positio	ns					
	AluĬ	5	331	1029	1422	1595	1977			
	BamHI	2	1836	2089						
5	BstEII	1	936							
	BstXI	1	1033							
	HaeIII	12	145	300	453	497	582	780		
			1102	1536	1561	1722	1981	2062		
	HinfI	12	5	154	205	325	397	473	610	820
10	968			1295	1426	2066				
	KpnI	1	1938	ý.						
	MspI	6	78	739	1098	2038	2077	2093		
	NcoI	2	2013	2058			,			
	PstI	1	1501							
15	PvuII	2	331	1422	•					
	Sau3AI	6	1270	1813	1819	1836	1894	2089		
	SphI	1	1870							
	XhoI	1	1413						•	
20	•									
20	SEQ ID NO:31	8								
	Enzyme	#Cuts	Positio	ns	,					
	AluI	9	19	245	367	553	586	874	904	996
	1214									
25	BamHI	1	407							
	BglI	1	1056							
	BglII	1	475							
	BstEI	1	1108							
	HaeIII	10	153	348	485	867	518	628	780	867
30	915			1016	1312					
	HindIII '	2	243	872		•				
	Hinfl	1	1353							
	KpnI	1	132							
	MspI	2	1196	1261						
35	PstI	1	823							
-	PvuII	1	996							
	Sau3AI	7	66	407	475	504	750	850	1024	

The restriction maps based on the identified sites can be used to determine the position of each clone relative to the genomic sequences, and to confirm the 5'-3'orientation of the clones.

Amplification and Purification of Transcript

A transcript in this region upregulated in low metastatic cancers which contain sequences from SEQ ID NOS: 315-318 is identified using a technique such as polymerase chain reaction

(PCR) amplification. Based on the sequences identified and the original sequences of the cluster, primers can be designed to isolate the full length cDNA from a library constructed from the breast cancer cell line with low metastatic potential.

A cDNA template for use in the amplification reaction is generated from total RNA isolated from the high metastatic breast cell line. RNA is reverse transcribed using oligo-dT primer to generate first strand cDNA. cDNA is synthesized by denaturing 3μl of total RNA, 2 μl oligo-dT primer at 20 μM, and 5 μl DEPC water for 8 minutes at 65°C followed by reverse transcription at 52°C for 1 hour in a reaction containing the denatured RNA/primer plus 4μl 15X cDNA buffer (GibcoBRL), 1 μl 0.1 M dithiothreitol, 1 μl 40 U/1 RNAseOUT (GibcoBRL), 1 μl DEPC water, 2 μl 10 mM dNTP (GibdoBRL), and 1 μl 15 U/1 Thermoscript reverse transcriptase (GibcoBRL). The reaction was terminated by a 5-min incubation at 85°C, and the RNA was removed by 1 μl 2 U/1 RNAse H at 37°C for thirty minutes.

Based on the determined orientation of the clones, primers are designed to amplify a full-length clone corresponding to the differentially expressed transcript in this region. Forward primers that are used to amplify the full-length clone are taken from the 5' end of SEQ ID NO:17 as follows:

F1 5'- TGGGATATAGTCTCGTGGTGCG -3' (SEQ ID NO:319) F2 5'- TGATTCGATGTCATCAGTCCCG-3' (SEQ ID NO:320)

5

10

15

20

25

Primer F1 is taken from residues 51-62 of SEQ ID NO: 317, and primer F2 is taken from residues 212-233 Of SEQ ID NO:17. Both forward primers are near the 5' end of this sequence.

Reverse Primers are designed using sequences complementary to the 3' end of clone 10154-3 as follows:

R1 5'- TGTGTCACAGCCAGACATGAGC (SEQ ID NO:321) R2 5'-TGCAAACATACACAGGGACCG (SEQ ID NO:322)

Primer R1 is based on residues 573-552 of SEQ ID NO:318, and R2 is based on residues 399-379 of SEQ ID NO:318.

PCR is performed using a 5μl aliquot of the first strand cDNA synthesis reaction, and a primer pair, e.g., F1 and R1, F1 and R2, F2 and R1, or F2 and R2. An open reading frame is amplified using 2 μl of the reverse transcription product as template in a PCR reaction containing 5 μl of 10x PCR buffer (GibcoBRL), 1 μl 50 mM Mg₂SO₄, 1 μl 10 mM dNTP, 1 μl F1 or F2 primer, 1 μl R1 primer, 2.5 U High Fidelity Platinum Taq DNA polymerase (GibcoBRL), and water to 50 μl. The molecule is amplified using 30 rounds of amplification in a thermal cycler at the following temperatures: 1 minute at 95°C; 1 minute at 55°C and 2 minutes at 72°C. The 30 cycles was followed by a 10 minute extension at 72°C.

Following amplification of the sequences, the PCR products are loaded on a 1% TEA gel and subjected to gel purification. One or more bands can be isolated from the gel and the DNA was purified using a QIAquick® Gel Extraction Kit (Qiagen, Valencia, CA). The purified fragment was cloned into a bacterial vector and transformed into the bacterial strain DH5α. Following cloning of the purified fragment(s), the DNA can be isolated and sequenced to confirm that a band corresponds to a transcript from this genetic region.

The reactions are carried out with two different 5' and 3' primers to increase the likelihood that the reaction will yield an amplification product. Other primers may also be designed from the predicted 5' and/or 3' end of the sequence, as will be apparent to one skilled in the art upon reading this disclosure, and thus other primers may be designed from the general region of SEQ ID NOS:317 and 318 that may yield better results than the disclosed primers.

In order to obtain additional sequences 5' to the end of a partial cDNA, 5' rapid amplification of cDNA ends (RACE) can be performed to ensure that the entire transcript has been identified. See *PCR Protocols: A Guide to Methods and Applications*, (1990) Academic Press, Inc. Following isolation of a cDNA using the F1-R1 or F2-R1 primer pairs, additional primers can be designed to perform RACE. The primers can be designed from the sequence of 10154-1 as follows:

5'-TTTAGCAGCACTAATGACTGTGGC-3' (SEQ ID NO:323) 5'-CGCCGTGAATTACTGTGGATGG-3' (SEQ ID NO:324)

The two RACE primers are designed based residues 286-263 and 396-375 of SEQ ID NO:317, respectively.

These sequences can be used to obtain any transcript sequences 5' to the amplification products obtained using the PCR protocol described above.

35 Northern Analysis

5

10

15

20

25

Other techniques can be used for confirming differential expression of the full-length transcript. For example, a Northern Blot can be used to verify differential expression of SEQ ID

NOS:317 and 318 in a breast cancer cells with low metastatic potential compared to breast cancer cells with high metastatic potential. Northern analysis can be accomplished by methods well-known in the art. Briefly, RNA is individually isolated from breast cancer cells having high metastatic potential and breast cancer cells having low metastatic potential, *e.g.*, a product such as RNeasy Mini Kits (Qiagen, CA) or NucleoSpin® RNA II Kit (Clontech, Palo Alto, CA). The isolated RNA samples are For Northern analysis, RNA isolated from the cells was electrophoresed on a denaturing formaldehyde agarose gel and transferred onto a membrane such as a supported nitrocellulose membrane (Schleicher & Schuell).

Rapid-Hyb buffer (Amersham Life Science, Little Chalfont, England) with 5 mg/ml denatured single stranded sperm DNA is pre-warmed to 65°C and the RNA blots are pre-hybridized in the buffer with shaking at 65°C for 30 minutes. Gene-specific DNA probes (50 ng per reaction) labeled with [α-32P]dCTP (3000Ci/mmol, Amersham Pharmacia Biotech Inc., Piscataway, NJ) (Prime-It RmT Kit, Stratagene, La Jolla, CA) and purified with ProbeQuantTM G-50 Micro Columns (Amersham Pharmacia Biotech Inc.) are added and hybridized to the blots with shaking at 65°C for overnight. The blots are washed in 2x SSC, 0.1%(w/v) SDS at room temperature for 20 minutes, twice in 1x SSC, 0.1%(w/v) SDS at 65°C for 15 minutes, then exposed to Hyperfilms (Amersham Life Science).

Example 6: Identification of Differentially Expressed Genes by Array Analysis with Patient Tissue Samples

Differentially expressed genes corresponding to the polynucleotides described herein were also identified by microarray hybridization analysis using materials obtained from patient tissue samples. The biological materials used in these experiments are described below.

Source of patient tissue samples

5

10

15

20

25

30

35

Normal and cancerous tissues were collected from patients using laser capture microdissection (LCM) techniques, which techniques are well known in the art (see, e.g., Ohyama et al. (2000) Biotechniques 29:530-6; Curran et al. (2000) Mol. Pathol. 53:64-8; Suarez-Quian et al. (1999) Biotechniques 26:328-35; Simone et al. (1998) Trends Genet 14:272-6; Conia et al. (1997) J. Clin. Lab. Anal. 11:28-38; Emmert-Buck et al. (1996) Science 274:998-1001). Table 8 (inserted following the last page of the Examples) provides information about each patient from which the samples were isolated, including: the Patient ID and Path ReportID, numbers assigned to the patient and the pathology reports for identification purposes; the anatomical location of the tumor (AnatomicalLoc); The Primary Tumor Size; the Primary Tumor Grade; the Histopathologic Grade; a description of local sites to which the tumor had invaded (Local Invasion); the presence of lymph node metastases (Lymph Node Metastasis); incidence of lymph node metastases (provided as number of lymph nodes positive for metastasis over the number of lymph nodes examined)

(Incidence Lymphnode Metastasis); the Regional Lymphnode Grade; the identification or detection of metastases to sites distant to the tumor and their location (Distant Met & Loc);a description of the distant metastases (Description Distant Met); the grade of distant metastasis (Distant Met Grade); and general comments about the patient or the tumor (Comments). Adenoma was not described in any of the patients.; adenoma dysplasia (described as hyperplasia by the pathologist) was described in Patient ID No. 695. Extranodal extensions were described in two patients, Patient ID Nos. 784 and 791. Lymphovascular invasion was described in seven patients, Patient ID Nos. 128, 278, 517, 534, 784, 786, and 791.. Crohn's-like infiltrates were described in seven patients, Patient ID Nos. 52, 264, 268, 392, 393, 784, and 791.

Source of polynucleotides on arrays

Polynucleotides on arrays

5

10

15

20

25 -

30

35

Polynucleotides spotted on the arrays were generated by PCR amplification of clones derived from cDNA libraries. The clones used for amplification were either the clones from which the sequences described herein (SEQ ID NOS:1-316) were derived, or are clones having inserts with significant polynucleotide sequence overlap with the sequences described herein (SEQ ID NO:1-316) as determined by BLAST2 homology searching.

Microarray Design

Each array used in the examples below had an identical spatial layout and control spot set. Each microarray was divided into two areas, each area having an array with, on each half, twelve groupings of 32 x 12 spots for a total of about 9,216 spots on each array. The two areas are spotted identically which provide for at least two duplicates of each clone per array. Spotting was accomplished using PCR amplified products from 0.5kb to 2.0 kb and spotted using a Molecular Dynamics Gen III spotter according to the manufacturer's recommendations. The first row of each of the 24 regions on the array had about 32 control spots, including 4 negative control spots and 8 test polynucleotides.

The test polynucleotides were spiked into each sample before the labeling reaction with a range of concentrations from 2-600 pg/slide and ratios of 1:1. For each array design, two slides were hybridized with the test samples reverse-labeled in the labeling reaction. This provided for about 4 duplicate measurements for each clone, two of one color and two of the other, for each sample.

Microarray analysis

cDNA probes were prepared from total RNA isolated from the patient cells described in above (Table 8). Since LCM provides for the isolation of specific cell types to provide a substantially homogenous cell sample, this provided for a similarly pure RNA sample.

Total RNA was first reverse transcribed into cDNA using a primer containing a T7 RNA polymerase promoter, followed by second strand DNA synthesis. cDNA was then transcribed *in*

vitro to produce antisense RNA using the T7 promoter-mediated expression (see, e.g., Luo et al. (1999) Nature Med 5:117-122), and the antisense RNA was then converted into cDNA. The second set of cDNAs were again transcribed in vitro, using the T7 promoter, to provide antisense RNA. Optionally, the RNA was again converted into cDNA, allowing for up to a third round of T7-mediated amplification to produce more antisense RNA. Thus the procedure provided for two or three rounds of in vitro transcription to produce the final RNA used for fluorescent labeling. Fluorescent probes were generated by first adding control RNA to the antisense RNA mix, and producing fluorescently labeled cDNA from the RNA starting material. Fluorescently labeled cDNAs prepared from the tumor RNA sample were compared to fluorescently labeled cDNAs prepared from normal cell RNA sample. For example, the cDNA probes from the normal cells were labeled with Cy3 fluorescent dye (green) and the cDNA probes prepared from the tumor cells were labeled with Cy5 fluorescent dye (red).

5

10

15

20

30

35

The differential expression assay was performed by mixing equal amounts of probes from tumor cells and normal cells of the same patient. The arrays were prehybridized by incubation for about 2 hrs at 60°C in 5X SSC/0.2% SDS/1 mM EDTA, and then washed three times in water and twice in isopropanol. Following prehybridization of the array, the probe mixture was then hybridized to the array under conditions of high stringency (overnight at 42°C in 50% formamide, 5X SSC, and 0.2% SDS. After hybridization, the array was washed at 55°C three times as follows: 1) first wash in 1X SSC/0.2% SDS; 2) second wash in 0.1X SSC/0.2% SDS; and 3) third wash in 0.1X SSC.

The arrays were then scanned for green and red fluorescence using a Molecular Dynamics Generation III dual color laser-scanner/detector. The images were processed using BioDiscovery Autogene software, and the data from each scan set normalized to provide for a ratio of expression relative to normal. Data from the microarray experiments was analyzed according to the algorithms described in U.S. application serial no. 60/252,358, filed November 20, 2000, by E.J. Moler, M.A. Boyle, and F.M. Randazzo, and entitled "Precision and accuracy in cDNA microarray data," which application is specifically incorporated herein by reference.

The experiment was repeated, this time labeling the two probes with the opposite color in order to perform the assay in both "color directions." Each experiment was sometimes repeated with two more slides (one in each color direction). The level fluorescence for each sequence on the array expressed as a ratio of the geometric mean of 8 replicate spots/genes from the four arrays or 4 replicate spots/gene from 2 arrays or some other permutation. The data were normalized using the spiked positive controls present in each duplicated area, and the precision of this normalization was included in the final determination of the significance of each differential. The fluorescent intensity of each spot was also compared to the negative controls in each duplicated area to determine which spots have detected significant expression levels in each sample.

A statistical analysis of the fluorescent intensities was applied to each set of duplicate spots to assess the precision and significance of each differential measurement, resulting in a p-value testing the null hypothesis that there is no differential in the expression level between the tumor and normal samples of each patient. For initial analysis of the microarrays, the hypothesis was accepted if p>10⁻³, and the differential ratio was set to 1.000 for those spots. All other spots have a significant difference in expression between the tumor and normal sample. If the tumor sample has detectable expression and the normal does not, the ratio is truncated at 1000 since the value for expression in the normal sample would be zero, and the ratio would not be a mathematically useful value (e.g., infinity). If the normal sample has detectable expression and the tumor does not, the ratio is truncated to 0.001, since the value for expression in the tumor sample would be zero and the ratio would not be a mathematically useful value. These latter two situations are referred to herein as "on/off." Database tables were populated using a 95% confidence level (p>0.05).

5

10

15

20

25 -

30

35

Table 9 below summarize the results of the differential expression analysis. Each table provides: the SEQ ID NO of the polynucleotide corresponding to the polynucleotide on the spot on the array; the Spot ID (an identifier assigned to the spot so as to distinguish it from spots on the same and different arrays), the number of patients for whom there was information obtained from the array (Num Ratios), and the percentage of patients in which expression was detected at greater than or equal to a two-fold increase (>=2x), greater than or equal to a five-fold increase (>=5x), or less than or equal to a 1/2 -fold decrease (<=halfx) relative to matched normal control tissue.

In general, a polynucleotide is said to represent a significantly differentially expressed gene between two samples when there is detectable levels of expression in at least one sample and the ratio value is greater than at least about 1.2 fold, preferably greater than at least about 1.5 fold, more preferably greater than at least about 2 fold, where the ratio value is calculated using the method described above.

A differential expression ratio of 1 indicates that the expression level of the gene in the tumor cell was not statistically different from expression of that gene in normal colon cells of the same patient. A differential expression ratio significantly greater than 1 in cancerous colon cells relative to normal colon cells indicates that the gene is increased in expression in cancerous cells relative to normal cells, indicating that the gene plays a role in the development of the cancerous phenotype, and may be involved in promoting metastasis of the cell. Detection of gene products from such genes can provide an indicator that the cell is cancerous, and may provide a therapeutic and/or diagnostic target.

Likewise, a differential expression ratio significantly less than 1 in cancerous colon cells relative to normal colon cells indicates that, for example, the gene is involved in suppression of the cancerous phenotype. Increasing activity of the gene product encoded by such a gene, or replacing such activity, can provide the basis for chemotherapy. Such gene can also serve as markers of

cancerous cells, e.g., the absence or decreased presence of the gene product in a colon cell relative to a normal colon cell indicates that the cell may be cancerous.

Table 9.

		Num			
SEQ ID NO:	SpotID	Ratios	>=2x	>=5x	<=halfx
8	579	33	87.88	39.39	3.03
12	22300	33	33.33	18.18	6.06
26	21886	33	33.33	0.00	3.03
64	9487	33	33.33	12.12	3.03
248	28179	28	32.14	0.00	0.00
253	28179	28	32.14	0.00	0.00
272	28179	28	32.14	0.00	0.00
292	9111	33	33.33	18.18	3.03
295	19980	33	33.33	6.06	0.00
309	23993	33	42.42	3.03	3.03

<u>Deposit Information</u>. The following materials were deposited with the American Type Culture Collection (CMCC = Chiron Master Culture Collection).

 Table 5. Cell Lines Deposited with ATCC

Cell Line	Deposit Date	ATCC Accession No.	CMCC Accession No.
KM12L4-A	March 19, 1998	CRL-12496	11606
Km12C	May 15, 1998	CRL-12533	11611
MDA-MB-231	May 15, 1998	CRL-12532	10583
MCF-7	October 9, 1998	CRL-12584	10377

In addition, pools of selected clones, as well as libraries containing specific clones, were assigned an "ES" number (internal reference) and deposited with the ATCC. Table 6 below provides the ATCC Accession Nos. of the ES deposits, all of which were deposited on or before May 13, 1999. The names of the clones contained within each of these deposits are provided in the Table 7 (inserted before the claims).

15 Table 6: Pools of Clones and Libraries Deposited with ATCC on or before March 28, 2000

Cell Line	CMCC	ATCC
ES75	5140	PTA-1102
ES76	5141	PTA-1103
ES77	5142	PTA-1104
ES78	5143	PTA-1105
ES79	5144	PTA-1106
ES80	5145	PTA-1107
ES81	5146	PTA-1108
ES82	5147	PTA-1109
ES83	5148	PTA-1110
ES84	5149	PTA-1111

5

10

The deposits described herein are provided merely as convenience to those of skill in the art, and is not an admission that a deposit is required under 35 U.S.C. §112. The sequence of the polynucleotides contained within the deposited material, as well as the amino acid sequence of the polypeptides encoded thereby, are incorporated herein by reference and are controlling in the event of any conflict with the written description of sequences herein. A license may be required to make, use, or sell the deposited material, and no such license is granted hereby.

5

10

15

20

25 -

30

35

Retrieval of Individual Clones from Deposit of Pooled Clones. Where the ATCC deposit is composed of a pool of cDNA clones or a library of cDNA clones, the deposit was prepared by first transfecting each of the clones into separate bacterial cells. The clones in the pool or library were then deposited as a pool of equal mixtures in the composite deposit. Particular clones can be obtained from the composite deposit using methods well known in the art. For example, a bacterial cell containing a particular clone can be identified by isolating single colonies, and identifying colonies containing the specific clone through standard colony hybridization techniques, using an oligonucleotide probe or probes designed to specifically hybridize to a sequence of the clone insert (e.g., a probe based upon unmasked sequence of the encoded polynucleotide having the indicated SEQ ID NO). The probe should be designed to have a T_m of approximately 80°C (assuming 2°C for each A or T and 4°C for each G or C). Positive colonies can then be picked, grown in culture. and the recombinant clone isolated. Alternatively, probes designed in this manner can be used to PCR to isolate a nucleic acid molecule from the pooled clones according to methods well known in the art, e.g., by purifying the cDNA from the deposited culture pool, and using the probes in PCR reactions to produce an amplified product having the corresponding desired polynucleotide sequence.

Those skilled in the art will recognize, or be able to ascertain, using not more than routine experimentation, many equivalents to the specific embodiments of the invention described herein. Such specific embodiments and equivalents are intended to be encompassed by the following claims.

All publications and patent applications cited in this specification are herein incorporated by reference as if each individual publication or patent application were specifically and individually indicated to be incorporated by reference. The citation of any publication is for its disclosure prior to the filing date and should not be construed as an admission that the present invention is not entitled to antedate such publication by virtue of prior invention.

Although the foregoing invention has been described in some detail by way of illustration and example for purposes of clarity of understanding, it is readily apparent to those of ordinary skill in the art in light of the teachings of this invention that certain changes and modifications may be made thereto without departing from the spirit or scope of the appended claims.

Table 1

SEQ	CLUSTER	SEQ NAME	ORIENT	CLONE ID	LIBRARY
ID					
1	819545	RTA22200265F.k.06.1.P.Seq	F	M00064554D:A03	CH22PRC
2	377944	RTA22200251F.j.02.1.P.Seq	F	M00063482A:A08	CH21PRN
3	818497	RTA22200252F.a.13.1.P.Seq	F	M00063514C:D03	CH21PRN
4	819498	RTA22200252F.n.05.1.P.Seq	F	M00063638C:G12	CH21PRN
5	455465	RTA22200264F.e.16.1.P.Seq	F	M00064454A:H10	CH22PRC
6	819069	RTA22200255F.f.01.1.P.Seq	F	M00063940D:F09	CH21PRN
7	672003	RTA22200265F.b.09.1.P.Seq	F	M00064517C:F11	CH22PRC
8	728115	RTA22200253F.o.24.1.P.Seq	F	M00063838B:G08	CH21PRN
9	372700	RTA22200260F.b.20.1.P.Seq	F	M00063580C:A06	CH22PRC
10	818056	RTA22200266F.c.13.1.P.Seq	F	M00064593D:C01	CH22PRC
11	818497	RTA22200255F.a.17.1.P.Seq	F	M00063920D:H02	CH21PRN
. 12	729832	RTA22200267F.1.21.1.P.Seq	F	M00064714A:G03	CH22PRC
13	505514	RTA22200251F.b.21.1.P.Seq	F	M00063158A:A01	CH21PRN
14	376488	RTA22200254F.c.05.1.P.Seq	F	M00063852B:D08	CH21PRN
15	376488	RTA22200260F.b.09.1.P.Seq	F	M00063578C:A06	CH22PRC
16	748572	RTA22200254F.c.07.1.P.Seq	F	M00063852D:F07	CH21PRN
17	549934	RTA22200253F.k.18.1.P.Seq	F	M00063801B:D04	CH21PRN
18	819069	RTA22200255F.e.24.1.P.Seq	F	M00063940D:F09	CH21PRN
19	817618	RTA22200253F.n.16.1.P.Seq	F	M00063828D:E05	CH21PRN
20	124396	RTA22200263F.a.11.2.P.Seq	F	M00064375B:G07	CH22PRC
21	404375	RTA22200260F.m.08.1.P.Seq	F	M00063967D:G02	CH22PRC
22	391820	RTA22200261F.f.02.1.P.Seq	F	M00064000B:C03	CH22PRC
23	672003	RTA22200267F.i.06.1.P.Seq	F	M00064693D:F08	CH22PRC
24	830620	RTA22200263F.n.09.1.P.Seq	F	M00064424B:C12	CH22PRC
25	450399	RTA22200251F.f.23.1.P.Seq	F	M00063467D:H07	CH21PRN
26	450982	RTA22200261F.n.18.1.P.Seq	F	M00064307B:G02	CH22PRC
27	819894	RTA22200264F.h.18.1.P.Seq	F	M00064467B:D06	CH22PRC
28	379302	RTA22200257F.j.02.3.P.Seq	F	M00064178C:C04	CH21PRN
29	379746	RTA22200256F.e.16.1.P.Seq	F	M00064086C:E01	CH21PRN
30	124863	RTA22200265F.m.06.1.P.Seq	F	M00064564A:C02	CH22PRC
31	379154	RTA22200257F.c.11.1.P.Seq	F	M00064151B:C07	CH21PRN
32	830620	RTA22200262F.1.23.1.P.Seq	F	M00064358C:D09	CH22PRC
33	389409	RTA22200266F.1.24.1.P.Seq	F	M00064631A:C07	CH22PRC
34	397284	RTA22200262F.i.22.1.P.Seq	F	M00064346C:B09	CH22PRC
35	819440	RTA22200264F.e.19.1.P.Seq	F	M00064454C:B06	CH22PRC
36	389409	RTA22200266F.m.01.1.P.Seq	F	M00064631A:C07	CH22PRC
37	518848	RTA22200265F.n.15.1.P.Seq	F	M00064571C:C04	CH22PRC
38	830620	RTA22200263F.a.21.1.P.Seq	F	M00064376A:A05	CH22PRC
39	379154	RTA22200256F.f.20.1.P.Seq	F	M00064090D:D09	CH21PRN
40	818544	RTA22200256F.h.04.1.P.Seq	F	M00064105B:A03	CH21PRN
41	817375	RTA22200251F.a.15.1.P.Seq	F	M00063152C:B07	CH21PRN

Table 1

1 able	T			•	
SEQ ID	CLUSTER	SEQ NAME	ORIENT	CLONE ID	LIBRARY
42	455264	RTA22200259F.e.23.1.P.Seq	F	M00063539C:C11	CH22PRC
43	817503	RTA22200266F.k.11.1.P.Seq	F	M00064624D:C09	CH22PRC
44	377696	RTA22200256F.d.21.1.P.Seq	F	M00064082D:D10	CH21PRN
45	375596	RTA22200261F.h.10.1.P.Seq	F	M00064009A:C01	CH22PRC
46	817689	RTA22200263F.h.05.1.P.Seq	F	M00064399A:E01	CH22PRC
47	831867	RTA22200262F.i.15.2.P.Seq	F	M00064345A:A03	CH22PRC
48	830085	RTA22200261F.k.14.1.P.Seq	F	M00064293D:B12	CH22PRC
49	389627	RTA22200264F.c.10.1.P.Seq	F	M00064447B:C06	CH22PRC
50	397284	RTA22200259F.k.09.1.P.Seq	F	M00063555B:D01	CH22PRC
51	380063	RTA22200261F.j.02.1.P.Seq	F	M00064014D:H05	CH22PRC
52	830931	RTA22200266F.m.23.1.P.Seq	F	M00064633C:A03	CH22PRC
53	819321	RTA22200257F.1.03.3.P.Seq	F	M00064194C:D02	CH21PRN
54	475587	RTA22200261F.c.01.1.P.Seq	F	M00063990A:D05	CH22PRC
55	819046	RTA22200255F.a.18.1.P.Seq	F	M00063920D:H05	CH21PRN
56	817477	RTA22200253F.g.21.1.P.Seq	F	M00063784A:H12	CH21PRN
57	475587	RTA22200261F.b.24.1.P.Seq	F	M00063990A:D05	CH22PRC
58	728115	RTA22200253F.p.01.1.P.Seq	F	M00063838B:G08	CH21PRN
59	389627	RTA22200260F.i.24.1.P.Seq	F	M00063957A:E02	CH22PRC
60	403453	RTA22200256F.i.24.1.P.Seq	F	M00064113B:C04	CH21PRN
61	508525	RTA22200255F.d.10.1.P.Seq	F	M00063931B:F07	CH21PRN
62	819525	RTA22200261F.n.20.1.P.Seq	F	M00064307C:G03	CH22PRC
63	817618	RTA22200255F.i.03.1.P.Seq	F	M00064025D:H12	CH21PRN
64	819403	RTA22200254F.h.14.1.P.Seq	F	M00063888D:D05	CH21PRN
65	553242	RTA22200254F.g.20.1.P.Seq	F	M00063886A:B06	CH21PRN
66	817417	RTA22200255F.a.10.1.P.Seq	F	M00063919C:E07	CH21PRN
67	817618	RTA22200252F.f.13.1.P.Seq	F	M00063604A:B11	CH21PRN
68	611440	RTA22200262F.e.04.2.P.Seq	F	M00064328B:H09	CH22PRC
69	817375	RTA22200260F.m.06.1.P.Seq	F	M00063967C:A12	CH22PRC
70	213577	RTA22200255F.i.23.1.P.Seq	F	M00064033C:C11	CH21PRN
71	820061	RTA22200265F.p.10.1.P.Seq	F	M00064579D:E11	CH22PRC
72	455264	RTA22200259F.m.06.1.P.Seq	F	M00063559D:G03	CH22PRC
73	455264	RTA22200255F.o.23.1.P.Seq	F	M00064059A:C11	CH21PRN
74	380331	RTA22200255F.b.19.1.P.Seq	F	M00063926A:H04	CH21PRN
75	380331	RTA22200252F.b.19.1.P.Seq	F	M00063518D:A01	CH21PRN
76	817455	RTA22200267F.o.01.1.P.Seq	F	M00064723D:H03	CH22PRC
77	423967	RTA22200252F.a.20.1.P.Seq	F	M00063515B:H02	CH21PRN
78	220584	RTA22200261F.m.14.1.P.Seq	F	M00064302A:D10	CH22PRC
79	817688	RTA22200251F.e.20.1.P.Seq	F	M00063462D:D07	CH21PRN
80	549934	RTA22200253F.n.10.1.P.Seq	F	M00063826A:D03	CH21PRN
81	819149	RTA22200255F.e.16.1.P.Seq	F	M00063938B:H07	CH21PRN
82	817455	RTA22200267F.n.24.1.P.Seq	F	M00064723D:H03	CH22PRC

Table 1

SEQ	CLUSTER	SEQ NAME	ORIENT	CLONE ID	LIBRARY
ID					
83	377696	RTA22200251F.j.03.1.P.Seq	F	M00063482A:F07	CH21PRN
84	830146	RTA22200260F.b.07.1.P.Seq	F	M00063578B:E02	CH22PRC
85	194490	RTA22200264F.1.07.1.P.Seq	F	M00064481C:F03	CH22PRC
86	819460	RTA22200257F.m.15.3.P.Seq	F	M00064200D:E08	CH21PRN
87	819018	RTA22200257F.p.01.3.P.Seq	F	M00064212D:E04	CH21PRN
88	830620	RTA22200259F.p.24.1.P.Seq	F	M00063571B:G03	CH22PRC
89	141079	RTA22200262F.k.19.1.P.Seq	F	M00064354A:A10	CH22PRC
90	376588	RTA22200256F.e.04.1.P.Seq	F	M00064083D:E05	CH21PRN
91	380604	RTA22200264F.g.05.1.P.Seq	F	M00064460C:B01	CH22PRC
92	413138	RTA22200260F.b.05.1.P.Seq	F	M00063577C:C02	CH22PRC
93	818544	RTA22200265F.e.12.1.P.Seq	F	M00064527A:H07	CH22PRC
94	647435	RTA22200257F.h.08.1.P.Seq	F	M00064172C:A02	CH21PRN
95	551785	RTA22200266F.c.09.1.P.Seq	F	M00064593A:A05	CH22PRC
96	17092	RTA22200261F.f.17.1.P.Seq	F	M00064002C:F06	CH22PRC
97	818326	RTA22200251F.i.06.1.P.Seq	F	M00063478C:D01	CH21PRN
98	377944	RTA22200262F.e.03.2.P.Seq	F	M00064328B:H04	CH22PRC
99	745559	RTA22200262F.m.04.1.P.Seq	F	M00064359B:H12	CH22PRC
100	818326	RTA22200265F.d.08.1.P.Seq	F	M00064524A:A09	CH22PRC
101	379879	RTA22200264F.b.23.1.P.Seq	F	M00064446A:D11	CH22PRC
102	819640	RTA22200257F.f.24.1.P.Seq	F	M00064165A:B12	CH21PRN
103	818326	RTA22200265F.a.14.1.P.Seq	F	M00064514D:F11	CH22PRC
104	243524	RTA22200265F.g.04.1.P.Seq	F	M00064532D:G06	CH22PRC
105	43995	RTA22200261F.1.02.1.P.Seq	F	M00064294D:F01	CH22PRC
106	597854	RTA22200262F.g.06.2.P.Seq	F	M00064337D:F01	CH22PRC
107	268290	RTA22200260F.p.14.1.P.Seq	F	M00063981D:A06	CH22PRC
108	818043	RTA22200256F.p.10.2.P.Seq	F	M00064138A:F11	CH21PRN
109	830930	RTA22200267F.b.03.1.P.Seq	F	M00064652B:D09	CH22PRC
110	389627	RTA22200260F.j.01.1.P.Seq	F	M00063957A:E02	CH22PRC
111	378730	RTA22200260F.i.07.1.P.Seq	F	M00063955C:F07	CH22PRC
112	819037	RTA22200260F.n.09.1.P.Seq	F	M00063972C:E10	CH22PRC
113	830397	RTA22200261F.g.14.1.P.Seq	F	M00064005D:A08	CH22PRC
114	450247	RTA22200261F.e.10.1.P.Seq	F	M00063998C:E09	CH22PRC
115	819273	RTA22200252F.b.09.1.P.Seq	F	M00063517A:A04	CH21PRN
116	587779	RTA22200257F.i.11.3.P.Seq	F	M00064175B:B09	CH21PRN
117	818639	RTA22200256F.j.09.1.P.Seq	F	M00064115B:E12	CH21PRN
118	615617	RTA22200261F.o.13.1.P.Seq	F	M00064309C:H09	CH22PRC
119	79309	RTA22200257F.j.13.3.P.Seq	F	M00064180A:G03	CH21PRN
120	748994	RTA22200261F.o.20.1.P.Seq	F	M00064310C:A10	CH22PRC
121	818682	RTA22200258F.h.07.1.P.Seq	F	M00064271B:D03	CH21PRN
122	373061	RTA22200253F.j.09.1.P.Seq	F	M00063795C:D09	CH21PRN
123	484413	RTA22200253F.g.09.1.P.Seq	F	M00063781B:B10	CH21PRN

Table 1

SEQ ID	CLUSTER	SEQ NAME	ORIENT	CLONE ID	LIBRARY
124	819273	RTA22200258F.h.04.1.P.Seq	F	M00064270B:B03	CH21PRN
125	569532	RTA22200252F.h.18.1.P.Seq	F	M00063613D:C11	CH21PRN
126	170313	RTA22200255F.g.20.1.P.Seq	F	M00063949D:A05	CH21PRN
127	818682	RTA22200253F.p.14.1.P.Seq	F	M00063841A:B09	CH21PRN
128	377188	RTA22200255F.l.06.1.P.Seq	F	M00064043D:C09	CH21PRN
129	518848	RTA22200257F.j.22.3.P.Seq	F	M00064186C:B03	CH21PRN
130	45592	RTA22200259F.1.08.1.P.Seq	F	M00063557D:C07	CH22PRC
131	819273	RTA22200255F.n.19.1.P.Seq	F	M00064053C:G04	CH21PRN
132	397284	RTA22200251F.a.06.1.P.Seq	F	M00063151D:B10	CH21PRN
133	818326	RTA22200258F.e.14.1.P.Seq	F	M00064260C:E05	CH21PRN
134	819037	RTA22200251F.c.15.1.P.Seq	F	M00063452A:F08	CH21PRN
135	817417	RTA22200253F.m.14.1.P.Seq	F	M00063818C:A09	CH21PRN
136	819640	RTA22200254F.i.11.1.P.Seq	F	M00063891A:F11	CH21PRN
137	818771	RTA22200254F.i.19.1.P.Seq	F	M00063892B:G02	CH21PRN
138	389627	RTA22200254F.k.10.1.P.Seq	F	M00063898A:A10	CH21PRN
139	379067	RTA22200260F.e.20.1.P.Seq	F	M00063593A:D03	CH22PRC
140	818544	RTA22200251F.f.02.1.P.Seq	F	M00063463D:B05	CH21PRN
141	819440	RTA22200251F.j.22.1.P.Seq	F	M00063485A:E05	CH21PRN
142	817417	RTA22200251F.k.10.1.P.Seq	F	M00063487C:C02	CH21PRN
143	385307	RTA22200262F.k.11.1.P.Seq	F	M00064352C:H01	CH22PRC
144	611440	RTA22200263F.d.24.2.P.Seq	F	M00064386B:C02	CH22PRC
145	376056	RTA22200259F.e.16.1.P.Seq	F	M00063538D:B01	CH22PRC
146	611440	RTA22200263F.d.24.1.P.Seq	F	M00064386B:C02	CH22PRC
147	820061	RTA22200264F.f.09.1.P.Seq	F	M00064457D:C09	CH22PRC
148	617825	RTA22200264F.p.06.1.P.Seq	F	M00064508A:B09	CH22PRC
149	819440	RTA22200257F.h.17.1.P.Seq	F	M00064173B:E01	CH21PRN
150	819145	RTA22200266F.m.08.1.P.Seq	F	M00064631C:H11	CH22PRC
151	817653	RTA22200265F.p.07.1.P.Seq	F	M00064579A:C06	CH22PRC
152	611440	RTA22200263F.e.01.1.P.Seq	F	M00064386B:C02	CH22PRC
153	375958	RTA22200264F.j.22.1.P.Seq	F	M00064476D:C04	CH22PRC
154	611440	RTA22200257F.a.20.1.P.Seq	F	M00064144D:A07	CH21PRN
155	831049	RTA22200266F.o.13.1.P.Seq	F	M00064637B:F03	CH22PRC
156	818162	RTA22200266F.g.18.1.P.Seq	F	M00064610D:H01	CH22PRC
157	553200	RTA22200263F.p.02.1.P.Seq	F	M00064429D:B07	CH22PRC
158	139677	RTA22200254F.o.07.1.P.Seq	F	M00063910D:A12	CH21PRN
159	139677	RTA22200252F.c.11.1.P.Seq	F	M00063520D:E11	CH21PRN
160	397284	RTA22200262F.i.22.2.P.Seq	F	M00064346C:B09	CH22PRC
161	385810	RTA22200256F.m.04.2.P.Seq	F	M00064126C:F12	CH21PRN
162	404624	RTA22200261F.e.07.1.P.Seq	F	M00063997C:B12	CH22PRC
163	375958	RTA22200262F.b.14.2.P.Seq	F	M00064322C:A10	CH22PRC
164	616555	RTA22200265F.b.24.1.P.Seq	F	M00064520A:E04	CH22PRC

Table 1

ID	SEQ	CLUSTER	SEQ NAME	ORIENT	CLONE ID	LIBRARY
The color of the	ID					
167 36113 RTA22200265F.e.06.1.P.Seq F M00064526D:F05 CH22PRC 168 831812 RTA22200253F.d.51.P.Seq F M00064390A:C05 CH22PRC 169 817653 RTA22200252F.g.23.1.P.Seq F M00063610D:C11 CH21PRN 170 397284 RTA22200252F.m.15.1.P.Seq F M00063610D:C11 CH21PRN 171 817979 RTA22200253F.m.15.1.P.Seq F M00063636A:E01 CH21PRN 171 817979 RTA22200255F.m.15.1.P.Seq F M00063841A:E08 CH21PRN 172 817653 RTA22200253F.f0.3.1.P.Seq F M0006374A:D09 CH21PRN 173 611440 RTA22200253F.f0.3.1.P.Seq F M000647048C:G12 CH21PRN 174 386014 RTA22200253F.f0.3.1.P.Seq F M00064701A:B03 CH22PRC 175 549981 RTA22200255F.b.10.1.P.Seq F M00064901A:B03 CH22PRC 175 549981 RTA22200255F.j.21.1.P.Seq F M00063925B:F04 CH21PRN 176 193373 RTA22200255F.g.14.1.P.Seq F M00063947D:D01 CH21PRN 178 831149 RTA22200255F.g.14.1.P.Seq F M00063947D:D01 CH21PRN 178 831149 RTA22200255F.d.16.1.P.Seq F M00063932D:G08 CH21PRN 178 831149 RTA22200255F.d.16.1.P.Seq F M00063932D:G08 CH21PRN 183 RTA22200255F.d.16.1.P.Seq F M00063932D:G08 CH21PRN 183 RTA22200255F.d.16.1.P.Seq F M0006395D:F05 CH22PRC 182 141079 RTA22200253F.n.16.1.P.Seq F M0006395D:F05 CH22PRC 182 141079 RTA22200253F.n.14.1.P.Seq F M00063893A:F01 CH21PRN 183 818063 RTA22200253F.n.14.1.P.Seq F M00063893A:F01 CH21PRN 184 455264 RTA22200253F.n.14.1.P.Seq F M00063893A:F01 CH21PRN 184 455264 RTA22200253F.n.16.1.P.Seq F M00063893A:F01 CH21PRN 185 189234 RTA22200253F.n.16.1.P.Seq F M00063894B:H07 CH22PRC 187 648679 RTA22200253F.n.16.1.P.Seq F M0006394B:H07 CH22PRC 188 839930 RTA22200266F.d.07.1.P.Seq F M0006450A:A07 CH22PRC 189 818497 RTA22200256F.d.07.1.P.Seq F M0006490B:H06 CH22PRC 199 403453 RTA22200256F.d.07.1.P.Seq F M0006490B:H06 CH22PRC 199 373318 RTA22200256F.d.07.1.P.Seq F M0006393B:H07 CH22PRC	165	616555	RTA22200265F.c.01.1.P.Seq	F	M00064520A:E04	CH22PRC
168 831812 RTA22200263F.6.05.1.P.Seq F M00064390A:C05 CH22PRC 169 817653 RTA22200252F.g.23.1.P.Seq F M00063610D:C11 CH21PRN 170 397284 RTA22200253F.m.15.1.P.Seq F M00063636A6:E01 CH21PRN 171 817979 RTA22200253F.p.15.1.P.Seq F M00063841A:E08 CH21PRN 172 817653 RTA22200253F.p.15.1.P.Seq F M00063841A:E08 CH21PRN 173 611440 RTA22200253F.f.03.1.P.Seq F M00064048C:G12 CH21PRN 173 611440 RTA22200253F.f.03.1.P.Seq F M000640401A:B03 CH22PRC 175 549981 RTA22200255F.b.10.1.P.Seq F M00064046A:G02 CH21PRN 176 193373 RTA22200255F.b.10.1.P.Seq F M00064046A:G02 CH21PRN 177 400619 RTA22200255F.g.14.1.P.Seq F M00063947D:D01 CH21PRN 178 831149 RTA22200255F.d.16.1.P.Seq F M00063947D:D01 CH21PRN 180 817503 RTA22200255F.d.16.1.P.Seq F M00063947D:D01 CH21PRN 181 376588 RTA22200255F.d.16.1.P.Seq F M00063935D:G05 CH21PRN 181 376588 RTA22200255F.d.3.1.P.Seq F M00063955D:G05 CH21PRN 183 818063 RTA22200255F.d.3.1.P.Seq F M0006395D:G05 CH21PRN 184 455264 RTA22200253F.D.4.1.P.Seq F M0006395D:G05 CH21PRN 184 455264 RTA22200253F.D.4.P.Seq F M00063828A:H12 CH21PRN 185 189234 RTA22200255F.d.16.1.P.Seq F M00063828A:H12 CH21PRN 186 295694 RTA22200253F.D.5.P.Seq F M00063828A:H12 CH21PRN 186 295694 RTA22200256F.d.07.1.P.Seq F M00063828A:H12 CH21PRN 186 295694 RTA22200256F.d.07.1.P.Seq F M00063950B:D05 CH21PRN 187 A48679 RTA22200256F.d.07.1.P.Seq F M00064079C:A10 CH21PRN 187 A48679 RTA22200256F.d.07.1.P.Seq F M00064097C:A10 CH21PRN 190 37928 RTA22200256F.d.07.1.P.Seq F M00064097C:A10 CH21PRN 190 379328 RTA22200256F.d.07.1.P.Seq F M00064097C:A10 CH21PRN 191 385307 RTA22200256F.d.07.1.P.Seq F M00063954B:H07 CH22PRC 192 403453 RTA22200256F.d.07.1.P.Seq F M000664097C:A10 CH21PRN 196 404624 RTA22200255F.d.05.1.P.Seq F M0006393	166	295694	RTA22200260F.o.20.1.P.Seq	F	M00063978B:B06	CH22PRC
169 817653 RTA22200252F,g.23.1,P.Seq F M00063610D:C11 CH21PRN 170 397284 RTA22200253F,m.15.1,P.Seq F M00063636A:E01 CH21PRN 171 817979 RTA22200253F,m.15.1,P.Seq F M0006341A:E08 CH21PRN 172 817653 RTA22200255F,m.18.1,P.Seq F M00064048C:G12 CH21PRN 173 611440 RTA22200255F,m.18.1,P.Seq F M00064048C:G12 CH21PRN 174 386014 RTA22200255F,b.10.1,P.Seq F M00064048C:G12 CH21PRN 174 386014 RTA22200255F,b.10.1,P.Seq F M00064046A:G02 CH21PRN 175 549981 RTA22200255F,b.10.1,P.Seq F M00064046A:G02 CH21PRN 176 193373 RTA22200255F,121.1,P.Seq F M00063947D:D01 CH21PRN 177 400619 RTA22200255F,121.1,P.Seq F M00063947D:D01 CH21PRN 178 831149 RTA22200255F,d.16.1,P.Seq F M00063947D:D01 CH21PRN 178 831149 RTA22200255F,d.16.1,P.Seq F M00063932D:G08 CH22PRC 179 36113 RTA22200255F,d.16.1,P.Seq F M00063932D:G08 CH22PRC 179 36113 RTA22200253F,d.16.1,P.Seq F M0006395D:E05 CH21PRN 181 376588 RTA22200253F,d.16.1,P.Seq F M0006395D:E05 CH21PRN 181 376588 RTA22200253F,d.16.1,P.Seq F M00063805D:E05 CH21PRN 183 818063 RTA22200253F,d.14.1,P.Seq F M0006389A:F01 CH21PRN 184 455264 RTA22200253F,d.14.1,P.Seq F M0006389A:F01 CH21PRN 185 189234 RTA22200253F,d.14.1,P.Seq F M0006389A:F01 CH21PRN 186 295694 RTA22200253F,d.16.1,P.Seq F M0006389A:H01 CH21PRN 186 295694 RTA22200256F,d.07.1,P.Seq F M00063450A:A07 CH22PRC 188 830930 RTA22200266F,d.07.1,P.Seq F M00063450A:A07 CH22PRC 188 830930 RTA22200266F,d.07.1,P.Seq F M00064059A:A08 CH21PRN 190 373928 RTA22200256F,d.07.1,P.Seq F M00064059A:A08 CH21PRN 191 385307 RTA22200256F,d.07.1,P.Seq F M00064059A:A08 CH21PRN 194 44183 RTA22200255F,d.05.1,P.Seq F M00064059A:A08 CH21PRN 195 3730318 RTA22200256F,d.07.1,P.Seq F M0006394B:H07 CH22PRC 193 473434 RTA22200255F,d.05.1,P.Seq F M0006394B:G	167	36113	RTA22200265F.e.06.1.P.Seq	F	M00064526D:F05	CH22PRC
170 397284 RTA22200252F.m.15.1.P.Seq F M00063636A:E01 CH21PRN 171 817979 RTA22200253F.p.15.1.P.Seq F M00063841A:E08 CH21PRN 172 817653 RTA22200255F.m.18.1.P.Seq F M00064048C:G12 CH21PRN 173 611440 RTA22200253F.f.03.1.P.Seq F M00064048C:G12 CH21PRN 174 386014 RTA22200251F.f.06.1.P.Seq F M00064001A:B03 CH22PRC 175 549981 RTA22200251F.b.10.1.P.Seq F M00064001A:B03 CH22PRC 176 193373 RTA22200255F.b.10.1.P.Seq F M00063925B:F04 CH21PRN 177 400619 RTA22200255F.g.14.1.P.Seq F M00063947D:D01 CH21PRN 178 831149 RTA22200251F.d.16.1.P.Seq F M00063947D:D01 CH21PRN 179 36113 RTA22200251F.d.16.1.P.Seq F M00063947D:D01 CH22PRC 179 36113 RTA22200255F.d.16.1.P.Seq F M00063932D:G08 CH21PRN 180 817503 RTA22200251F.d.16.1.P.Seq F M0006395D:F05 CH21PRN 181 376588 RTA22200250F.i.16.1.P.Seq F M0006395D:F05 CH21PRN 182 141079 RTA22200252F.f.23.1.P.Seq F M00063805D:E05 CH21PRN 183 818063 RTA22200252F.f.23.1.P.Seq F M00063893A:F01 CH21PRN 184 455264 RTA22200252F.f.21.1.1.P.Seq F M00063893A:F01 CH21PRN 185 189234 RTA22200255F.j.10.1.P.Seq F M00063828A:H12 CH21PRN 186 295694 RTA22200256F.j.05.1.P.Seq F M00063466C:C11 CH21PRN 187 648679 RTA22200266F.i.06.1.P.Seq F M00063450A:A07 CH22PRC 188 830930 RTA22200266F.e.10.1.P.Seq F M0006445D:E11 CH22PRC 189 818497 RTA22200266F.d.07.1.P.Seq F M0006445D:E11 CH22PRC 190 373928 RTA22200256F.d.19.1.P.Seq F M0006409D:CA10 CH21PRN 191 385307 RTA22200266F.e.10.1.P.Seq F M0006409B:H06 CH22PRC 192 403453 RTA22200256F.d.05.1.P.Seq F M0006409B:H06 CH22PRC 193 730318 RTA22200255F.d.22.1.P.Seq F M00066408B:H06 CH22PRC 194 44183 RTA22200255F.d.22.1.P.Seq F M00066408B:H06 CH22PRC 195 373928 RTA22200255F.d.22.1.P.Seq F M00066408B:H06 CH22PRC	168	831812	RTA22200263F.f.05.1.P.Seq	F	M00064390A:C05	CH22PRC
T71 817979 RTA22200255F.p.15.1.P.Seq F M00063841A:E08 CH21PRN	169	817653	RTA22200252F.g.23.1.P.Seq	F	M00063610D:C11	CH21PRN
172	170	397284	RTA22200252F.m.15.1.P.Seq	F	M00063636A:E01	CH21PRN
173 611440 RTA22200253F, f.03.1.P.Seq F M00063774A:D09 CH21PRN 174 386014 RTA22200261F, f.06.1.P.Seq F M00064001A:B03 CH22PRC 175 549981 RTA22200255F, b.10.1.P.Seq F M00064046A:G02 CH21PRN 176 193373 RTA22200255F, g.14.1.P.Seq F M00064046A:G02 CH21PRN 177 400619 RTA22200255F, g.14.1.P.Seq F M00063947D:D01 CH21PRN 178 831149 RTA22200261F, o.21.1.P.Seq F M00063932D:G08 CH21PRN 179 36113 RTA22200255F, d.16.1.P.Seq F M00063932D:G08 CH21PRN 180 817503 RTA22200255F, d.16.1.P.Seq F M00063955D:E05 CH21PRN 181 376588 RTA22200253F, d.23.1.P.Seq F M00063955D:E05 CH21PRN 183 818063 RTA22200253F, d.23.1.P.Seq F M0006389A:F01 CH21PRN 184 455264 RTA22200253F, d.41.P.Seq F M00063828A:H12 CH21PRN 185	171	817979	RTA22200253F.p.15.1.P.Seq	F	M00063841A:E08	CH21PRN
174 386014 RTA22200261F.f.06.1.P.Seq F M00064001A:B03 CH22PRC 175 549981 RTA22200255F.b.10.1.P.Seq F M00063925B:F04 CH21PRN 176 193373 RTA22200255F.b.12.1.P.Seq F M00064046A:G02 CH21PRN 177 400619 RTA22200255F.g.14.1.P.Seq F M00064310D:F03 CH21PRN 178 831149 RTA22200255F.g.14.1.P.Seq F M00063947D:D01 CH21PRN 179 36113 RTA22200255F.d.16.1.P.Seq F M00063932D:G08 CH21PRN 180 817503 RTA22200255F.d.16.1.P.Seq F M00063895D:E05 CH21PRN 181 376588 RTA22200255F.f.23.1.P.Seq F M00063895D:F05 CH21PRN 182 141079 RTA22200253F.p.04.1.P.Seq F M00063893A:F01 CH21PRN 183 1818063 RTA22200253F.p.04.1.P.Seq F M00063893A:F01 CH21PRN 184 455264 RTA22200255F.d.21.P.Seq F M00063893A:F01 CH21PRN 185	172	817653	RTA22200255F.m.18.1.P.Seq	F	M00064048C:G12	CH21PRN
175 549981 RTA22200255F.b.10.1.P.Seq F M00063925B:F04 CH21PRN 176 193373 RTA22200255F.1.21.1.P.Seq F M00064046A:G02 CH21PRN 177 400619 RTA22200255F.g.14.1.P.Seq F M00063947D:D01 CH21PRN 178 831149 RTA22200255F.d.16.1.P.Seq F M00063932D:G08 CH21PRN 180 817503 RTA22200255F.d.16.1.P.Seq F M00063932D:G08 CH21PRN 181 376588 RTA22200253F.1.6.1.P.Seq F M00063955D:F05 CH21PRN 181 376588 RTA22200253F.p.04.1.P.Seq F M00063955D:F05 CH21PRN 182 141079 RTA22200253F.p.04.1.P.Seq F M00063805D:F05 CH21PRN 183 818063 RTA22200253F.p.04.1.P.Seq F M00063806C:B04 CH21PRN 184 455264 RTA22200253F.n.14.P.Seq F M00063828A:H12 CH21PRN 185 189234 RTA22200255F.j.05.1.P.Seq F M00064550A:A07 CH22PRC 187	173	611440	RTA22200253F.f.03.1.P.Seq	F	M00063774A:D09	CH21PRN
176 193373 RTA22200255F.1.21.1.P.Seq F M00064046A:G02 CH21PRN 177 400619 RTA22200255F.g.14.1.P.Seq F M00063947D:D01 CH21PRN 178 831149 RTA22200251F.o.21.1.P.Seq F M0006393D:G03 CH22PRC 179 36113 RTA22200255F.d.16.1.P.Seq F M0006393D:G08 CH21PRN 180 817503 RTA22200255F.d.16.1.P.Seq F M00063955D:F05 CH21PRN 181 376588 RTA22200255F.d.23.1.P.Seq F M00063955D:F05 CH21PRN 182 141079 RTA22200253F.p.04.1.P.Seq F M000639839A:F01 CH21PRN 183 818063 RTA22200253F.p.04.1.P.Seq F M00063828A:H12 CH21PRN 184 455264 RTA22200253F.p.05.1.P.Seq F M00063828A:H12 CH21PRN 185 189234 RTA22200255F.j.05.1.P.Seq F M00064550A:A07 CH22PRC 187 648679 RTA22200265F.j.05.1.P.Seq F M00064452D:E11 CH22PRC 188	174	386014	RTA22200261F.f.06.1.P.Seq	F	M00064001A:B03	CH22PRC
177 400619 RTA22200255F.g.14.1.P.Seq F M00063947D:D01 CH21PRN 178 831149 RTA22200261F.o.21.1.P.Seq F M00064310D:F03 CH22PRC 179 36113 RTA22200255F.d.16.1.P.Seq F M00063932D:G08 CH21PRN 180 817503 RTA22200253F.l.16.1.P.Seq F M00063805D:E05 CH21PRN 181 376588 RTA22200253F.l.16.1.P.Seq F M0006395D:F05 CH21PRN 182 141079 RTA22200252F.f.23.1.P.Seq F M00063805D:F05 CH21PRN 183 818063 RTA22200253F.p.04.1.P.Seq F M00063828A:H02 CH21PRN 184 455264 RTA22200253F.p.04.1.P.Seq F M00063828A:H12 CH21PRN 185 189234 RTA22200255F.j.05.1.P.Seq F M00063466C:C11 CH21PRN 186 295694 RTA22200260F.f.06.1.P.Seq F M00063594B:H07 CH22PRC 187 648679 RTA22200260F.f.06.1.P.Seq F M00063594B:H07 CH22PRC 188	175	549981	RTA22200255F.b.10.1.P.Seq	F	M00063925B:F04	CH21PRN
178 831149 RTA22200261F.0.21.1.P.Seq F M00064310D:F03 CH22PRC 179 36113 RTA22200255F.d.16.1.P.Seq F M00063932D:G08 CH21PRN 180 817503 RTA22200255F.d.16.1.P.Seq F M00063805D:E05 CH21PRN 181 376588 RTA22200252F.f.23.1.P.Seq F M00063955D:F05 CH22PRC 182 141079 RTA22200252F.f.23.1.P.Seq F M00063606C:B04 CH21PRN 183 818063 RTA22200253F.p.04.1.P.Seq F M00063839A:F01 CH21PRN 184 455264 RTA22200253F.n.14.1.P.Seq F M00063828A:H12 CH21PRN 185 189234 RTA22200251F.f.17.1.P.Seq F M00063466C:C11 CH21PRN 186 295694 RTA22200265F.j.05.1.P.Seq F M00064550A:A07 CH22PRC 187 648679 RTA22200266F.d.07.1.P.Seq F M00064979C:A10 CH21PRN 189 818497 RTA22200256F.d.07.1.P.Seq F M00064097C:A10 CH21PRN 190	176	193373	RTA22200255F.1.21.1.P.Seq	F	M00064046A:G02	CH21PRN
179 36113 RTA22200255F.d.16.1.P.Seq F M00063932D:G08 CH21PRN	177	400619	RTA22200255F.g.14.1.P.Seq	F	M00063947D:D01	CH21PRN
180 817503 RTA22200253F.I.16.1.P.Seq F M00063805D:E05 CH21PRN 181 376588 RTA22200260F.i.11.1.P.Seq F M00063955D:F05 CH22PRC 182 141079 RTA22200252F.f.23.1.P.Seq F M00063606C:B04 CH21PRN 183 818063 RTA22200253F.p.04.1.P.Seq F M00063839A:F01 CH21PRN 184 455264 RTA22200253F.p.04.1.P.Seq F M00063828A:H12 CH21PRN 185 189234 RTA22200251F.f.17.1.P.Seq F M00063466C:C11 CH21PRN 186 295694 RTA22200265F.j.05.1.P.Seq F M00064550A:A07 CH22PRC 187 648679 RTA22200260F.f.06.1.P.Seq F M00064550E:H1 CH22PRC 188 830930 RTA22200264F.e.10.1.P.Seq F M00064079C:A10 CH21PRN 190 373928 RTA22200256F.d.19.1.P.Seq F M000640982A:A08 CH21PRN 191 385307 RTA22200264F.e.10.1.P.Seq F M000640601D:B05 CH22PRC 192	178	831149	RTA22200261F.o.21.1.P.Seq	F	M00064310D:F03	CH22PRC
181 376588 RTA22200260F.i.11.1.P.Seq F M00063955D:F05 CH22PRC 182 141079 RTA22200252F.f.23.1.P.Seq F M00063606C:B04 CH21PRN 183 818063 RTA22200253F.p.04.1.P.Seq F M00063839A:F01 CH21PRN 184 455264 RTA22200253F.n.14.1.P.Seq F M00063828A:H12 CH21PRN 185 189234 RTA22200251F.f.17.1.P.Seq F M00063466C:C11 CH21PRN 186 295694 RTA22200265F.j.05.1.P.Seq F M00064550A:A07 CH22PRC 187 648679 RTA22200266F.d.01.P.Seq F M0006452D:E11 CH22PRC 188 830930 RTA22200266F.d.07.1.P.Seq F M00064952D:E11 CH22PRC 189 818497 RTA22200256F.d.19.1.P.Seq F M00064082A:A08 CH21PRN 190 373928 RTA22200266F.e.10.1.P.Seq F M00064406B:H06 CH22PRC 192 403453 RTA22200266F.e.10.1.P.Seq F M000644079C:A10 CH22PRC 193	179	36113	RTA22200255F.d.16.1.P.Seq	F	M00063932D:G08	CH21PRN
182 141079 RTA22200252F.f.23.1.P.Seq F M00063606C:B04 CH21PRN 183 818063 RTA22200253F.p.04.1.P.Seq F M00063839A:F01 CH21PRN 184 455264 RTA22200253F.n.14.1.P.Seq F M00063828A:H12 CH21PRN 185 189234 RTA22200251F.f.17.1.P.Seq F M00063466C:C11 CH21PRN 186 295694 RTA22200265F.j.05.1.P.Seq F M00064550A:A07 CH22PRC 187 648679 RTA22200260F.f.06.1.P.Seq F M00063594B:H07 CH22PRC 188 830930 RTA22200264F.e.10.1.P.Seq F M00064079C:A10 CH21PRN 190 373928 RTA22200256F.d.19.1.P.Seq F M00064082A:A08 CH21PRN 191 385307 RTA22200266F.e.10.1.P.Seq F M000640082A:A08 CH21PRN 192 403453 RTA22200266F.e.10.1.P.Seq F M0006401B:B06 CH22PRC 193 730318 RTA22200264F.c.09.1.P.Seq F M00064447B:A07 CH22PRC 194	180	817503	RTA22200253F.1.16.1.P.Seq	F	M00063805D:E05	CH21PRN
183 818063 RTA22200253F.p.04.1.P.Seq F M00063839A:F01 CH21PRN 184 455264 RTA22200253F.p.14.1.P.Seq F M00063828A:H12 CH21PRN 185 189234 RTA22200251F.f.17.1.P.Seq F M00063466C:C11 CH21PRN 186 295694 RTA22200265F.j.05.1.P.Seq F M00064550A:A07 CH22PRC 187 648679 RTA22200260F.f.06.1.P.Seq F M00063594B:H07 CH22PRC 188 830930 RTA22200264F.e.10.1.P.Seq F M00064079C:A10 CH21PRN 190 373928 RTA22200256F.d.07.1.P.Seq F M00064082A:A08 CH21PRN 191 385307 RTA22200263F.j.12.1.P.Seq F M00064082A:A08 CH21PRN 192 403453 RTA22200266F.e.10.1.P.Seq F M0006401D:B05 CH22PRC 193 730318 RTA22200264F.c.09.1.P.Seq F M00064447B:A07 CH22PRC 194 44183 RTA22200264F.c.09.1.P.Seq F M00063934B:E04 CH21PRN 195	181	376588	RTA22200260F.i.11.1.P.Seq	F	M00063955D:F05	CH22PRC
184 455264 RTA22200253F.n.14.1.P.Seq F M00063828A:H12 CH21PRN 185 189234 RTA22200251F.f.17.1.P.Seq F M00063466C:C11 CH21PRN 186 295694 RTA22200265F.j.05.1.P.Seq F M00064550A:A07 CH22PRC 187 648679 RTA22200260F.f.06.1.P.Seq F M00063594B:H07 CH22PRC 188 830930 RTA22200264F.e.10.1.P.Seq F M00064452D:E11 CH22PRC 189 818497 RTA22200256F.d.07.1.P.Seq F M00064079C:A10 CH21PRN 190 373928 RTA22200256F.d.19.1.P.Seq F M00064082A:A08 CH21PRN 191 385307 RTA22200263F.j.12.1.P.Seq F M00064406B:H06 CH22PRC 192 403453 RTA22200266F.e.10.1.P.Seq F M0006401D:B05 CH22PRC 193 730318 RTA22200264F.c.09.1.P.Seq F M00064447B:A07 CH22PRC 194 44183 RTA22200255F.d.22.1.P.Seq F M00063934B:E04 CH21PRN 195	182	141079	RTA22200252F.f.23.1.P.Seq	F	M00063606C:B04	CH21PRN
185 189234 RTA22200251F.f.17.1.P.Seq F M00063466C:C11 CH21PRN 186 295694 RTA22200265F.j.05.1.P.Seq F M00064550A:A07 CH22PRC 187 648679 RTA22200260F.f.06.1.P.Seq F M00063594B:H07 CH22PRC 188 830930 RTA22200264F.e.10.1.P.Seq F M00064452D:E11 CH22PRC 189 818497 RTA22200256F.d.07.1.P.Seq F M00064079C:A10 CH21PRN 190 373928 RTA22200256F.d.19.1.P.Seq F M00064082A:A08 CH21PRN 191 385307 RTA22200263F.j.12.1.P.Seq F M00064406B:H06 CH22PRC 192 403453 RTA22200266F.e.10.1.P.Seq F M0006440B:H06 CH22PRC 193 730318 RTA22200264F.c.09.1.P.Seq F M00064447B:A07 CH22PRC 194 44183 RTA222002271F.a.01.1.P.Seq F M00063934B:E04 CH21PRN 195 373928 RTA22200255F.d.23.1.P.Seq F M00063934B:E04 CH21PRN 196	183	818063	RTA22200253F.p.04.1.P.Seq	F	M00063839A:F01	CH21PRN
186 295694 RTA22200265F.j.05.1.P.Seq F M00064550A:A07 CH22PRC 187 648679 RTA22200260F.f.06.1.P.Seq F M00063594B:H07 CH22PRC 188 830930 RTA22200264F.e.10.1.P.Seq F M00064452D:E11 CH22PRC 189 818497 RTA22200256F.d.07.1.P.Seq F M00064079C:A10 CH21PRN 190 373928 RTA22200256F.d.19.1.P.Seq F M00064082A:A08 CH21PRN 191 385307 RTA22200263F.j.12.1.P.Seq F M00064406B:H06 CH22PRC 192 403453 RTA22200266F.e.10.1.P.Seq F M00064401D:B05 CH22PRC 193 730318 RTA22200264F.c.09.1.P.Seq F M00064447B:A07 CH22PRC 194 44183 RTA22200271F.a.01.1.P.Seq F M00063934B:E04 CH21PRN 195 373928 RTA22200255F.d.22.1.P.Seq F M00063934C:C10 CH21PRN 196 404624 RTA22200255F.d.23.1.P.Seq F M000639834C:C10 CH21PRN 198	184	455264	RTA22200253F.n.14.1.P.Seq	F	M00063828A:H12	CH21PRN
187 648679 RTA22200260F.f.06.1.P.Seq F M00063594B:H07 CH22PRC 188 830930 RTA22200264F.e.10.1.P.Seq F M00064452D:E11 CH22PRC 189 818497 RTA22200256F.d.07.1.P.Seq F M00064079C:A10 CH21PRN 190 373928 RTA22200256F.d.19.1.P.Seq F M00064082A:A08 CH21PRN 191 385307 RTA22200263F.j.12.1.P.Seq F M00064406B:H06 CH22PRC 192 403453 RTA22200266F.e.10.1.P.Seq F M00064406B:H06 CH22PRC 193 730318 RTA22200264F.c.09.1.P.Seq F M00064447B:A07 CH22PRC 194 44183 RTA22200271F.a.01.1.P.Seq F M00063934B:E04 CH21PRN 195 373928 RTA22200255F.d.22.1.P.Seq F M00063934B:E04 CH21PRN 196 404624 RTA22200255F.d.23.1.P.Seq F M00063934C:C10 CH21PRN 198 372700 RTA22200253F.c.06.1.P.Seq F M00063689D:E12 CH21PRN 200	185	189234	RTA22200251F.f.17.1.P.Seq	F	M00063466C:C11	CH21PRN
188 830930 RTA22200264F.e.10.1.P.Seq F M00064452D:E11 CH22PRC 189 818497 RTA22200256F.d.07.1.P.Seq F M00064079C:A10 CH21PRN 190 373928 RTA22200256F.d.19.1.P.Seq F M00064082A:A08 CH21PRN 191 385307 RTA22200263F.j.12.1.P.Seq F M00064406B:H06 CH22PRC 192 403453 RTA22200266F.e.10.1.P.Seq F M00064407B:A07 CH22PRC 193 730318 RTA22200264F.c.09.1.P.Seq F M00064447B:A07 CH22PRC 194 44183 RTA22200264F.c.09.1.P.Seq F M00064447B:A07 CH22PRC 194 44183 RTA22200257F.a.01.1.P.Seq F M00063934B:E04 CH21PRN 195 373928 RTA22200255F.d.23.1.P.Seq F M00063934B:E04 CH21PRN 196 404624 RTA22200255F.d.23.1.P.Seq F M00063934C:C10 CH21PRN 197 403173 RTA22200255F.d.06.1.P.Seq F M00063689D:E12 CH21PRN 198	186	295694	RTA22200265F.j.05.1.P.Seq	F	M00064550A:A07	CH22PRC
189 818497 RTA22200256F.d.07.1.P.Seq F M00064079C:A10 CH21PRN 190 373928 RTA22200256F.d.19.1.P.Seq F M00064082A:A08 CH21PRN 191 385307 RTA22200263F.j.12.1.P.Seq F M00064406B:H06 CH22PRC 192 403453 RTA22200266F.e.10.1.P.Seq F M00064601D:B05 CH22PRC 193 730318 RTA22200264F.c.09.1.P.Seq F M00064447B:A07 CH22PRC 194 44183 RTA22200271F.a.01.1.P.Seq F M00021929A:D03 CH03MAH 195 373928 RTA22200255F.d.22.1.P.Seq F M00063934B:E04 CH21PRN 196 404624 RTA22200255F.d.23.1.P.Seq F M00063934C:C10 CH21PRN 197 403173 RTA22200253F.a.21.1.P.Seq F M00063685A:C02 CH21PRN 198 372700 RTA22200253F.c.06.1.P.Seq F M00063689D:E12 CH21PRN 200 597854 RTA22200255F.j.03.1.P.Seq F M00064033D:B01 CH21PRN 201	187	648679	RTA22200260F.f.06.1.P.Seq	F	M00063594B:H07	CH22PRC
190 373928 RTA22200256F.d.19.1.P.Seq F M00064082A:A08 CH21PRN 191 385307 RTA22200263F.j.12.1.P.Seq F M00064406B:H06 CH22PRC 192 403453 RTA22200266F.e.10.1.P.Seq F M00064601D:B05 CH22PRC 193 730318 RTA22200264F.c.09.1.P.Seq F M00064447B:A07 CH22PRC 194 44183 RTA22200271F.a.01.1.P.Seq F M00021929A:D03 CH03MAH 195 373928 RTA22200255F.d.22.1.P.Seq F M00063934B:E04 CH21PRN 196 404624 RTA22200255F.d.23.1.P.Seq F M00063934C:C10 CH21PRN 197 403173 RTA22200253F.a.21.1.P.Seq F M00063685A:C02 CH21PRN 198 372700 RTA22200253F.c.06.1.P.Seq F M00063689D:E12 CH21PRN 199 374343 RTA22200255F.j.03.1.P.Seq F M0006408A:B01 CH22PRC 200 597854 RTA22200255F.a.23.1.P.Seq F M00064033D:B01 CH21PRN 202	188	830930	RTA22200264F.e.10.1.P.Seq	F	M00064452D:E11	CH22PRC
191 385307 RTA22200263F.j.12.1.P.Seq F M00064406B:H06 CH22PRC 192 403453 RTA22200266F.e.10.1.P.Seq F M00064601D:B05 CH22PRC 193 730318 RTA22200264F.c.09.1.P.Seq F M00064447B:A07 CH22PRC 194 44183 RTA22200271F.a.01.1.P.Seq F M00021929A:D03 CH03MAH 195 373928 RTA22200255F.d.22.1.P.Seq F M00063934B:E04 CH21PRN 196 404624 RTA22200255F.d.23.1.P.Seq F M00063934C:C10 CH21PRN 197 403173 RTA22200253F.a.21.1.P.Seq F M00063685A:C02 CH21PRN 198 372700 RTA22200253F.c.06.1.P.Seq F M00063689D:E12 CH21PRN 199 374343 RTA22200255F.j.03.1.P.Seq F M00064008A:B01 CH22PRC 200 597854 RTA22200255F.a.23.1.P.Seq F M00064033D:B01 CH21PRN 201 818497 RTA22200257F.k.05.3.P.Seq F M00063943B:G02 CH21PRN 203	189	818497	RTA22200256F.d.07.1.P.Seq	F	M00064079C:A10	CH21PRN
192 403453 RTA22200266F.e.10.1.P.Seq F M00064601D:B05 CH22PRC 193 730318 RTA22200264F.c.09.1.P.Seq F M00064447B:A07 CH22PRC 194 44183 RTA22200271F.a.01.1.P.Seq F M00021929A:D03 CH03MAH 195 373928 RTA22200255F.d.22.1.P.Seq F M00063934B:E04 CH21PRN 196 404624 RTA22200255F.d.23.1.P.Seq F M00063934C:C10 CH21PRN 197 403173 RTA22200253F.a.21.1.P.Seq F M00063685A:C02 CH21PRN 198 372700 RTA22200253F.c.06.1.P.Seq F M00063689D:E12 CH21PRN 199 374343 RTA22200255F.j.03.1.P.Seq F M00064008A:B01 CH22PRC 200 597854 RTA22200255F.j.03.1.P.Seq F M00063922B:A12 CH21PRN 201 817417 RTA22200255F.a.23.1.P.Seq F M00063922B:A12 CH21PRN 202 818497 RTA22200255F.f.15.1.P.Seq F M00063943B:G12 CH21PRN 204	190	373928	RTA22200256F.d.19.1.P.Seq	F	M00064082A:A08	CH21PRN
193 730318 RTA22200264F.c.09.1.P.Seq F M00064447B:A07 CH22PRC 194 44183 RTA22200271F.a.01.1.P.Seq F M00021929A:D03 CH03MAH 195 ' 373928 RTA22200255F.d.22.1.P.Seq F M00063934B:E04 CH21PRN 196 404624 RTA22200255F.d.23.1.P.Seq F M00063934C:C10 CH21PRN 197 403173 RTA22200253F.a.21.1.P.Seq F M00063685A:C02 CH21PRN 198 372700 RTA22200253F.c.06.1.P.Seq F M00063689D:E12 CH21PRN 199 374343 RTA22200261F.h.04.1.P.Seq F M00064008A:B01 CH22PRC 200 597854 RTA22200255F.j.03.1.P.Seq F M00064033D:B01 CH21PRN 201 817417 RTA22200255F.a.23.1.P.Seq F M00063922B:A12 CH21PRN 202 818497 RTA22200257F.k.05.3.P.Seq F M00063943B:G12 CH21PRN 204 379105 RTA22200255F.n.19.1.P.Seq F M00063642B:A08 CH21PRN	191	385307	RTA22200263F.j.12.1.P.Seq	F	M00064406B:H06	CH22PRC
194 44183 RTA22200271F.a.01.1.P.Seq F M00021929A:D03 CH03MAH 195 ' 373928 RTA22200255F.d.22.1.P.Seq F M00063934B:E04 CH21PRN 196 404624 RTA22200255F.d.23.1.P.Seq F M00063934C:C10 CH21PRN 197 403173 RTA22200253F.a.21.1.P.Seq F M00063685A:C02 CH21PRN 198 372700 RTA22200253F.c.06.1.P.Seq F M00063689D:E12 CH21PRN 199 374343 RTA22200261F.h.04.1.P.Seq F M00064008A:B01 CH22PRC 200 597854 RTA22200255F.j.03.1.P.Seq F M00064033D:B01 CH21PRN 201 817417 RTA22200255F.a.23.1.P.Seq F M00063922B:A12 CH21PRN 202 818497 RTA22200257F.k.05.3.P.Seq F M00063943B:G12 CH21PRN 203 377696 RTA22200255F.f.15.1.P.Seq F M00063642B:A08 CH21PRN 204 379105 RTA22200255F.n.19.1.P.Seq F M00063642B:A08 CH21PRN	192	403453	RTA22200266F.e.10.1.P.Seq	F	M00064601D:B05	CH22PRC
195 ' 373928 RTA22200255F.d.22.1.P.Seq F M00063934B:E04 CH21PRN 196 404624 RTA22200255F.d.23.1.P.Seq F M00063934C:C10 CH21PRN 197 403173 RTA22200253F.a.21.1.P.Seq F M00063685A:C02 CH21PRN 198 372700 RTA22200253F.c.06.1.P.Seq F M00063689D:E12 CH21PRN 199 374343 RTA22200261F.h.04.1.P.Seq F M00064008A:B01 CH22PRC 200 597854 RTA22200255F.j.03.1.P.Seq F M00064033D:B01 CH21PRN 201 817417 RTA22200255F.a.23.1.P.Seq F M00063922B:A12 CH21PRN 202 818497 RTA22200257F.k.05.3.P.Seq F M00064188B:G08 CH21PRN 203 377696 RTA22200255F.f.15.1.P.Seq F M00063642B:A08 CH21PRN 204 379105 RTA22200252F.n.19.1.P.Seq F M00063642B:A08 CH21PRN	193	730318	RTA22200264F.c.09.1.P.Seq	F	M00064447B:A07	CH22PRC
196 404624 RTA22200255F.d.23.1.P.Seq F M00063934C:C10 CH21PRN 197 403173 RTA22200253F.a.21.1.P.Seq F M00063685A:C02 CH21PRN 198 372700 RTA22200253F.c.06.1.P.Seq F M00063689D:E12 CH21PRN 199 374343 RTA22200261F.h.04.1.P.Seq F M00064008A:B01 CH22PRC 200 597854 RTA22200255F.j.03.1.P.Seq F M00064033D:B01 CH21PRN 201 817417 RTA22200255F.a.23.1.P.Seq F M00063922B:A12 CH21PRN 202 818497 RTA22200257F.k.05.3.P.Seq F M00064188B:G08 CH21PRN 203 377696 RTA22200255F.f.15.1.P.Seq F M00063943B:G12 CH21PRN 204 379105 RTA22200252F.n.19.1.P.Seq F M00063642B:A08 CH21PRN	194	44183	RTA22200271F.a.01.1.P.Seq	F	M00021929A:D03	CH03MAH
197 403173 RTA22200253F.a.21.1.P.Seq F M00063685A:C02 CH21PRN 198 372700 RTA22200253F.c.06.1.P.Seq F M00063689D:E12 CH21PRN 199 374343 RTA22200261F.h.04.1.P.Seq F M00064008A:B01 CH22PRC 200 597854 RTA22200255F.j.03.1.P.Seq F M00064033D:B01 CH21PRN 201 817417 RTA22200255F.a.23.1.P.Seq F M00063922B:A12 CH21PRN 202 818497 RTA22200257F.k.05.3.P.Seq F M00064188B:G08 CH21PRN 203 377696 RTA22200255F.f.15.1.P.Seq F M00063943B:G12 CH21PRN 204 379105 RTA22200252F.n.19.1.P.Seq F M00063642B:A08 CH21PRN	195	373928	RTA22200255F.d.22.1.P.Seq	F	M00063934B:E04	CH21PRN
198 372700 RTA22200253F.c.06.1.P.Seq F M00063689D:E12 CH21PRN 199 374343 RTA22200261F.h.04.1.P.Seq F M00064008A:B01 CH22PRC 200 597854 RTA22200255F.j.03.1.P.Seq F M00064033D:B01 CH21PRN 201 817417 RTA22200255F.a.23.1.P.Seq F M00063922B:A12 CH21PRN 202 818497 RTA22200257F.k.05.3.P.Seq F M00064188B:G08 CH21PRN 203 377696 RTA22200255F.f.15.1.P.Seq F M00063943B:G12 CH21PRN 204 379105 RTA22200252F.n.19.1.P.Seq F M00063642B:A08 CH21PRN	196	404624	RTA22200255F.d.23.1.P.Seq	F	M00063934C:C10	CH21PRN
199 374343 RTA22200261F.h.04.1.P.Seq F M00064008A:B01 CH22PRC 200 597854 RTA22200255F.j.03.1.P.Seq F M00064033D:B01 CH21PRN 201 817417 RTA22200255F.a.23.1.P.Seq F M00063922B:A12 CH21PRN 202 818497 RTA22200257F.k.05.3.P.Seq F M00064188B:G08 CH21PRN 203 377696 RTA22200255F.f.15.1.P.Seq F M00063943B:G12 CH21PRN 204 379105 RTA22200252F.n.19.1.P.Seq F M00063642B:A08 CH21PRN	197	403173	RTA22200253F.a.21.1.P.Seq	F	M00063685A:C02	CH21PRN
200 597854 RTA22200255F.j.03.1.P.Seq F M00064033D:B01 CH21PRN 201 817417 RTA22200255F.a.23.1.P.Seq F M00063922B:A12 CH21PRN 202 818497 RTA22200257F.k.05.3.P.Seq F M00064188B:G08 CH21PRN 203 377696 RTA22200255F.f.15.1.P.Seq F M00063943B:G12 CH21PRN 204 379105 RTA22200252F.n.19.1.P.Seq F M00063642B:A08 CH21PRN	198	372700	RTA22200253F.c.06.1.P.Seq	F	M00063689D:E12	CH21PRN
200 597854 RTA22200255F.j.03.1.P.Seq F M00064033D:B01 CH21PRN 201 817417 RTA22200255F.a.23.1.P.Seq F M00063922B:A12 CH21PRN 202 818497 RTA22200257F.k.05.3.P.Seq F M00064188B:G08 CH21PRN 203 377696 RTA22200255F.f.15.1.P.Seq F M00063943B:G12 CH21PRN 204 379105 RTA22200252F.n.19.1.P.Seq F M00063642B:A08 CH21PRN	199	374343	RTA22200261F.h.04.1.P.Seq	F	M00064008A:B01	CH22PRC
201 817417 RTA22200255F.a.23.1.P.Seq F M00063922B:A12 CH21PRN 202 818497 RTA22200257F.k.05.3.P.Seq F M00064188B:G08 CH21PRN 203 377696 RTA22200255F.f.15.1.P.Seq F M00063943B:G12 CH21PRN 204 379105 RTA22200252F.n.19.1.P.Seq F M00063642B:A08 CH21PRN				F	M00064033D:B01	CH21PRN
202 818497 RTA22200257F.k.05.3.P.Seq F M00064188B:G08 CH21PRN 203 377696 RTA22200255F.f.15.1.P.Seq F M00063943B:G12 CH21PRN 204 379105 RTA22200252F.n.19.1.P.Seq F M00063642B:A08 CH21PRN					M00063922B:A12	CH21PRN
203 377696 RTA22200255F.f.15.1.P.Seq F M00063943B:G12 CH21PRN 204 379105 RTA22200252F.n.19.1.P.Seq F M00063642B:A08 CH21PRN					M00064188B:G08	
204 379105 RTA22200252F.n.19.1.P.Seq F M00063642B:A08 CH21PRN	-					
		L				
LUZ ODITOO KIWAZAAAAALI, OGA L. MIOOOOALADA HII CUSTUC	205	831188	RTA22200267F.o.02.1.P.Seq	F	M00064723D:H11	CH22PRC

Table 1

Table	Ť				
SEQ ID	CLUSTER	SEQ NAME	ORIENT	CLONE ID	LIBRARY
206	376056	RTA22200253F.m.09.1.P.Seq	F	M00063810C:E03	CH21PRN
207	124863	RTA22200255F.n.15.1.P.Seq	F	M00064053B:D09	CH21PRN
208	376056	RTA22200254F.i.03.1.P.Seq	F	M00063890A:F11	CH21PRN
209	831812	RTA22200266F.j.10.1.P.Seq	F	M00064620C:D01	CH22PRC
210	141079	RTA22200260F.i.14.1.P.Seq	F	M00063956A:F05	CH22PRC
211	19148	RTA22200265F.o.18.1.P.Seq	F	M00064577C:B12	CH22PRC
212	124396	RTA22200252F.a.14.1.P.Seq	F	M00063514C:E08	CH21PRN
213	831026	RTA22200265F.c.03.1.P.Seq	F	M00064520A:F08	CH22PRC
214	819037	RTA22200263F.i.23.1.P.Seq	F	M00064405B:C04	CH22PRC
215	380207	RTA22200263F.i.19.1.P.Seq	F	M00064404C:G05	CH22PRC
216	819460	RTA22200255F.c.13.1.P.Seq	F	M00063928A:G09	CH21PRN
217	379067	RTA22200253F.g.23.1.P.Seq	F	M00063784C:E10	CH21PRN
218	403173	RTA22200252F.p.23.1.P.Seq	F	M00063682A:C04	CH21PRN
219	3856	RTA22200269F.a.05.1.P.Seq	F	M00003773D:H02	CH01COH
220	378551	RTA22200263F.d.17.1.P.Seq	F	M00064385D:C11	CH22PRC
221	456089	RTA22200272F.a.09.1.P.Seq	F	M00043134A:A05	CH19COP
222	549981	RTA22200267F.a.22.1.P.Seq	F	M00064650B:B07	CH22PRC
223	378551	RTA22200265F.m.21.1.P.Seq	F	M00064568A:H06	CH22PRC
224	819201	RTA22200256F.n.23.2.P.Seq	F	M00064132B:B07	CH21PRN
225	374826	RTA22200251F.c.20.1.P.Seq	F	M00063453B:F08	CH21PRN
226	389409	RTA22200253F.1.23.1.P.Seq	F	M00063807A:D12	CH21PRN
227	819149	RTA22200260F.a.17.1.P.Seq	F	M00063575B:G02	CH22PRC
228	389409	RTA22200255F.e.18.1.P.Seq	F	M00063939C:D06	CH21PRN
229	818165	RTA22200254F.h.15.1.P.Seq	F	M00063888D:F02	CH21PRN
230	817757	RTA22200252F.i.15.1.P.Seq	F	M00063617D:F09	CH21PRN
231	553242	RTA22200263F.i.20.1.P.Seq	F	M00064404D:A06	CH22PRC
232	385615	RTA22200265F.b.08.1.P.Seq	F	M00064517B:F10	CH22PRC
233	819102	RTA22200258F.h.19.1.P.Seq	F	M00064272C:G01	CH21PRN
234	817757	RTA22200255F.o.16.1.P.Seq	F	M00064057C:H10	CH21PRN
235	385615	RTA22200265F.b.07.1.P.Seq	F	M00064517B:F04	CH22PRC
236	385615	RTA22200253F.1.06.1.P.Seq	F	M00063804C:A11	CH21PRN
237	827355	RTA22200266F.n.23.1.P.Seq	F	M00064636B:A04	CH22PRC
238	817629	RTA22200259F.a.13.1.P.Seq	F	M00063165A:C09	CH22PRC
239	817514	RTA22200260F.h.02.1.P.Seq	F	M00063600C:C09	CH22PRC
240	817514	RTA22200252F.p.21.1.P.Seq	F	M00063681B:C02	CH21PRN
241	680563	RTA22200265F.f.13.1.P.Seq	F	M00064530B:H02	CH22PRC
242	827355	RTA22200255F.e.20.1.P.Seq	F	M00063939C:H01	CH21PRN
243	377286	RTA22200254F.a.04.1.P.Seq	F	M00063843B:D07	CH21PRN
244	680563	RTA22200258F.g.18.1.P.Seq	F	M00064268D:G03	CH21PRN
245	819156	RTA22200255F.h.06.1.P.Seq	F	M00064021D:H01	CH21PRN
246	220584	RTA22200261F.f.22.1.P.Seq	F	M00064003B:C10	CH22PRC

Table 1

Table		GEO 33113 EE	I ODY	GT OTTER	
SEQ ID	CLUSTER	SEQ NAME	ORIENT	CLONE ID	LIBRARY
247	616555	RTA22200263F.o.12.1.P.Seq H		M00064428B:A12	CH22PRC
248	819498	RTA22200254F.o.14.1.P.Seq	F F	M00063912A:D06	CH22PRC CH21PRN
249	817508	RTA22200257F.h.01.1.P.Seq	F	M00063912A:D00	CH21PRN
250	817690	RTA22200257F.n.01.1.F.Seq	F	M00064171D.E03	ļ <u> </u>
251	817090	RTA2220025/F.e.05.1.F.Seq	F	M00064106C:G03	CH21PRN
252	830904	RTA22200256F.j.12.1.P.Seq	F		CH21PRN
253	819498		F	M00064620D:G05 M00063686B:E07	CH22PRC
254	817508	RTA22200253F.b.04.1.P.Seq			CH21PRN
		RTA22200257F.g.24.1.P.Seq	F	M00064171D:E05	CH21PRN
255	817508	RTA22200252F.a.19.1.P.Seq	F	M00063515B:F06	CH21PRN
256	831160	RTA22200267F.h.01.1.P.Seq	F	M00064690A:C04	CH22PRC
257	817762	RTA22200252F.k.13.1.P.Seq	F	M00063627C:F06	CH21PRN
258	377286	RTA22200266F.k.07.1.P.Seq	F	M00064624C:B03	CH22PRC
259	831160	RTA22200267F.g.24.1.P.Seq	F	M00064690A:C04	CH22PRC
260	819994	RTA22200256F.k.11.1.P.Seq	F	M00064119C:D12	CH21PRN
261	819994	RTA22200256F.k.09.1.P.Seq	F	M00064119B:H10	CH21PRN
262	373298	RTA22200259F.c.19.1.P.Seq	F	M00063533A:C12	CH22PRC
263	819894	RTA22200256F.m.03.2.P.Seq	F	M00064126C:C02	CH21PRN
264	372718	RTA22200260F.b.22.1.P.Seq	F	M00063580D:B06	CH22PRC
265	827355	RTA22200262F.1.20.1.P.Seq	F	M00064358A:G03	CH22PRC
266	819894	RTA22200255F.d.09.1.P.Seq	F	M00063931B:E10	CH21PRN
267	827355	RTA22200266F.e.07.1.P.Seq	F	M00064601C:G07	CH22PRC
268	372718	RTA22200256F.1.03.1.P.Seq	F	M00064122C:B06	CH21PRN
269	647435	RTA22200251F.b.10.1.P.Seq	F	M00063156D:H10	CH21PRN
270	450262	RTA22200265F.a.10.1.P.Seq	F	M00064514A:G10	CH22PRC
271	484703	RTA22200255F.i.20.1.P.Seq	F	M00064032D:G04	CH21PRN
272	819498	RTA22200256F.f.12.1.P.Seq	F	M00064089B:F09	CH21PRN
273	406043	RTA22200263F.i.12.1.P.Seq	F	M00064404A:B05	CH22PRC
274	817500	RTA22200255F.f.24.1.P.Seq	F	M00063945A:C03	CH21PRN
275	818180	RTA22200264F.o.18.1.P.Seq	F	M00064506A:C07	CH22PRC
276	818143	RTA22200251F.a.03.1.P.Seq	F	M00063151A:G06	CH21PRN
277	819756	RTA22200267F.a.18.1.P.Seq	F	M00064649A:E04	CH22PRC
278	406908	RTA22200257F.i.18.3.P.Seq	F	M00064176D:H10	CH21PRN
279	124863	RTA22200256F.o.21.2.P.Seq	F	M00064136C:D12	CH21PRN
280	429009	RTA22200257F.e.24.1.P.Seq	F	M00064161B:G04	CH21PRN
281	402586	RTA22200257F.i.24.3.P.Seq	F	M00064178B:A05	CH21PRN
282	400475	RTA22200254F.i.04.1.P.Seq	F	M00063890A:H04	CH21PRN
283	403453	RTA22200264F.d.12.1.P.Seq	F	M00064450C:E07	CH22PRC
284	383021	RTA22200259F.d.06.1.P.Seq	F	M00063534C:A02	CH22PRC
285	394913	RTA22200254F.p.10.1.P.Seq	F	M00063915C:E01	CH21PRN
286	831361	RTA22200263F.k.19.1.P.Seq	F	M00064414D:D06	CH22PRC
287	646020	RTA22200267F.n.21.1.P.Seq	F	M00064723C:H04	CH22PRC

Table 1

SEQ	CLUSTER	SEQ NAME	ORIENT	CLONE ID	LIBRARY
ID					
288	831361	RTA22200263F.1.03.1.P.Seq	F	M00064415B:G03	CH22PRC
289	831580	RTA22200261F.f.18.1.P.Seq	F	M00064002C:H09	CH22PRC
290	402586	RTA22200257F.j.01.3.P.Seq	F	M00064178B:A05	CH21PRN
291	400475	RTA22200262F.j.21.1.P.Seq	F	M00064349D:H01	CH22PRC
292	818937	RTA22200262F.h.14.2.P.Seq	F	M00064341A:C02	CH22PRC
293	557697	RTA22200261F.j.20.1.P.Seq	F	M00064018C:E07	CH22PRC
294	831361	RTA22200265F.m.24.1.P.Seq	F	M00064569B:A09	CH22PRC
295	194490	RTA22200252F.c.10.1.P.Seq	F	M00063520D:D08	CH21PRN
296	818143	RTA22200254F.b.18.1.P.Seq	F	M00063848C:G11	CH21PRN
297	377286	RTA22200259F.a.10.1.P.Seq	F	M00063163A:G04	CH22PRC
298	831361	RTA22200265F.n.01.1.P.Seq	F	M00064569B:A09	CH22PRC
299	385307	RTA22200255F.p.07.1.P.Seq	.F	M00064060B:D03	CH21PRN
300	378447	RTA22200251F.c.01.1.P.Seq	F	M00063158A:E11	CH21PRN
301	378447	RTA22200251F.b.24.1.P.Seq	F	M00063158A:E11	CH21PRN
302	817514	RTA22200260F.m.17.1.P.Seq	F	M00063968D:G08	CH22PRC
303	818942	RTA22200255F.f.03.1.P.Seq	F	M00063941B:C12	CH21PRN
304	818942	RTA22200267F.e.23.1.P.Seq	F	M00064678D:F05	CH22PRC
305	817363	RTA22200266F.f.04.1.P.Seq	F	M00064605C:G05	CH22PRC
306	818942	RTA22200255F.i.02.1.P.Seq	F	M00064025D:E07	CH21PRN
307	818942	RTA22200265F.g.23.1.P.Seq	F	M00064534D:F06	CH22PRC
308	817457	RTA22200267F.e.15.1.P.Seq	F	M00064675C:E09	CH22PRC
309	831968	RTA22200263F.f.23.1.P.Seq	F	M00064393B:H04	CH22PRC
310	530941	RTA22200253F.h.05.1.P.Seq	F	M00063785C:F03	CH21PRN
311	763446	RTA22200257F.j.05.3.P.Seq	F	M00064179A:C04	CH21PRN
312	763446	RTA22200255F.n.21.1.P.Seq	F	M00064053D:F02	CH21PRN
313	819219	RTA22200256F.f.16.1.P.Seq	F	M00064090C:A02	CH21PRN
314	763446	RTA22200258F.b.19.2.P.Seq	F	M00064248A:E02	CH21PRN
315	10154				
316	10154				

Table	2					
	Nearest			Nearest Neighbor		
	Neighbor		İ	(BlastX vs. Non-		
1	(BlastN vs.			Redundant		
	Genbank)			Proteins)		
SEQ	ACCESSIO	DESCRIPTION	P VALUE	ACCESSION	DESCRIPTION	P VALUE
ID	N					
19	<none></none>	<none></none>	<none< td=""><td>1077580</td><td>hypothetical</td><td>7</td></none<>	1077580	hypothetical	7
			>		protein YDR125c - yeast	
20	<none></none>	<none></none>	<none< td=""><td>4585925</td><td>(AC007211)</td><td>6</td></none<>	4585925	(AC007211)	6
			>		unknown protein	
21	<none></none>	<none></none>	<none></none>	1085306	EVI1 protein - human	4.3
22	<none></none>	<none></none>	<none ></none 	3876587	(Z81521) predicted using Genefinder; cDNA EST yk233g4.5 comes from this gene; cDNA EST yk233g4.3 comes from this gene [Caenorhabditis elegans]	0.85
23	<none></none>	<none></none>	<none ></none 	1086591	(U41007) similar to S. cervisiae nuclear protein SNF2	0.34
24	<none></none>	<none></none>	<none ></none 	157272	(L11345) DNA- binding protein [Drosophila melanogaster]	0.29
25	<none></none>	<none></none>	<none></none>	2633160	(Z99108) similar to surface adhesion YfiQ [Bacillus subtilis]	0.19
26	<none></none>	<none></none>	<none ></none 	755468	(U19879) transmembrane protein [Xenopus laevis]	0.042
27	<none></none>	<none></none>	<none ></none 	4507339	T brachyury (mouse) homolog protein [Homo sapiens]	0.029

PCT/US01/09952 WO 01/72781

Table 2

Table	e 2			1		
	Nearest			Nearest Neighbor		
	Neighbor			(BlastX vs. Non-		
	(BlastN vs.			Redundant		141
	Genbank)	· ·		Proteins)		
28	<none></none>	<none></none>	<none ></none 	729711	PROTEASE DEGS PRECURSOR 3.4.21) hhoB - Escherichia coli > gi 558913 (U15661) HhoB [Escherichia coli] > gi 606174 (U18997) ORF_0355 coli] > gi 1789630 (AE000402) protease [Escherichia coli]	0.004
29	<none></none>	<none></none>	<none ></none 	3168911	(AF068718) No definition line found [Caenorhabditis elegans]	8e-013
30	<none></none>	<none></none>	<none< td=""><td>2832777</td><td>(AL021086) /prediction=(me thod:; comes from the 5' UTR [Drosophila melanogaster]</td><td>3e-040</td></none<>	2832777	(AL021086) /prediction=(me thod:; comes from the 5' UTR [Drosophila melanogaster]	3e-040
31	X78712	H.sapiens mRNA for glycerol kinase testis specific 2	2.1	2852449	(D88207) protein kinase [Arabidopsis thaliana] > gi 2947061 (AC002521) putative protein kinase	9.1
32	X60760	L.esculentum TDR8 mRNA	2.1	157272	(L11345) DNA- binding protein [Drosophila melanogaster]	5

Table	e 2					
	Nearest Neighbor (BlastN vs. Genbank)			Nearest Neighbor (BlastX vs. Non- Redundant Proteins)		
33	U40853	Oryctolagus cuniculus pulmonary surfactant protein B (SP-B) gene, complete cds	2	<none></none>	<none></none>	<none ></none
34	AF083655	Homo sapiens procollagen C- proteinase enhancer protein (PCOLCE) gene, 5' flanking region and complete cds	2	<none></none>	<none></none>	<none ></none
35	AJ223776	Staphylococcus warneri hld gene	2	<none></none>	<none></none>	<none ></none
36	U40853	Oryctolagus cuniculus pulmonary surfactant protein B (SP-B) gene, complete cds	2	<none></none>	<none></none>	<none ></none
37	X04436	Clostridium tetani gene for tetanus toxin	2	<none></none>	<none></none>	<none ></none
38	Z35787	S.cerevisiae chromosome II reading frame ORF YBL026w	2	157272	(L11345) DNA- binding protein [Drosophila melanogaster]	8.4
39	X78712	H.sapiens mRNA for glycerol kinase testis specific 2	2	2852449	(D88207) protein kinase [Arabidopsis thaliana] > gi 2947061 (AC002521) putative protein kinase	8.2

T_{α}	hla	2
1 2	ınıe	

Table	Table 2					
	Nearest Neighbor (BlastN vs. Genbank)		-	Nearest Neighbor (BlastX vs. Non- Redundant Proteins)		
40	Z15056	B.subtilis genes spoVD, murE, mraY, murD	2	477124	P3A2 DNA binding protein homolog EWG - fruit fly (Drosophila melanogaster)	2.8
41	S65623	cAMP-regulated enhancer- binding protein 1 of 3]		119266	PROTEIN GRAINY- HEAD (DNA- BINDING PROTEIN ELF- 1) (ELEMENT I-BINDING ACTIVITY) regulatory protein elf-1 - fruit fly (Drosophila melanogaster) > gi 7939 emb CAA33692 (X15657) Elf-1 protein (AA 1- 1063) [Drosophila melanogaster]	0.55
42	NM_004415 .1	desmoplakin (DPI, DPII) (DSP) mRNA mRNA, complete cds	2	2649177	(AE001008) conserved hypothetical protein [Archaeoglobus fulgidus]	0.2
43	AF031552	Vibrio cholerae magnesium transporter (mgtE) gene, partial cds; sensor kinase (vieS), response regulator (vieA), and response regulator (vieB) genes, complete cds; and collagenase (vcc) gene,		2088714	(AF003139) strong similarity to NADPH oxidases; partial CDS, the gene begins in the neighboring clone	2e-013

Tab!	le 2			1		
·····	Nearest			Nearest Neighbor		
	Neighbor		!	(BlastX vs. Non-		
	(BlastN vs.			Redundant		
	Genbank)		·	Proteins)		
	Genbank)	(vcc) gene, partial cds		·		
44	AF116852.1	Danio rerio dickkopf-1 (dkk1) mRNA, complete cds	2	3800951	(AF100657) No definition line found [Caenorhabditis elegans]	2e-019
45	X82595	P.sativum fuc gene .	1.9	<none></none>	<none></none>	<none></none>
46	AF008216	Homo sapiens candidate tumor suppressor pp32r1	1.9	<none></none>	<none></none>	<none ></none
47	AF130672.1	Felis catus clone Fca603 microsatellite sequence	1.9	<none></none>	<none></none>	<none< td=""></none<>
48	AJ007044	Oryctolagus Cuniculus sod gene	1.9	388055	(L22981) merozoite surface protein- 1 [Plasmodium chabaudi]	7.8
49	AC004497	Homo sapiens chromosome 21, P1 clone LBNL#6	1.9	160925	(M94346) A.1.12/9 antigen [Schistosoma mansoni]	7.7

Table 2

Table	2					
	Nearest Neighbor (BlastN vs. Genbank)			Nearest Neighbor (BlastX vs. Non- Redundant Proteins)		
50	U30290	Rattus norvegicus galanin receptor GALR1 mRNA, complete cds	1.9	3024079	GALECTIN-4 (LACTOSE-BINDING LECTIN 4) (L- 36 LACTOSE BINDING PROTEIN) (L36LBP) > gi 2281707 sapiens] > gi 2623387 (U82953) galectin-4 [Homo sapiens]	4.5
51	Y13234	Chironomus tentans mRNA for chitinase, 1695 bp	1.9	4567068	(AF125568) tumor suppressing STF cDNA 4 [Homo sapiens]	3.4
52	NM_003644 .1	Homo sapiens growth arrest-specific 7 (GAS7) mRNA > :: emb AJ224876 HSAJ4876 Homo sapience mRNA for GAS7 protein	1.9	125560	PROTEIN KINASE C, GAMMA TYPE C (EC 2.7.1) gamma - rabbit > gi 165652 (M19338) protein kinase delta [Oryctolagus cuniculus]	0.53
53	AB013448.1	Oryza sativa gene for Pib, complete cds	1.8	<none></none>	<none></none>	<none ></none
54	D63854	Human cytomegalovirus DNA,replication origin	1.8	<none></none>	<none></none>	<none></none>
55	AB002340	Human mRNA for KIAA0342 gene, complete cds	1.8	<none></none>	<none></none>	<none></none>
56	AF017779	Mus musculus vitamin D receptor gene, promoter region	1.8	<none></none>	<none></none>	<none></none>

Tab						
	Nearest Neighbor (BlastN vs. Genbank)			Nearest Neighbor (BlastX vs. Non- Redundant Proteins)		
57	D63854	Human cytomegalovirus DNA, replication origin	1.8	<none></none>	<none></none>	<none ></none
58	M24102	Bovine ADP/ATP translocase T1 mRNA, complete cds.	1.8	<none></none>	<none></none>	<none ></none
59	AC004497	Homo sapiens chromosome 21, P1 clone LBNL#6	1.8	<none></none>	<none></none>	<none ></none
60	M37394	Rat epidermal growth factor receptor mRNA.	1.8	<none></none>	<none></none>	<none ></none
61	AF006304	Saccharomyces cerevisiae protein tyrosine phosphatase (PTP3) gene, complete cds	1.8	<none></none>	<none></none>	<none< td=""></none<>
62	D13454	Candida albicans CACHS3 gene for chitin synthase III	1.8	<none></none>	<none></none>	<none ></none
63	Y00354	Xenopus laevis gene encoding vitellogenin A2	1.8	1077580	hypothetical protein YDR125c - yeast	7.5
64	U90936	Aspergillus niger px27 gene, promoter region	1.8	4337033	(AF124138) transcriptional activator protein CdaR [Streptomyces coelicolor] transcriptional regulator [Streptomyces coelicolor]	7.3

Table 2 Nearest Neighbor Nearest (BlastX vs. Non-Neighbor (BlastN vs. Redundant Genbank) Proteins) 65 D84448 Cavia cobaya 1.8 4704603 (AF109916) 7.1 putative mRNA for Na+,K+dehydrin ATPase beta-3 subunit, complete cds 66 AF039948 Xenopus laevis 1.8 1695839 (U58151) 5.6 clone H-0 envelope transcription glycoprotein elongation factor [Human S-II (TFIIS) immunodeficien precursor RNA, cy virus type 1] isoform TFIIS.h, partial cds 67 M18061 Xenopus laevis 1.8 780502 (U18466) AP 3.1 vitelloginin endonuclease gene, complete class II [African swine fever cds. virus] > gi | 1097525 | prf | 2113434ET AP endonuclease: IS OTYPE=class II [African swine fever virus] 68 U61112 Mus musculus 1.8 (AB011133) 3043646 1.9 Eya3 homolog **KIAA0561** mRNA, protein [Homo complete cds sapiens] (AF116463) 69 AB018442 Oryza sativa 1.8 4455041 0.49 mRNA for unknown phytochrome C, [Streptomyces complete cds lincolnensis]

Table 2

Tabl	e 2					
	Nearest			Nearest Neighbor		
	Neighbor			(BlastX vs. Non-		
	(BlastN vs.			Redundant		
	Genbank)			Proteins)		
70	D63854	Human	1.8	1169200	DNA-	0.22
		cytomegalovirus			DAMAGE-	
		DNA, replication			REPAIR/TOLE	
		origin			RATION]
				1	PROTEIN	
				1	DRT111	
					PRECURSOR	
					>gi 421829 pi	
					r S33706	
					DNA-damage	
			:		resistance	
					protein -	
					Arabidopsis	
					thaliana and	
					DNA-damage	
					resistance	
l					protein	
					(DRT111)	
					mRNA,	
					complete cds.],	
					gene product	
					[Arabidopsis	
					thaliana]	
71	D26549	Bovine mRNA	1.8	755468	(U19879)	0.042
1		for adseverin,			transmembrane	
		complete cds			protein	
					[Xenopus laevis]	
72	J05211	Human	1.8	728867	ANTER-	0.015
		desmoplakin			SPECIFIC	
		mRNA, 3' end.			PROLINE-	
					RICH	
i					PROTEIN APG	
					PRECURSOR	
					>gi 99694 pir	
					S21961	
					proline-rich	
					protein APG -	
					Arabidopsis	
					thaliana	
					>gi 22599 em	
	L				b CAA42925	

Table 2 Nearest Nearest Neighbor Neighbor (BlastX vs. Non-(BlastN vs. Redundant Genbank) Proteins) 73 NM 004415 Homo sapiens 1.8 0.015 728867 ANTER-.1 desmoplakin **SPECIFIC** (DPI, DPII) PROLINE-(DSP) mRNA **RICH** mRNA. PROTEIN APG complete cds **PRECURSOR** > gi | 99694 | pir||S21961 proline-rich protein APG -Arabidopsis thaliana > gi | 22599 | emb | CAA42925 | 74 AF038604 Caenorhabditis (Z81555) 1.8 3877951 3e-008 predicted using elegans cosmid B0546 Genefinder 75 AF038604 Caenorhabditis 3877951 (Z81555) 1.8 2e-011 elegans cosmid predicted using B0546 Genefinder 76 U23551 Prochlorothrix 1.8 2828280 (AL021687) 2e-013 hollandica putative protein phosphomannom [Arabidopsis thaliana] utase >gi|2832633|e mb | CAA16762 (AL021711) putative protein [Arabidopsis thalianal 77 S60150 ORF1...ORF6 1.8 1065454 (U40410) 2e-019 {3' terminal C54G7.2 gene reigon} product [chrysanthemum] [Caenorhabditis virus B CVB, elegans Genomic RNA, 6 genes, 3426 ntl 78 AB014558 (AL033385) Homo sapiens 1.83850072 6e-027 mRNA for dna-directed rna KIAA0658 polymerase iii protein, partial subunit [Schizosaccharo cds myces pombe]

Table	e 2			I		
	Nearest Neighbor (BlastN vs. Genbank)		÷	Nearest Neighbor (BlastX vs. Non- Redundant Proteins)		
79	X17191	E.gracilis chloroplast RNA polymerase rpoB-rpoC1- rpoC2 operon	1.7	<none></none>	<none></none>	<none ></none
80	X07729	R.norvegicus gene encoding neuron-specific enolase, exons 8-12	1.7	4584544	(AL049608) extensin-like protein	8.8
81	D38178	Human gene for cytosolic phospholipase A2, exon 1	1.7	73714	infected cell protein ICP34.5 - human herpesvirus 1 (strain F) > gi 330123 (M12240) infected cell protein [Herpes simplex virus type 1]	1.1
82	U23551	Prochlorothrix hollandica phosphomannom utase	1.7	2828280	(AL021687) putative protein [Arabidopsis thaliana] > gi 2832633 e mb CAA16762 (AL021711) putative protein [Arabidopsis thaliana]	2e-010
83	Y00525	Klebsiella pneumoniae nifL gene for regulatory protein	1.6	3800951	(AF100657) No definition line found [Caenorhabditis elegans]	6e-013
84	AF100170.1	Bos taurus major fibrous sheath protein precursor, mRNA, complete cds	1.5	463552	(U05877) AF-1 [Homo sapiens]	0.074
85	Y13441	Homo sapiens Rox gene, exon 2	0.74	<none></none>	<none></none>	<none ></none

Table	e 2			1		
	Nearest Neighbor (BlastN vs. Genbank)			Nearest Neighbor (BlastX vs. Non- Redundant Proteins)		
86	L46792	Actinidia deliciosa clone AdXET-5 xyloglucan endotransglycos ylase precursor (XET) mRNA, complete cds	0.73	3170252	(AF043636) circumsporozoit e protein [Plasmodium chabaudi]	0.001
87	U73489	Drosophila melanogaster Nem (nem) mRNA, complete cds	0.7	3915994	HYPOTHETIC AL 53.2 KD PROTEIN IN PRC-PRPA INTERGENIC REGION	3e-005
88	U95097	Xenopus laevis mitotic phosphoprotein 43 mRNA, partial cds	0.68	157272	(L11345) DNA- binding protein [Drosophila melanogaster]	8.5
89	AF082012	Caenorhabditis elegans UDP-N- acetylglucosami ne:a-3-D- mannoside b- 1,2-N- acetylglucosami nyltransferase I (gly-14) mRNA, complete cds	0.67	2494313	PUTATIVE TRANSLATIO N INITIATION FACTOR EIF- 2B SUBUNIT 1 (EIF-2B GDP- GTP EXCHANGE FACTOR) eIF- 2B, subunit alpha - Methanococcus jannaschii aIF- 2B, subunit delta (aIF2BD) [Methanococcus jannaschii]	8.4
90	U04354	Mus musculus ADSEVERIN mRNA, complete cds	0.67	4755188	(AC007018) unknown protein	8e-026

PCT/US01/09952 WO 01/72781

Table 2

Tabl	e 2			1		
-	Nearest Neighbor (BlastN vs. Genbank)			Nearest Neighbor (BlastX vs. Non- Redundant Proteins)		
91	M68881	S.pombe cigl+ gene, complete cds.	0.67	2078441	(U56964) weak similarity to S. cerevisiae intracellular protein transport protein US)1 (SP:P25386)	2e-030
92	U95097	Xenopus laevis mitotic phosphoprotein 43 mRNA, partial cds	0.66	2829685	PROTEIN- TYROSINE PHOSPHATAS E X PRECURSOR (R-PTP-X) (PTP IA- 2BETA) (PROTEIN TYROSINE PHOSPHATAS E-NP) (PTP- NP) > gi 1515425 (U57345) protein tyrosine phosphatase-NP [Mus musculus]	6.2
93	Z15056	B.subtilis genes spoVD, murE, mraY, murD	0.66	477124	P3A2 DNA binding protein homolog EWG - fruit fly (Drosophila melanogaster)	2.1
94	M86808	Human pyruvate dehydrogenase complex (PDHA2) gene, complete cds.	0.65	<none></none>	<none></none>	<none ></none
95	J03754	Rat plasma membrane Ca2+ ATPase- isoform 2 mRNA, complete cds.	0.65	4507549	transmembrane protein with EGF-like and two follistatin-like domains 1 > gi 755466	8e-006

T	ał	١Ĭ	Δ.	7
10	Ш	"	_	~

Tabl	e 2					
	Nearest			Nearest Neighbor		
}	Neighbor			(BlastX vs. Non-		
	(BlastN vs.			Redundant		
	Genbank)			Proteins)		
96	NM 000887	Homo sapiens	0.64	<none></none>	<none></none>	<none< td=""></none<>
	1.1	integrin, alpha		1210212	41101127	>
		X (antigen				-
		CD11C				
	1	emb Y00093 H				
		SP15095				
		H.sapiens				
		mRNA for				
		leukocyte		·		
		adhesion				
		glycoprotein				
		p150,95				
97	L27080	Human	0.64	<none></none>	<none></none>	<none< td=""></none<>
	127000	melanocortin 5	0.04	\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\		> NONE
		receptor				
		(MC5R) gene,				
		complete cds.				
		complete cus.				
98	U07890	Mus musculus	0.64	<none></none>	<none></none>	<none< td=""></none<>
		C57BL/6J				>
		epidermal				
		surface antigen		0		
		(mesa) mRNA,				
		complete cds.				
	1,7050100				(======================================	
99	AF079139	Streptomyces	0.64	3041869	(U96109)	2.8
		venezuelae			proline-rich	
		pikCD operon,			transcription	
1		complete			factor ALX3	
		sequence			[Mus musculus]	
100	M16140	Chicken	0.64	123984	ACROSIN	4e-008
		ovoinhibitor			INHIBITORS	
		gene, exon 15.			IIA AND IIB	
101	NM 000887	Homo sapiens	0.63	<none></none>	<none></none>	<none< td=""></none<>
	1.1	integrin, alpha				>
		X (antigen				
		CD11C				
		emb Y00093 H				
		SP15095				
		H.sapiens				
		mRNA for				
		leukocyte				
		adhesion	•			
		glycoprotein				
		p150,95				
	.L	12-20,25				

Table	e 2			1		
	Nearest Neighbor (BlastN vs. Genbank)			Nearest Neighbor (BlastX vs. Non- Redundant Proteins)		
102	Z17316	Kluyveromyces lactis for gene encoding phosphofructoki nase beta subunit	0.63	<none></none>	<none></none>	<none ></none
103	Z25470	H.sapiens melanocortin 5 receptor gene, complete CDS	0.63	<none></none>	<none></none>	<none></none>
104	L19954	Bacillus subtilis feuA, B, and C genes, 3 ORFs, 2 complete cds's and 5'end.	0.63	<none></none>	<none></none>	<none></none>
105	U44405	Spiroplasma citri chromosome pre-inversion border, SPV1-like sequences, transposase gene, partial cds, adhesin-like protein P58 gene, complete cds.	0.63		SERINE/THRE ONINE- PROTEIN KINASE STE20 HOMOLOG > gi 1737181 (U73457) Cst20p [Candida albicans]	7.7

PCT/US01/09952 WO 01/72781

Table 2

Table		T	1	NT		
	Nearest		Ĺ	Nearest Neighbor		
	Neighbor			(BlastX vs. Non-		
	(BlastN vs.			Redundant		
100	Genbank)			Proteins)		
106	Z28264	S.cerevisiae chromosome XI reading frame ORF YKR039w	0.63	3880930	(AL021481) similar to Phosphoglucom utase and phosphomannom utase phosphoserine; cDNA EST EMBL:D36168 comes from this gene; cDNA EST EMBL:D70697 comes from this gene; cDNA	2e-014
.07	AE001107	Archaeoglobus	0.62	<none></none>	EST yk373h9.5 comes from this gene; cDNA EST EMBL:T00805	
		fulgidus section 172 of 172 of the complete genome				>
108	Z14112	B.firmus TopA gene encoding DNA topoisomerase I	0.62	310115	(L02530) Drosophila polarity gene (frizzled) homologue	0.026
109	AF118101	Toxoplasma gondii protein kinase 6 (tpk6) mRNA, complete cds	0.62	726403	similar to anion exchange protein [Caenorhabditis elegans]	4e-018
110	M59743	Rabbit cardiac muscle Ca-2+ release channel	0.61	<none></none>	<none></none>	<none ></none
111	M12036	Human tyrosine kinase-type receptor (HER2) gene, partial cds.	0.61	61962	(X58484) gag [Simian foamy virus]	7.5

Table	2			I		
	Nearest Neighbor (BlastN vs. Genbank)			Nearest Neighbor (BlastX vs. Non- Redundant Proteins)		
112	AF043195	Homo sapiens tight junction protein ZO (ZO- 2) gene, alternative splice products, promoter and exon A	0.61	1572629	(U69699) unknown protein precursor [Mus musculus]	7.5
113	U18178	Human HLA class I genomic survey sequence.	0.61	1336688	(S81116) properdin [guinea pigs, spleen, Peptide, 470 aa] [Cavia]	5.7
114	U44405	Spiroplasma citri chromosome pre-inversion border, SPV1-like sequences, transposase gene, partial cds, adhesin-like protein P58 gene, complete cds.	0.61	2827531	(AL021633) hypothetical protein	3.3
115	Z33011	M.capricolum DNA for CONTIG MC008	0.61	3915729	HYPERPLASTI C DISCS PROTEIN (HYD PROTEIN) > gi 2673887 (L14644) hyperplastic discs protein	0.26
116	NM_001429 .1	Homo sapiens E1A binding protein p300 mRNA, complete cds. > :: gb I62297 I622 97 Sequence 1 from patent US 5658784	0.61	4204294	(AC003027) lcl prt_seq No definition line found	5e-005

Table 2 Nearest Nearest Neighbor Neighbor (BlastX vs. Non-(BlastN vs. Redundant Genbank) Proteins) 117 Z25418 C.familiaris 0.61 3877493 (Z48583) 1e-007 MHC class Ib similar to gene (DLA-79) **ATPases** gene, complete associated with CDS various cellular activities (AAA); cDNA **EST** EMBL:Z14623 comes from this gene; cDNA **EST** EMBL:D75090 comes from this gene; cDNA **EST** EMBL:D72255 comes from this gene; cDNA EST yk200e4.5 118 AB002150 Bacillus subtilis <NONE> 0.6 <NONE> <NONE DNA for FeuB, > FeuA, YbbB, YbbC, YbbD, YbzA, YbbE, YbbF, YbbH, YbbI, YbbJ, YbbK, YbbL, YbbM, YbbP, complete cds 119 Y07786 V.cholerae 0.6 <NONE> <NONE> < NONE ORF's involved >

in

Z17316

120

lipopolysacchari de synthese

Kluyveromyces

phosphofructoki

lactis for gene

encoding

nase beta subunit 0.6

Table 2 Nearest Nearest Neighbor Neighbor (BlastX vs. Non-(BlastN vs. Redundant Genbank) Proteins) 121 Z71403 S.cerevisiae 0.6 <NONE> <NONE> < NONE chromosome > XIV reading frame ORF YNL127w 122 L34641 Homo sapiens 0.6 1147634 (U42213) 9.6 platelet/endothel micronemal ial cell adhesion TRAP-C1 molecule-1 protein homolog (PECAM-1) gene, exon 10. 123 AF070572 399034 Homo sapiens 0.6 N-2.5 clone 24778 **ACETYLMUR** unknown AMOYL-LmRNA ALANINE AMIDASE **AMIB PRECURSOR** >gi|628763|pi r | | S41741 Nacetylmuramoyl-L-alanine amidase (EC 3.5.1.28) -Escherichia coli > gi | 304914(L19346) Nacetylmuramoyl-L-alanine amidase [Escherichia colil Nacetylmuramoyl-1-alanine amidase II; a C.burnetii trxB. 124 X75627 0.6 3036833 (AJ003163) 0.28 spoIIIE and serS apsB genes [Emericella nidulansl Z99765 Flaveria pringlei 0.59 125 <NONE> <NONE> < NONE gdcsH gene

Table	2					
	Nearest			Nearest Neighbor		
	Neighbor			(BlastX vs. Non-		
	(BlastN vs.			Redundant		
	Genbank)			Proteins)		<u> </u>
126	U02538	Mycoplasma	0.59	<none></none>	<none></none>	<none< td=""></none<>
		hyopneumoniae				>
		J ATCC 25934				
		23S rRNA gene,	1			
		partial sequence				
127	Z71403	S.cerevisiae	0.59	<none></none>	<none></none>	<none< td=""></none<>
		chromosome				>
		XIV reading				
l		frame ORF				
		YNL127w				
128	X03942	Mouse simple	0.59	<none></none>	<none></none>	<none< td=""></none<>
		repetitive DNA	l .			>
1		(sqr family)				
		transcript (clone pmlc 2) with				
		conserved	,			
		GACA/GATA				
		repeats				
129	U11844	Mus musculus	0.59	<none></none>	<none></none>	<none< td=""></none<>
1	1	glucose				>
		transporter				
	İ	(GLUT3) gene,				
		exon 1				
130	D63395	Homo sapiens	0.59	4433616	(AF107018)	1.8
		mRNA for	<u> </u>	•	alpha-	
		NOTCH4,			mannosidase IIx	
		partial cds			[Mus musculus]	
131	Z33011	M.capricolum	0.59	3915729	HYPERPLASTI	0.27
	<u> </u>	DNA for			C DISCS	
		CONTIG			PROTEIN	
		MC008			(HYD	
					PROTEIN)	
				,	>gi 2673887	
					(L14644)	
					hyperplastic discs protein	,
132	U05670	Haemophilus	0.58	<none></none>	<none></none>	<none< td=""></none<>
		influenzae DL42				>
		Lex2A and				
		Lex2B genes,				
	1	complete cds.				
1		_	l .			1

Table	e 2			1		
	Nearest Neighbor (BlastN vs. Genbank)			Nearest Neighbor (BlastX vs. Non- Redundant Proteins)		
133	L27080	Human melanocortin 5 receptor (MC5R) gene, complete cds.	0.58	123984	ACROSIN INHIBITORS IIA AND IIB	2e-006
134	AF043195	Homo sapiens tight junction protein ZO (ZO- 2) gene, alternative splice products, promoter and exon A	0.57	1572629	(U69699) unknown protein precursor [Mus musculus]	6.7
135	U57707	Bos taurus activin receptor type IIB precursor	0.57	807646	(M17294) unknown protein [Human herpesvirus 4]	0.068
136	Z17316	Kluyveromyces lactis for gene encoding phosphofructoki nase beta subunit	0.56	<none></none>	<none></none>	<none ></none
137	M21535	Human erg protein (ets- related gene) mRNA, complete cds.	0.56	<none></none>	<none></none>	<none ></none
138	M64932	Candida maltosa cyclohexamide resistance protein	0.56	3219524	(AF069428) NADH dehydrogenase subunit IV [Alligator mississippiensis] > gi 3367630 e mb CAA73570 (Y13113) NADH dehydrogenase subunit 4 [Alligator mississippiensis]	1.3

PCT/US01/09952 WO 01/72781

Table 2

Table	e 2			i		
	Nearest Neighbor (BlastN vs. Genbank)			Nearest Neighbor (BlastX vs. Non- Redundant Proteins)		
139	AE000342	Escherichia coli K-12 MG1655 section 232 of 400 of the complete genome	0.56	3874685	(Z78539) Similarity to S.pombe hypothetical protein C4G8.04 (SW:YAD4_SC HPO); cDNA EST EMBL:D27846 comes from this gene; cDNA EST EMBL:D27845 comes from this gene; cDNA EST yk202h7.3 comes from this gene; cDNA EST yk202h7.5 come	0.088
140	Z15056	B.subtilis genes spoVD, murE, mraY, murD	0.55	477124	P3A2 DNA binding protein homolog EWG - fruit fly (Drosophila melanogaster)	3.7
141	Z58167	H.sapiens CpG island DNA genomic Mse1 fragment, clone 30e10, forward read cpg30e10.ft1b	0.53	<none></none>	<none></none>	<none ></none
142	M27159	Rat potassium channel-Kv2 gene, partial cds.	0.53	1850920	(U21247) Bet [Human spumaretrovirus	0.9
143	M15555	Mouse Ig germline V- kappa-24 chain (VK24C) gene, exons 1 and 2.	0.24	<none></none>	<none></none>	<none ></none

Table	2					
	Nearest Neighbor (BlastN vs. Genbank)			Nearest Neighbor (BlastX vs. Non- Redundant Proteins)		
144	U95097	Xenopus laevis mitotic phosphoprotein 43 mRNA, partial cds	0.24	399109	TRANSCRIPTI ON FACTOR BF-1 (BRAIN FACTOR 1) (BF1) >gi 92020 pir JH0672 brain factor 1 protein - rat >gi 203135 (M87634) BF-1 [Rattus norvegicus]	4
145	AJ002014	Crythecodinium cohnii mRNA for nuclear protein JUS1	0.24	416704	BALBIANI RING PROTEIN 3 PRECURSOR balbiani ring 3 (BR3) [Chironomus tentans]	0.36
146	L35330	Rattus norvegicus glutathione S- transferase Yb3 subunit gene, complete cds.	0.23	1388158	(U58204) myomesin [Gallus gallus]	8.8
147	NM_001432 .1	Homo sapiens epiregulin (EREG) mRNA > :: dbj D30783 D3 0783 Homo sapiens mRNA for epiregulin, complete cds	0.23	2851520	TRANSFORMI NG GROWTH FACTOR ALPHA PRECURSOR (TGF-ALPHA) (EGF-LIKE TGF) (ETGF) (TGF TYPE 1) precursor - rat > gi 207282 (M31076) transforming growth factor alpha precursor [Rattus norvegicus]	2e-008

Table 2 Nearest Neighbor Nearest Neighbor (BlastX vs. Non-(BlastN vs. Redundant Genbank) Proteins) 148 Cebus apella 0.22 U57043 <NONE> <NONE> < NONE gamma globin (gamma1) gene, complete cds 149 AB023188.1 Homo sapiens 0.22 <NONE> <NONE> < NONE mRNA for > **KIAA0971** protein, complete cds 150 M18105 Yeast 0.22 <NONE> <NONE> <NONE (S.cerevisiae) > SST2 gene encoding desensitization to alpha- factor pheromone, complete cds. 151 AJ001113 0.22 3122961 Homo sapiens **ENHANCER** 8.5 UBE3A gene, OF SPLIT exon 16 **GROUCHO-**LIKE PROTEIN 1 > gi | 2408145(U18775) enhancer of split groucho L35330 0.22 152 Rattus 1388158 (U58204) 8.1 norvegicus myomesin glutathione S-[Gallus gallus] transferase Yb3 subunit gene, complete cds. 153 D42042 Human mRNA 0.22 4827063 zinc finger 6.1 protein 142 for KIAA0085 gene, partial cds (clone pHZ-49) > gi|3123312|sp | P52746 | Z142 HUMAN ZINC FINGER PROTEIN 142 (KIAA0236) (HA4654) > gi | 1510147 | dbi BAA13242

Table	e 2					
	Nearest Neighbor (BlastN vs. Genbank)			Nearest Neighbor (BlastX vs. Non- Redundant Proteins)		
154	L35330	Rattus norvegicus glutathione S- transferase Yb3 subunit gene, complete cds.	0.22	2853301	(AF007194) mucin [Homo sapiens]	1.6
155	Z11653	H.sapiens DBH gene complex repeat polymorphism DNA	0.22	3819705	(AL032824) syntaxin binding protein 1; sec1 family secretor y protein [Schizosaccharo myces pombe]	1.2
156	L29063	Candida albicans fatty acid synthase alpha subunit (FAS2) gene, complete cds.	0.22	3046871	(AB003753) high sulfur protein B2E [Rattus norvegicus]	0.32
157	M64865	Horse alcohol dehydrogenase- S-isoenzyme mRNA, complete cds.	0.22	2213909	(AF004874) latent TGF-beta binding protein- 2 [Mus musculus]	0.037
158	Y09472	B.taurus gene encoding preprododecape ptide	0.21	2909874	(AF047829) melatonin- related receptor [Ovis aries]	7.6
159	Y09472	B.taurus gene encoding preprododecape ptide	0.21	2909874	(AF047829) melatonin- related receptor [Ovis aries]	7.5
160	X80301	N.tabacum axi 1 gene	0.21	2832715	(AJ003066) subunit beta of the mitochondrial fatty acid beta- oxydation multienzyme complex [Bos taurus]	6

Table 2 Nearest Nearest Neighbor (BlastX vs. Non-Neighbor (BlastN vs. Redundant Genbank) Proteins) 161 AF073485 0.21 Homo sapiens 2224559 (AB002307) 3.3 MHC class I-KIAA0309 related protein [Homo sapiens] MR1 precursor (MR1) gene, partial cds 162 S78251 growth hormone 0.21 729381 DYNAMIN-1 receptor (DYNAMIN {alternatively BREDNM19) spliced, exon 1B} [sheep, Merino, skeletal muscle, mRNA. Partial, 438 nt] 163 U16135 Synechococcus 0.21 135514 T-CELL 0.02 sp. Clp protease RECEPTOR proteolytic BETA CHAIN subunit **PRECURSOR** precursor (ANA 11) - rabbit 164 X95601 (Y10496) CDV-M.hominis lmp3 0.21 2995445 0.005 and lmp4 genes 1 protein [Mus musculus] M.hominis lmp3 0.21 165 (Y10495) CDV-X95601 2995447 0.005 and lmp4 genes 1R protein [Mus musculus] AF124249.1 Homo sapiens 0.21epidermal 166 423456 8e-010 SH2-containing growth factorprotein Nsp1 receptor-binding mRNA, protein GRB-4 complete cds mouse (fragment) 167 AF030282 Danio rerio 0.21 (AC005770) 3928083 2e-014 homeobox unknown protein protein Six7 [Arabidopsis (six7) mRNA, thaliana] complete cds 168 X83427 0.21 RIBONUCLEA O.anatinus 132575 3e-021 mitochondrial SE INHIBITOR DNA, complete genome

Table	2					
169	Nearest Neighbor (BlastN vs. Genbank) AJ001113	Homo sapiens	0.2	Nearest Neighbor (BlastX vs. Non- Redundant Proteins)	<none></none>	<none< td=""></none<>
109	AJUUTTS	UBE3A gene, exon 16	0.2	<none></none>	< NONE>	> NONE
170	AF081533.1	Anopheles gambiae putative gram negative bacteria binding protein gene, complete cds	0.2	<none></none>	<none></none>	<none ></none
171	U70316	Dictyostelium discoideum IonA (iona) gene, partial cds	0.2	<none></none>	<none></none>	<none ></none
172	AF009341	Homo sapiens E6-AP ubiquitin-protein ligase	0.2	<none></none>	<none></none>	<none ></none
173	L35330	Rattus norvegicus glutathione S- transferase Yb3 subunit gene, complete cds.	0.2	3702275	(AC005793) KIAA0561 protein [AA 1- 593] [Homo sapiens]	2.5
174	AE000573.1	pylori 26695 section 51 of 134 of the complete genome	0.2	3947855	(AL034381) putative Golgi membrane protein	2.5
175	X83230	G.gallus hsp90beta gene	0.2	3258596	(U95821) putative transmembrane GTPase [Drosophila melanogaster]	0.81
176	X57157	Chicken mRNA for Hsp47, heat shock protein 47	0.2	108325	insulin-like growth factor- binding protein 6	0.17

Tabl	e 2			ı		
	Nearest Neighbor (BlastN vs. Genbank)			Nearest Neighbor (BlastX vs. Non- Redundant Proteins)		
177	M58748	Chicken alphaglobin gene domain with structural matrix attachment sites.	0.2	1086863	(U41272) T03G11.6 gene product [Caenorhabditis elegans]	4e-005
178	AB016815	Anthocidaris crassispina mRNA for Src- type protein tyrosine kinase, complete cds	0.2	423456	epidermal growth factor- receptor-binding protein GRB-4 - mouse (fragment)	1e-012
179	AF030282	Danio rerio homeobox protein Six7 (six7) mRNA, complete cds	0.2	3928083	(AC005770) unknown protein [Arabidopsis thaliana]	3e-014
180	AL035559	Streptomyces coelicolor cosmid 9F2	0.2	2088714	(AF003139) strong similarity to NADPH oxidases; partial CDS, the gene begins in the neighboring clone	3e-022
181	S79641	SDH=succinate dehydrogenase flavoprotein subunit Mutant, 387 nt]	0.2	4755188	(AC007018) unknown protein	2e-022
182	X75383	H.sapiens mRNA for TFIIA-alpha	0.19	<none></none>	<none></none>	<none ></none
183	U53901	Hippopotamus amphibius b- casein gene, exon 7, partial cds	0.19	<none></none>	<none></none>	<none ></none
184	J05265	Mouse interferon gamma receptor mRNA, complete cds.	0.19	77356	hypothetical 70K protein - eggplant mosaic virus	0.0005

Table	e 2			1		
	Nearest Neighbor (BlastN vs. Genbank)			Nearest Neighbor (BlastX vs. Non- Redundant Proteins)		
185	U72353	Rattus norvegicus lamin B1 mRNA, complete cds	0.19	3880857	(AL031633) cDNA EST yk404d1.5 comes from this gene; cDNA EST yk404d1.3 comes from this gene	2e-006
186	AB016815	Anthocidaris crassispina mRNA for Src- type protein tyrosine kinase, complete cds	0.19	3930217	(AF047487) Nck-2 [Homo sapiens]	2e-007
187	D10911	Mus musculus DNA for MS2 protein, complete cds	0.19	2662366	(D86332) membrane type- 2 matrix metalloproteinas e [Mus musculus]	5e-011
188	AB015345	Homo sapiens HRIHFB2216 mRNA, partial cds	0.075	3877417	(Z66564) similar to anion exchange protein	6.4
189	AF086410	Homo sapiens full length insert cDNA clone ZD77B03	0.075	3023371	PHEROMONE B BETA 1 RECEPTOR	4.9
190	K02024	Human T-cell lymphotropic virue type II env gene encoding envelope glycoprotein, complete cds.	0.075	2791527	(AL021246) PE_PGRS [Mycobacterium tuberculosis]	0.11

Table	e 2					
	Nearest Neighbor (BlastN vs. Genbank)			Nearest Neighbor (BlastX vs. Non- Redundant Proteins)		
191	M10188	X.laevis mitochondrial DNA containing the D-loop, and the 12S rRNA, apocytochrome b, Glu-tRNA, Thr-tRNA, ProtRNA and PhetRNA genes.	0.074	4753163	huntingtin DISEASE PROTEIN) (HD PROTEIN) > gi 454415 (L12392) Huntington's Disease protein [Homo sapiens]	2.8
192	X85525	G.gallus AG repeat region (GgaMU130)	0.073	984339	(U20966) Rev [Simian immunodeficien cy virus]	3.6
193	AJ238394.1	Homo sapiens AML2 gene (partial)	0.07	4240219	(AB020672) KIAA0865 protein [Homo sapiens]	2
194	AF039704	Homo sapiens lysosomal pepstatin insensitive protease (CLN2) gene, complete cds	0.069	2894106	(Z78279) Collagen alpha1 [Rattus norvegicus]	0.39
195	K02024	Human T-cell lymphotropic virue type II env gene encoding envelope glycoprotein, complete cds.	0.068	4504857	potassium intermediate/sm all conductance calcium- activated channel, subfamily N, member 3 > gi 3309531 (AF031815) calcium- activated potassium channel [Homo sapiens]	0.5

Table 2 Nearest Nearest Neighbor Neighbor (BlastX vs. Non-(BlastN vs. Redundant Genbank) Proteins) 196 Z60719 H.sapiens CpG 0.068 4826874 nucleoporin 0.044 island DNA 214kD (CAIN) genomic Mse1 **PROTEIN** fragment, clone NUP214 33a11, forward (NUCLEOPORI read N NUP214) cpg33a11.ft1m (214 KD **NUCLEOPORI** N) transforming protein (can) human sapiens] 197 AF053994 Lycopersicon 0.068 2842699 **PUTATIVE** 9e-009 esculentum **UBIQUITIN** Hcr2-0A (Hcr2-CARBOXYL-0A) gene, TERMINAL complete cds HYDROLASE C6G9.08 (UBIQUITIN THIOLESTERA SE) (UBIQUITIN-**SPECIFIC PROCESSING** PROTEASE) 198 Equus caballus AJ233650.1 0.067 <NONE> <NONE> < NONE endogenous > retroviral sequence ERV-L pol gene, clone ERV-L Horse1 199 M10188 0.067 X.laevis 4753163 huntingtin 2.5 mitochondrial **DISEASE** PROTEIN) (HD DNA containing the D-loop, and PROTEIN) the 12S rRNA, > gi | 454415apocytochrome (L12392) b, Glu-tRNA, Huntington's Thr-tRNA, Pro-Disease protein tRNA and Phe-[Homo sapiens] tRNA genes.

PCT/US01/09952 WO 01/72781

Table	2					
	Nearest Neighbor (BlastN vs. Genbank)			Nearest Neighbor (BlastX vs. Non- Redundant Proteins)		
200	U14646	virus Y strain S glycoprotein gene, complete cds.	0.067	3880930	(AL021481) similar to Phosphoglucom utase and phosphomannom utase phosphoserine; cDNA EST EMBL:D36168 comes from this gene; cDNA EST EMBL:D70697 comes from this gene; cDNA EST yk373h9.5 comes from this gene; cDNA EST yk373h9.5 comes from this gene; cDNA EST EMBL:T00805	1e-019
201	X15373	Mouse cerebellum mRNA for P400 protein	0.066	164507	(M81771) immunoglobulin gamma-chain [Sus scrofa]	9.4
202	AF086410	Homo sapiens full length insert cDNA clone ZD77B03	0.066	3023371	PHEROMONE B BETA 1 RECEPTOR	4.2
203	AL034492	coelicolor cosmid 6C5	0.066	3800951	(AF100657) No definition line found [Caenorhabditis elegans]	
204	L13377	Staphylococcus aureus enterotoxin gene, 3' end.	0.065	<none></none>	<none></none>	<none></none>
205	U83478	Thelephoraceae sp. 'Taylor #13' ITS1, 5.8S ribosomal RNA gene, and ITS2, complete sequence	0.065	3877335	(Z92786) predicted using Genefinder	9.1

Table	e 2			l		
	Nearest Neighbor (BlastN vs. Genbank)			Nearest Neighbor (BlastX vs. Non- Redundant Proteins)		
206	AJ002014	Crythecodinium cohnii mRNA for nuclear protein JUS1	0.065	1213283	(U40576) SIM2 [Mus musculus]	0.47
207	AB016804	Aloe arborescens mRNA for NADP-malic enzyme, complete cds	0.065	2832777	(AL021086) /prediction=(me thod:; comes from the 5' UTR [Drosophila melanogaster]	5e-036
208	AJ002014	Crythecodinium cohnii mRNA for nuclear protein JUS1	0.063	1213283	(U40576) SIM2 [Mus musculus]	0.45
209	AB023143.1	Homo sapiens mRNA for KIAA0926 protein, complete cds	0.024	132575	RIBONUCLEA SE INHIBITOR	8e-026
210	U72966	Human hepatocyte nuclear factor 4- alpha gene, exon 7	0.022	<none></none>	<none></none>	<none ></none
211	X02801	Mouse gene for glial fibrillary acidic protein	0.022	2231607	(U85917) nef protein [Human immunodeficien cy virus type 1]	7
212	AF017636	Mesocricetus auratus 3-keto- steroid reductase	0.022	2723362	(AF023459) lustrin A [Haliotis rufescens]	0.097
213	Z36879	F.pringlei gdcsPA gene for P-protein of the glycine cleavage system	0.008	<none></none>	<none></none>	<none ></none
214	X73150	P.sativum GapC1 gene	0.008	1572629	(U69699) unknown protein precursor [Mus musculus]	8.6

Table 2 Nearest Nearest Neighbor Neighbor (BlastX vs. Non-(BlastN vs. Redundant Genbank) Proteins) 215 AJ239031.1 Homo sapiens 0.008 4508019 zinc finger 0.01 LSS gene, protein 231 partial, exons protein [Homo 22, 23 and sapiens] joined CDS U76602 216 Human 180 kDa 0.007 3170252 (AF043636) 0.0001 bullous circumsporozoit pemphigoid e protein antigen 2/type [Plasmodium XVII collagen chabaudil (BPAG2/COL17 A1) gene, exons 49, 50, 51 and 52 217 M11283 Aplysia 0.007 3874685 (Z78539) 9e-013 californica Similarity to **FMRFamide** S.pombe mRNA, partial hypothetical cds, clone protein FMRF-2. C4G8.04 (SW:YAD4 SC HPO); cDNA **EST** EMBL:D27846 comes from this gene; cDNA **EST** EMBL:D27845 comes from this gene; cDNA EST yk202h7.3 comes from this gene; cDNA EST yk202h7.5 come... 218 J03998 P.falciparum 0.003 <NONE> <NONE> < NONE glutamic acid-> rich protein gnen, complete cds. 219 Z23143 M.musculus 0.002 (AF006064) 2393890 1e-011 ALK-6 mRNA, protein kinase complete CDS homolog [Fowlpox virus]

Table 2 Nearest Nearest Neighbor Neighbor (BlastX vs. Non-(BlastN vs. Redundant Genbank) Proteins) 220 AB007914 0.001 Homo sapiens 2136964 cysteine-rich 1.9 mRNA for hair keratin **KIAA0445** associated protein, protein - rabbit complete cds >gi|510541|e mb | CAA56339 (X80035) cysteine rich hair keratin associated protein 221 0.0008 AB012105 Brassica rapa 3687246 (AC005169) 5.5 mRNA for putative SLG45, suppressor complete cds protein [Arabidopsis thaliana] 222 L41608 Methylobacteriu 0.0008 3024235 **NERVOUS-**5.1 m extorquens **SYSTEM** (clone pDN9, **SPECIFIC** HINDIIIAB) OCTAMERmxaS gene 3' **BINDING** end, mxaA, TRANSCRIPTI mxaC, mxaK, ON FACTOR mxaL and mxaD N-OCT 3 genes, complete PROTEIN) cds. 223 AB007914 Homo sapiens 0.0008 2136964 cysteine-rich $\frac{}{2.5}$ mRNA for hair keratin **KIAA0445** associated protein, protein - rabbit complete cds > gi | 510541 | emb | CAA56339 (X80035) cysteine rich hair keratin associated protein 224 AC002293 Genomic 0.0008 2789557 (AF034316) 0.0002 sequence from MHC class I Human 9q34, antigen [Triakis complete scyllium] sequence [Homo scyllium] sapiens]

Table						
	Nearest Neighbor (BlastN vs. Genbank)			Nearest Neighbor (BlastX vs. Non- Redundant Proteins)		
225	L16013	Rattus norvegicus Q- like gene sequence	9e-005	<none></none>	<none></none>	<none ></none
226	AF148512.1	Homo sapiens hexokinase II gene, promoter region	9e-005	<none></none>	<none></none>	<none ></none
227	U94776	Human muscle glycogen phosphorylase (PYGM) gene, exons 6 through 17	9e-005	4759138	solute carrier family 7 transporter 3 [Homo sapiens]	5.4
228	X56030	H.sapiens IAPP gene for amyloid polypeptide, exon 1	1e-005	<none></none>	<none></none>	<none ></none
229	U36515	Human CT microsatellite, clone GM5927-CT-2-3, from the tandemly repeated genes encoding U2 small nuclear RNA (RNU2 locus)	4e-007	2435616	(AF026215) No definition line found [Caenorhabditis elegans]	0.85
230	AB011119	Homo sapiens mRNA for KIAA0547 protein, complete cds	4e-007	4758508	airway trypsin- like protease protease [Homo sapiens]	3e-031
231	NM_000521 .1	Homo sapiens hexosaminidase B (beta polypeptide) (HEXB) mRNA	5e-008	2119379	slow muscle troponin T - chicken T [Gallus gallus]	2.8
232	X13895	Human serum amyloid A (GSAA1) gene, complete cds	4e-008	699405	(U18682) novel antigen receptor [Ginglymostoma cirratum]	7.7

Table	2					
	Nearest Neighbor (BlastN vs. Genbank)			Nearest Neighbor (BlastX vs. Non- Redundant Proteins)		
233	AB009288.1	Homo sapiens mRNA for N- copine, complete cds	4e-008	4520342	(AB008893) N-copine [Mus musculus]	3e-006
234	AB011119	Homo sapiens mRNA for KIAA0547 protein, complete cds	4e-008	4758508	airway trypsin- like protease protease [Homo sapiens]	1e-028
235	X13895	Human serum amyloid A (GSAA1) gene, complete cds	5e-009	699405	(U18682) novel antigen receptor [Ginglymostoma cirratum]	7.8
236	X13895	Human serum amyloid A (GSAA1) gene, complete cds	2e-009	699405	(U18682) novel antigen receptor [Ginglymostoma cirratum]	7.2
237	U64997	Bos taurus ribonuclease K6 gene, partial cds	2e-009	3914810	RIBONUCLEA SE K6 PRECURSOR (RNASE K6) > gi 2745760 (AF037086) ribonuclease k6 precursor	3e-018
238	J02635	Rat liver alpha- 2-macroglobulin mRNA, complete cds.	2e-009	112913	ALPHA-2- MACROGLOB ULIN PRECURSOR precursor - rat > gi 202592 (J02635) prealpha-2- macroglobulin [Rattus norvegicus]	4e-019
239	Z78141	M.musculus partial cochlear mRNA (clone 29C9)	5e-010	3219569	(AL023893) /prediction=(me thod:;	4e-009

PCT/US01/09952 WO 01/72781

Table 2

Гable	2			1		
-	Nearest			Nearest Neighbor		
	Neighbor			(BlastX vs. Non-		ļ
	(BlastN vs.			Redundant		
	Genbank)			Proteins)		
240	AF060917	Gambusia	2e-010	3874618	(Z48241)	0.096
		affinis			similar to coiled	
		microsatellite			coil domains;	
	ļ	Gafu6			cDNA EST	
					yk302g12.5	
		;			comes from this	
			ļ		gene; cDNA	
			-		EST	
					yk365d10.5	
	Į		[comes from this	
					gene; cDNA	
			[EST yk461c1.5	
					comes from this	
					gene	
					[Caenorhabditis	
					elegans] coil	
					domains; cDNA	
					EST	
					yk302g12.5	
					comes from this	
	ļ		ļ		gene; cDNA EST	
241	U68138	Harman DCD 05	2e-010	4521241		2e-022
41	008138	Human PSD-95	26-010	4321241	(AB024927) CsENDO-3	26-022
		mRNA, partial				
		cds			[Ciona savignyi]	
42	U88827	Aotus trivirgatus	6e-011	3914810	RIBONUCLEA	1e-016
		ribonuclease			SE K6	
		precursor gene,			PRECURSOR	
		complete cds			(RNASE K6)	
		_			>gi 2745760	
					(AF037086)	
					ribonuclease k6	
			ļ		precursor	
243	AF045573	Mus musculus	2e-012	3025718	(AF045573)	3e-016
		FLI-LRR			FLI-LRR	
		associated			associated	
		protein-1			protein-1 [Mus	
	1	mRNA,			musculus]	
		complete cds				

Table	2					
	Nearest Neighbor (BlastN vs. Genbank)			Nearest Neighbor (BlastX vs. Non- Redundant Proteins)		
244	.1	Homo sapiens discs, large (Drosophila) homolog 4 (DLG4) mRNA > :: gb U83192 HS U83192 Homo sapiens post-synaptic density protein 95 (PSD95) mRNA, complete cds	2e-012	4521241	(AB024927) CsENDO-3 [Ciona savignyi]	5e-020
245	U28049	Human TBX2 (TXB2) mRNA, complete cds.	7e-013	2501115	TBX2 PROTEIN (T- BOX PROTEIN 2)	2e-011
246	M23404	Chicken erythrocyte anion transport protein (band3) mRNA, complete cds.	2e-013	726403	(U23175) similar to anion exchange protein [Caenorhabditis elegans]	1e-025
247	AF005963	Homo sapiens XY homologous region, partial sequence	1e-014	104270	Ig heavy chain - clawed frog	1.9
248	M29863	Human farnesyl pyrophosphate synthetase mRNA	9e-015	182405	(M29863) farnesyl pyrophosphate synthetase [Homo sapiens]	0.005
249	D28126	Human gene for ATP synthase alpha subunit, complete cds (exon 1 to 12)	3e-015	<none></none>	<none></none>	<none ></none

Table 2 Nearest Nearest Neighbor Neighbor (BlastX vs. Non-(BlastN vs. Redundant Genbank) Proteins) 250 Z80150 H.sapiens 3e-015 3387914 (AF070550) 3.5 CACNL1A4 cote1 [Homo gene, exons 41 sapiens] and 42 > :: emb | A70716.1 | A70716 Sequence 37 from Patent WO9813490 U28049 Human TBX2 4e-016 6e-009 251 2501116 TBX2 PROTEIN (T-(TXB2) mRNA, **BOX PROTEIN** complete cds. 2) tbx gene [Mus musculus] 1e-017 252 U31629 Mus musculus 3024998 HYPOTHETIC 3e-017 C2C12 unknown AL HEART mRNA, partial **PROTEIN** cds. 253 J05262 0.0001 Human farnesyl 1e-018 182405 (M29863) pyrophosphate farnesyl synthetase pyrophosphate mRNA, synthetase [Homo sapiens] complete cds. 254 D28126 Human gene for 5e-019 <NONE> <NONE> <NONE ATP synthase > alpha subunit, complete cds (exon 1 to 12) 255 D28126 Human gene for 5e-019 5.7 3219984 HYPOTHETIC ATP synthase AL PROTEIN alpha subunit, MJ1597.1 complete cds region (exon 1 to 12) MJ1597.1 [Methanococcus jannaschii]

Table 2 Nearest Nearest Neighbor (BlastX vs. Non-Neighbor (BlastN vs. Redundant Genbank) Proteins) NM 004587 0.004 256 Homo sapiens 2e-019 4759056 ribosome ribosome binding protein binding protein 1 (dog 180kD 1 (dog 180kD homolog) homolog) > gi | 3299885(RRBP1) (AF006751) mRNA > ::ES/130 [Homo gb|AF006751| sapiens] AF006751 Homo sapiens ES/130 mRNA, complete cds 257 U89915 Mus musculus 5e-020 3462455 2e-005 (U89915) junctional junctional adhesion adhesion molecule (Jam) molecule [Mus mRNA, musculus] complete cds 5e-020 3025718 258 AF045573 Mus musculus (AF045573) 9e-025 FLI-LRR FLI-LRR associated associated protein-1 protein-1 [Mus mRNA, musculus] complete cds 259 NM 004587 Homo sapiens 2e-020 4759056 0.0008 ribosome ribosome binding protein .1 binding protein 1 (dog 180kD 1 (dog 180kD homolog) homolog) > gi | 3299885(RRBP1) (AF006751) ES/130 [Homo mRNA > ::gb | AF006751 | sapiens] AF006751 Homo sapiens ES/130 mRNA, complete cds

Table 2 Nearest Neighbor Nearest Neighbor (BlastX vs. Non-(BlastN vs. Redundant Genbank) Proteins) 260 AF051098 2e-021 3858883 (U67056) 0.002 Mus musculus myosin I heavy seven transmembrane chain kinase [Acanthamoeba domain orphan receptor mRNA, castellanii] complete cds > gi | 4206769 (AF104910) myosin I heavy chain kinase [Acanthamoeba castellanii] 261 AF051098 Mus musculus 2e-021 3858883 (U67056) 0.001 myosin I heavy seven transmembrane chain kinase [Acanthamoeba domain orphan receptor mRNA, castellanii] complete cds >gi | 4206769 (AF104910) myosin I heavy chain kinase [Acanthamoeba castellaniil 262 M13519 Human N-2e-021 4504373 hexosaminidase 2e-007 acetyl-beta-B (beta glucosaminidase polypeptide) > gi | 123081 | sp(HEXB) mRNA, 3' end. |P07686|HEXB HUMAN BETA-**HEXOSAMINI** DASE BETA CHAIN PRECURSOR beta-Nacetylhexosamin idase (EC 3.2.1.52) beta chain - human

> gi | 386770 (M23294) betahexosaminidase beta-subunit [Homo sapiens]

PCT/US01/09952 WO 01/72781

Table 2

Table	e 2			l		
	Nearest Neighbor (BlastN vs. Genbank)		,	Nearest Neighbor (BlastX vs. Non- Redundant Proteins)		
263	Z81014	Human DNA sequence from cosmid U65A4, between markers DXS366 and DXS87 on chromosome X *	2e-022	<none></none>	<none></none>	<none ></none
264	AF147311.1	Homo sapiens full length insert cDNA clone YA82F10	2e-022	3875904	(Z70207) predicted using Genefinder; similar to collagen; cDNA EST EMBL:D65905 comes from this gene; cDNA EST EMBL:D65858 comes from this gene; cDNA EST EMBL:D69306 comes from this gene; cDNA EST EMBL:D69306 comes from this gene; cDNA EST EMBL:D65755 comes from this	0.07
265	AF037088	Gorilla gorilla ribonuclease k6 precursor, gene, complete cds	9e-024	3914791	RIBONUCLEA SE K6 PRECURSOR (RNASE K6) > gi 2745752 (AF037082) ribonuclease k6 precursor	3e-019
266	Z81014	Human DNA sequence from cosmid U65A4, between markers DXS366 and DXS87 on chromosome X	8e-024	<none></none>	<none></none>	<none< td=""></none<>

Table 2

Table	e 2					
	Nearest			Nearest Neighbor		
ļ	Neighbor		\	(BlastX vs. Non-		
ŀ	(BlastN vs.			Redundant		
	Genbank)			Proteins)		
		*				,
						İ
	}					
						1
		•				
267	AF037088	Gorilla gorilla	9e-025	3914810	RIBONUCLEA	4e-018
	-	ribonuclease k6			SE K6	}
		precursor, gene,			PRECURSOR	l
		complete cds		•	(RNASE K6)	
					>gi 2745760	
					(AF037086)	
		·			ribonuclease k6	
			<u> </u>		precursor	
268	AF147311.1	Homo sapiens	1e-026	131413	PULMONARY	0.059
		full length insert			SURFACTANT	
ĺ		cDNA clone			-ASSOCIATED	
		YA82F10			PROTEIN A	
					PRECURSOR	ŀ
)	Ì			!	(SP-A) (PSP-A)	ì
					(PSAP)	
				:	precursor -	ļ
	1				rabbit	l
					>gi 165706	
					(J03542)	
					apoprotein of	
	ı				surfactant	
	ļ				[Oryctolagus	
					cuniculus]	
269	Z46786	D.melanogaster	1e-027	1079042	acetyl-CoA	4e-025
		mRNA for			synthetase - fruit	
		acetyl-CoA			fly	
250	373 £ 00 105 =	synthetase		150110	(2.500.05)	
270	NM_004039	Homo sapiens	4e-028	450448	(M33322)	0.1
	.1	annexin II			calpactin I	
	\	(lipocortin II)			heavy chain	
		for lipocortin II,			[Mus musculus]	
		complete cds				
271	X53064	Homo sapiens	1e-028	134846	SMALL	0.005
- ' - 1	110000	SPRR2A gene	10 020	ADTOTO	PROLINE-	0.005
		encoding small			RICH	
	\	proline rich			PROTEIN II	
		protein			rich protein	
		Protom			[Homo sapiens]	
	L	L	L		[1101110 gabicits]	

Table 2

Table	: <i>Z</i>			į		
	Nearest			Nearest Neighbor		
	Neighbor			(BlastX vs. Non-		
	(BlastN vs.			Redundant	,	Į
	Genbank)			Proteins)		
272	M29863	Human farnesyl pyrophosphate	1e-028	4503685	farnesyl	2e-008
		synthetase			diphosphate	
		mRNA			synthase	1
					dimethylallyltra	
					nstransferase,	
					geranyltranstran	·
					sferase) bp313	
					to bp1374 is	
					almost identical	
					to human	
					farnesyl	
					pyrophosphate	
					synthetase	
					mRNA. [Homo	
					sapiens]	
273	Z18950	H.sapiens genes	5e-029	2493898	DOPAMINE-	1.4
		for S100E			BETA-	
		calcium binding			MONOOXYGE	
	i	protein, CAPL,			NASE	
		and S100D			PRECURSOR	
1		calcium binding			(DOPAMINE	
1		protein EF-			BETA-	
1		Hand patent US			HYDROXYLA	
		5789248			SE) (DBH)	
					1.14.17.1)	
					precursor -	
		ļ			mouse	
i					>gi 260873 bb	
					s 119249 621	
					aa] [Mus sp.]	
274	M19481	Human	5e-030	<none></none>	<none></none>	< NONE
		follistatin gene,				>
		exon 6.				

Table 2 Nearest Nearest Neighbor Neighbor (BlastX vs. Non-(BlastN vs. Redundant Genbank) Proteins) 275 AF007155 2e-032 Homo sapiens 4502641 chemokine (C-1.6 clone 23763 C) receptor 7 unknown TYPE 7 mRNA, partial PRECURSOR cds (C-C CKR-7) (CC-CKR-7) (CCR-7) (MIP-3 **BETA** RECEPTOR) (EBV-INDUCED G PROTEIN-**COUPLED** RECEPTOR 1) (EBI1) (BLR2) > gi | 1082381 | pir | | B55735 lymphocytespecific Gprotein-coupled receptor EBI1 human > gi | 468316(L3158 276 M99624 8e-034 (L13655) Human 294845 9e-014 epidermal membrane growth factor protein receptor-related [Saccharum gene, 5' end. hybrid cultivar H65-7052] 277 U49082 Human 8e-035 1840045 (U49082) 1e-014 transporter transporter

protein (g17) mRNA,

complete cds

protein [Homo

sapiens]

PCT/US01/09952 WO 01/72781

Table						
	Nearest Neighbor (BlastN vs. Genbank)			Nearest Neighbor (BlastX vs. Non- Redundant Proteins)		
278	D50369	Homo sapiens mRNA for low molecular mass ubiquinone- binding protein, complete cds	9e-036	3024781	UBIQUINOL- CYTOCHROM E C REDUCTASE COMPLEX UBIQUINONE- BINDING PROTEIN QP- C PROTEIN) (COMPLEX III SUBUNIT VII) ubiquinone- binding protein [Homo sapiens]	0.0002
279	AF086313	Homo sapiens full length insert cDNA clone ZD52B10	9e-036	2832777	(AL021086) /prediction=(me thod:; comes from the 5' UTR [Drosophila melanogaster]	1e-039
280	NM_004074 .1	Homo sapiens cytochrome c oxidase subunit VIII (COX8), nuclear gene encoding mitochondrial protein, mRNA > :: gb J04823 HU MCOX8A Human cytochrome c oxidase subunit VIII (COX8) mRNA, complete cds.	1e-038	2499854	PROBABLE PEPTIDASE Y4SO > gi 2182630	2
281	AB024436.1	Homo sapiens mRNA for beta- 1,4- galactosyltransfe rase IV, complete cds	2e-041	3132900	(AF038662) beta-1,4- galactosyltransfe rase [Homo sapiens] beta- 1,4- galactosyltransfe	4e-016

PCT/US01/09952 WO 01/72781

Table 2

Table	e 2			I		
	Nearest Neighbor (BlastN vs. Genbank)			Nearest Neighbor (BlastX vs. Non- Redundant Proteins)	galactosyltransfe	
					rase IV [Homo sapiens]	
282	AF057734	Homo sapiens 17-beta- hydroxysteroid dehydrogenase IV (HSD17B4) gene, exon 16	2e-043	2842416	(AL008730) dJ487J7.1.1 (putative protein dJ487J7.1 isoform 1) [Homo sapiens]	3e-062
283	Z69650.1	Human DNA sequence from cosmid L69F7B, Huntington's Disease Region, chromosome 4p16.3 contains Huntington Disease (HD) gene	2e-044	1872200	(U22376) alternatively spliced product using exon 13A	1e-008
284	NM_003938 .1	Homo sapiens adaptin, delta (ADTD) mRNA > :: gb U91930 HS U91930 Homo sapiens AP-3 complex delta subunit mRNA, complete cds	2e-044	3478639	(AC005545) delta-adaptin, partial CDS [Homo sapiens]	3e-016
285	AF026029	Homo sapiens poly(A) binding protein II (PABP2) gene, complete cds	8e-045	1916930	(U88570) CREB-binding protein homolog [Drosophila melanogaster]	7.6
286	AB006622	Homo sapiens mRNA for KIAA0284 gene, partial cds	1e-045	73404	E2 protein - human papillomavirus type 5	0.11

Table	e 2			1		
	Nearest Neighbor (BlastN vs. Genbank)			Nearest Neighbor (BlastX vs. Non- Redundant Proteins)		
287	U90918	Human clone 23654 mRNA sequence	1e-048	3877568	(Z70208) similar to collagen	0.042
288	AB006622	Homo sapiens mRNA for KIAA0284 gene, partial cds	1e-049	73404	E2 protein - human papillomavirus type 5	0.11
289	AL049258.1	Homo sapiens mRNA; cDNA DKFZp564E173 (from clone DKFZp564E173	1e-050	<none></none>	<none></none>	<none ></none
290	AF022367	Homo sapiens beta-1,4- galactosyltransfe rase mRNA, complete cds	5e-051	3132900	(AF038662) beta-1,4- galactosyltransfe rase [Homo sapiens] beta- 1,4- galactosyltransfe rase IV [Homo sapiens]	6e-019
291	AF057734	Homo sapiens 17-beta- hydroxysteroid dehydrogenase IV (HSD17B4) gene, exon 16	7e-053	2842416	(AL008730) dJ487J7.1.1 (putative protein dJ487J7.1 isoform 1) [Homo sapiens]	6e-055
292	AF097709	Homo sapiens serine protease (PRSS11) mRNA, partial cds	8e-055	4506141	protease, serine, 11 (IGF binding) > gi 1513059 d bj BAA13322 (D87258) serin protease with IGF-binding motif [Homo sapiens] protease, PRSS11 [Homo sapiens]	2e-017

Table 2

Table	2					
	Nearest Neighbor (BlastN vs. Genbank)			Nearest Neighbor (BlastX vs. Non- Redundant Proteins)		
293	U31629	Mus musculus C2C12 unknown mRNA, partial cds.	9e-057	3025215	HYPOTHETIC AL 81.0 KD PROTEIN C35D10.4 IN CHROMOSOM E III > gi 2146877 p ir S72572 probable ABC1 protein homolog - Caenorhabditis elegans protein (Swiss-Prot Acc: P27697) [Caenorhabditis elegans]	5e-033
294	AB006622	Homo sapiens mRNA for KIAA0284 gene, partial cds	8e-057	73404	E2 protein - human papillomavirus type 5	1.7
295	AF025439	Homo sapiens Opa-interacting protein OIP3 mRNA, partial cds	4e-059	<none></none>	<none></none>	<none ></none
296	M99624	Human epidermal growth factor receptor-related gene, 5' end.	1e-060	123364	SEGMENTATI ON PROTEIN EVEN- SKIPPED fly (Drosophila sp.) > gi 157387 (M14767) even- skipped gene [Drosophila melanogaster]	5.3
297	AF045573	Mus musculus FLI-LRR associated protein-1 mRNA, complete cds	5e-061	3025718	(AF045573) FLI-LRR associated protein-1 [Mus musculus]	7e-029
298	AB006622	Homo sapiens mRNA for KIAA0284 gene, partial cds	2e-062	2119133	ribosomal protein S17 - cat (fragment) musculus]	2e-015

Table 2 Nearest Nearest Neighbor Neighbor (BlastX vs. Non-(BlastN vs. Redundant Genbank) Proteins) 299 M30702 2e-063 4502199 0.0002 Human amphiregulin amphiregulin (schwannoma-(AR) gene, exon derived growth 5, clones factor) lambda-> gi | 113754 | spARH(6,12). |P15514|AMP R HUMAN AMPHIREGUL IN **PRECURSOR** (AR) (COLORECTU M CELL-DERIVED **GROWTH** FACTOR) (CRDGF) >gi|107391|pi r | A34702 amphiregulin precursor human >gi|178890 (M30703) amphiregulin [Homo sapien (AJ235272) 300 L38847 Mus musculus 6e-064 3861228 2.9 hepatoma unknown transmembrane [Rickettsia prowazekii] kinase ligand Sequence 1 from patent US 5624899 Mus musculus 301 L38847 6e-064 3861228 (AJ235272) 2.9 hepatoma unknown Rickettsia transmembrane kinase ligand prowazekii] Sequence 1 from patent US 5624899 302 Z78141 8e-066 1490324 (Z78141) 8e-019 M.musculus unknown [Mus partial cochlear mRNA (clone musculus] 29C9)

Table	2					
	Nearest Neighbor (BlastN vs. Genbank)			Nearest Neighbor (BlastX vs. Non- Redundant Proteins)		
303	X12650	Mus musculus gene for beta- tropomyosin	2e-072	833602	(X54277) cardiac tropomyosin [Coturnix coturnix]	7e-022
304	M87635	Mouse beta- tropomyosin 2 mRNA, complete cds.	2e-084	1216293	(L35239) cardiac tropomyosin [Xenopus laevis]	5e-019
305	M13364	Rabbit calcium-dependent protease, small subunit mRNA, complete cds.	2e-084	115611	CALCIUM-DEPENDENT PROTEASE, SMALL NEUTRAL PROTEINASE) (CANP) > gi 108563 pi r A34466 calpain (EC 3.4.22.17) II light chain - bovine 3.4.22.17) [Bos taurus]	1e-058
306	M87635	Mouse beta- tropomyosin 2 mRNA, complete cds.	3e-088	1216293	(L35239) cardiac tropomyosin [Xenopus laevis]	9e-028
307	M87635	Mouse beta- tropomyosin 2 mRNA, complete cds.	5e-092	1216293	(L35239) cardiac tropomyosin [Xenopus laevis]	2e-035
308	X85992	M.musculus mRNA for semaphorin C	8e-097	2137756	semaphorin C - mouse (fragment) musculus]	2e-048

Table 2 Nearest Neighbor Nearest (BlastX vs. Non-Neighbor (BlastN vs. Redundant Genbank) Proteins) 309 e-103 M24103 113463 ADP, ATP 2e-035 Bovine **CARRIER** ADP/ATP translocase T2 PROTEIN, mRNA, LIVER complete cds. ISOFORM T2 (ADP/ATP **TRANSLOCAS** E 3) (ADENINE **NUCLEOTIDE** TRANSLOCAT OR 3) (ANT 3) > gi | 86757 | pir||S03894 ADP, ATP carrier protein T2 - human 310 U48852 Cricetulus e-107 1216486 (U48852) HT 3e-057 protein griseus HT protein mRNA, [Cricetulus complete cds. griseus] 311 X76168 R.norvegicus e-112 544118 GAP 1e-063 mRNA for **JUNCTION** connexin 30.3 BETA-5 **PROTEIN** (CONNEXIN 30.3) (CX30.3) >gi|481577|pi r||S38891 connexin 30.3 rat >gi|431204|e mb | CAA53762 (X76168) connexin 30.3 312 X76168 R.norvegicus e-115 461864 **GAP** 7e-064 mRNA for JUNCTION connexin 30.3 BETA-5 **PROTEIN** junction protein Cx30.3 - mouse > gi | 192647(M91443) connexin 30.3 [Mus musculus]

Table	2					
	Nearest Neighbor (BlastN vs. Genbank)			Nearest Neighbor (BlastX vs. Non- Redundant Proteins)		
313	AJ009634.1	Mus musculus fjx1 gene	e-137	4138203	(AJ009634) Fjx1 [Mus musculus]	5e-065
314	X76168	R.norvegicus mRNA for connexin 30.3	e-130	544118	GAP JUNCTION BETA-5 PROTEIN (CONNEXIN 30.3) (CX30.3) > gi 481577 pi r S38891 connexin 30.3 - rat > gi 431204 e mb CAA53762 (X76168) connexin 30.3	2e-074

able 4

	۲.	טוו זת	OTTIVE C
ın A	ın B	PLUS	MINUS
9		5.9	
	·		
0			6.62
7		7.11	
3			11.93
8		5.98	
0			10.41
11		11.17	
26		2.63	
8		7.87	
E			6.56
11	3	3.88	
		•	
	26 8 8 3 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6		0 7 7 0 0 0 11 0 10 20 0 0 11 0 10 20 3 3

rable 4

SEQ	CLUST	PairAB-text	CLONES	CLONES	RATIO	RATIO
a			in A	in B	PLUS	MINUS
		_15,16 (Normal Colon vs. Colon Tumor)	28	89		2.3
		_15,17 (Normal Colon vs. Colon Metastasis)	28	117		3.89
76	450982					
		_16,17 (Colon Tumor vs. Colon Metastasis)	14	32		2.25
28	379302					
		_21,22 (Normal Prostate vs. Cancerous Prostate)	8		7.87	
43	817503					
	i					
		_21,22 (Normal Prostate vs. Cancerous Prostate)	18	4	4.43	
48	830085					
		21,22 (Normal Prostate vs. Cancerous Prostate)	0	6		9.15
52	830931					
		21,22 (Normal Prostate vs. Cancerous Prostate)	0	7		7.12
55	819046					
		_21,22 (Normal Prostate vs. Cancerous Prostate)	2	13		6.61
58	728115					
		_15,16 (Normal Colon vs. Colon Tumor)	0	7		6.62
		_16,17 (Colon Tumor vs. Colon Metastasis)	7	0	7.11	
65	553242					

l'able 4

SEO	CLUST	Pair AB-text	CLONES	CLONES	RATIO	RATIO
			in A	in B	PLUS	MINUS
		_16,17 (Colon Tumor vs. Colon Metastasis)	0	9		5.91
71	820061					
		_21,22 (Normal Prostate vs. Cancerous Prostate)	1	20		20.33
78	220584					
		_08,09 (Lung, High Metastatic Potential vs. Lung, Low Metastatic Potential)		12		8.59
80	549934					
•						
		_16,17 (Colon Tumor vs. Colon Metastasis)	3	20		6.56
		_15,16 (Normal Colon vs. Colon Tumor)	11	3	3.88	
		_21,22 (Normal Prostate vs. Cancerous Prostate)	8	0	7.87	
98	819460					
		_21,22 (Normal Prostate vs. Cancerous Prostate)	18	1	17.7	
95	551785					
		21,22 (Normal Prostate vs. Cancerous Prostate)	0	9		6.1
96	17092					
		_03,04 (Breast, High Metastatic Potential vs. Breast, Non-Metastatic)	0	25		25.62
66	745559					
		_21,22 (Normal Prostate vs. Cancerous Prostate)		6		9.15

able 4

- 1	CLUST	Pair A B-text	CLONES	CLONES	RATIO	RATIO
, A			in A	in B	PLUS	MINUS
101	379879					
		_21,22 (Normal Prostate vs. Cancerous Prostate)	0	6		9.15
		_08,09 (Lung, High Metastatic Potential vs. Lung, Low Metastatic Potential)	0	13		9.3
107	268290					
		_21,22 (Normal Prostate vs. Cancerous Prostate)	33	69		2.13
108	818043					
		21,22 (Normal Prostate vs. Cancerous Prostate)	9	0	5.9	
114	450247					
			-			
		21,22 (Normal Prostate vs. Cancerous Prostate)	23	8	2.83	
115	819273					
	·	_21,22 (Normal Prostate vs. Cancerous Prostate)	7	0	98.9	
116	587779					
		21,22 (Normal Prostate vs. Cancerous Prostate)	9	0	5.9	
118	615617					
		_21,22 (Normal Prostate vs. Cancerous Prostate)	0	7		7.12
121	818682		•			
		_21,22 (Normal Prostate vs. Cancerous Prostate)	11	2	5.41	

able 4

SEQ ID	CLUST	PairAB-text	CLONES in A	CLONES in B	RATIO PLUS	RATIO MINUS
123	484413					
		21,22 (Normal Prostate vs. Cancerous Prostate)	7	0	6.88	
124	819273					
	-	_21,22 (Normal Prostate vs. Cancerous Prostate)	7	0	6.88	
127	818682					
		_21,22 (Normal Prostate vs. Cancerous Prostate)	11	2	5.41	
131	819273					
		21,22 (Normal Prostate vs. Cancerous Prostate)	7	0	6.88	
147	820061					
		21,22 (Normal Prostate vs. Cancerous Prostate)		20		20.33
153	375958					
		_21,22 (Normal Prostate vs. Cancerous Prostate)	2	11		5.59
		08,09 (Lung, High Metastatic Potential vs. Lung, Low Metastatic Potential)	0	6		6.44
155	831049					
		21,22 (Normal Prostate vs. Cancerous Prostate)	0	11		11.18
157	553200					
		21,22 (Normal Prostate vs. Cancerous Prostate)	0	9		6.1

Fable 4

SEQ ID	CLUST	PairAB-text	CLONES in A	CLONES in B	RATIO PLUS	RATIO MINUS
158	139677					
		21,22 (Normal Prostate vs. Cancerous Prostate)	9	0	5.9	
159	139677					
		21,22 (Normal Prostate vs. Cancerous Prostate)	9	0	5.9	
163	375958		-			
	-					
		_08,09 (Lung, High Metastatic Potential vs. Lung, Low Metastatic Potential)	0	6		6.44
		_21,22 (Normal Prostate vs. Cancerous Prostate)	2	11		5.59
168	831812					
		_21,22 (Normal Prostate vs. Cancerous Prostate)	0	7		7.12
176	193373					
		21,22 (Normal Prostate vs. Cancerous Prostate)	9	0	5.9	
177	400619					
		08,09 (Lung, High Metastatic Potential vs. Lung, Low Metastatic Potential)	9	0	8.38	
178	831149					
						*
		21,22 (Normal Prostate vs. Cancerous Prostate)	0	7		7.12
180	817503	•				
		21,22 (Normal Prostate vs. Cancerous Prostate)	18	4	4.43	

rable 4

SEQ ID	CLUST	PairAB-text	CLONES in A	CLONES in B	RATIO PLUS	RATIO MINUS
187	648679					
		_23,24 (Normal Lung vs. Lung Tumor)	11		11.11	
		_16,17 (Colon Tumor vs. Colon Metastasis)	67	0	80.23	
		Į . I	7	0	7.51	
		_15,16 (Normal Colon vs. Colon Tumor)	7	62		10.68
190	373928					
		21,22 (Normal Prostate vs. Cancerous Prostate)	7	0	98.9	
195	373928					
		21,22 (Normal Prostate vs. Cancerous Prostate)	7	0	98.9	
198	372700					
		_19,20 (Colon Tumor vs. Colon Tumor Metastasis)	8	0	5.98	
		_08,09 (Lung, High Metastatic Potential vs. Lung, Low Metastatic Potential)	3	50		11.93
204	379105		;			
		_15,16 (Normal Colon vs. Colon Tumor)	0	8		7.57
205	831188					
		21,22 (Normal Prostate vs. Cancerous Prostate)	0	8		8.13
209	831812					
		_21,22 (Normal Prostate vs. Cancerous Prostate)	0	7		7.12

Table 4

in B PLUS MIN 0 0 0 0 0 8 8 8 1 17.7 6 0 0 5.9 6 1 0 0 0 7 1 17.7 9 18 132 9 18 132 1 1 12 12	SEQ	CLUST	Pair AB-text	CLONES	CLONES	RATIO	RATIO
21,22 (Normal Prostate vs. Cancerous Prostate) 0 10 10 21,22 (Normal Prostate vs. Cancerous Prostate) 0 6 21,22 (Normal Prostate vs. Cancerous Prostate) 0 6 21,22 (Normal Prostate vs. Cancerous Prostate) 18 1 21,22 (Normal Prostate vs. Cancerous Prostate) 6 0 21,22 (Normal Prostate vs. Cancerous Prostate) 6 0 21,22 (Normal Prostate vs. Colon Metastatis) 5 20 15,17 (Normal Colon vs. Colon Metastatis Potential vs. Lung, Low Metastatic Potential) 5 18 15,17 (Normal Colon vs. Colon Metastatis) 6 6 16,17 (Colon Thunor vs. Colon Metastatis) 0 6 16,17 (Colon Thunor vs. Colon Metastatis) 1 12				in A	in B	PLUS	MINUS
21,22 (Normal Prostate vs. Cancerous Prostate) 0 10 10 21,22 (Normal Prostate vs. Cancerous Prostate) 0 6 21,22 (Normal Prostate vs. Cancerous Prostate) 0 6 21,22 (Normal Prostate vs. Cancerous Prostate) 18 1 21,22 (Normal Prostate vs. Cancerous Prostate) 6 0 21,22 (Normal Prostate vs. Cancerous Prostate) 6 0 21,22 (Normal Prostate vs. Cancerous Prostate) 6 0 21,22 (Normal Colon vs. Colon Metastasis) 5 18 15,17 (Normal Colon vs. Colon Metastasis) 5 18 21,517 (Normal Colon vs. Colon Metastasis) 6 6 21,517 (Normal Colon vs. Colon Metastasis) 6 6 21,517 (Normal Colon vs. Colon Metastasis) 6 6		831026					
21,22 (Normal Prostate vs. Cancerous Prostate) 0 10 10 21,22 (Normal Prostate vs. Cancerous Prostate) 0 6 6 08,09 (Lung, High Metastatic Potential vs. Lung, Low Metastatic Potential) 18 1 17.7 21,22 (Normal Prostate vs. Cancerous Prostate) 6 0 5.9 21,22 (Normal Prostate vs. Cancerous Prostate) 6 0 5.9 21,22 (Normal Prostate vs. Cancerous Prostate) 6 0 5.9 21,22 (Normal Colon vs. Colon Metastasis) 5 20 08,09 (Lung, High Metastatic Potential vs. Lung, Low Metastatic Potential) 5 18 15,17 (Colon Tumor vs. Colon Metastasis) 0 6 26,17 (Colon Tumor vs. Colon Metastasis) 0 6 208,09 (Lung, High Metastatic Potential vs. Lung, Low Metastatic Potential) 1 12							
21,22 (Normal Prostate vs. Cancerous Prostate) 0 6 _08,09 (Lung, High Metastatic Potential vs. Lung, Low Metastatic Potential) 0 6 _21,22 (Normal Prostate vs. Cancerous Prostate) 18 1 17.7 _21,22 (Normal Prostate vs. Cancerous Prostate) 6 0 5.9 _21,22 (Normal Prostate vs. Cancerous Prostate) 6 0 5.9 _21,22 (Normal Colon vs. Colon Metastasis) 5 20 _15,17 (Normal Colon vs. Colon Metastasis) 5 18 _15,16 (Normal Colon vs. Colon Metastasis) 6 6 _16,17 (Colon Tumor vs. Colon Metastasis) 0 6 _26,17 (Colon Tumor vs. Colon Metastasis) 1 1 _26,09 (Lung, High Metastatic Potential vs. Lung, Low Metastatic Potential) 1 12			_21,22 (Normal Prostate vs. Cancerous Prostate)	0	10		10.17
21,22 (Normal Prostate vs. Cancerous Prostate) 0 6 _08,09 (Lung, High Metastatic Potential vs. Lung, Low Metastatic Potential) 0 6 _21,22 (Normal Prostate vs. Cancerous Prostate) 18 1 _21,22 (Normal Prostate vs. Cancerous Prostate) 6 0 5.9 _21,22 (Normal Prostate vs. Cancerous Prostate) 6 0 5.9 _15,17 (Normal Colon vs. Colon Metastasis) 5 20 _15,16 (Normal Colon vs. Colon Tumor) 5 18 _16,17 (Colon Tumor vs. Colon Metastasis) 0 6 _16,17 (Colon Tumor vs. Colon Metastasis) 0 6 _08,09 (Lung, High Metastatic Potential vs. Lung, Low Metastatic Potential) 1 12		380207					
21,22 (Normal Prostate vs. Cancerous Prostate) 0 6 _08,09 (Lung, High Metastatic Potential vs. Lung, Low Metastatic Potential) 18 1 17.7 _21,22 (Normal Prostate vs. Cancerous Prostate) 6 0 5.9 _21,22 (Normal Prostate vs. Cancerous Prostate) 6 0 5.9 _21,22 (Normal Prostate vs. Cancerous Prostate) 6 0 5.9 _15,17 (Normal Colon vs. Colon Metastasis) 5 20 _15,16 (Normal Colon vs. Colon Metastasis) 5 18 _16,17 (Colon Tumor vs. Colon Metastasis) 6 6 _16,17 (Colon Tumor vs. Colon Metastasis) 6 6 _16,17 (Colon Tumor vs. Colon Metastasis) 1 1 _208,09 (Lung, High Metastatic Potential vs. Lung, Low Metastatic Potential) 1 1							
_08,09 (Lung, High Metastatic Potential vs. Lung, Low Metastatic Potential) 0 _21,22 (Normal Prostate vs. Cancerous Prostate) 18 1 17.7 _21,22 (Normal Prostate vs. Cancerous Prostate) 6 0 5.9 _21,22 (Normal Prostate vs. Cancerous Prostate) 6 0 5.9 _15,17 (Normal Colon vs. Colon Metastasis) 5 20 _08,09 (Lung, High Metastatic Potential vs. Lung, Low Metastatic Potential) 5 18 _16,17 (Colon Tumor vs. Colon Metastasis) 6 6 _16,17 (Colon Tumor vs. Colon Metastasis) 6 6 _08,09 (Lung, High Metastatic Potential vs. Lung, Low Metastatic Potential) 1 12	1		_21,22 (Normal Prostate vs. Cancerous Prostate)	0	9		6.1
21,22 (Normal Prostate vs. Cancerous Prostate) 18 1 17.7 21,22 (Normal Prostate vs. Cancerous Prostate) 6 0 5.9 21,22 (Normal Prostate vs. Cancerous Prostate) 6 0 5.9 15,17 (Normal Colon vs. Colon Metastasis) 5 20 08,09 (Lung, High Metastatic Potential vs. Lung, Low Metastatic Potential) 5 18 16,17 (Colon Tumor vs. Colon Metastasis) 0 6 16,17 (Colon Tumor vs. Colon Metastasis) 0 6 16,17 (Lung, High Metastatic Potential vs. Lung, Low Metastatic Potential) 1 12			08,09 (Lung, High Metastatic Potential vs. Lung, Low Metastatic Potential)	0	8		5.72
21,22 (Normal Prostate vs. Cancerous Prostate) 18 1 17.7 21,22 (Normal Prostate vs. Cancerous Prostate) 6 0 5.9 21,22 (Normal Prostate vs. Cancerous Prostate) 6 0 5.9 15,17 (Normal Colon vs. Colon Metastasis) 5 20 15,16 (Normal Colon vs. Colon Tumor) 5 18 15,16 (Normal Colon vs. Colon Metastasis) 6 6 16,17 (Colon Tumor vs. Colon Metastasis) 0 6 16,17 (Colon Tumor vs. Colon Metastasis) 1 12 16,17 (Lung, High Metastatic Potential vs. Lung, Low Metastatic Potential) 1 12		819460					
21,22 (Normal Prostate vs. Cancerous Prostate) 18 1 17.7 21,22 (Normal Prostate vs. Cancerous Prostate) 6 0 5.9 21,22 (Normal Prostate vs. Cancerous Prostate) 5 20 15,17 (Normal Colon vs. Colon Metastasis) 5 20 08,09 (Lung, High Metastatic Potential vs. Lung, Low Metastatic Potential) 5 18 16,17 (Colon Tumor vs. Colon Metastasis) 6 6 16,17 (Colon Tumor vs. Colon Metastasis) 6 6 08,09 (Lung, High Metastatic Potential vs. Lung, Low Metastatic Potential) 1 12	— —						
21,22 (Normal Prostate vs. Cancerous Prostate) 6 0 5.9 21,22 (Normal Colon vs. Colon Metastasis) 5 20 15,17 (Normal Colon vs. Colon Tumor) 38 132 15,16 (Normal Colon vs. Colon Tumor) 5 18 15,16 (Normal Colon vs. Colon Metastasis) 6 16,17 (Colon Tumor vs. Colon Metastasis) 0 6 16,17 (Lung, High Metastatic Potential vs. Lung, Low Metastatic Potential) 1 12			21,22 (Normal Prostate vs. Cancerous Prostate)	18	1		
21,22 (Normal Prostate vs. Cancerous Prostate) 6 0 5.9 21,22 (Normal Prostate vs. Cancerous Prostate) 5 20 15,17 (Normal Colon vs. Colon Metastatic Potential) 38 132 08,09 (Lung, High Metastatic Potential vs. Lung, Low Metastatic Potential) 5 18 16,17 (Colon Tumor vs. Colon Metastasis) 0 6 -08,09 (Lung, High Metastatic Potential vs. Lung, Low Metastatic Potential) 1 12		819201					
21,22 (Normal Prostate vs. Cancerous Prostate) 6 0 5.9 21,22 (Normal Prostate vs. Cancerous Prostate) 6 0 5.9 25,17 (Normal Colon vs. Colon Metastasis) 6 20 28,09 (Lung, High Metastatic Potential vs. Lung, Low Metastatic Potential) 7 18 26,17 (Colon Tumor vs. Colon Metastasis) 7 10,17 (Colon Tumor vs. Colon Metastasis) 7 1 12							
15,17 (Normal Colon vs. Colon Metastasis)520-08,09 (Lung, High Metastatic Potential vs. Lung, Low Metastatic Potential)38132-15,16 (Normal Colon vs. Colon Tumor)518-16,17 (Colon Tumor vs. Colon Metastasis)06-08,09 (Lung, High Metastatic Potential vs. Lung, Low Metastatic Potential)112			_21,22 (Normal Prostate vs. Cancerous Prostate)	9			
15,17 (Normal Colon vs. Colon Metastasis) 208,09 (Lung, High Metastatic Potential vs. Lung, Low Metastatic Potential) 38 132 18 18 15,16 (Normal Colon vs. Colon Tumor) 5 18 6 6 6 6 16,17 (Colon Tumor vs. Colon Metastasis) 6 0 6 7 08;09 (Lung, High Metastatic Potential vs. Lung, Low Metastatic Potential) 1 12		374826					
_15,17 (Normal Colon vs. Colon Metastasis)520_08,09 (Lung, High Metastatic Potential vs. Lung, Low Metastatic Potential)5132_15,16 (Normal Colon vs. Colon Tumor)518_15,16 (Normal Colon vs. Colon Metastasis)6_16,17 (Colon Tumor vs. Colon Metastasis)6_08;09 (Lung, High Metastatic Potential vs. Lung, Low Metastatic Potential)1							
_08,09 (Lung, High Metastatic Potential vs. Lung, Low Metastatic Potential) 38 132				5	20		3.73
_15,16 (Normal Colon vs. Colon Tumor) 5 18 _16,17 (Colon Tumor vs. Colon Metastasis) 0 6 _08,09 (Lung, High Metastatic Potential vs. Lung, Low Metastatic Potential) 1 12			_08,09 (Lung, High Metastatic Potential vs. Lung, Low Metastatic Potential)	38	132		2.49
_16,17 (Colon Tumor vs. Colon Metastasis) 0 6 _08,09 (Lung, High Metastatic Potential vs. Lung, Low Metastatic Potential) 1 12	1			5	18		3.41
_16,17 (Colon Tumor vs. Colon Metastasis) 0 6 6	1	553242					
16,17 (Colon Tumor vs. Colon Metastasis)	i						
			_	0	9		5.91
08,09 (Lung, High Metastatic Potential vs. Lung, Low Metastatic Potential) 1 12		220584					
_08,09 (Lung, High Metastatic Potential vs. Lung, Low Metastatic Potential) 1 12							
819498			08,09 (Lung, High Metastatic Potential vs. Lung, Low Metastatic Potential)	1	12		8.59
		819498					

Fable 4

SEQ ID	CLUST	PairAB-text	CLONES in A	CLONES in B	RATIO PLUS	RATIO MINUS
		21,22 (Normal Prostate vs. Cancerous Prostate)	9	0	5.9	
253	819498					
		21,22 (Normal Prostate vs. Cancerous Prostate)	9	0	5.9	
256	831160					
		21,22 (Normal Prostate vs. Cancerous Prostate)	0	12		12.2
259	831160					
		_21,22 (Normal Prostate vs. Cancerous Prostate)	0	12		12.2
797	373298					
		_15,17 (Normal Colon vs. Colon Metastasis)	126	42	3.22	
		_15,16 (Normal Colon vs. Colon Tumor)	126	59	2.26	
270	450262					
		21,22 (Normal Prostate vs. Cancerous Prostate)	0	∞		8.13
271	484703					
		21,22 (Normal Prostate vs. Cancerous Prostate)	28	0	27.54	
272	819498					
		21,22 (Normal Prostate vs. Cancerous Prostate)	9	0	5.9	

able 4

SEO	CITICT	Dair A B. text	CLONES	CLONES	PATIO	DATIO
D.			in A	in B		MINUS
273	406043					
		_21,22 (Normal Prostate vs. Cancerous Prostate)	0	9		6.1
274	817500					
		21,22 (Normal Prostate vs. Cancerous Prostate)	2	18		9.15
275	818180					
		21,22 (Normal Prostate vs. Cancerous Prostate)	2	10		5.08
280	429009					
		21,22 (Normal Prostate vs. Cancerous Prostate)	8	1	7.87	
284	383021					
		_21,22 (Normal Prostate vs. Cancerous Prostate)	3	12		4.07
289	831580					
		_21,22 (Normal Prostate vs. Cancerous Prostate)	0	9		6.1
311	763446					
		_21,22 (Normal Prostate vs. Cancerous Prostate)	11	1	10.82	
312	763446					
		_21,22 (Normal Prostate vs. Cancerous Prostate)	11		10.82	
314	763446					
		_21,22 (Normal Prostate vs. Cancerous Prostate)	11		10.82	
315	10154					
		_3,4 (Breast, High Metastatic Potential vs. Breast, Low Metastatic)	3	317		108.1

Table 7

Library No.	Clones		
es75	M00063947D:D01	es79	M00064003B:C10
	M00063158A:A01		M00064302A:D10
	M00063517A:A04		M00064309C:H09
	M00063520D:E11		M00064310D:F03
	M00063638C:G12		M00064322C:A10
	M00063642B:A08		M00064359B:H12
	M00063686B:E07		M00064390A:C05
	M00063689D:E12		M00064404A:B05
	M00063781B:B10		M00064404C:G05
	M00063826A:D03		M00064404D:A06
7.0	1 1000 (2002) COO	20	1.4000.64.400D DOZ
es76	M00063838B:G08	es80	M00064429D:B07
	M00063838B:G08		M00064446A:D11
	M00063841A:B09		M00064457D:C09
	M00063886A:B06		M00064476D:C04
	M00063910D:A12		M00064506A:C07
	M00063912A:D06		M00064514A:G10
	M00063920D:H05		M00064520A:F08
	M00063928A:G09		M00064579D:E11
	M00063934B:E04		M00064620C:D01
	M00063945A:C03		M00064624D:C09
es77	M00064032D:G04	es81	M00064633C:A03
	M00064046A:G02		M00064637B:F03
	M00064053C:G04		M00064690A:C04
·	M00064053D:F02		M00064690A:C04
	M00064082A:A08		M00064714A:G03
	M00064089B:F09		M00064723D:H11
	M00064132B:B07		GKC10154-1
	M00064138A:F11		GKC10154-3
	M00064161B:G04		
	M00064175B:B09		
es78	M00064178C:C04		
	M00064179A:C04		
	M00064200D:E08		
	M00064248A:E02		
	M00064270B:B03	1	
	M00064271B:D03		
	M00063580C:A06		
	M00063594B:H07		
	M00064002C:F06		
	M00064002C:H09	400	

es82	M00063151A:G06	M00063852D:F07
	M00063151D:B10	M00063888D:D05
	M00063152C:B07	M00063888D:F02
	M00063156D:H10	M00063890A:F11
	M00063158A:E11	M00063890A:H04
	M00063158A:E11	M00063891A:F11
	M00063452A:F08	M00063892B:G02
	M00063453B:F08	M00063898A:A10
	M00063462D:D07	M00063915C:E01
	M00063463D:B05	M00063919C:E07
	M00063466C:C11	M00063920D:H02
	M00063467D:H07	M00063922B:A12
	M00063478C:D01	M00063925B:F04
	M00063482A:A08	M00063926A:H04
	M00063482A:F07	M00063931B:E10
	M00063485A:E05	M00063931B:F07
	M00063487C:C02	M00063932D:G08
	M00063514C:D03	M00063934C:C10
	M00063514C:E08	M00063938B:H07
	M00063515B:F06	M00063939C:D06
	M00063515B:H02	M00063939C:H01
	M00063518D:A01	M00063940D:F09
	M00063520D:D08	M00063940D:F09
	M00063604A:B11	M00063941B:C12
	M00063606C:B04	M00063943B:G12
	M00063610D:C11	M00063949D:A05
	M00063613D:C11	M00064021D:H01
	M00063617D:F09	M00064025D:E07
	M00063627C:F06	M00064025D:H12
	M00063636A:E01	M00064033C:C11
	M00063681B:C02	M00064033D:B01
	M00063682A:C04	M00063843B:D07
	M00063685A:C02	M00063848C:G11
	M00063774A:D09	M00063852B:D08
	M00063784A:H12	M00063818C:A09
	M00063784C:E10	M00063828A:H12
	M00063785C:F03	M00063828D:E05
	M00063795C:D09	M00063839A:F01
	M00063801B:D04	M00063841A:E08
	M00063804C:A11	
	M00063805D:E05	
	M00063807A:D12	
	M00063810C:E03	

es83	M00064043D:C09	M00063577C:C02
	M00064048C:G12	M00063578B:E02
	M00064053B:D09	M00063578C:A06
	M00064057C:H10	M00063580D:B06
	M00064059A:C11	M00063593A:D03
	M00064060B:D03	M00063600C:C09
	M00064079C:A10	M00063955C:F07
	M00064082D:D10	M00063955D:F05
	M00064083D:E05	M00063956A:F05
	M00064086C:E01	M00063957A:E02
	M00064090C:A02	M00063957A:E02
	M00064090D:D09	M00063967C:A12
	M00064105B:A03	M00063967D:G02
	M00064106C:G03	M00063968D:G08
	M00064113B:C04	M00063972C:E10
	M00064115B:E12	M00063978B:B06
	M00064119B:H10	M00063981D:A06
	M00064119C:D12	M00063990A:D05
	M00064122C:B06	M00063990A:D05
	M00064126C:C02	M00063997C:B12
	M00064126C:F12	M00063998C:E09
	M00064136C:D12	M00064000B:C03
	M00064144D:A07	M00064001A:B03
	M00064151B:C07	M00064005D:A08
	M00064159A:H03	M00064008A:B01
	M00064165A:B12	M00064009A:C01
	M00064171D:E05	M00064014D:H05
	M00064171D:E05	M00064018C:E07
	M00064172C:A02	M00064293D:B12
	M00064173B:E01	M00064294D:F01
	M00064176D:H10	M00063557D:C07
	M00064178B:A05	M00063559D:G03
	M00064178B:A05	M00063571B:G03
	M00064180A:G03	M00063575B:G02
	M00064186C:B03	M00063555B:D01
	M00064188B:G08	M00063533A:C12
	M00064194C:D02	M00063534C:A02
	M00064212D:E04	M00063538D:B01
	M00064260C:E05	M00063539C:C11
	M00064268D:G03	
	M00064272C:G01	
	M00063163A:G04	
	M00063165A:C09	

es84	M00064307B:G02	M00064564A:C02
	M00064307C:G03	M00064568A:H06
	M00064310C:A10	M00064569B:A09
	M00064328B:H04	M00064569B:A09
	M00064328B:H09	M00064571C:C04
	M00064337D:F01	M0064577C:B120
	M00064341A:C02	M00064579A:C06
	M00064345A:A03	M00064593A:A05
	M00064346C:B09	M00064593D:C01
	M00064349D:H01	M00064601C:G07
	M00064352C:H01	M00064601D:B05
	M00064354A:A10	M00064605C:G05
	M00064358A:G03	M00064610D:H01
	M00064358C:D09	M00064620D:G05
	M00064375B:G07	M00064624C:B03
	M00064376A:A05	M00064631A:C07
	M00064385D:C11	M00064631A:C07
	M00064386B:C02	M00064631C:H11
	M00064386B:C02	M00064636B:A04
	M00064393B:H04	M00064649A:E04
	M00064399A:E01	M00064650B:B07
	M00064405B:C04	M00064652B:D09
	M00064406B:H06	M00064675C:E09
	M00064414D:D06	M00064678D:F05
	M00064415B:G03	M00064693D:F08
	M00064424B:C12	M00064723C:H04
	M00064428B:A12	M00064723D:H03
	M00064447B:A07	M00064723D:H03
	M00064447B:C06	M00003773D:H02
	M00064450C:E07	M00021929A:D03
	M00064452D:E11	M00043134A:A05
	M00064454A:H10	M00064534D:F06
	M00064454C:B06	M00064550A:A07
	M00064460C:B01	M00064554D:A03
	M00064467B:D06	M00064526D:F05
	M00064481C:F03	M00064527A:H07
	M00064508A:B09	M00064530B:H02
	M00064514D:F11	M00064532D:G06
	M00064517B:F04	M00064520A:E04
	M00064517B:F10	M00064520A:E04
	M00064517C:F11	M00064524A:A09

Comment	invasive adenocarcin oma, moderately differentiate d; focal perineural invasion is seen		Hyperplastic polyp in appendix.	Perineural invasion; donut	anastomosis negative. One tubulovillou	s and one tubular adenoma with no high
Dist Met Grade		MX	H H B MO	ш.:: о с	<u> </u>	s tr W0
Descrip Distant Met						
Incidence Regional Distant Descrip Lymphnod Lymphnod Met & Loc Distant e Met e Grade Met		negative	negative			negative
Regional Lymphnod e Grade		N	NO			0N
Incidence Lymphnod e Met		3/8	0/12			0/34
Lymphnode Met		positive	negative			negative
Anatomical Primary Primary Histopath Local Invasion Lymphnode Incidence Loc Tumor Tumor Grade Met Lymphnod Size Grade e Met	extending into subserosal adipose tissue		Invasion through muscularis propria, subserosal involvement; ileocec. valve involvement	Invasion of muscularis propria into	ser Osa, involving submucosa of urinary bladder	
Histopath Grade		62	B			G 2
Primary Tumor Grade		T3	T3			T4
Primary Tumor Size		4.0	9.0			9
Anatomical Loc	Ascending	colon _i	Ascending			Sigmoid
		21	71			140
Table 8 Path PatientI Report D ID		15	52			. 121

Comment	grade dysplasia.	patient history of metastatic melanoma			
Descrip Dist Met Distant Grade Met			M0	M0	M1
Descrip Distant Met					
Distant Met & Loc			negative	negative	negative
Regional Lymphnod e Grade		·	0N	N	N2
Incidence Lymphnod e Met			0/19	1/5	10/24
Lymphnode Met			negative	positive	positive
Anatomical PrimaryPrimaryHistopathLocal InvasionLymphnode Incidence Regional Loc Tumor Tumor Grade Met LymphnodLymphnod Size Grade e Grade		Invasion through the muscularis propria into suserosal adipose tissue. Ileocecal junction.		Invasion of muscularis propria into percolonic fat	through wall and into surrounding adipose tissue
Histopath Grade			G2	G2	
Primary Tumor Grade			T3	T3	T3
Primary Tumor Size			9	5.0	5.5
Anatomical Loc	,	****	Cecum	Transverse colon	Splenic flexure
Path Report ID			144	147	149
Table 8 Path PatientI Report D ID		138	125	128	130

Comment	Small separate tubular adenoma (0.4 cm)	Fermeural invasion identified adjacent to metastatic adenocarcin oma.
Descrip Dist Met Distant Grade Met	M0	M1
Descrip Distant Met		adenoca rcinoma consista nt with
Distant Met & Loc	negative	positive (Liver)
Regional Lymphnod e Grade	NO	N2
Incidence Lymphnod e Met	6/0	7/21
Lymphnode Met	negative	positive
Anatomical Primary Primary Histopath Local Invasion Lymphnode Incidence Regional Loc Tumor Grade Size Grade Grade e Grade	Invasion through muscularis propria into non- peritonealized pericolic tissue; gross configuration is annular.	Invasion of muscularis propria into pericolonic adipose tissue, but not through serosa. Arising from tubular adenoma.
Histopath Grade	62	G2
Primary Tumor Grade	. T3	T3
Primary Tumor Size	5.0	5.5
Anatomical Loc	Rectum	Cecum
	152	160
Table 8 Path Patientl Report D ID	133	141

81	P
Separate tubolovillou s and tubular adenomas Hyperplastic polyps	
. M	MX
negative	negative
Z	NI
2/13	8/1
positive	positive
Invasion through mucsularis propria into subserosa/peric olic adipose, no serosal involvement. Gross configuration annular. Invasion through muscularis propria to involve subserosal, perirectoal adipose, and serosa	
G2	G2 to G3
57	T3
3.8	5.8
Hepatic	Rectum
175	247
156	228
	Hepatic Hepatic 175 flexure 3.8 T3 G2 muscularis Propria to involve subscrosal, subsectoral adipose, and though a muscularis The particular adipose, and adipose, and adipose, and adipose, and adipose, and a serosal adipose, and a serosal adipose, and adipose, and a serosal adipose, and a serosal adipose, and a serosal adipose, and serosal adipose, and serosal

Comment	Tubulovillo us adenoma with high grade dysplasia		
Descrip Dist Met Distant Grade Met	M0	MX	M0
Descrip Distant Met		0.4 cm, may represen t lymph node complet ely replaced by tumor	
Incidence Regional Distant Descrip Lymphnod Lymphnod Met & Loc Distant e Met e Grade Met	negative	0.4 mas rep (0.4 m	negative
Regional Lymphnod e Grade	NO	NI	N0
Incidence Lymphnod e Met	0/10	. 0/15	0/12
Lymphnode Met	negative	negative	negative
Anatomical Primary Primary Histopath Local Invasion Lymphnode Incidence Loc Tumor Grade Size Grade e Met e Met e Met	Invasion through muscularis propria into subserosal adipose tissue.	Invades through muscularis propria to involve pericolonic adipose, extends to serosa.	Invades full thickness of muscularis propria, but mesenteric adipose free of malignancy
Histopath Grade	G2	G2	G2
PrimaryPrimary Tumor Tumor Size Grade	T3	T3	12
Primary Tumor Size	5.5	6	6.5
	Ascending	Transverse	Cecum
Path Report ID	283	285	287
Table 8 Path Patientl Report D ID	264	141	268

Comment	Descending colon polyps, no HGD or carcinoma identified	Melanosis coli and diverticular disease.	1 hyperplastic polyp identified	
Dist Met Grade	M0	M0	M0	MX
Descrip Distant Met				
Incidence Regional Distant Descrip Lymphnod Lymphnod Met & Loc Distant e Met e Grade Met	negative	negative	negative	negative
Regional Lymphnod e Grade	SN	NO	N0	NO
Incidence Lymphnod e Met	7/10	0/12	9/0	0/4
Lymphnode Met	positive	negative	negative	negative
Anatomical Primary Primary Histopath Local Invasion Lymphnode Incidence Loc Tumor Tumor Grade Grade e Met Lymphnod Size Grade	Invasion into perirectal adipose tissue.	Invasion through muscularis propria into percolic adipose tissue.	Extends into perirectal fat but does not reach serosa	Invasion through muscularis propria to involve pericolonic fat. Arising from villous adenoma.
Histopath Grade	G2	G2	G2	G2
Primary Tumor Grade	T3	T3	T3	T3
Primary Tumor Size	4	5.0	9	2 cm invasive
	Rectum	Ascending	Rectosigmoid	Ascending
Path Report ID	297	314	358	360
Table 8 Path Patientl Report D ID	278	295	339	341

Comment		Two mucosal polyps	Tumor arising at prior ileocolic surgical anastomosis.
Dist Met Grade	W	M0	M1
Descrip Distant Met			Macrov esicular and microve sicular steatosis
Distant Met & Loo	педатіле	negative	positive (Liver)
Regional Lymphnod e Grade	No.	Z	N
Incidence Regional Distant Descrip Lymphnod Lymphnod Met & Loc Distant e Met e Grade Met	9/9	1/5	1/6
Lymphnode Met	negative	positive	positive
Anatomical Primary Primary Histopath Local Invasion Lymphnode Incidence Regional Distant Descrip Dist Met Loc Tumor Tumor Grade Size Grade Size Grade E Met Cymphnod Met & Loc Distant Grade E Met Cade	Through colon wall into subserosal adipose tissue. No serosal spread seen.	Invasion thru muscularis propria to pericolonic fat	Invasion through muscularis propria into subserosal adipose tissue, not serosa.
Histopath Grade	G2	G2	G2
PrimaryPrimary Tumor Tumor Size Grade	T.	T3	T3
Primary Tumor Size	6.5	4.3	2
Anatomical Loc	Sigmoid	Ascending	Ascending
Table 8 Path PatientI Report D ID	375	412	444
Table 8 PatientI D	356	360	392

Comment	rediagnosis of oophorecto my path to metastatic colon cancer.
Dist Met Grade	M0 M1
Descrip Distant Met	adenoca rcinoma in multiple slides
Distant Descrip Dist Met Met & Loc Distant Grade Met	negative positive (Liver)
Regional Lymphnod e Grade	NO NO
Incidence Regional Distant Descrip Lymphnod Lymphnod Met & Loc Distant e Met e Grade Met	0/21
Lymphnode Met	negative
Anatomical Primary Primary Histopath Local Invasion Lymphnode Incidence Regional Loc Tumor Tumor Grade Age Size Grade e Grade	Cecum, invades through muscularis propria to involve subserosal adipose tissue but not serosa. Invasive through muscularis to involve periserosal fat; abutting ileocecal junction.
Histopath Grade	G2 G2
Primary Tumor Grade	ET ET
Primary Tumor Size	6.0
Anatomical Loc	Cecum
Path Report ID	445
Table 8 Path PatientI Report D ID	393

Comment	Anatomical location of primary not notated in report. Evidence of chronic colitis. No mention of distant met in report	
Dist Met Grade	M1	M0
Descrip Distant Met	moderat ely different iated adenoca rcinoma, consista nt with primary	
Distant Met & Loc	positive (Liver)	negative
Regional Lymphnod e Grade	N	N2
Incidence Lymphnod e Met	2/17	9/9
Lymphnode Met	positive	positive
Table 8 Path Anatomical Primary Primary Histopath Local Invasion Lymphnode Incidence Regional Distant Descrip Dist Met Patient Report Loc Tumor Tumor Grade Size Grade Grade Amet Comment e Grade Size Grade Grade Grade Amet Comment Report Comment Report Loc Tumor Grade Grade Grade Amet Regional Distant Grade Amet Comment Report Comment Report Loc Distant Grade Amet Regional Distant Grade Amet Region Grade Amet Regi	Invasion through muscularis propria involving pericolic adipose, serosal surface uninvolved penetrates muscularis propria, involves pericolonic fat.	
Histopath Grade	Ğ2	G2
Primary Tumor Grade	T3	T3
Primary Tumor Size	7.5 cm max dim	3
Anatomical Loc		Sigmoid
Path Report ID	383	395
Table 8 PatientI D	505	517

Comment	Omentum with fibrosis and fat necrosis. Small bowel with acute and chronic serositis, focal abscess and adhesions.
Dist Met Grade	M0 M1
Descrip Distant Met	metastat ic adenoca
Distant Descrip Dist Met Met & Loc Distant Grade Met	negative positive (Liver)
Regional Lymphnod e Grade	NO N2
Incidence Regional Distant Descrip Lymphnod Lymphnod Met & Loc Distant e Met e Grade Met	
Lymphnode Met	negative
Anatomical Primary Primary Histopath Local Invasion Lymphnode Incidence Regional Loc Tumor Tumor Grade Asize Grade Grade Grade Grade Grade	Invasion through the muscularis propria involving pericolic fat. Serosa free of tumor. Invasion through muscularis propria extensively through submucosal and extending to serosa.
Histopath Grade	G2
Primary Tumor Grade	T3
Primary Tumor Size	5.5
Anatomical Loc	Ascending colon Ascending colon colon
Path Report ID	553
Table 8 Path A Patientl Report D ID	534

Comment	Appendix dilated and fibrotic, but not involved by tumor	tubular adenoma and hyperplstic polyps present, moderately differentiate d adenoma with mucinous diferentiatio	stated) invasive poorly differentiate d adenosquam ous
	Appendized ar filbrotic, I fibrotic, by tumor	tubular adenoma and hyperplst polyps present, moderate differenti d adenom with mucinous differentia	stated) invasive poorly different d adenosqu
Descrip Dist Met Distant Grade Met	Mo		MI
Descrip Distant Met			
Incidence Regional Distant Descrip Lymphnod Lymphnod Met & Loc Distant e Met e Grade Met	negative		negative positive (Liver)
Regional Lymphnod e Grade	NO NO		N
Incidence Lymphnod e Met	85/0		0/22
Lymphnode Met	negative		negative positive
Histopath Local Invasion Lymphnode Incidence Grade Met Lymphnod e Met	Invasion through the bowel wall, into suberosal adipose. Serosal surface free of tumor.	extending through bowel wall into serosal fat	through muscularis propria into pericolic soft tissues
Histopath Grade	G2		G2 G3
Primary Tumor Grade	T3		T3 T3
Primary Tumor Size	11.5		3.5
Anatomical PrimaryPrimary Loc Tumor Tumor Size Grade	Cecum		Cecum Ascending
Path Report ID	596		714
Table 8 PatientI D	577	,	695

Distant Descrip Dist Met Comment Met & Loc Distant Grade Met	carcinoma	moderately differentiate d invasive adenocarcin oma		poorly differentiate d invasive colonic	adenocarcin oma
Dist Met Grade			M1		M1
Descrip Distant Met					
Incidence Regional Distant Descrip Lymphnod Lymphnod Met & Loc Distant e Met e Grade Met			positive (Liver)		positive (Liver)
Regional Lymphnod e Grade			N0		N2
Incidence Lymphnod e Met			0/12		13/25
Lymphnode Met			negative		positive
Table 8 Path Anatomical Primary Primary Histopath Local Invasion Lymphnode Incidence Regional PatientI Report Loc Tumor Grade D Grade Grade Grade Met Lymphnod Lymphnod Lymphnod Lymphnod Lymphnod Companies		through muscularis propria into pericolic fat, but not at scrosal surface		through the muscularis propria into pericolic fat	!
Histopath Grade			G2		G3
Primary Tumor Grade			T3		T3
Primary Tumor Size			9.5		5.8
Anatomical Loc			Descending colon		Ascending colon
Path Report ID			805		810
Table 8 PatientI D			786		791

Comment	well- to	moderately-	differentiate		adenocarcin	oma; this	patient has	tumors of	the	ascending	colon and	the sigmoid	colon	moderately	differentiate	p	adenocarcin	oma
Dist Met Grade									•				M1					M1
Descrip Distant Met																		
Distant Met & Loc												positive	(Liver)				positive	(Liver)
Regional Lymphnod e Grade													0N					NI
Incidence Lymphnod e Met					-								3/21					1/4
Lymphnode Met													positive					positive
Table 8 Path Anatomical Primary Primary Histopath Local Invasion Lymphnode Incidence Regional Distant Descrip Distant Grade Date of Tumor Tumor Grade Size Grade Grade Grade Tumor Grade	into muscularis	propria												through	muscularis	propria int	subserosal	tissue
Histopath Grade				•									G1					GZ
Primary Tumor Grade													T2					T3
Primary Tumor Size													2.0					4.8
Anatomical Loc		_			_						_	Ascending	colon					Cecum
Path Report ID													806					606
Table 8 PatientI D													888					688

We Claim:

1. An isolated polynucleotide comprising a nucleotide sequence which hybridizes under stringent conditions to a sequence selected from the group consisting of SEQ ID NOS: 1-316.

5

2. An isolated polynucleotide comprising at least 15 contiguous nucleotides of a nucleotide sequence having at least 90% sequence identity to a sequence selected from the group consisting of: SEQ ID NOS:1-316, a degenerate variant of SEQ ID NOS:1-316, an antisense of SEQ ID NOS:1-316, and a complement of SEQ ID NOS:1-316.

10

3. A polynucleotide comprising a nucleotide sequence of an insert contained in a clone deposited as clone number xx of ATCC Deposit Number xx.

4. An isolated cDNA obtained by the process of amplification using a polynucleotide
 comprising at least 15 contiguous nucleotides of a nucleotide sequence of a sequence selected from the group consisting of SEQ ID NOS:1-316.

5. The isolated cDNA of claim 4, wherein amplification is by polymerase chain reaction (PCR) amplification.

20

- 6. An isolated recombinant host cell containing the polynucleotide according to claims 1, 2, 3, or 4.
 - 7. An isolated vector comprising the polynucleotide according to claims 1, 2, 3, or 4.

25

8. A method for producing a polypeptide, the method comprising the steps of: culturing a recombinant host cell containing the polynucleotide according to claims 1, 2, 3, or 4, said culturing being under conditions suitable for the expression of an encoded polypeptide; recovering the polypeptide from the host cell culture.

30

- 9. An isolated polypeptide encoded by the polynucleotide according to claims 1, 2, 3, or 4.
- 10. An antibody that specifically binds the polypeptide of claim 9.
- 35 11. A method of detecting differentially expressed genes correlated with a cancerous state of a mammalian cell, the method comprising the step of:

detecting at least one differentially expressed gene product in a test sample derived from a cell suspected of being cancerous, where the gene product is encoded by a gene comprising an identifying sequence of at least one of SEQ ID NOS:1-316;


wherein detection of the differentially expressed gene product is correlated with a cancerous state of the cell from which the test sample was derived.

- 12. A library of polynucleotides, wherein at least one of the polynucleotides comprises the sequence information of the polynucleotide according to claims 1, 2, 3, or 4
- 10 13. The library of claim 12, wherein the library is provided on a nucleic acid array.


5

- 14. The library of claim 12, wherein the library is provided in a computer-readable format.
- 15. A method of inhibiting tumor growth by modulating expression of a gene product, the
 gene product being encoded by a gene identified by a sequence selected from the group consisting of
 SEQ ID NOS:1-316.

3	GCCAGATTCGGCACGAGGGGGTAGGACCCTCCGAGCCAGGTGTGGGATATAGTCTCGTGGTGCGCCCGTTTTTTAAGCCG	80
81 81	GTCTGAAAAGCGCAATATTCGGGTGGGAGTGACCCGATTTTCCAGGCTGCTATCCATGTCCAGGGCCAAACATGAATCCT	160
161	ATTGCTCTTGGGAGCCGCTTGCTTATGCAGAAAACAAGTTGATTCGATGTCATCAGTCCGTGGTGGAGCCTGTGG	0 240
1 241	. ACACAACATTCAGTCTTATACTGCCACAGTCATTAGTGCTGCTAAAACATTGAAAAGTGGCCTGACAATGGTAGGGAAAG	0 320
321	TOOTCACTCAGCTGACAGGCACACTGCCTTCAGGTGTGACAGAAGATGATGTTGCCATCCACAGTAATTCACGGCGGAGT	400
1 401	CCTTTGGTCCCAGGCATCATCACAGTTATTCACACCGAAACCGTTGGAGAGGGCCAGGTGGTTGTGAGTGA	0 480
1 481	CAGTOATGGCATTGTGGCCCACTTCCCTGCCCATGAGAAGCCAGTGTGCTGCATGGCTTTTAATACAAGTGGAATGCTTC	0 560
. 1 561	TAGTCACAACAGACACCCTTGGCCATGACTTTCATGTCTTCCAAAATTCTGACTCATCATCACCAATGAGCT	0 640
1 641	OTCCACCATCTOTATACTCTTCACAGGGGAGAAACTGAAGGCCAAAGTACAGGACATCTGCTTCAGCCATGACTOTCGCTG	0 720
1 721	COTTOTOOTEMOTACTCTCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCC	0 800
501	MTNTGTCACCACGAGTAGTGAATCGCATGAGCCGTTTCCAGAAAAGTGCTGGACTGGAAGAGATTGAACAAGAACTGACG	88.0
1 551	TCTAAGCAAGGAGGTCGCTGTAGCCCTGTTCCAGGTCTATCAAGCAGCCCTTCTGGGTCACCCTTGCATGGGAAACTGAA	0 960
1 961	CAGCCAAGACTCCTATAACAATTTTACCAACAACAACCCTGGCAACCCTCGGCTCTCTCCTCTCCCAGCTTGATGGTAG	0 1040
1041	TGATGCCTCTTGCACAAATCAAGCAGCCAATGACATTGGGGACCATCACCAAACGAACCGGGCCTTATCTCTTTGGAGCG	. 0 L120
1 1121	GGGTGTTTTTCCRTRARAGCCCCATGCRAAGTTRARACCTCCTCCACAAATTCACCCAGCAAATTGATGGGCGGAGAATT	0 1200
1201	TTGTGTGGCTGCTATCTTCGGAACATCCAGGTCATGGTTTGCAAATAATGCAGGTCTGAAAACAGAAAAAAAA	0 L280



1 1281	AACAAGTTGTAGTTGAGTCCCTGTACATTATCAGTTGCTATGGCACCTTAGTGGAACACATGATGGAGCCGCGACCCCTC	1360
1 1361	AGCACTGCACCCAAGATTAGTGACGACACACCACTGGAAATGATGACATCGCCTCGAGCCAGCTGGACTCTGGTTAGAAC	0 1440
1 1441	CCCTCAATGGAATGAATTGCAGCCACCGTTTAATGCAAACCACCCTCTGCTCCTCGCTGCAGATGCAGTACAGTATTATC	0 1520
1 1521	ACTICCTCCTCCCCCCCCCCCCCCCCCCCCCCCCCCCCC	0 1600
1 1601	GACCATACTGCACACGAAGAATGAAGAATGCTTTCCCAGGTTGAAATTGTAACACACAC	0 1680
1 1681	GATGGGTCCACAGTTCCAGTTCAAAACCATCCATCCCTCAGGCCAAACCACAGTTATCTCATCCAGTTCATCTGTGTTGC	. 0 1760
1 1761	AGTCTCATGGTCCGAGTGACACGCCACAGCCTCTTTTGGATTTTGATACAGATGATCTTGATCTCAACAGTCTCAGGATC	0 1840
1 1841	TCGAGCCCATGCGCAGGGGGGGGGGGTTAGCTCGGGCTCTTGCTGACCCC CAGCCAGTCCGCTCTGACCCCGTCAGCATGCCAGGGAGTTTCCACAGTGAT CAGCCAGTCGCTCTGATCGCTCAGCTCTGATCGACAGTGATGATGATGATGACAGTGAT	50 1920
51 1921	CCATTCTTGGGCCCGAGGTACCTTTGACAGGAGCGTGACCCTGCTGGAGGTGTGCGGGAGCTGGCCTGAGGGCTTCGGGCT TGATGCTGCCTCAGGTACCTTTGACAGGAGCGTGACCCTGCCGGAGGTGTGCGGAGCTGGCCTGAGGGCTTCGGGCT	130 1998
-131 1999	GCGCCACATGTCCTCCATGGAGCACACGGAGGGGGCCTCCGGGAGCGACTTGCCGACGCCATGGCCGAGTCACCTAGCC GCGGCACATGTCCTCCATGGAGCACACGGAGGAGGGGCTCCGGGAGCGACTTGCCGACGCCATGGCCGAGTCACCTAGCC	210 2078
211 2079	GGGACGTCGTGGGATCCGGAACAGAACTTCAGCGAGAGGGAAGGATCGAGACTCTGAGTAACAGCTCAGGCTCACCAGC GG-ACGTCGTGGGATCGGACAGGAAAAAAAAAAAAAAAAA	290 2124
291 2125	CCCACCATACCAAGAAACTTTGATGGCTACCGATCTCCGCTGCCCACCAATGAGAGCCAGCC	370 2124
371 2125	TGGCTTCCCGTAGCTACCAGCAACCTGCTTCTGACTGGCCAG 412 STQ VO NO.315	



1	COAGRACTCTOAGOTAACAGCTCAGGCTCACCAGGGGGGGGCATACCAAGAAACTTTGATGCCTACGGATCTCCGCTGCCC	\$ 0
1 81	GCCACCCCTCAGCTCTCCCCACACCCCCCCCCCCCCCCC	70 160
71 161	CCTCCCTGCTGGAGGAGGAGAAAACCCCGCTCTGGTCCTACCTTCAGTCTTGTCTTCATCAACCACCTTCC CCTCCCCTGCTGGAGGAGGAGAAAACCCCCGCTCGGTCTTAGTCTTCTTCTTCTTCATCAACCACCTTCA	150 240
151 241	CCAAGCTTAGTGACAGCAGCGGCGATCCTAGCTGGATGGA	320 320
131 321	CTGCACACTGTGGGGGGGGGGGGGGGGGGGGGGGGGGGG	1300 400
301 401	TGCATTGGATCCCCTTTTGTATTTTTAACCATACCCACGGTCCCCCCCC	300 480
301 481	CECCCCTOACTCCCCACTTCATCCTCCACCTCCCCTTTTCACCCTCACTCCACACTCACACCCTCACCTCATCT	300 560
301 561		300 640
301 641	GOGNAGENAGGONGGNCATGCCTCTTCTTCCTCCTTTTTCCCCNTCTGTTCCTGGGANGNGTHTGTCTTTCTTAT	300 720
. 301 721	CTTTRAGCCCCTTTACCCTCGTCCTGTACTGATCAGTGAAGGAAACCGTGGTTACTGAGGCCCTGTTGAAAACTGCACGT	300 800
302 802	CTTGTCCAATAAATCACGCTGGGAAAAAAAAAAAAAAAA	300 886
301 88:	CCCTTIAGTGAGGGTTAATTYTAGCTTGGCACTGGCCGTCGTTTTACAACGTCGTGACTGGTAAACCCTGGCGTTACCCA	300 950
30: 96:	L ACITANTOGOCITGOGRADATCCCCCTTTCGCCAGCTGGCGTANTAGCGAAGAGGCCCCCACGGATGGCCCTTCCCAAC	300 1040
30 104	1 1. agittgegengeetgantgoognatgognegegegetgtnageggegenttanggggggggtttgotgotgottanegegeng	300 1120
. 30 - 112	l 1 CHTGACCGCTACACTTGCCAGCGCGTAGCGCGCGCTCCTTTCGCTTTCTTCCCCTTCCTT	300 1200
- 30 120	l 1 TTTCCCCCCTCAAGCTCTAAATCGGGGGCTCCCCTTTAGGGTTCCCGATTTAGTGCTTTACCGGCACCTCGACCCCAAAA	300 1280
30: 128:	i I arcttorptrocercatgoticacgirotoggcckicgccctgriangrcggtttttcgcccttttgacgttggacgcccc	300 1360
30 136	1 300 1 GTTCT 1365 SED IN NOVER 18	

FIGURE 2

SEQUENCE LISTING

<110> Williams, Lewis T. Escobedo, Jaime Innis, Michael A. Garcia, Pablo Dominiguez Sudduth-Klinger, Julie Reinhard, Christoph He, Zhijun Randazzo, Filippo Kennedy, Giulia C. Pot, David Kassam, Altaf Lamson, George Drmanac, Radoje Crkvenjakov, Radomir Dickson, Mark Drmanac, Snezana Labat, Ivan Leshkowitz, Dena Kita, David Garcia, Veronica Jones, Lee William Stache-Crain, Birgit <120> Human Genes and Gene Expression Products <130> PP-01625,001PC <150> 60/192,583 <151> 2000-03-28 <160> 324 <170> FastSEQ for Windows Version 4.0 <210> 1 <211> 214 <212> DNA <213> Homo sapiens <400> 1 ttagtactgc atatgtaaat actacctttt caatgagcta tataaacaat gatagcacat 60 ccttcctttt actatgtctc acctccttta ggagagaact tccttaagta agtgctaaac 120 atacatatac ggaacttgaa agetttggtt ageettgeet taggtaatca gaetagttta 180 cactgtttcc agggagtagt tgaattacta taag 214 <210> 2 <211> 353 <212> DNA <213> Homo sapiens <220> <221> misc_feature <222> (1)...(353) <223> n = A, T, C or G<400> 2 ggcacgagga gagaactaga aaatatgtat attggatata ctatgtgcca ggcacgattc 60 120 nnnnnnnnn nnnnnnnnn nnaaagtgga acactgggat ttgaacaagg ttttggttgg 180 qcatcttttc ctatgggagc tcagaaatat ctgttgtcta gccctttctc agcctcccaa 240

ccttctcggt tccttaccta taggtgccta tgtgagctgg	tgtcacagct cgttcatttc	gactttgagc tcactgtttc	taaagtcatc tccttccaaa	teggggeage tae	300 353
<210> 3 <211> 399 <212> DNA <213> Homo sapiens					
<400> 3 ggcacgagcc caccaagagc tcatatggga aatgctgctg tagcacactt gaaacactgc ataaatagtt tacctgagcc gatggcatgg accctacagg aaaggagtgc tgaagccaat cccatctctg ttccatacat	ctatactttt gtatcatttt ctttaacaac aaaaaccaca caccatgtaa	aggaattict cctcactcat ctcaaatagg ccttaccgct gcaagataaa	gagtgcaatt gaatatagtc ccatatttct tctgaccagc	tagaaacatc atcagaattc ctctctggtt atcactacaa	60 120 180 240 300 360 399
<210> 4 <211> 389 <212> DNA <213> Homo sapiens					
<220> <221> misc_feature <222> (1)(389) <223> n = A,T,C or G					
<400> 4 ggcacgagga gagggtggtg nnnnnnnnnn nnnnnnnnn nnnnnnnnn nnnnnnnn	nnnnnnnnn nnnnnnnnn nnnnnnnnn nnnnnnnn	nnnnnnnn nnnnnnnnn nnnnnnnnn nngagtagag	nnnnnnnn nnnnnnnnn nnnnnnnnn gatgcctggt	nnnnnnnnn nnnnnnnnn nnnnnnnnn atgaggcaat	60 120 180 240 300 360 389
<210> 5 <211> 279 <212> DNA <213> Homo sapiens					
<220> <221> misc_feature <222> (1)(279) <223> n = A,T,C or G	•				
<400> 5 cctctcccct tggaacccaa aaagggcgtg nnnnnnnnn aacctttggt tacaaaaatt atttgagaat tcttacccgg catgtgcgtg aggggaatac	nnggggccaa gcggggaaaa agagtgtgac	ggggcatttc tttatttcgg ataatttaag	ccaagcgatt gagcaatttt	aaaatttggg ccctttaaaa	60 120 180 240 279
<210> 6 <211> 388 <212> DNA <213> Homo sapiens					
<400> 6 ggcacgaggc agaggcctcc ggcccagggc catggaggga ctttcccctt cccaggcctc agtgtcccac aggtgcctgg	cccttaggag ctgggtgcca	ttcaatgaga ccccttacg	gagaccatga ttattcttgg	ggccactggg gcctctaata	60 120 180 240

```
gtgtgggtgt gtgtgggcac aggtgtgagt gtgtgagcaa cagtacccca ttccagtcgt
                                                                    300
ttcctgctgt gactaagtca gcaacacagt tcctctgaca tgggccttgg ctgtgcttct
                                                                    360
ttgggggtga agagattgcg gaggaagt
                                                                    388
<210> 7
<211> 410
<212> DNA
<213> Homo sapiens
<220>
<221> misc_feature
<222> (1)...(410)
<223> n = A,T,C or G
qqcacqaqqq qaaqtcqcqc atqcqcqaqt qtacqcqttq ccqqcqaaqa qqqqaqcctq
                                                                     60
acgactcgga aatttgaata ccacagtagc atggagtgtg acctcatgga gactgacatc
                                                                    120
                                                                    180
ttggagtcgt tggaagatct aggttacaag ggcccattgt tggaagatgg agcgctctct
caggeagtet etgetggage cagtteecee gagtttacca aactetgtge ttggetggtg
                                                                    240
tctgaattaa gagtgctctg taaactagag gaaaacgtgc aagcaactaa cagtccgagt
                                                                    300
qaaqctqaaq aattccaqct tqaqqtqaqt qqqctactaq qqqaqatqaa ctqcccqtat
                                                                    360
ctttcactga catctgnnga tgtgaccaag cgccttctca ttcagaaaaa
                                                                    410
<210> 8
<211> 229
<212> DNA
<213> Homo sapiens
<400> 8
ctaacaaaaa acactaaaaa aaaataaaag aaattaattg aaactgacct aactcgtggc
                                                                     60
agggggaact cggctataag acccacaaac cctgctgact cataacaaac tgagttgtaa
                                                                    120
gacattcatc gccgcgatat ccttgagtaa agaatgaact ctggaagccc acccacggac
                                                                    180
                                                                    229
aatqcacctt cacaaagatt ctgcactaat ctgagtgaag gtctttggt
<210> 9
<211> 380
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (1)...(380)
<223> n = A,T,C or G
<400> 9
ggcacgagag tagttgggaa atcttttata aatccaccta ttactaccta ttqqtaqqqq
                                                                      60
agattaaatt totacaggta tggagagtog gottgactac actgtgtgga gcaagtttta
                                                                    120
                                                                    180
aagaagcaaa ggtatagcag ttccaagtan nnnnnnnnn nnnnnagacc aaactctaga
tcttgcccaa aatggacggc cgcggcattt aaatgaagaa agatttattt ttcctttttt
                                                                    240
cttttaagaa aaatttttt aaaaaatttt gattnnnnnn nnnnnnnnn nnnnnnnnn
                                                                    300
360
                                                                    380
nnnnnnnnn nnnnnnnnn
<210> 10
<211> 317
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (1)...(317)
<223> n = A,T,C or G
```

```
<400> 10
cacacacaca catccactct ctctttttgc tctcttctca cacacacata tctcccttac
                                                                     60
teacacacte teteteacae accecetett tetttteece egeactitet tieteteacg
                                                                    120
180
tcacacgctt tatatctctc tctctgaggg acttctctct cctctcactc ttattttttt
                                                                    240
gttgtgtttt atagegtete tetetteeet nnnnnnnnn ntetatatat acagagagag
                                                                    300
                                                                    317
atctctctgc tctctcc
<210> 11
<211> 391
<212> DNA
<213> Homo sapiens
<400> 11
ggcacgagag aattagctga aacccaccaa gagctgcata gagcacgttt agctagagta
                                                                      60
ggagtttgca gtgctcatat gggaaatgct gctgctatac ttttaggaat ttctgagtgc
                                                                     120
                                                                     180
aatttagaaa catctagcac acttgaaaca ctgcgtatca ttttcctcac tcatgaatat
agtcatcaga attcataaat agtttacctg agccctttaa caacctcaaa taggccatat
                                                                    240
ttctctctct ggttgatggc atggacccta caggaaaaac cacaccttac cgcttctgac
                                                                    300
                                                                    360
cagcatcact acaaaaagga gtgctgaagc caatcaccat gtaagcaaga taaaagcaaa
                                                                    391
gggggtcttg cctgcccatc tctgttccat a
<210> 12
<211> 280
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (1)...(280)
<223> n = A, T, C or G
<400> 12
                                                                      60
tgtgcgcgcc cccccggggc gctctctctc tacactcgtg cgctcccccc tctgtctgtc
tctctctcta gagtcacggt ctcctacacg gcgcgcacat gcgaggggca ctnnnnnnn
                                                                    120
                                                                    180
nnngctcnnn nnnnnnnnn nnnnnnnnn cgnnnnnnnn nnnnnntcc cttgtatact
                                                                    240
ctctqtqtqc qcqqqacan nnnnnnnnn nnqtqcqcqc qcqaqaqcqc qcqcqccaca
caagagagag cgcgcctnn nnnnnnnnn naccgcgaac
                                                                    280
<210> 13
<211> 311
<212> DNA
<213> Homo sapiens
<400> 13
                                                                      60
cgcttttttg ggaacccaaa ccttttttgg ctggccggaa aaaatttcca cgggaagggt
                                                                     120
aaaggggttt attaattttt ttggcaaaac aggggttaag aaaccttccc tcccggccta
agggtgggct aggctttgga aaggctaaaa gggggaaatt tctggccctt gttccaaggg
                                                                    180
aaacatgggc tagggggaaa ccccaccct tcagggccct ttaaaagggc ccccaaaaaa
                                                                    240
agaacccctt tattaagggt taaaaaaggt taaaaaaggt gggaacctca tgggccaagg
                                                                     300
                                                                     311
caaatttttg t
<210> 14
<211> 387
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (1)...(387)
<223> n = A, T, C or G
<400> 14
```

```
ggcacgaggt cttttctgcc cacatctcac acaattgagg tgtctgaaca agcttgggga
                                                                        60
gggtctataa ggggtaggct cnnnnnnnn nnncccattt ggaaagggcg ttttgccaac
                                                                       120
ccaagggctt ttttaagccg atttttnnnn nnnnnccgg acttggtaat tggcttttgg
                                                                       180
ctttttaaag cccaaaaaat aataattaag gggcccaaaa taaggaaggg caaaaaaagc
                                                                       240
ctttactccc cctgcctttc aaaaagaaaa ggaaaaaccg gcccccctt aataattggc
                                                                       300
acccctaaaa aaaggggttt taaaaaaagc caaaaacaaa agggcctgga aaaaaatttt
                                                                       360
gactttttt aacccggaac ctgggaa
                                                                       387
<210> 15
<211> 273
<212> DNA
<213> Homo sapiens
<220>
<221> misc_feature
<222> (1)...(273)
<223> n = A,T,C or G
<400> 15
etgtetetet eteteecece eteteectee egegegegea egetetttea tetetetete
                                                                        60
tacagacagg ggggggtgtt ctctctccct ctcgagaggg accgcttttt ttttctcccc
                                                                       120
ctctctcaca ctcggggtgt gcgcgctccc tttgggggct tttctatagg gcgcgctcta
                                                                       180
aagaaagece geetttetee tetgggtgee teeteeeaca eeegggtttt eteeeeeget
                                                                       240
gtttttgaag aaactcctcc tggtctcctt atn
                                                                       273
<210> 16
<211> 283
<212> DNA
<213> Homo sapiens
<220>
<221> misc_feature
<222> (1)...(283)
<223> n = A, T, C or G
<400> 16
ctctctctct ggccccccc ctctctttac acacactttc tctcctctct ctcgctctct
                                                                        60
ctttttttt ctctcccc tcgctctctc tgtgtgtctc tatctcgtgt ctctctctgc
                                                                       120
gtgtccctca cacacactcg cgcgagagat ctctctctat atctctcctt tgtctgtgtc
                                                                       180
tctctctcgc gcgcccacac atctatatat ttttgcgcgc acacgcgaga gtgtgtccct
                                                                       240
ctctctctct gcacnnnnn nnnnnnnnn cacaccctcc ccc
                                                                       283
<210> 17
<211> 392
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (1)...(392)
<223> n = A, T, C or G
<400> 17
                                                                        60
ggcacgagat gactccttcc ttaaaatcca gctcaaatct ccccctttt ggtggctttc
tetgacacte cateataaag etaattgttt aagtatgate caqtqqcaca gtttatteet
                                                                       120
                                                                       180
acttcataac ttttatctca ctatgttgta agatattagg tatgtttctt ctactaccag
                                                                       240
taattttcaa agagttaagg aagaaggata gaagacagca gtataggtga atgtgtgcat
gtgttnnnnn nnnnnnnngc catattggcc aaaatttttg gactggctgg taaaacaaag
                                                                       300
gcttttcaaa ttttcaaata cctttaaaaa aaacctggaa attgttttgt nnnnnnnnn
                                                                       360
                                                                       392
cgcccaaaaa aaaattttgg gcctgggggg ga
<210> 18
<211> 385
```

```
<212> DNA
<213> Homo sapiens
<400> 18
ggcacgaggc agaggcctcc ctgcactggt cctggcctca ctcttttccc tqacccttqq
                                                                        60
ggcccagggc catggaggga cccttaggag ttcaatgaga gagaccatga ggccactqqq
                                                                       120
ctttcccctt cccaggcctc ctgggtgcca cccccttacg ttattcttgg gcctctaata
                                                                       180
agtgtcccac aggtgcctqq ccaqqcccac ctqctqcaqa tqtqqtctqt qtqtqtqcat
                                                                       240
gtgtgggtgt gtgtgggcac aggcgtgagt gtgtgagcaa cagtacccca ttccagtcgt
                                                                       300
ttcctgctgt gactaagtca gcaacacagt tcctctgaca tgggccttgg ctgtgcttct
                                                                       360
ttgggggtga agagattgct gaggc
                                                                       385
<210> 19
<211> 383
<212> DNA
<213> Homo sapiens
<400> 19
gaaggcttgc ggagagaaaa ccctggagcc atcttcatag gaagaggaaa ggaaactgta
                                                                        60
tgacaggaga atgaatcaag tttggggctc aaggtgccgg ccactgggaa aaacagctgc
                                                                       120
cccgagttgc aaaactctgg gtcctatatg tataaactat gccctgagga aggaatctca
                                                                       180
qqcqtatctt aqqaqaaaat gttctagctt gggaaacaaa cacaacagga ccgtgaatcc
                                                                       240
aaatatttca agtgggttta gaggactgga gttctaaacg ctgcttttac tgtaagtgat
                                                                       300
cacgccccgg aatgtgctga agaaaggaaa atgagccagt atcggcgagg actatgggca
                                                                       360
                                                                       383
aggaaaacga gagtgtgcga tgt
<210> 20
<211> 313
<212> DNA
<213> Homo sapiens
<400> 20
ctctccccg cgctcttgag atatgcgcgc cccttttttc ttctacacgg gggggggcgc
                                                                        60
qcctetttt ctcqcqcqcc ccctctctc tcttttqtqc qcacqcqcqc qcqcqqqqq
                                                                       120
qttctttttt tgtgcgqaga qaqagtctgt ctcaggggtt tttttgtttt ctttcacgac
                                                                       180
                                                                       240
acacactttc tcccctgtgc atgtgttttg atgctctctc gagatatgtc tctctctctc
tgtgtgtgtg tgttgtgcgc ccccctggg gagagcgctc ttctctctct cctcatatag
                                                                       300
                                                                       313
cgcgcgcgcg cga
<210> 21
<211> 396
<212> DNA
<213> Homo sapiens
<400> 21
ggcacgaggg gacccccttc acctctgtct agagagctgg gtagatcaga aacttggtga
                                                                        60
cacctggcta gcacagagca ggctcacttg tcttggtccc actacccaga ttcctgcaga
                                                                       120
cattgcaaac caaatgaagg ttgttgaatg acccctgtcc ccagccactt gttttgttat
                                                                       180
                                                                       240
catctgctct gcagtggaat gcctgtgtgt ttgagttcac tctgcatctg tatatttgag
                                                                       300
tatagaaacc gagtcaagtg atcatgtgca tccagacaca ctgtgtcacc tgagccacag
agcaaatcac cttaacgatc tggaatgaaa ctgtgaccag tgccgccctg ggtggttctg
                                                                       360
                                                                       396
gagagactgc cgtcttcttg tttggccata ggtgcg
<210> 22
<211> 310
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (1)...(310)
<223> n = A,T,C or G
```

```
<400> 22
tgaatatcag ggccctgaac atctctcacg cccgtcttct aaaagagaag aaaaaaacgc
                                                                     60
gcgcgggctt tttctctctc tcagaggggt gaaacacaca atatctcggg gggccggggg
                                                                    120
agageceget etetetgeet gtaaaacaca cagaagtgeg eteacgeeet gegegggage
                                                                    180
ccacagactt ttttttaaaa caaaaagtat attggggtgt gttttaatct ccctctccgc
                                                                    240
tcctagaggg ggggcgnnnn nnnnnnnnn ntttttaaat aggggggccc gagtctcacc
                                                                    300
caatagaagg
                                                                    310
<210> 23
<211> 375
<212> DNA
<213> Homo sapiens
<400> 23
ggcacgagcc ggcgaagagg ggagcctgac gactcggaaa tttgaatacc acagtagcat
                                                                     60
ggagtgtgac ctcatggaga ctgacatctt ggagtcgttg gaagatctag gttacaaggg
                                                                    120
cccattgttg gaagatggag cgctctctca ggcagtctct gctggagcca gttcccccga
                                                                    180
                                                                    240
gtttaccaaa ctctgtgctt ggctggtgtc tgaattaaga gtgctctgta aactagagga
aaacgtgcaa gcaactaaca gtccgagtga agctgaagaa ttccagcttg aggtgagtgg
                                                                    300
gctactaggg gagatgaact gccgtatct ttcactgaca tctggggatg tgaccaagcg
                                                                    360
ccttctcatt cagaa
                                                                    375
<210> 24
<211> 477
<212> DNA
<213> Homo sapiens
<220>
<221> misc_feature
<222> (1)...(477)
<223> n = A, T, C or G
<400> 24
gctccttctt cttnttgttg atcccatcga tccgaattcg gcacgagagc acctctgtgc
                                                                     60
ctetetgaga geacteacag ceaaaagtae acagetgeee ceaggetgag agtgettgat
                                                                    120
acaccettqa atcccetett atatqatqcc ccaqcecaqq aqaqataaaa gcatcagcac
                                                                    180
                                                                    240
catgagattc acctgcctct ggtcgtnnnn nnnnnnnnn nnnnnnnnn nnnnnnnnn
                                                                    300
360
nnnnnnnnn nnnnnnnnn nnnnnnnnn nnnnnnact cttagacagc aaaaatgctt
tctcccagtc ttgttccctt gttctcagtt cccaccctgc ctggataact actgttcttg
                                                                    420
qtttnnnnn nnnnnnnn nnnnnnnag tctcgtacca gattcataaa tcagccg
                                                                    477
<210> 25
<211> 265
<212> DNA
<213> Homo sapiens
<400> 25
cgcgcggggg ggacccctct ctctctct gttgcgcgcg ctctctcacc ccgtgtqtcq
                                                                     60
                                                                    120
cccccgatat tgtcagagag accccctatt tttttctccc gccccacaca catctatgtg
                                                                    180
taaaatgtgc gtgtctgtcg cgcacaccca cacactctcc ccggggggtt tataaaatac
tegegegeta tattttegee eceetttttg tgtgtgggeg ccacaaaaac accacacget
                                                                    240
                                                                    265
ctccccctg tctctcgcgg gtgtt
<210> 26
<211> 388
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (1)...(388)
<223> n = A,T,C or G
```

```
<400> 26
ggcacgaggg aggetetttg ttatagatge ttttgecece ttaatacage aatgagagea
                                                                        60
ctgaccgaag aggcagccgt gactgtaaca cctccaatca cagcccagca agctgacaac
                                                                       120
atagaaggac ccatagcctt gaagttctca cacctttgcc tggaagatca taacagttac
                                                                       180
tgcatcaacg gtgcttgtgc attccaccat gagctagaga aagccatctg caggtgtcta
                                                                       240
aaattgaaat cgccttacaa tgtctgttct ggagaaagac gaccactgtg aggcctttgt
                                                                       300
gaagaatttt catcaaggca tctgtagaga tcagtgagcc caaaattaaa gttttcagat
                                                                       360
gaaacaacaa aacttgtcaa gctgactn
                                                                       388
<210> 27
<211> 431
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (1)...(431)
<223> n = A, T, C or G
<400> 27
ggcacgagag aggggctact ttagatgcaa aggggacaat tagaaggcta ctgaggtaat
                                                                        60
ccggacaaaa agttgtaaat aaatcacggt ggcagtatgg tgaatagtgg aaggggtgta
                                                                       120
tttgaagaaa ctggggaggc cgtgggagag gctggctagt gagaaatggg ccgaaggtga
                                                                       180
aaqcagctta ggggctggtt tccagttttc tggcactgca gactgggtag tgggaggtgg
                                                                       240
ctttctcaag aggagaggtg agtgggaagg agcagggctg caggggaggt catggtcttg
                                                                       300
ggagtggtgc tcagtctgac ttgcacatag gggagattat tttagatttc cgcaagaaaa
                                                                       360
tgtccagcat gtagtcatat caatgnnnnn nnnnnnnnn nnnnnnnnn nntgagattt
                                                                       420
acccaaaaag a
                                                                       431
<210> 28
<211> 389
<212> DNA
<213> Homo sapiens
<400> 28
                                                                        60
ggcacgagcc acccccaaga gtgtggccat ctggggccgt gtggtatttg ccactcagga
qacatqtccc tatqacataq caqtqqtqaq cctqqaqqaq qacctqqatq atqtccccat
                                                                       120
ccctqtqccc qctqaqcact tccatqaaqg cqaggctqtg aqtqtqgtgq qctttqqcqt
                                                                       180
                                                                       240
ctttggccag tcttgcgggc cctcggtgac ctcaggcatc ctttccgctg tggtgcaggt
gaatggcacg cccgtaatgc tgcagaccac gtgtgctgtg cacagcggct ccagtggggg
                                                                       300
                                                                       360
acceptette tecaaceact caggaaacet cettggcata atcaccagea acacceggga
caataatacg ggggccacct accccacc
                                                                       389
<210> 29
<211> 431
<212> DNA
<213> Homo sapiens
<400> 29
ggacgaggct ccagcgcact tttccaacac atcactgcat tatttgaatg caccatggca
                                                                        60
                                                                       120
gctattgtca ccttacttgg gagtgatcca gttggagctc tttatattcg gacatgtcga
                                                                       180
gtattgatgc tttctgactg ggacacgatg ctttacaacc caaggccaga ttacggtacc
acagtgcact gtactcatga agccggctac ccactatata ccatcgtatt tatctattac
                                                                       240
gcattctgct tggtattaat gatgctgctc cgacctcttc tggtgaagaa gaatgcatgt
                                                                       300
gggttaggga aatctgatcg atataaaagt atttatgctg cactttactt cttcccaaat
                                                                       360
qtaaccqtqc ttcaqqcaqc tqtqqqaqqc cttttatatt acgccttccc atacattata
                                                                       420
ttagtggtat c
                                                                       431
<210> 30
<211> 393
<212> DNA
<213> Homo sapiens
```

```
<400> 30
ggcacgagac tacacccgct tcgatgactg gtacctgtgg gttcagatgt acaaggggac
                                                                    60
tgtgtccatg ccagtcttcc agtccttgga ggcctactgg cctggtcttc agagcctcat
                                                                   120
tggagacatt gacaatgcca tgaggacctt cctcaactac tacactgtat ggaagcagtt
                                                                   180
tggggggctc ccggaattct acaacattcc tcagggatac acagtggaga agcgagaggg
                                                                   240
ctacccactt cggccagaac ttattgaaag cgcaatgtac ctctaccgtg ccacggggga
                                                                   300
teceaecete ctagaacteg gaagagatge tgtggaatee attgaaaaaa teagcaaggt
                                                                   360
ggagtgcgga tttgcaacaa tcaaagatct gcg
                                                                  393
<210> 31
<211> 459
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (1)...(459)
<223> n = A, T, C or G
<400> 31
gcaatcgcat tgtctttttg aggatnnnat naatgtcaat tcggcacgag ctttgtggat
                                                                   60
gtttccagct gccatcgtca cccttctgtc tgctccctgg accagcttca ggacttgaag
                                                                  120
gccctcgtgg ctgagatcat cacacatttg caggggctgc agagggactt atctctagca
                                                                   180
gtctcctaca gcaggctcca ttcctcagac tggaatctgt gtactgtatt tgggatcctc
                                                                   240
                                                                   300
ctgggctatc ctgttcccta tacctttcac ctgaaccagg gagatgacaa ctgcttagct
ctgactccac tacgagtatt cactgcccgg atctcatggt tgctaggtca acccccaatc
                                                                   360
ctgctctatt cttttagtgt cccagagagt ttgttcccac gcctgaggga cattctgaac
                                                                   420
acctgggaga aagacctcag aacccgattt atgactcac
                                                                   459
<210> 32
<211> 445
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (1)...(445)
<223> n = A, T, C or G
<400> 32
ggcacgagat ggagagcacc tctgtgcctc tctgagagca ctcacagcca aaagtacaca
                                                                    60
gctgcccca ggctgagagt gcttgataca cccttgaatc ccctcttata tgatgcccca
                                                                   120
                                                                   180
gcccaggaga gataaaagca tcagcaccat gagattcacc tgcctctggt cgtnnnnnnn
                                                                   240
300
nnnnactctt agacagcaaa aatgctnttc tccagtcttt gttccttggt ctcaaggtcc
                                                                   360
                                                                   420
accettgetg gataactact ggtcttgggt teetggggta aagatggaac ttgagtaage
tcgacccaaa tccaaaatca atccg
                                                                   445
<210> 33
<211> 429
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (1)...(429)
<223> n = A, T, C or G
<400> 33
qqcacqaqcq cctqcctqc atcaqqqaqa catqtcaqct qaqqaqtaat tgaccagatt
                                                                    60
                                                                   120
tctgctttag aaatatggca gtggaggcag gagatggcat ctgaggccca ggctggggag
                                                                   180
aagggtgctg ggatgagaac ctggagttca gaccagggaa gggatgagag cctaagaaga
```

ggagctctca ccctgagaca ggttccctct gagcttggga cccttgtatt attcatcnnn nnnnnnnnn nnnnnnnnn tgatggccc	ggactatgtg nnnnnnnnn	agacagaaca nnnnnnnnn	ggaccagggg nnnnnnnnn	cctgcattcc nnnnnnnnn	240 300 360 420 429
<210> 34 <211> 439 <212> DNA <213> Homo sapiens					
<220> <221> misc_feature <222> (1)(439) <223> n = A,T,C or G					
<400> 34 gttctgtggg aatagagggt ggcctgtgac atactgtctt gagacttctg tgactactta ttagaaaaaa aaagagaagg nnnnnnnccc caaacttcaa tctgatgttt gaggtttggt cccattggaa agttttccta cctgggaaag gccccaaag	gtttctgaga atcacaaagg gatttgaatg aatggaggcc tgccaattaa	atcctccct aaattttcag ttttcagttc ccccctcct ccaaacccc	acttctctag gaatattatc agtttagnta ttaaccccc aaaaaaaag	ttaatctcca aaatactatt tcnnnnnnn taaaaaaaat ggggttaaac	60 120 180 240 300 360 420 439
<210> 35 <211> 440 <212> DNA <213> Homo sapiens					
<220> <221> misc_feature <222> (1)(440) <223> n = A,T,C or G		,			
<400> 35 ggcacgaggt gaagtcctgg agctggtgcc tatagtccta ttcagccctt cactggacag tcacggcaca aattcatgga gtgtgtttta gaaatatctc taatgacaat catgttatgt ttcaggtccc aactgtccac cacattntgt gggagttgaa	gagagctaga aagaggaaac agaagcagca cacagggtta ttgtttctgt acctgcagga	gatggaggga tgaggctcca ggaaactcag atgactcaat agctttggaa	aattcagatc tctgcatgac ttctccagtc ttttcatgca atcactcctt	atctaaaccc gttcccagag tgggtccaat tgattgctag ccacttgagt	60 120 180 240 300 360 420 440
<210> 36 <211> 423 <212> DNA <213> Homo sapiens					
<220> <221> misc_feature <222> (1)(423) <223> n = A,T,C or G					
<400> 36 acgagcgcnn nncctgcatc gctttagaaa tatggcagtg ggtgctggga tgagaacctg gctctcaccc tgagacaggc tccctctgag cttgggagga ttgtattatt catcnnnnn	gaggcaggag gagttcagac tggtgcagga ctatgtgaga	atggcatctg cagggaaggg gtctgctcga cagaacagga	aggcccaggc atgagagcct tccaggcctg ccaggggcct	tggggagaag aagaagagga ggtccctggt gcattcccc	60 120 180 240 300 360

nnnnnnnnn tgg	nnnnnnnnn	nnnnnnnnn	nnnnnnnnn	nnnnnnnnn	nnnnnatga	420 423
<210> 37 <211> 424 <212> DNA <213> Homo	sapiens					
<220> <221> misc_ <222> (1) <223> n = A	. (424)					
<400> 37 ggcttgtaga ctctcttata tgttaaccac gactactttc tggtaactcc cttttcatgg gtccactgtt taga	tttgttgctg catgggaaaa tactctcagc tataagctgg actgaaggca	gaataaatga ttaaataaat ttctgattcc tcctcctccc ccaccaagat	atgaactaag gcggggaagg ctctgagcta atgctgaccc agatccagga	gcagtcttgt aaaacgttct agaaccagac catctttact gtgacaactc	agggatttac aaaattagaa agccttaggc gtacaattca cagtgtaggt	60 120 180 240 300 360 420
<210> 38 <211> 434 <212> DNA <213> Homo	sapiens					
<220> <221> misc <222> (1) <223> n = A	. (434)					
<400> 38 ggcacgaggt ttatatgatg ctggtcgtnn nnnnnnnnn nnnnnnnnn ttgttctcag nnnnnnnnnn tgctggctac	ccccagccca nnnnnnnnn nnnnnnnnn nnnnnnnnna ttcccaccct agtctcgtac	ggagagataa nnnnnnnnn nnnnnnnnn ctcttagaca gcctggataa	aagcatcagc nnnnnnnnn nnnnnnnnn gcaaaaatgc ctactgttct	accatgagat nnnnnnnnn nnnnnnnnn tttctcccag tggtttnnnn	tcacctgcct nnnnnnnnn nnnnnnnnn tcttgttccc nnnnnnnnn	60 120 180 240 300 360 420 434
<210> 39 <211> 428 <212> DNA <213> Homo	sapiens					
<400> 39 ggcacgagct cagcttcagg agggacttat actgtatttg gatgacaact ctaggtcaac ctgagggaca gactttgc	acttgaagge ctctagcagt ggatcctcct gcttagctct ccccaatcct	cctcgtggct ctcctacagc gggctatcct gactccacta gctctattct	gagatcatca aggctccatt gttccctata cgagtattca tttagtgtcc	cacatttgca cctcagactg cctttcacct ctgcccggat cagagagttt	ggggctgcag gaatctgtgt gaaccaggga ctcatggttg gttcccaggc	60 120 180 240 300 360 420 428
<210> 40 <211> 429 <212> DNA <213> Homo	sapiens					

```
<220>
<221> misc_feature
<222> (1)...(429)
<223> n = A,T,C or G
<400> 40
ggcacgagtg gagagcacct ctgtgcctct ctgagagcac tcacagccaa aagtacacag
                                                                        60
ctgcccccag gctgagagtg cttgatacac ccttgaatcc cctcttatat gatgccccag
                                                                       120
cccaggagag ataaaagcat cagcaccatg agattcacct gcctctggtc gttagggaac
                                                                       180
aatggaggcc tgcgatttgg agttaaactc tcagtgatct ctgtgttgac aacaccaaag
                                                                       240
ctagaggaat ccagtaggat gtgggcatgg ttttcccgga aggctgactg agcagttctg
                                                                       300
caaatgtttg caagtacagg gcagaatttc atccagcctc agaaccttga gccaagactc
                                                                       360
agcatcagca aagccaaaag tttcattttc ttgactgtgg gagtgctagt cccaaccttt
                                                                       420
agatggccn
                                                                       429
<210> 41
<211> 430
<212> DNA
<213> Homo sapiens
<400> 41
actetgeaaa cagetaettg tgetgattge aggagaeeca taaattegaa egaggaacaa
                                                                        60
ccgagacctg aaggggctga cgaacgcgat ttctgataag tatggggtcc ctgaagagaa
                                                                       120
catttaccaa gcctacaata aatgcacgcg aggaatctta tgcaacatgg acaacaacat
                                                                       180
                                                                       240
cattcagcat tacagcaacc acgtcgcctt cctgctggac atggcggagc tggacggcaa
aattcagatc atccttaagg agctggaagg cctctcgagc atacaaaccc tcacgacctg
                                                                       300
catggggcca gcagggacgt ggccccacgc cacacacac ctctccacat gcctcaacgc
                                                                       360
                                                                       420
tgttacttga atgccttccc tgagggaaga ggcccttgag tcacagaccc acagacgtca
                                                                       430
ggaccatggg
<210> 42
<211> 437
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (1)...(437)
<223> n = A, T, C or G
ggcacgaggc gcctctgcc ccctcagag ggtctctcct ctcgaccccc aaattccccc
                                                                        60
                                                                       120
agcatctcaa tcccttgcat ggggagcaag gcctcgagcc cccatggttt gggctccccg
ctggtggctt ctccaagact ggagaagcgg ctgggaggcc tggccccaca gcggggcagc
                                                                       180
aggatetetg tgetgteage cageceagtg tetgatgtea getatatgtt tggaageage
                                                                       240
cagtecetee tgeacteeag caacteeage cateagteat ettecagate ettggaaagt
                                                                       300
                                                                       360
ccaqccaact cttcctccaq cctccacagc cttqqctcaq tqtccctqtq tacaaqaccc
agtgacttcc aggctcccag aaaccccacc ctaaccatgg gccaacccag aacacccac
                                                                       420
tctccaccac tgggcan
                                                                       437
<210> 43
<211> 432
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (1)...(432)
<223> n = A, T, C or G
<400> 43
ggnncagtga ccaccaggac ctggtgtctg tgcacatcta catcacccag ctggctgaga
                                                                        60
agttcgacct caggaccact atgctgtaca tctgtgagcg gcacttccag aaggttctga
                                                                       120
```

accggagtct attcacaggc ccttcttcaa ctccctgcag gtggcccccc tggcatgacc accggactca cttctcccac cactgtccag ttgagcagag ctgcctcagc cc	gaggtccacc aagaatgtgg cattatgaga	cccaggtccg aaaaggcctg acttctaggc	gaagatcggg tcagctcatc cccttcccgg	gtgtttagct aacaggcagg gggttctgcc	180 240 300 360 420 432
<210> 44 <211> 436 <212> DNA <213> Homo sapiens					
<220> <221> misc_feature <222> (1)(436) <223> n = A,T,C or G					
<400> 44 ggcacgagcc gaggcgcgcg gcaccgcttc cccaagggct gacggtgcag gaggcccggg tgtctttttt gtggactatg gactgttcga gattatattc caacttagcc aagacaattg tggtgatctc accacctcca gctcatagac tntggg	accggcaccc cgctcctccg cttccaactg agtccactat ggcaggtttt	ggcgctggag ctgtcgccgc cttatatatg ggagactgaa ggctcgaatg	gcgcggcttg gctggaatat gaagaaattg aaaactcccc cacgatgaag	gcagacggcg ctgccccagt aaggctcagt agggtctctc acctcattca	60 120 180 240 300 360 420 436
<210> 45 <211> 300 <212> DNA <213> Homo sapiens					
<400> 45 tctctctctc tctctctcac gagagagaga gagccctctc atccccacac tttatagggc tatatctgtg gggggagaga gatgtgtgag cgccccccc	gctctatata gggctcccc gagatctctc	tatccccgcg ctctatcctg accccccgc	ggggggagat tgtgtagaga acacgcgagc	aaaaatatat gaaatatata tctttcttaa	60 120 180 240 300
<210> 46 <211> 191 <212> DNA <213> Homo sapiens					
<400> 46 caaaacaaaa ccatgttccc aaatgaaggg tcttcaagct aatgaatcgg gaacattatc tccctgacct g	tcgagagaac	cttcaaaatt	gtcacaattg	ctgaaaacag	60 120 180 191
<210> 47 <211> 302 <212> DNA <213> Homo sapiens					
<220> <221> misc_feature <222> (1)(302) <223> n = A,T,C or G					
<400> 47 gcccgggcgt gtgtgtatgt nnnnnnnnn nnnnnnnnn					60 120

gcgcgcgctc	agagacacca ttctttgtct tgtgcgcgca	cgcgcgcgcg	cccgctatgt	ggagggtata	tgtgggggaa	180 240 300 302
<210> 48 <211> 411 <212> DNA <213> Homo	sapiens					
cttgacaaag aaagggatct aagtcaacct gctgaaaaca atagaaggag	ttgcggggca agaagacagc gattggtgac tcatcttta attaagagtt catagtgttc taacatagca	aacaactgta ctctgggctt caatagaaat atgggtactt tatacagtca	acaattatct tatcaaatta catatgtttt aaaaaaatca cacacataca	tatgaatatt acatcacaac gctaacccat ttatgtttat cttccttatt	tgcgaaactc ttctagaaga tcctatttag aaaattagtg tcttttattt	60 120 180 240 300 360 411
<210> 49 <211> 408 <212> DNA <213> Homo	sapiens					
tctcatgtgc gccccctgtc agatacaagt aagcttgcta aacttacgca	acacaaagcc agctgaaata tcacacagtt tcagggactc tgctgttctt tcacaccact tagttaagag	gtgatctgct tgtaatgaag agcaatgcac tccattcctt gagtcctcta	tctgtcactg acagctcctt tttaggactg ttccctctga actaatcata	tcacatagac ctcatctttc agctaggagg aacacacaaa tgtgctcaga	agccctgcat cataagcctg caaatatctg ataccaaagg	60 120 180 240 300 360 408
<210> 50 <211> 407 <212> DNA <213> Homo	sapiens					
<220> <221> misc <222> (1). <223> n = 1	. (407)					
cttggcctgt ccagagactt attttagaaa nnnnnnnnn ttttttgggg	ccactcgaat gacatactgt ctgtgactac aaaaaagaga ncccaaactc ttcagggtgg aaaagttttc	ctggtgtctg ttaatcacaa agggatttga aagtatggag gttggccaac	agaatctcc aggaaatttt atgttttcag gccccccct tacccaaacc	cctacttctc caggaatatt ttcagtttag ctttaaaccc cccaaagaaa	tagttaatct atcaaatact ttatcnnnnn accaaaaaaa	60 120 180 240 300 360 407
<210> 51 <211> 312 <212> DNA <213> Homo	sapiens					
ctcgcatttt agaatgtgcg tctctttta	gctctcttt ttcgacaccc tggtgtgtct gggggcgggg gagtgttttt	cccttgtgtg gagagacact ggggagtttt	gggcggggcg cttcgcgctt atgtgtgcca	cgcgtctgtg gtgtgtgaga catgttttct	tgtgatacac cacgagactt gtgtataaaa	60 120 180 240 300

```
312
agaggggaga gg
<210> 52
<211> 420
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (1) ... (420)
<223> n = A, T, C or G
<400> 52
acgagggnnn nnaagcaccg cgggtacccc atgagggcct acaagctggc caccctggcc
                                                                        60
atgacccatc tcaacctgag ctacaatcag gacacacac ctgccattaa tgatgttttg
                                                                       120
tgggcctgtg cgcttagcca ctcccttggt aaaaatgagc ttgcagctat aatacctctg
                                                                       180
gtggtcaaga gtgtcaagtg tgcaacggta ctgtcagaca ttttgcgcag atgcactctg
                                                                       240
                                                                       300
accactectg geatggtggg actteatggg aggaggaact etggtaaget eatgteaetg
                                                                       360
qacaaagccc ccttgaggca actcttggat qccacgatcg gggcctacat caacacaacg
cactcacgge teacacacat cagtectegg cactatagtg agtttataga gttectcage
                                                                       420
<210> 53
<211> 394
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (1)...(394)
<223> n = A, T, C or G
<400> 53
ggcacgaggt gtggatgaca gagcgagacc ctgcctcatn nnnnnnnnn nnnnnnnnnc
                                                                        60
cccccnnnn nnnnnnaaa aacccggttg ggccccggct gttctttagg gccctaaaaa
                                                                       120
ttqccccaaa aaaaattqqc cqqqccctaa aaaaaccccq qttttttqqq qaqaattcaa
                                                                       180
aaaagggtcg gtnnnnnnn nntttttaaa cttccaaccg gcctcagggg gaaaaaacct
                                                                       240
                                                                       300
ggaaaactca atgggggttg gaacaaaatc aatatttggt cctaccggaa agcgttaaga
ttttaaacca gtaaaaatgg ccaannnnnn nnnnnnnnn nnnnaacagg gcccccgggg
                                                                       360
taagggctaa aaattttcag atttgaacct tttt
                                                                       394
<210> 54
<211> 390
<212> DNA
<213> Homo sapiens
<400> 54
ggcacgagat tttcttggca ataagcggac tctgggactc cggctcccta ccccaaactg
                                                                        60
aaqcgcttcc gtgaacaccc ccgtcctccg tagggggagg ggagcaggcg ggatcctggg
                                                                       120
                                                                       180
tccctcataa gcactttggt tttaccgcct gcaacctcac tgtgcccgcc ccgcaccatg
                                                                       240
ccctagcccc aggtctagcc gggcccattg cagggggcag cacttggggg catctccggc
                                                                       300
acttgggtgg gaccaaggag atgccaccat agacctttcc ctcgccttct tcctccctag
tccgggttcc attcttttca ccagcaccca tcgcccaagg ggtaccgagg gggggcaggg
                                                                       360
                                                                       390
ggtggtcaat tcaaacccaa ccccgctcg
<210> 55
<211> 280
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (1)...(280)
<223> n = A,T,C or G
```

<400> 55 tetetetete tetetgegee nnnnnnnnn ttttttttag etetttete gegegegege tgegegegan nnnnnnnnt ttttgggggg eggggeet	agagacatct gcacccccc ctctctctgt	cgcgcgtgtc tgtgtggggc ggcgnnnnn	tctcttttc gcgcgctctc	ccgcccgccg tttttttttg	60 120 180 240 280
<210> 56 <211> 398 <212> DNA <213> Homo sapiens					·
<220> <221> misc_feature <222> (1)(398) <223> n = A,T,C or G					
<400> 56 ggcacgaggt ccacctcagc cgatgcctgc ccatcagttc ttacnnnnn nnnnnnnnca ccctaaaat tcatggagag gggcggnnn nnnnnnnngt atttttgct ttttttggac cnnnnnnnn nnnnnnaacc	tttactctga atacccaacc gcctatttcg gaaggggga acattttgcg	ggtgttagag ccctcccatt tagccagcca aaaaaaagcc ggacaaagaa	tggaataaaa nnnnnnnnn ctatataaac tttttttgaa	atataaatac nnngcccgcc cctgctggtt aaaattagtc	60 120 180 240 300 360 398
<210> 57 <211> 386 <212> DNA <213> Homo sapiens					
<400> 57 ggcacgagat tttcttggca aagcgcttcc gtgaacaccc tccctcataa gcactttggt ccctagcccc aggtctagcc acttgggtgg gaccaaggag tccgggttcc attctttca gggggtcaag tccaggcca	ccgtcctccg tttaccgcct gggcccattg atgccaccat ccagcaccca	tagggggagg gcaacctcac cagggggcag agacctttcc	ggagcaggcg tgtgcccgcc cacttggggg ctcgccttct	ggatcctggg ccgcaccatg catctccggc tcctccctag	60 120 180 240 300 360 386
<210> 58 <211> 202 <212> DNA <213> Homo sapiens					
<400> 58 cactttttct atatgaatat tctttctgcc cccacctgcg cagttgtggt gataattttt gctttatttt tgttatgtgt	ccaggggaga tatgctgaac	agtttacctt	cgggaactcc	agagttaaag	60 120 180 202
<210> 59 <211> 394 <212> DNA <213> Homo sapiens					
<400> 59 ggcacgagtc tgcttctgtc agtttgtaat gaagacagct actcagcaat gcactttagg tctttccatt cctttccct cactgagtcc tctaactaat agaaagaacc tccatataca	ccttctcatc actgagctag ctgaaacaca catatgtgct	tttccataag gaggcaaata caaaatacca cagacacagc	cctgagatac tctgaagctt aaggaactta tcaagcacac	aagttcaggg gctatgctgt cgcaacacac cccttagtta	60 120 180 240 300 360

gcaatttgga aactacagca	aagtctccaa	aaaa			394
<210> 60 <211> 246 <212> DNA <213> Homo sapiens		,			
<220> <221> misc_feature <222> (1)(246) <223> n = A,T,C or G					
<400> 60 cccctccttt tttaggcctg atttctagat actacagntc ggcgggaggg gatctgtgtc atctaaattg caggatggtg gccttn	ttactcctct actgtaggta	cttccctttg ctgtgcccag	ttattcaggg gaaggctggg	tgaccaggat tgaagtgacc	60 120 180 240 246
<210> 61 <211> 395 <212> DNA <213> Homo sapiens					
<220> <221> misc_feature <222> (1)(395) <223> n = A,T,C or G					
<400> 61 ggcacgagct tgcttccctc nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn	nnnnnnnnn catatcgtaa ggatgctgac ctatgagttt cttgtgacca	nnnnnnnnn actgccttgg aggagcagca tcaagtataa ggacaacagg	nnnnnnnnn aaccaattac tgccaaaatt aagacttttt	nnnnnnnnn cactaccagg ggaagaagga cttccacgat	60 120 180 240 300 360 395
<210> 62 <211> 387 <212> DNA <213> Homo sapiens					
<400> 62 ggcacgaggc ttgcggggca cttgacaaag agaagacagc aaagggatct gattggtgac aagtcaacct tcatcttta gctgaaaaca attaagagtt atagaaggag catagtgttc aaactttgag taacatagca	aacaactgta ctctgggctt caatagaaat atgggtactt tatacagtca	acaattatct tatcaaatta catatgtttt aaaaaaatca	tatgaatatt acatcacaac gctaacccat ttatgtttat	tgcgaaactc ttctagaaga tcctatttag aaaattagtg	60 120 180 240 300 360 387
<210> 63 <211> 401 <212> DNA <213> Homo sapiens					
<pre><400> 63 ggcacgaggg aaactgtatg actgggaaaa acagctgccc cctgaggaag gaatctcagg caacaggacc gtgaatccaa gcttttactg taagtgatca</pre>	cgagttgcaa cgtatcttag atatttcaag	aactctgggt gagaaaatgt tgggtttaga	cctatatgta tctagcttgg ggactggagt	taaactatgc gaaacaaaca tctaaacgct	60 120 180 240 300

cggcgaggac tatgggcaag gtatagtaat ataaccaagt				agacatctgt	360 401
<210> 64 <211> 274 <212> DNA <213> Homo sapiens					
<220> <221> misc_feature <222> (1)(274) <223> n = A,T,C or G					
<400> 64 cacgcacccg cctgtgtgtg tgcgcgctcg ctctctctt ctctatatnn nnnnnnnnn gcgcgttttt tttatatata ttttgtgggt tcgctgtccg	tgtgtgcgct nnnnntctga tattttgtgc	ctccgtgctc gagctcgcgc gcgccggggg	ccccctctc gctcagcgtt	tctcttttt ctattcacac	60 120 180 240 274
<210> 65 <211> 279 <212> DNA <213> Homo sapiens					
<220> <221> misc_feature <222> (1)(279) <223> n = A,T,C or G					
<400> 65 ccctttttt tatacacccc gttgtgatct ccctctctct cacatacccc ctctctctc ctacccctct ctcgtctgta agttgcgttc cccactctcc	tttttctccc cttttttgaa cccccacan	cccgcgctct ccacacattc nnnnnnnnn	ctctctcttg cgtttctctt	cggggaggct ttttttatct	60 120 180 240 279
<210> 66 <211> 311 <212> DNA <213> Homo sapiens					
<400> 66 caaaacaaaa attaaaaatg ttaacagttt aaaggttctt aggggatttt tttccaacat ctgtgcacca cgccaaaacc tttctcagaa gattaacaca ttatggggct t	ggtcagtttg agcgagcggt tccagaggtc	gggaacccca ttagattttt ttctttttt	ccttgagatg tttgtcccgt acacaccctg	ggagcaaaaa tagagttgcc tctgggggtg	60 120 180 240 300 311
<210> 67 <211> 386 <212> DNA <213> Homo sapiens					
<400> 67 ggcacgaggg aatctcaggc aacaggaccg tgaatccaaa cttttactgt aagtgatcac ggcgaggact atgggcaagg tatagtaata taatcaagta ccgcgggagg atgaggcaac ggggctcgag gaaggggaaa	tatttcaagt gccccggaat aaaacgagag atagatagtc tcccatcaga	gggtttagag gtgctgaaga tgtgcgatgt atagaatcaa	gactggagtt aaggaaaatg gtcaaagcaa gctgatgtat	ctaaacgctg agccagtatc gacatctgtg ttggcagggg	60 120 180 240 300 360 386

```
<210> 68
<211> 396
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (1)...(396)
<223> n = A, T, C or G
<400> 68
ggcacgagga ggcagctgcc tttgtttgcc atggatgggt aggggctgca ctgagcagca
                                                                        60
ccggtgttct tcatccggct gcacccccaa cagagetett tettecccag atecetttta
                                                                       120
cagttggatt ctccctcttg gatctggctc tgccttagtc cgacctagag ggatcagctt
                                                                       180
cgcccacgcc cactctcacc cggaaccttt catctcttat tgaagccttt taggcccatt
                                                                       240
gggatgttca ttagaactct gaaaactaca gttctcccct ttatgaggac tgcaccacag
                                                                       300
ctcgccctct cctgggttcc gcctgggtgc agagtgagcc catgggacag ccctctgaaa
                                                                       360
ttatactgct tacaaccatg ctgagtctgc aaggan
                                                                       396
<210> 69
<211> 397
<212> DNA
<213> Homo sapiens
<400> 69
ggcacgagtc ttagtcaaca tggacaacaa catcattcag cattacagca accacgtcgc
                                                                        60
cttcctgctg gacatggggg agctggacgg caaaattcag atcatcctta aggagctgta
                                                                       120
aggecteteg ageatecaaa eeeteacgae etgeaagggg eeageaggga egtggeeeca
                                                                       180
cgccacacac aacctctcca catgcctcag cgctgttact tgaatgcctt ccctgaggga
                                                                       240
agaggccctt gagtcacaga cccacagacg tcagggccag ggagagacct agggggtccc
                                                                       300
ctggcctgga tccccatggt atgcttgaat ctgctccctg aacttcctgc cagtgcctcc
                                                                       360
ccgtacccca aaacaatgtc accatggtta ccaccta
                                                                       397
<210> 70
<211> 394
<212> DNA
<213> Homo sapiens
<400> 70
ggcacgagcc aaacctagca caaaacgggg ttcacaagcc atggtcgggg tccggggggg
                                                                        60
acagaaatgg attttcttgg caataagcgg actctgggac tccggctccc taccccaaac
                                                                       120
                                                                       180
tqaaqcqctt ccqtqaacac ccccqtcctc cqtaqqqqqa gqqqaqcaqq cqqqatcctq
ggtccctcat aagcactttg gttttaccgc ctgcaacctc actgtgcccg ccccgcacca
                                                                       240
tgccctagcc ccaggtctag ccgggcccat tgcagggggc agcacttggg ggcatctccg
                                                                       300
gcacttgggt gggaccaagg agatgccacc atagaccttt ccctcgcctt cttcctccct
                                                                       360
                                                                       394
agtccgggtt ccattctttt caccagcacc catc
<210> 71
<211> 389
<212> DNA
<213> Homo sapiens
<400> 71
qqcacqaqqa aaqttaaqca tctacaqqtt atqqctttqq qaqttccaat atcaqtctat
                                                                        60
                                                                       120
cttttattca acqcaatgac agcactgacc gaagaggcag ccgtgactgt aacacctcca
atcacagece ageaaggtaa etggacagtt aacaaaacag aagetgacaa catagaagga
                                                                       180
eccatageet tgaagttete acacettige etggaagate ataacagtta etgcatcaac
                                                                       240
                                                                       300
qqtqcttqtq cattccacca tqaqctaqaq aaaqccatct qcaqqtqtct aaaattqaaa
tegeettaca atgtetgtte tggagaaaga egaceaetgt gaageetttg tgaagaattt
                                                                       360
                                                                       389
tcatcaaggc atctgtagag atcagtgag
```

<210> 72 <211> 396

<212> DNA <213> Homo sapiens					
<220> <221> misc_feature <222> (1)(396) <223> n = A,T,C or G					
<400> 72 ggcacgaggc ctggcccac gtctgatgtc agctatatgt ccatcagtca tcttccagat ccttggctca gtgtccctgt cctaaccatg ggccaaccca cagctgccc ccatccatca ctgcccagaa ccagggtctt	ttggaagcag ccttggaaag gtacaagacc gaacaccca ccaactccat	ccagtccctc tccagccaac cagtgacttc ctctccacca ggtggacata	ctgcactcca tcttcctcca caggctccca ctggccaaag	gcaactccag gcctccacag gaaaccccac aacatgccag	60 120 180 240 300 360 396
<210> 73 <211> 386 <212> DNA <213> Homo sapiens					
<pre><400> 73 ggcacgaggc cacctgttgc tccctcctgc actccagcaa gccaactctt cctccagcct gacttccagg ctcccagaaa ccaccactgg ccaaagaaca gacataccca ttgtgctgat accccaggac accagaactc</pre>	ctccagccat ccacagcctt ccccacccta tgccagcagc caacggctgc	cagtcatctt ggctcagtgt accatgggcc tgcccccat	ccagatcctt ccctgtgtac aacccagaac ccatcaccaa	ggaaagtcca aagacccagt accccactct ctccatggtg	60 120 180 240 300 360 386
<210> 74 <211> 390 <212> DNA <213> Homo sapiens					
<400> 74 ggcacgagct cagatccggg ttgcgttccg gtgtgggtgt tctttctgct tagctacccg ccatctgctg ctcgcctcag cgccatctgc gttttgagca ttcagaaaag acttgcaagc agatttctgt aaagatcatt	gggtgtgcct gagccgacta ctgcctgggt ctgttctcat agctagattt	ccgacggcgt cggaggagga ccccgacgag aatggagttt	ctcggtgcca cacctgagtt agccaggtga cctgatttgg	gtgtcgaggt tacgtctctt cacttaactc ggaagcattg	60 120 180 240 300 360 390
<210> 75 <211> 399 <212> DNA <213> Homo sapiens					
<400> 75 ggcacgagaa atggccttag gtgtgcctcc gacggcgtct gccgactacg gaggaggaca gcctgggtcc ccgacgagag gttctcataa tggagtttcc ctagattttc ttccagtaaa ccatacgctg cacataagtg	cggtgccagt cctgagttta ccaggtgaca tgatttgggg atgtgatgca	gtcgaggttc cgtctctcc cttaactccg aagcattgtt tgtaaacaag	tttctgctta atctgctgct ccatctgcgt cagaaaagac	gctacccgga cgcctcagct tttgagcact ttgcaagcag	60 120 180 240 300 360 399
<210> 76 <211> 386 <212> DNA <213> Homo sapiens				·	

ccgctgcccg gcgggggcca agccgctctt gaactcttaa ttgcctgagg	aaggctcgca tgagctaagg ggggcccctc ctaaaacatt aacatgcaga gagaggatct atggtttttg	acggtccgct gcctcccctc cataccaaag agcaactcta caatgaatgg	ccctctatcc tgaggaccga aagaatatcc ggaagaggga	agctccgaat agatgagctt ctgatggatc atctgagaca	cctgatccag cctcttcagc tcatcagtat agctgctatg	60 120 180 240 300 360 386
<210> 77 <211> 395 <212> DNA <213> Homo	sapiens					
ttgttatttc tttcaagcta gccagaccca tttggtttca agaattcaac	catctccaaa acttgaccat cagcttcgtg aatactattt gagggtatga aaatagagat tttggctcaa	ctgtacaaca gccaacaaag tgcatggacg cgaaaatgga gtcaacaagt	ttacctgtgg attatctatc ctagctgatg gcagctcgct ttcaagatgt	agtacaacat tgtatatctc ccattaataa gggacttaat	tgatgagcat tcttttggct tgctgcaggc ttccaatttg	60 120 180 240 300 360 395
<210> 78 <211> 389 <212> DNA <213> Homo	sapiens					
ccttggcagt gccaacaagg gaggatgcct gtggtgtttc gaaggagtgc	aggccgggat ttgagaggaa tcgtgtacaa atgtattccc atccattcct acgtctctct ccaagttcga	gctcaacgac cgtgggactc tggggatggc agatgagatt aggcttcttc	tccattgccg tgcatttgtc gcatcacaca ctcattggga	aggagctgaa tgtttgatat ccaaagtcca agatcaaagg	caagaagttg caccaaactg ttttcgctgc ctgcagccca	60 120 180 240 300 360 389
<210> 79 <211> 365 <212> DNA <213> Homo	sapiens					
<220> <221> misc <222> (1). <223> n = 2	(365)					
tgtataatac gatgtatctg ttttatcccg nnnnnnnnn	aacatttcat acatttgcat tgacctcaac cccccacccc nnnnnnnnn atctgggtta	gcattaggaa gagtaggcac caacctcagc nnnnnaaaac	gtttttttg ttctgtactg ctcaagtatg aaagccccgt	ggttttattc tactggtttc taannnnnn tttgtccca	atcctgtagt ttaaagtttc nnnnnnnnn ggctggataa	60 120 180 240 300 360 365
<210> 80 <211> 376 <212> DNA <213> Homo	sapiens					
<400> 80 ggcacgagct	ggaaaccagc	ccctaagctg	ctttcacctt	cggcccattt	ctcactagcc	60

gccaccgtga cctttgcatc aattctggct	acggcctccc tttatttaca taaagtagcc ttccatgacc gatcttaatt gagaac	actttttgtc cctctcatcc cataaaccac	cggattacct cccaaatctt atttctcaag	cagtagcctt accatgtcac tgtgctctat	ctaattgtcc tcttctacat gctggcttga	120 180 240 300 360 376
<210> 81 <211> 384 <212> DNA <213> Homo	sapiens					
ggagggcccc attgctgtga tacatgaata cttagactct gcctccttgc	gattgtgtga ggagcagccc tgccagcagc ggtgtggcag tgcgagagcc cccttagttc tctcggtgga	acctggggtc ccactgcaag gggtggggc tgcaccccat tggtgtggtg	ctatctagta catcctcttc tcctgaagac atcaggtggg	gacgcgcccg ctttccaagg caactagggg gtcaatagat	gtgcccaccc ttctgtctgg tactagggac aaatacccct	60 120 180 240 300 360 384
<210> 82 <211> 383 <212> DNA <213> Homo	sapiens					
ccgctgcccg gcgggggcca agccgctctt gaactcttaa ttgcctgagg	aaggctcgca tgagctaagg ggggcccctc ctaaaacatt aacatgcaga gagaggatct atggtaatat	acggtccgct gcctcccctc caaaccaaag agcaactcta caatgaatgg	ccctctagcc tgaggaccga aagaatatcc ggaagtggga	agctccgaat agatgagctt ctgaaggatc atctgagaca	cctgatccag cctcttcagc tcatcagtat agctgttatg	60 120 180 240 300 360 383
<210> 83 <211> 358 <212> DNA <213> Homo	sapiens					
cggcgctgga gctgtcgccg gcttatatat tggagactga	gggccgcgcg ggcgcggctt cgctggaata ggaagaaatt aaaaaactcc tgcacgatga	ggcagacggc tctgccccag gaaggctcag ccagggtctc	ggacggtgca ttgtctttt tgactgttcg tccaacttag	ggaggcccgg tgtggactat agattatatt ccaagacaat	gcgctcctcc gcttccaact cagtccacta tgggcaggtt	60 120 180 240 300 358
<210> 84 <211> 338 <212> DNA <213> Homo	sapiens					
tgagtctacc atgtggtttt gcccctcaga gtgatcgcgc	agagggacag aaatgcacac tctacgcatt acctctctgt ctggagagac gccacatctg	tttcacaatg gattacatgt actctcaacc agtgtactat	ggtctagaag ttgctcacag aacatgaagc tctgtcgaat	aaatctggac atgaagtggc atctcttgat	aagtettte cattetgeet gtggageeca	60 120 180 240 300 338
<210> 85						

<210> 85 <211> 475

```
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (1)...(475)
<223> n = A, T, C or G
<400> 85
gtcgctcaat aggcaggagt ccatcgattc gaattcggca cgagnnnnnn nnnnnnnnn
                                                                     60
120
nnnnnnnnc gctccactgt gcactcctga cacatacttt ccccqctaca ctctctattc
                                                                    180
tececetett gtgttetete tetatagegg tagatagaga ggcetgtgtg tagataataa
                                                                    240
acgtgtgtgt gtgtgtaaga aaggagacac aaacacgccc acnnnnnnn nnnttggggc
                                                                    300
cttttttct tttgagccct ttggggaaaa aacccgggga aaacagccca tacccactat
                                                                    360
ttggggcgcg ccaaaaaacc ttctttaaaa aaaatgtgtt aaatgttaaa ttttttagga
                                                                    420
acannnnnn nnnngcaaaa aatagcaccc caaaagcagg ggttttacat ttttg
                                                                    475
<210> 86
<211> 467
<212> DNA
<213> Homo sapiens
<400> 86
gagegatttt ctgcaggatt ctatcgattc gaattcggca cgagccatgg tctcagtgag
                                                                     60
ggctggaatt tacagagaag tttggccagg gggtccacca tgctgccagt cagtttggga
                                                                    120
aggaaacaga gaagctcggc catggggtcc accatggggt taatgaggcc tggaaggaag
                                                                    180
cagagaagtt tggccagggt gtccaccatg ctgcctcgca ggtggggaag gaggaagaca
                                                                    240
                                                                    300
gagtggtcca aggcctccat catggcgtta gtcaggctgg aagggaggcg gggcagtttg
gccacgacat tcaccacaca gcagggcagg ctgggaaaga gggagacata gcagttcatg
                                                                    360
gtgtccaacc tggggtccac gaggccggga aggaggcagg gcaatttggc cagggagttc
                                                                    420
accataccct tgaacaggcc gggaaggaag caaacaaagc ggtccag
                                                                    467
<210> 87
<211> 449
<212> DNA
<213> Homo sapiens
<220>
<221> misc_feature
<222> (1)...(449)
<223> n = A, T, C or G
cggggtggga aaccngannt tnannaancg gacggattct cccgttccga atagcctttt
                                                                     60
                                                                    120
acagaagatt cttcacagct atgtgcctga agagatcang gatggaaatc aagttcgagt
                                                                    180
tacctcatgg gatggcagga aatgggggaga actggagggg gacacctatg accgggtgct
ggtggatgtg ccctgtacca cagaccgcca ctcccttcat gaggaggaga acaacatctt
                                                                    240
taaqcggtca aggaagaagg agcgacagat attgcctgtg ctgcaagtgc agcttcttgc
                                                                    300
ggctggactc cttgccacca aaccaggagg ccatgttgtc tattctacct gctcactctc
                                                                    360
acacttacag aacgagtatg tggtgcaagg tgccattgag ctcctgggca atcaatacag
                                                                    420
catccaggta caggtggaag atctgactg
                                                                    449
<210> 88
<211> 439
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (1)...(439)
<223> n = A, T, C or G
```

<400> 88 gtagtgtatg tgcagcctc gccccagccc aggagagat nnnnnnnnnn nnnnnnnnn nnnnnnnnnn actcttaga gttcccaccc tgcctggat nagtctcgta ccagattca cttagataga agaggaggc	a aaagcatcag n nnnnnnnnn n nnnnnnnnn c agcaaaaatg a actactgttc	caccatgaga nnnnnnnnn nnnnnnnnn ctttctcca ttggtttnnn	ttcacctgcc nnnnnnnnn nnnnnnnnn gtcttgttcc nnnnnnnnn	tctggtcgtn nnnnnnnnn nnnnnnnnn cttgttctca nnnnnnnn	60 120 180 240 300 360 420 439
<210> 89 <211> 436 <212> DNA <213> Homo sapiens <220> <221> misc_feature					
$\langle 222 \rangle$ (1)(436) $\langle 223 \rangle$ n = A,T,C or G					
<pre><400> 89 ggcacgagca tcaaatagt ctgtaacgcc catcattga ctgtcgatgc agttatatc tggttgatgc aattcataa aaggaacatc tattgtggt ttgtaacaat ttcatatcc agttacatga tctttcaa atcactttcc agatgn</pre>	a agggaaagcg t gttgctccag t caactaactg c cctgaaccac t tcaggaatac	gaggacacca aagaaacatg acatggaaaa tgcacttttt cagatggcca	ttatgttaat gggaaaagtt atgtattttg attaccaggg gctgcaggcc	atgactttac cgtaaactcc aaatatatga aaaaaaaatc tataggaagg	60 120 180 240 300 360 420 436
<210> 90 <211> 437 <212> DNA <213> Homo sapiens					
<220> <221> misc_feature <222> (1)(437) <223> n = A,T,C or G					
<400> 90 ggcacgagag atcatgcac gtgtgagcgc catggggag tcgcaaggag gaggactgc gaacctcatg ccacctctt ctccgtcatc agggactac ggatgagctg cgggtgcgg agagctcaag gccagtcct cttggagttg ccctcan	c aggacccctc a aggagtatgt c tagtggtgca c tggtccaaaa c ggtaccgaga	cttgtgggag ggcagctgtc gaccctggcc actacagaaa ggagaccacc	caggccctca ctcaagcata cacaactcca cagagccagc cgtatccgcc	gctacttcgc tcgagaacaa cagccacact agattgcaca aggagatcca	60 120 180 240 300 360 420 437
<210> 91 <211> 437 <212> DNA <213> Homo sapiens					
<400> 91 ggcacgagct tcagtctta atttctttga aggtgttga accaacttgc atttaacaa aagtaaaaaa aggtctaga agaacttact tcaggtggt actttgaagg tttgatagc ttcaggacat tctggatta	a getegegtgg a caagaaette t aacetetaca g tggeaeteca t egetgttate	cacagggcat gtaaagtcat agaaagttga tgcaagatga ctggatctgg	aaggaggag taaggagtac taaacattta atttatacgc tgttacaatg	gaagtaagtt cctggaaagg tgtgaagaag cagtataagc gaattcacta	60 120 180 240 300 360 420

```
agaaaagata actgaat
                                                                     437
<210> 92
<211> 427
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (1)...(427)
<223> n = A, T, C or G
<400> 92
aacggctctt ctncttttga ggagcccatc gagtcgaatt cggcacgagg cgagtctctg
                                                                      60
ggtcgcgacg ggaaggagtg aaacacctct ctgcgcctgc gcgctccgtg cctgcgaagc
                                                                     120
aaacccggcc tcaccttttc ctgcccgaag cagaagattc tcgcaggcct ggtttctccc
                                                                     180
tecagaagae ecceeaceea aateetetgt ageteetggg agtgeeetga eccetgetge
                                                                     240
caccgtcctt cagagagcaa cggaagagct tcccggaggg cgaggaaaag agggaaagta
                                                                     300
gccagcaatg tcgaacgcag tgtataataa gatgtggcat cagacccaag aagccctcgg
                                                                     360
tgctttactc gatgaagagc ctcagacgat gattgaacca cacagaaatc aggttttcat
                                                                     420
ctttcaa
                                                                     427
<210> 93
<211> 429
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (1)...(429)
<223> n = A, T, C or G
<400> 93
gtgacgatcc catcattcaa ttcggcacga gctcacagcc aaagttcctt ctgcccccag
                                                                      60
gctgagagtg cttgatacac ccttgaatcc cctcttatat gatgccccag cccaggagag
                                                                     120
                                                                     180
ataaaagcat cagcaccatg agattcacct gcctctggtc gttagggaac aatggaggcc
tgcgatttgg agttaaactc tcagtgatct ctgtgttgac aacaccaaag ctagaggaat
                                                                     240
ccagtaggat gtgggcatgg ttttcccgga aggctgactg agcagttctg caaatgtttg
                                                                     300
caagtacagg gcagaatttc atccagcctc agaaccttga gccaagactc agcatcagca
                                                                     360
aagccaaaag tttcatttct tcgactgtgg gagtgctagt cccaaccttt agatggccat
                                                                     420
tcagttnta
                                                                     429
<210> 94
<211> 421
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (1)...(421)
<223> n = A, T, C or G
<400> 94
ggcacgagat tatttacttg gtgtgtggtc accactgttt tttaaatgag tgttttcatt
                                                                      60
                                                                     120
tqtatcaaac tqqacctqct ttcctcaaqq attqcccaaa aggaqacaca aatttactaa
acacttatca ataatagaac accgtgctag gcaatttcca tatactatta atttaatcct
                                                                     180
cacaataact ttggaagaca gaaagtattt tctctgannn nnnnnnnnn nnnnnnnnn
                                                                     240
300
nnnnnnnnn atcetetgte tecaaageet gtaetteatt caggacaett tececcaeat
                                                                     360
                                                                     420
ttagaaaagc tgtaattatc ttccagtgag acagcatagc acatgtgatc actgtccctt
                                                                     421
```

<210> 95

```
<211> 421
<212> DNA
<213> Homo sapiens
<400> 95
ggcacgagat gagaagataa aattcagcgt tggcctttag actttgccat ccttaaggag
                                                             60
tgatggaagc caagtgaaca agcctcagtg acacaagtca aattcatagt ttcactctgg
                                                            120
gttttttgtt gttgtgtgt tattattctc actacagaaa gactgagttt catgctcctg
                                                            180
gctatgtcag atgtgaattt tcatgggtaa ctggacagtt aacaaaacag aagctgacaa
                                                            240
catagaagga cccatagcct tgaagttctc acacctttgc ctggaagatc ataacagtta
                                                            300
ctgcatcaac ggtgcttgtg cattccacca tgagctagag aaagccatct gcaggtgttt
                                                            360
                                                            420
tactggttat actggagaaa ggtgtctaaa attgaaatcg ccttacaatg tctgttctgg
                                                            421
<210> 96
<211> 418
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (1)...(418)
<223> n = A,T,C or G
<400> 96
tggatccatc gattcaattc ggcacgaggt tatttttaag aacttttgct tactatattg
                                                             60
gatttacctg cggtgtgagt agctttaaat gtttgtgttt atacagataa gaaatgctat
                                                            120
ttctttctgg ttcctgcagc cattgaaaaa cctttttcct tgcaaattat aatgtttttg
                                                            180
atagattttt atcaactgtg ggaaaccaaa cacaaagctg ataacctttc ttaaaaacga
                                                            240
300
360
                                                            418
<210> 97
<211> 418
<212> DNA
<213> Homo sapiens
<400> 97
atgctacatt gctactttgt tgcattgatc gccagacgac cactagattc gaaactgagc
                                                             60
gcgagatgat gaatctgtgt gttatgaaaa tgcatgctac cagtataaaa tgacattctc
                                                            120
tattaataac atctgcggtg cgacacacat aattgtccca atttttaata ttgatgggga
                                                            180
gcatgaagca tttttttaat gtgttggcag gccccattaa atgcataaac tgcataggac
                                                            240
tcatgtggtc tgaatgtatt ttagggcttt ctgggaattg tcttgacaga gaacctcagc
                                                            300
tggacaaagc agccttgatc tgagtgagct aactgacaca atgaaactgt caggcatgtt
                                                            360
tctgctcctc tctctggctc ttttctgctt tttaacaggt gtcttcagtc agggaggg
                                                            418
<210> 98
<211> 417
<212> DNA
<213> Homo sapiens
<220>
<221> misc_feature
<222> (1)...(417)
<223> n = A,T,C or G
<400> 98
categatteq aatteggeac gaggecaagt ggacaggeca tageececac agactggagg
                                                             60
gacgcggcta gggaatgtcc cacagagtgg ccagttatcc ctgagagaaa gagcaggttt
                                                            120
                                                            180
tagcqqaqac tctqaqqctq ctttaqaata tqqtqqqtqt qtqqqqcaaa aggqacaccc
                                                            240
300
```

nnnnnnnnn nnnnnnnnn nnnnnnnnn nnnnnnnnn					360 417
<210> 99 <211> 416 <212> DNA <213> Homo sapiens					
<400> 99 ggcacgagct acctcagccc agatggccc gaagggagca gagaactatg agtgggactc ctgggcttgg ccagctcccg ccagaggagg gctgcctcct gcccttcggg aggaattcct ccagcctatc gacagccagt	tgtggtgaca agaattccct gctcagacct gacactgcc ggccttccgc	gtcagcaaga ggggacatgg gaagctgagc catgttactg cgccgccgag	ggaggaacac aattgctgga cagagctagg gccctgaggc atgctactag	atctgtggac gactttgcac tgtgaagact ccgctgtgct ggctcggcta	60 120 180 240 300 360 416
<210> 100 <211> 417 <212> DNA <213> Homo sapiens					
<400> 100 ggcacgaggg aaaatgtagg ggtgcgacac acataattgt taatgtgttg gcaggcccca tattttaggg ctttctggga gatctgagtg agctaactga gctcttttct gctttttaac ttccaggaca ccaaggtcta	cccaattttt ttaaatgcat attgtcttga cacaatgaaa aggtgtcttc	aagattgatg aaactgcata cagagaacct ctgtcaggca agtcaaggag	gggagcatga ggactcatgt cagctggaca tgtttctgct gacaggttga	agcatttttt ggtctgaatg aagcagcctt cctctctctg ctgtggtgag	60 120 180 240 300 360 417
<210> 101 <211> 412 <212> DNA <213> Homo sapiens					
<220> <221> misc_feature <222> (1)(412) <223> n = A,T,C or G					
<pre><400> 101 ggcacgagga aagtaaacgt ttggatttac ctgcggtgtg tatttctttc tggttcctgc ttgatagatt tttatcaact cgacccagtc acagtaaaga nnnnnnnnnn nnnnnnnnnnnnnnnnnnnnnnn</pre>	actagettta agecattgaa gtgggaaace agacacaaga nnnnnnnnn	aatgtttgtg aaaccttttt aaacacaaag nnnnnnnnn nnnnnnnnn	tttatacaga ccttgcaaat ctgataacct nnnnnnnnn nnnnnnnnn	taagaaatgc tataatgttt ttcttaaaaa nnnnnnnnn nnnnnnnnn	60 120 180 240 300 360 412
<210> 102 <211> 414 <212> DNA <213> Homo sapiens					
<pre><400> 102 ggcacgaggt cttgctcaca ccagccctcc tttctccaga caatgatttt cctaaaacaa ctggcctgcc ctgactccac caaggtatta gctgctgtgg gtttatttct tactcacgct tgagacctaa gcagaaatga</pre>	tggcttcttc tggaagtgtt tttaccagaa caaatcaact gggtgcactg	ataaccacca ttccaaagag ccatctgctg ctgaaatctc ccacttggta	ggtcagaaga cttataaggc ctcttctctc cgtgacttaa acagaggagc	ggatccgttc attgtaggat ttgtgttact tacaagagag tatggaaact	60 120 180 240 300 360 414

```
<210> 103
<211> 410
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (1)...(410)
<223> n = A, T, C or G
<400> 103
ggcacgagga agagccggga ggatgtattg gttgttagga aaatgtaggc taccagtaga
                                                                        60
                                                                       120
aaatgacatt ctctattaat aagatctgag gtgcgacaca cataattgtc ccaattttta
agattgatgg ggagcatgaa gcattttttt aatgtgttgg caggccccat taaatgcata
                                                                       180
                                                                       240
aactgcatag gactcatgtg gtctgaatgt attttagggc tttctgggaa ttgtcttgac
agagaacctc agctggacaa agcagccttg atctgagtga gctaactgac acaatgaaac
                                                                       300
tgtcaggcat gtttctgctc ctctctctgg ctcttttctg ctttttaaca ggtgtcttca
                                                                       360
gtcaaggagg acaggttgac tgtggtgagt tccaagacac ccaaggctan
                                                                       410
<210> 104
<211> 411
<212> DNA
<213> Homo sapiens
<400> 104
ggcacgagat acgaatgggg tgtatttttc gactgctcgc aggcaccccc aggttatgtg
                                                                        60
gacagagcta agcccaaagt tgtgattttc cactctgttc tgtccatgtc gagggaagat
                                                                       120
aagtagaaag tgacacagta agagccagaa tacaccaggt gaaggagaga attgcattgt
                                                                       180
                                                                       240
gttttgagaa gtttcactga caagttatcc tgggctgtgg gacatcacta gctttgaaag
tqtaqctqqc acctcqtcca tctaatttqa tqqqtqtqtg tqqqqtqttq tqcacqcqtc
                                                                       300
ggtctaacat atctgaaccc aggtgatttc tgttctcagg acgcttttag gtgacaagga
                                                                       360
                                                                       411
tcaggcatgt gaacaaataa ccatactgta aagctggctg tgctgggtct c
<210> 105
<211> 413
<212> DNA
<213> Homo sapiens
<220>
<221> misc_feature
<222> (1)...(413)
<223> n = A,T,C or G
                                                                        60
ggcacgagga agattctcgc agtcctggtt tctccctcca gaagaccccc cacccaaatg
ctctgtagct cctggtagtg ccctgacccc tgctgccacc gtccttcaga gagcaacgga
                                                                       120
agagettece ggagggegag gaaaagaggg aaagtageea geaatgtega acgeaatgta
                                                                       180
taataagatg tggcatcaga cccaagaagc cctcggtgct ttactcgata aagagcctca
                                                                       240
qaaqatqatt qaaccacaaa gaaatcaggt tttcatcttt caaacattag ccaccttcta
                                                                       300
                                                                       360
cgtaaagtat gtgcagatct ttagaaacct agagaatgtc tacgaccagt tcgtccaccc
                                                                       413
ccagaaacga atactgatca ggaaagtcct ggacggngtg atgggccgca tcc
<210> 106
<211> 412
<212> DNA
<213> Homo sapiens
<400> 106
aggateceat egattetaat teggeaegag etecataagg cagaggteta tgegaggaeg
                                                                        60
cccqqctqqa ccacqaqacc qcccattqat tqcqctqqqa caaqaattcc ttatctttqq
                                                                       120
aggcagtgaa acgactaata gctaaaggta atacagaaga actacgaaaa tgttttgggg
                                                                       180
                                                                       240
tecqaatqqa qtttqtqaca qetqqeetec qaqetqetat qqqaeetqga atttetegta
                                                                       300
tgaatgactt gaccatcatc cagactacac agggattttg cagatacctg gaaaaacaat
```

tcagtgactt atagcagaaa gagggggtag catcaaaagg	ggcatccgga tttgcccgac	tcagttatga ttgctgcaac	cgcccgagct cacatttatc	catccatcca ag	360 412
<210> 107 <211> 408 <212> DNA <213> Homo sapiens					
<220> <221> misc_feature <222> (1)(408) <223> n = A,T,C or G					
<400> 107 ggcacgagga aaaaccagtt cagctcaatt ctcaaccata cttcaattcc actttcctct nnnnnnnnnnn nnnnnnnnn nnnnnnnnnn	ctccaaactc gcttacnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnn	tctcttttcc nnnnnnnnn nnnnnnnnn nnnnnnnnn	agctaccttt nnnnnnnnn nnnnnnnnn nnnnnnnnn nnnnnn	actccctctc nnnnnnnnn nnnnnnggnn nnnnnnnnn	60 120 180 240 300 360 408
<210> 108 <211> 405 <212> DNA <213> Homo sapiens					
<400> 108 ggcacgaggc ttacaggggt gctggcttgg gagggaggct gctgtcaggg gccaccttgc cagaaccgtc caaaggtgga ccatgggaga cccagtgaaa aaccctcttt gtaagcaaac gctcattctg catgaacttc	gtccgatgct ctcaccaggc cctgatgtgg cgactctagt ttgacaaata	gacattcccc cagccccact gccctgccgg gtgaggcagt atgaatctac	ttaacatggc gggaatgggg gggcgcttgg ggtcctgcca tgaactctgt	cctgaccgtg tcagtcacag cctcagcggg ctgactgaca	60 120 180 240 300 360 405
<210> 109 <211> 403 <212> DNA <213> Homo sapiens					
<220> <221> misc_feature <222> (1)(403) <223> n = A,T,C or G					
<400> 109 ggatcccatc gnttcgnatt gctcaaggag cagactgcgt gatccactac ttcacgggcc gagctccctg ccctacatga ccgctatatc ctgctgccc gcacaggcct tgactggcag caagctggct ctggaactgt	acccccgac tgcaggcgct agatgatctt gaatcattga accctgccca	acactacatc tcagctgctg tcccctcatc agccaagtac cgccccattc	cggagggtgc ctgctgtgtg atgatcgcca ttggatgtca gccagccctc	cccagaggaa ccttcggcat tgatccccat tggacgctga	60 120 180 240 300 360 403
<210> 110 <211> 397 <212> DNA <213> Homo sapiens					
<400> 110 ggcacgagtc tgcttctgtc aggttgtaat gaagacagct					60 120

```
actcagcaat gcactttagg actgagctag gaggcaaata tctgaagctt gctatgctgt
                                                                     180
totttccatt cottttccct ctgaaacaca caaaatacca aaggaactta cgcaacacac
                                                                     240
cactgagtcc tctaactaat catatgtgct cagacacagc tcaagcacac cccttagtta
                                                                     300
agaaagaacc tccatataca ttaatttttt tctgcctaaa aataaaattg cgttgtggca
                                                                     360
gcaatttgga aactacagca aagtctccaa aaaaatc
                                                                     397
<210> 111
<211> 401
<212> DNA
<213> Homo sapiens
<220>
<221> misc_feature
<222> (1)...(401)
<223> n = A,T,C or G
<400> 111
ggcacgagag ccgttgcctt caccgccctt tctcctttta tccttttta aacgctcttg
                                                                      60
ggggttatgt ccgctgcttc ttgggtgccg agacatatag atggtggtct cgggccagcc
                                                                     120
cctcctctcc ccgccttctg ggaggaggag gtcacacgct gatgggcact ggagaggcca
                                                                     180
gaagagactc acaggagcgg gctgccttcc gcctggggct ccctgtgacc tctcagtccc
                                                                     240
ctggccggc cagccaccgt ccccagcacc caagcatgca attgcctgtc cccccggcc
                                                                     300
agcctcccca acttgatgtt tgcgttttgt ttggggggat atttttcata attatttnnn
                                                                     360
                                                                     401
<210> 112
<211> 401
<212> DNA
<213> Homo sapiens
<400> 112
ggcacgaggg cagtccagca acaagccttt catttacatt aaattataac ttttcattca
                                                                      60
ttcctaaacc aaacttaaaa ttctgctttc ctttgagtag aaggtattta acttgttttg
                                                                     120
tttttccttc agaaggaatt taatgcaaac ggattgcagt cagcactttc tgaatgtttt
                                                                     180
cacacagtat gcaaagctta catcatacca aggagtggag agttgaagtt tcctcccagt
                                                                     240
                                                                     300
gactccagtg acagaccaca cctagaaagc gtttctcttc ctgagtattt caaaaagatg
taaaagagct ggggagagta tgggaagaaa caatacagga ttgcctttaa ttaattaaga
                                                                     360
                                                                     401
attgcctcct gataaaagga aaaagaaatt aatgctggag g
<210> 113
<211> 401
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (1)...(401)
<223> n = A,T,C or G
<400> 113
ggcacgaggc cccacgggcc ccatctcccc acaggcattg agggtaactg gggtaggctc
                                                                      60
ctggagcagg tgggcaccat ggctttgtgg gccagccaaa gggaaaagga ggtgcttagg
                                                                     120
                                                                     180
agggaaaggg cagtggaatg gcgggagagg gctgtggaaa aaagggagcg agccctggag
                                                                     240
gaggtggaaa gggccatcct ggagatgaag tggaaggtga gggctgagaa ggaggcatgc
                                                                     300
cagogggaga aagagotgoo tgoagcagta catocottoo attitgtita aattgggott
ggagaatcta ttctgaaaac attgactcta gacttgtaga anagagccat tttaattttc
                                                                     360
accttcaatg gtaaaagcaa gggtaatttg gttgacattt t
                                                                     401
<210> 114
<211> 399
<212> DNA
```

<213> Homo sapiens

aatcctctgt cggaagagct tgtataataa ctcagaagat tctacgtaaa	cagaagattc agctcctggt tcccggaggg gatgtggcat gattgaacca gtatgtgcag acgaatactg	agtgccctga cgaggaaaag cagacccaag caaagaaatc atctttagaa	ccctgctgc agggaaagta aagccctcgg aggttttcat acctagagaa	caccgtcctt gccagcaatg tgctttactc ctttcaaaca	cagagagcaa tcgaacgcaa gataaagagc ttagccacct	60 120 180 240 300 360 399
<210> 115 <211> 399 <212> DNA <213> Homo	sapiens					
<220> <221> misc <222> (1) <223> n = 1	. (399)					
gtttctgcca ggtccagatg gaagtggcag gaagaatcag agtttatcag	tttttccaac gtggctacac ataaaaatat aaaaagcaga agggctgcta aagagagtgc taaaagggca	aaaggaaatg tgaaacaaaa ggtttacagg ttgcagatca tgatgcacgg	caggcagatg gagggatctg tcagaaaatg tctggagacc agttttgaaa	atgaactgct aattctcatt aaagtgaacg ctgaacaaat	tcatccatta ttcagatgga gaactgtcta aaaggaagac	60 120 180 240 300 360 399
<210> 116 <211> 400 <212> DNA <213> Homo	sapiens					
tcttcaagaa cacagagggc tagaaattaa aacttgtgca ctatgtctac	gaccgggccg gaaaactgtg tataatcaga gaaaatggcc tctacggaaa acaaacaaaa aacaatgcag	gatgatgtaa gatcgagcag aagattggta cagaagacga gtgatgaatt	taaaggaaca ctttagagaa ataaggaagc gaacttttgc cccaaatgaa	gaatcgagag acaagaaaaa ttgcaaagtt tgtaagttca	ttacgaggta cagctggaat ttagccaaac aaagttactt	60 120 180 240 300 360 400
<210> 117 <211> 402 <212> DNA <213> Homo	sapiens					
ggacggggtc ccgacagaag atccggagtc ctgccttgcc agggcctctg	gagatcgctc ctcactgagg atgcgctggc caaggcgaga ggcccctgca tcccccagga taggcactgg	ccatgatgga tgaaggcgga ccctcacctc catttaggat tgtcttgtgg	cgcctgtgtg ggggcctggg atggagcctg atgctcctgg tggcggtcgg	caagatgctg cgcggggtcg gccacggacc atggggactg ccgttctgcc	tccagcagta agcacccct cctcctaccc ggctgtgccc	60 120 180 240 300 360 402
<210> 118 <211> 395 <212> DNA <213> Homo	sapiens	•				
<400> 118 ggcacgaggt	agagatacga	atggggtgta	gtagccgact	gctcgcaggc	acccccaggt	60

tatgtggaca gagctaagcc caaagttgtg attttccact ctgttctgtc catgtcgagg gaagataagt agaaagtgac acagtaagag ccagaataca ccaggtgaag gagagaattg cattgtgttt tgagaagttt cactgacaag ttatcctggg ctgtgggaca tcactagctt tgaaagtgta gctggcacct cgtccatcta atttgatggg tgtgtgtggg gtgttgggca cgcgtcggcc tagcagatct gaacccaggt gatttctgtt ctcaggaagc ttttaggtga caaggatcag gcatgtgaac aaataaccat actgg	120 180 240 300 360 395
<210> 119 <211> 144 <212> DNA <213> Homo sapiens	
<220> <221> misc_feature <222> (1)(144) <223> n = A,T,C or G	
<400> 119 ccggtaagga atatacttct tctgatacta aatatgccaa tatttaaaat gtaatattca gggattacaa ctgtgagggc taaacacacg gaattaccca ccaattcctc tgtagttctc tactaattca attttgcatc ctcn	60 120 144
<210> 120 <211> 392 <212> DNA <213> Homo sapiens	
<pre><400> 120 ggcacgagac caggtcataa gaggatccgt tccaatgatt ttcctaaaac aatggaagtg ttttccaaag agcttataag gcattgtagg atctggcctg ccctgactcc actttaccag aaccatctgc tgctcttctc tcttgtgtta ctcaaggtat tagctgctgt ggcaaatcaa ctctgaaatc tccgtgactt aatacaagag aggtttattt cttactcacg ctgggtgcac tgccacttgg taacagagga gctatggaaa cttgagacct aagcagaaat gagttcaata atattgctac actctaggac tttctccaaa attaacaaca gaacaaaagt gcaaggcagt gataacccat ctgacagcat ttggggagtg tt</pre>	60 120 180 240 300 360 392
<210> 121 <211> 395 <212> DNA <213> Homo sapiens	
<pre><400> 121 ggcacgagat caatcacaaa agtttatcct taagacttcc cttcagctgc tggaaggcag tcatcacatc tgtgaaaaga gtgctagtta taacaaatga gatcacaaat ttgaccattt tattagacac cctctattag tgttaacaga caaagatgaa ggttaagttg aaatcaaatt gaaatcatct tccctctgta cagattgcaa tatctgataa taccctcaac tttcttggtg caaattaatt gcctggtact cacagtccag tgttaacagg caataatggt gtgattccag aggagaggac taggtggcag gaaaataaat gagattagca gtatttgatt ggagccataa gcataatttg gttccggcgg cggccaggtt taaaa</pre>	60 120 180 240 300 360 395
<210> 122 <211> 288 <212> DNA <213> Homo sapiens	
<220> <221> misc_feature <222> (1)(288) <223> n = A,T,C or G	
<400> 122 cgcccgcgcc tctctgttct ctctcgcgcg cggtgtctct ctcgatagag tgcgcgacct gcacaccctc tgtgtggggt tctcgctccc cgtgtgcgcg cgcgcgcg	60 120

tgtgtgtctg tgttatctct gccctccgcg ccgtgtctgt		cgtgnnnnnn	nnnnntctgt		180 240 288
<210> 123 <211> 393 <212> DNA <213> Homo sapiens					
<400> 123 ggcacgagga tccattcttc tccaaattgc catgcagata ttttctccca aacaggacaa tagaattaat tgcccactct aggcctaagg tgggcatgaa agacctctag gctggaagct gacaacccca ggaacttgga	tcttgaacag gcccaggcag cccaccctac agcttgggaa tgggcttgca	caggacattt ggctgcatgg cagtgcagcc gcactgtcgt agtggatccg	gcaggcettg agaggaatgg cggcaagggc ctctcagaca	tctactggac aacctggagc aggaattggg ggcgtcctaa	60 120 180 240 300 360 393
<210> 124 <211> 394 <212> DNA <213> Homo sapiens					
<400> 124 ccgcgacgag atgatgatct aaaagaggga tctgaattct caggtcagaa aatgaaagtg atcatctgga gaccctgaac acggagtttt gaaatgactg tgaaaacacc tctgtaactg gcctaatgtc caagaattca	cattttcaga aacggaactg aaataaagga aactcaatca aattttctga	tggagaagtg cctagaagaa cgacagttta agctttagaa ggagaaacac	gccgaaaaag tcagagggct tcagaagaga gaaataaaag	cagaggttta gctattgcag gtgctgatgc ggcaggctgt	60 120 180 240 300 360 394
<210> 125 <211> 390 <212> DNA					
<213> Homo sapiens					
<213> Homo sapiens <220> <221> misc_feature <222> (1)(390)	ttctgtaact gttctaactt tattcaagta agcaatactt gatatgctgg	ttctgttttc nnnnnnnnn cttcacattt tgagaaaggt	acccaaaata nnnnnnnnn taagtggaca ctttgcaagt	cagcagagca nnnnnnnnn ttccatttgt atatccatat	60 120 180 240 300 360 390
<213> Homo sapiens <220> <221> misc_feature <222> (1)(390) <223> n = A,T,C or G <400> 125 ggcacgagcc cttatacaaa ggatcacatt atagatatta ctatttcca gaagcacgta nnnnnnnnn nnnnnaactt ctgctataat ttacaattat gaactaatgt ctatgtagaa	ttctgtaact gttctaactt tattcaagta agcaatactt gatatgctgg	ttctgttttc nnnnnnnnn cttcacattt tgagaaaggt	acccaaaata nnnnnnnnn taagtggaca ctttgcaagt	cagcagagca nnnnnnnnn ttccatttgt atatccatat	120 180 240 300 360

acagtaagtg caaaattata	atccaagg				388
<210> 127 <211> 388 <212> DNA <213> Homo sapiens					
<pre><400> 127 ggcacgagag ttaatccaaa tgaaaagagt gctagttata tctattagtg ttaacagaca cctctgtaca gattgcaata ctggtactca cagtccagtg ggtggcagga aaataaatga gctccagctg tcgaccaggt</pre>	acaaatgaga aagatgaagg tctgataata ttaacaggca gattagcagt	tcacaaattt ttaagttgaa ccctcaactt ataatggtgt	gaccatttta atcaaattga tcttggtgca gattccagag	ttagacaccc aatcatcttc aattaattgc gagaggacta	60 120 180 240 300 360 388
<210> 128 <211> 267 <212> DNA <213> Homo sapiens					
<220> <221> misc_feature <222> (1)(267) <223> n = A,T,C or G					
<400> 128 actgtgtgtg tgtctgtttt accctccatc cgcggggggg ctgcgcgcct ctctttttc ggggggtttt cgcgcgttcn gtttattatc tttcttctc	tttttttccc tctctcttcc nnnnnnnnn	ggcgcgcgcc cccccgctt	ctttttttt annnnnnnn	gtgtgtttct nnnnngcgg	60 120 180 240 267
<210> 129 <211> 389 <212> DNA <213> Homo sapiens		9			
<400> 129 ggcacgagct tgactgcaaa cagtccttag aacagtgtct tgaatgaact aaatcagtct aatgcgggga aggaaaacgt tccctctgag ctaagaacca cccatgctga ccccatcttt gatagatcca ggagtgacaa	gggacacagt tttagggatt tctaaaatta gacagcctta actgtacaat	gtgttctcaa tactgttaac gaagactact ggctggtaac	atatttgttg caccatggga ttctactctc tcctataagc	ctggaataaa aaattaaata agcttctgat tggtcctcct	60 120 180 240 300 360 389
<210> 130 <211> 319 <212> DNA <213> Homo sapiens					
<400> 130 tgttgtaact gggagtggag cgacctccag gttcttcctt ttgtcccctt ggaagcttgc ttgcacccat ttcaacccta gggtaaggct ctgttcactt ttcctccagt tttgttcct	ctccctagct cctgccctca gggcgggggc	gttgctttgg tcttgcccat aagtggggca	tctggccact gccttctact aggatggacc	cccagcccc gccaggagac agcagaaggg	60 120 180 240 300 319
<210> 131 <211> 385 <212> DNA					

```
<213> Homo sapiens
<400> 131
ggcacgagaa acgtttcagc tacgaaagtg agctttttcc aacttttaag gatatcagga
                                                                    60
gagaagacac tettgatgtg gaggtttetg ceagtggeta cacaaaggaa atgeaggeag
                                                                   120
atgatgaact gcttcatcca ttaggtccag atgataaaaa tattgaaaca aaagagggat
                                                                   180
ctgaattctc attttcagat ggagaagtgg cagaaaaagc agaggtttac aggtcagaaa
                                                                   240
atgaaagtga acggaactgt ctagaagaat cagagggctg ctattgcaga tcatctggag
                                                                   300
accetgaaca aataaaggaa gacagtttat cagaagagag tgetgatgea eggagttitg
                                                                   360
aaatgactga attcaatcaa gcttt
                                                                   385
<210> 132
<211> 383
<212> DNA
<213> Homo sapiens
<221> misc feature
<222> (1)...(383)
<223> n = A, T, C or G
<400> 132
ggcacgaggg gaatagaggg tccctgqtga caggqcaagg ctagatctgg agcctgcact
                                                                    60
tggcctgtga catactgtct tgtttctgag aatcctcccc tacttctcta gataatctcc
                                                                   120
                                                                   180
aaacacttct gtgactactt aatcacaaag gaaattttca ggagatataa tcgaattcta
ttttacaaaa aaaaagagaa gggatctgaa tgttttcagt tcacgctagg gatcnnnnnn
                                                                   240
nnnnnnnnc ccaaacctga cgtttgagga cccgcctttt tttcagccaa tttaaaagat
                                                                   300
                                                                   360
tttttaaggt ttagggttgg ttggccatta aaccatcccc ggaaagaaaa tgggggtaaa
                                                                   383
agaccaagaa ggaggtcgcc aag
<210> 133
<211> 382
<212> DNA
<213> Homo sapiens
<400> 133
ggcacgagat aagatctgag gtgttacaca cataattgtc ccaattttta agattgatgg
                                                                    60
                                                                   120
ggagcatgaa gcattttttt aatgtgttgg caggccccat taaatgcata aactgcatag
gactcatgtg gtctgaatgt attttagggc tttctgggaa ttgtcttgac agagaacctc
                                                                   180
agctggacaa agcagccttg atctgagtga gctaactgac acaatgaaac tgtcaggcat
                                                                   240
gtttctgctc ctctctctgg ctcttttctg ctttttaaca ggtgtcttca gtcagggagg
                                                                   300
acaggttgac tgtggtgagt tccaggacac caaggtctac tgcactcggg aatctaaccc
                                                                   360
                                                                   382
acactggggc cttgaatggc ca
<210> 134
<211> 375
<212> DNA
<213> Homo sapiens
<400> 134
                                                                    60
120
                                                                   180
aggaatttaa tgcaaacgga ttgcagtcag cactttctga atgttttcac acagtatgca
aagcttacat cataccaagg agtggagagt tgaagtttcc tcccagtgac tccagtgaca
                                                                   240
                                                                   300
qaccacacct aqaaaqcqtt tctcttcctq aqtatttcaa aaaqatqtaa aaqaqctqqq
                                                                   360
gagagtatgg gaagaaacaa tacaggattg cctttaatta attaagaatt gcctcctgat
                                                                   375
aaaaggaaaa agaaa
<210> 135
<211> 376
<212> DNA
<213> Homo sapiens
```

<400> 135			•			
ggcacgagac ccagagtctg cacgggctca ccctgaccgg ggagctgctt	ctgtttgagg gaggcagctg gatctgctcc cagttgcgtc gccgtgttga ctgggcctgg ctgctg	agatagagcc ctggagcccc gctatttggt ccccagtcac	ggaggcccag catcctcagt gctggagcct caatgtggct	gcccagaggt ctgcgcttct gatgcccacg gttcccctgc	cgcccaggcc cctacatctg cagctgtcca aggatctgag	60 120 180 240 300 360 376
<210> 136 <211> 371 <212> DNA <213> Homo	sapiens					
tcagaagagg tataaggcat cttctctctt tgacttaata	cacctctacc atccgttcca tgtaggatct gtgttactca caagagaggt tggaaacttg t	atgattttcc ggcctgccct aggtattagc ttatttctta	taaaacaatg gactccactt tgctgtggca ctcacgctgg	gaagtgtttt taccagaacc aatcaactct gtgcactgcc	ccaaagagct atctgctgct gaaatctccg acttggtaac	60 120 180 240 300 360 371
<210> 137 <211> 258 <212> DNA <213> Homo	sapiens					
<220> <221> misc <222> (1) <223> n = 1	(258)					
ccnnnnnnnn gannnnnnnn	gtgcgcgcgc nnctgtgtgt nntctctcta ctttctttt tcacatct	gcgctctctc gagtcttttc	cgccccatat tctcccctcg	atattgtgtt cgcgcacatt	tttctctgtg gttatacact	60 120 180 240 258
<210> 138 <211> 368 <212> DNA <213> Homo	sapiens					
ctctcactta atgagttgga catgaaccat ggccacattc	attttgagac tgtcactgtt ctgaacagtg tcatattaca atttagggat tatacatctg	tataccacca gttaatcctg gctcttactt catgttttcc	ctgactgctg actctgtttt aaatttgacc aaagcaggtt	cctgctttat tgactgacag aagccaggat tgggcaaaat	tatttcttta ttaacagtta atatctgtta taatccacag	60 120 180 240 300 360 368
<210> 139 <211> 372 <212> DNA <213> Homo	sapiens					
gggtctagga	ctggctcctc tgcctttctg caacgagaag	ctcgagggga	ccaacgcggc	gattcgctat	gccttggcca	60 120 180

PCT/US01/09952 WO 01/72781

atgacatgaa	cttcaccaat ccccttccgc tgatctgccg ca	atgaaactat	tgcggcagct	gtgcatggcc	caccgtgagc	240 300 360 372
<210> 140 <211> 365 <212> DNA <213> Homo	sapiens					
caggagagat tggaggcctg agaggaatcc aatgtttgca	tgagagtgct aaaagcatca cgatttggag agtaggatgt agtacagggc gccaaaagtt	gcaccatgag ttaaactctc gggcatggtt agaatttcat	attcacctgc agtgatctct ttcccggaag ccagcctcag	ctctggtcgt gtgttgacaa gctgactgag aaccttgagc	tagggaacaa caccaaagct cagttctgca caagactcag	60 120 180 240 300 360 365
<210> 141 <211> 353 <212> DNA <213> Homo	sapiens					
cccctttttg tatcttcggg tctaaaccct ttcccagagt	acaaaagaga ccgggatatg ccaggtgcct tcagcccttc cacggcacaa tgtgttttag	atggatctgt agagtcctag actggacaga attcatggaa	cagctggtga agagctagag agaggaaact gaagcagcag	ggcccctcta atggagggaa gaggctccat gaaactcagt	agaggggtgg attcagatca ctgcatgacg tctccagtct	60 120 180 240 300 353
<210> 142 <211> 352 <212> DNA <213> Homo	sapiens					
gaaggtgccc ggctcctgct gggctgggct gaggctgcag	cactcggggg ccagaggggg ggcctccct gtcagtggtc gtgtggcagg gagagccagg	cagccgcctg gcctgtcccc ccaggtgcat agggggccca	tgaggagcag aaagcacagg cccactttcc gccgtgaggg	gcgtgtctgg gctcagctcc agcagcactt caccaggttc	gtaaccatgt agagggagac ggtgccagca aggcccggca	60 120 180 240 300 352
<210> 143 <211> 470 <212> DNA <213> Homo	sapiens					
ccaatggagt ggaagaggaa ttggttcaag ttagaaactt gataggttga gggcatggag	tttttaggat atgagaagtt aagatgtgtt aaactgtgaa gcgaaaaatg gctcacatgg acagacaata aatttgatca	tccagtgaaa cggggtggcc gggaaagaaa gcttaatcta tggagagcca agttgaatgc	aacagaaaga ttggaagtga gggttatact aatgagtgtt cagttgcggg tctttttta	atccagtaga acgttgaagg gagaaatgga aggggagata tgcttgcact acaaaggaag	atttatttag actactgaga agagataatt cagctgtgat gataatgtga	60 120 180 240 300 360 420 470
<210> 144 <211> 456 <212> DNA						
			-37-			

```
<213> Homo sapiens
<220>
<221> misc feature
<222> (1)...(456)
<223> n = A,T,C or G
<400> 144
tagcactttt gtttaggagg accccatcga ttcgaattcg gcacgagctg cactgagcag
                                                                      б0
caccggtgtt cttcatccgg ctgcaccccc aacagagctc tttcttcccc agatcccttt
                                                                     120
tacagttgga ttctccctct tggatctggc tctgccttag tccgacctag agggatcagc
                                                                     1.80
ttcgcccacg cccactctca cccggaacct ttcatctctt attgaagcct tttaggccca
                                                                     240
ttgggatgtt cattagaact ctgaaaacta cagttctccc ctttatgagg actgcaccac
                                                                     300
agetegeect etectgggtt eegeetggtt geagagtgag eecatgggae ageeetetga
                                                                     360
aattatactg cttacaacca tgctgagtct gcaaggactt cgtccaagcc tttccgtcca
                                                                     420
ggacctcaaa cagatccaat cacaagaaga gagatn
                                                                     456
<210> 145
<211> 464
<212> DNA
<213> Homo sapiens
<400> 145
ategeceata eggegagece acegaegega atteggeaeg aggggaaaca eaggeetett
                                                                      60
ctgcttttag gaccctcccc ctgccttgca gggggctcgg ggagagcaat atcaggagct
                                                                     120
agggettget getgeecaca etectgettt ttgggatate taactgetaa ggagggagtt
                                                                     180
gacatccccc ttctggctca tgtgtctgac accaacaaca tgggctctgt ccctctctct
                                                                     240
300
aggcagcccc aaagtggtgg agggggatgg caaagactgt ataggcgcca ctggactctg
                                                                     360
gcaaggeett tattacettt acteeette eteteeate accageetea aggeetgagg
                                                                     420
tgtgcagggg ctcctggcag ctactgagtg agggttcctg gtcg
                                                                     464
<210> 146
<211> 448
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (1)...(448)
<223> n = A,T,C or G
<400> 146
ggcacgaget gcactgagea gcaccggtgt tetteateeg getgeaceee caacagaget
                                                                      60
                                                                     120
ctttcttccc cagatccctt ttacagttgg attctccctc ttggatctgg ctctgcctta
                                                                     180
gtccqaccta qagggatcag cttcgcccac gcccactctc acccggaacc tttcatctct
                                                                     240
tattgaagcc ttttaggccc attgggatgt tcattagaac tctgaaaact acagttctcc
cctttatgag gactgcacca cagctcgccc tctcctgggt tccgcctggt tgcagagtga
                                                                     300
gcccatggga cagccctctg aaattatact gcttacaacc atgctgagtc tgcaaggact
                                                                     360
tcgtccaagc ctttccgtcc aggacctcaa acagatccaa tcacaagaag agagatttca
                                                                     420
ggaaagagaa nattattcct atcatcgn
                                                                     448
<210> 147
<211> 439
<212> DNA
<213> Homo sapiens
<400> 147
                                                                      60
ggcacgagga aagttaagca actacaggaa atggctttgg gagttccaat atcagtctat
                                                                     120
cttttattca acgcaatgac agcactgacc gaagaggcag ccgtgactgt aacacctcca
                                                                     180
atcacagccc agcaagctga caacatagaa ggacccatag ccttgaagtt ctcacacctt
tgcctggaag atcataacag ttactgcatc aacggtgctt gtgcattcca ccatgagcta
                                                                     240
gagaaagcca tctgcaggtg ttttactggt tatactggag aaaggtgtga gcacttgact
                                                                     300
```

```
ttaacttcat atgctgtgga ttcttatgaa aaatacattg caattgggat tggtgttgga
                                                                     360
ttactattaa gtggttttct tgttattttt tactgctata taagaaagag gtgtctaaaa
                                                                     420
ttgaaatcgc cttacaatg
                                                                     439
<210> 148
<211> 334
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (1)...(334)
<223> n = A,T,C or G
<400> 148
ccccgcgcgc gctccctctc tatcttttat acaaaatata gagagcgcac atctctgtgt
                                                                      60
gtgagagagt ctgtgcgcgc gcgcatatat atatgggagg ggtgtctccc cccatctgtg
                                                                     120
tgtctctcct cttgcggggc atatgcgtgc gcacacccgc gcgctgtgtc tcttttgtgc
                                                                     180
240
nnnnnnnn nnnnnnnn nnnnnnnnn nnnnnnnncg cgcgcacaca cccacacac
                                                                     300
gtgtgttcta cagcgcgata aagagagaca caca
                                                                     334
<210> 149
<211> 428
<212> DNA
<213> Homo sapiens
<400> 149
ggcacgaggt cctgagcagc ctcatgggag gtgaattaga gaaaacaaaa gagagcaaga
                                                                      60
gagaagacag tgggtgaagt cctggttcca gactcccctt tttgccggga tatgatggat
                                                                     120
ctgtcagctg gtgcctagag tcctagagag ctagagatgg agggaaattc agatcatcta
                                                                     180
aaccetteag ceetteactg gacagaagag gaaactgagg etecatetge atgacgttee
                                                                     240
cagagtcacg gcacaaattc atggaagaag cagcaggaaa ctcagttctc cagtctgggt
                                                                     300
ccaatgtgtg ttttagaaat atctccacag ggttaatgac tcaatttttc atgcatgatt
                                                                     360
gctagtaatg acaatcatgt tatgtttggt tctgtagctt tggaaatcac tccttccact
                                                                     420
tgagtttc
                                                                     428
<210> 150
<211> 427
<212> DNA
<213> Homo sapiens
<220>
<221> misc_feature
<222> (1)...(427)
<223> n = A, T, C or G
<400> 150
cgccccaaan nnnaatctct aaaggggtaa gggagatacc taccttgtct ggtaggggag
                                                                      60
                                                                     120
atgtttcgtt ttcatgcttt accagaaaat ccacttccct gccgacctta gtttcaaagc
                                                                     180
ttattcttaa ttagagacaa gaaacctgtt tcaacttgaa gacaccgtat gaggtgaatg
gacagccagc caccacatg aaagaaatca aaccaggaat aacctatgct gaacccacgc
                                                                     240
ctcaatcgtc cccaagtgtt tcctgacacg catctttgct tacagtgcat cacaactgaa
                                                                     300
                                                                     360
gaatggggtt caacttgacg cttgcaaaat taccaaataa cgagctgcac ggccaagaga
qtcacaattc aggcaacagg agcgacgggc caggaaagaa caccaccctt cacaatgaat
                                                                     420
                                                                     427
ttgacac
<210> 151
<211> 437
<212> DNA
<213> Homo sapiens
<220>
```

```
<221> misc feature
<222> (1)...(437)
<223> n = A, T, C or G
<400> 151
ccgagccgga tgnccttnnn gagtatngca angattccaa ttcggcacga gagacagtgg
                                                                        60
catggagctt tgaaagacga gtaggtgtta gcaaggaaat aaggaggaac gggggttacg
                                                                       120
ggcagaggag aaagcacatg ccaagtcagc aaagaaaagt agaattcgaa aactttttaa
                                                                       180
aaatattact aaggattttc acaatgctgc actgggctag aaactgaagc taaaacagat
                                                                       240
acgtggtccc tgctgctatg gggcttacgt tctacaggca aggacaggtt gtgatgaggg
                                                                       300
ttctgaagga tagagaccaa gcatggaggg tgttgaggag gcttctgcga gacctgaatg
                                                                       360
atgggaagcc acgaagtggg aggggtgggg gtccaggctg gaggggccca atgtatgtgt
                                                                       420
agagggacta cagccct
                                                                       437
<210> 152
<211> 425
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (1)...(425)
<223> n = A, T, C or G
<400> 152
ggcacgaget gcactgagea gcaccggtgt tetteateeg getgeaceee caacagaget
                                                                        60
ctttcttccc cagatccctt ttacagttgg attctccctc ttggatctgg ctctgcctta
                                                                       120
gtccgaccta gagggatcag cttcgcccac gcccactctc acccggaacc tttcatctct
                                                                       180
tattgaagcc ttttaggccc attgggatgt tcattagaac tctgaaaact acagttctcc
                                                                       240
cctttatgag gactgcacca cagctcgccc tctcctgggt tccgcctggt tgcagagtga
                                                                       300
gcccatggga cagccctctg aaattatact gcttacaacc atgctgagtc tgcaaggact
                                                                       360
                                                                       420
tcgtccaagc ctttccgtcc agggacctca acagatccaa tcacaagaag agagatttca
                                                                       425
ggaan
<210> 153
<211> 421
<212> DNA
<213> Homo sapiens
<400> 153
ggcacqagcc gtggctgcct cgtgagcctc ccagagccca ggcctccgtg gcctcctcct
                                                                        60
gtgtgagtcc caccaggagc cacgtgcccg gccttgccct caaggatttt tgcttttctc
                                                                       120
                                                                       180
ctgtgcacct ggcgaggctg aaggcgaggg gtggaggagg ccccagcaca gcctcatctc
catgtgtaca cgtgtgtacg tgtgtatgcg tgtgtgtacg tgtgtatgcg tgtgtgtacg
                                                                       240
cgtgtgtacg tgcgtgtgta cacatgcgtg gccgcctgtg gtgtgcacgt gtgctctggg
                                                                       300
ctccgaggct tctccagagc tgggagctgg ctggcgtggc aagggcatgc tctggggcag
                                                                       360
                                                                       420
tgtgtccctc aggaaccagg gtcctccctc ccctttctgc ctggtcagcc ccgtggcctc
                                                                       421
<210> 154
<211> 423
<212> DNA
<213> Homo sapiens
<400> 154
                                                                        60
ggcatgagtg gaagggaggc agctgccttt gtttgccatg gatgggtagg ggctgcactg
agcagcagcg gtgttcttca tccggctgca cccccaacag agctctttct tccccagatc
                                                                       120
ccttttacag ttggattctc cctcttggat ctggctctgc cttagtccga cctagaggga
                                                                       180
teagettege ceaegeceae teteaceegg aacettteat etettattga ageettttag
                                                                       240
gcccattggg atgttcatta gaactctgaa aactacagtt ctccccttta tgaggactgc
                                                                       300
accacaqctc qcctctcct qqqttccqcc tqqttqcaga qtqaqcccat qggacagccc
                                                                       360
                                                                       420
tetgaaatta taetgettae aaccatgetg agtetgeaag gaetteegee aageetttee
                                                                       423
gtc
```

<210> 155 <211> 312 <212> DNA <213> Homo	sapiens					
tgtgtgtata tatacacaca gtgtgtgaga	acaaaacaca caacccgcgc cgtgtgtgtg cacacactcc cgctcacaga ct	gcgagagagc tgtcgctctc tctctccgag	gctctcttt cgaaaataca tggggagaga	gtgggggga cactataaca gagatcgcgc	aaaaaactct aacgcactgt tccactctta	60 120 180 240 300 312
<210> 156 <211> 428 <212> DNA <213> Homo	sapiens					
aggaggaggt ttgccttaga tccaggtgca cgctctacct tgagcctctt	ggctacctac gaagcagcat gcgcaagggc tggattggtg gctgcttcat tcctgatacc cctcacgctg	gcccaggaac caggccctgg ctgcccctca gagcgggagg caactgctcg	tctgggctgc aggaggatga tgctgcccag acagcttcta agttcctgga	ctacaggggt agacacagag cttctactca cagccagggc tgtgcagaag	ctgctgcgag acaagggacc gagctcttca attgccaact cacttgtggc	60 120 180 240 300 360 420 428
<210> 157 <211> 430 <212> DNA <213> Homo	sapiens					
gaagggcttg gcagcttggt ccacttgatg ggcagtgccc cttctccctt	gactttgagc gagaaggaga ttgctgcagc ggggccaact tgagaaccac ctgtctagca gcacccgatg	aggggtctga agactcggac ccaacccaat caacctcaca cctgtttgca	aggtggtgtg aagcattgtt gtcccattcc gcctgtctcc ctgggattgt	ggacacatga tcagtgcctg tatcctgaaa attttattgt cctgtctgtc	gagtgatctc gtttctccct tgcttctaaa cttctgggaa cttcagttgg	60 120 180 240 300 360 420 430
<210> 158 <211> 405 <212> DNA <213> Homo	sapiens					
gttgaattag attatgcaga cccttccatg tccaagtcca aggggctgct	aagatttcca aggtgaaagc atttgttgag agccctcaac ggcctgtgat ccatgggggt gctgcattga	ctccttcctc caaattgcaa ctgggatctc ttagaagggt cacacctctc	actcttttt cagcccaagc gtgtatcttt caggttgggt tcctgtgggt	agaaacagtt cacagctagc gttggaatgg aggagagagg tttcgctggt	tagttttatt tccacaagag acattaggtt agagtcttgg	60 120 180 240 300 360 405
<210> 159 <211> 403 <212> DNA <213> Homo <400> 159	sapiens	·				
-400% TO3						

```
ggcacgagcc tgactcaagg ggttttggaa gatttccagt ggtctcaatg gtgtgaatcc
                                                                    60
tatgaaggtg tettatttgt tgaattagag gtgaaageet eetteeteac tettttttag
                                                                   120
aaacagttta gttttattat tatgcagaat ttgttgagca aattgcaaca gcccaagcca
                                                                   180
cagctagctc cacaagagcc cttccatgag ccctcaacct gggatctcgt qtatctttqt
                                                                   240
tggaatggac attaggtttc caagtccagg cctgtgattt agaagggtca ggttgggtag
                                                                   300
gagagaggag agtettggag gggetgetee atgggggtea eacetetete etgtgggttt
                                                                   360
                                                                   403
tcgctgqtga ttgagttctg aggcatttgc tgcattgact gtg
<210> 160
<211> 417
<212> DNA
<213> Homo sapiens
<220>
<221> misc_feature
<222> (1)...(417)
<223> n = A, T, C or G
<400> 160
                                                                    60
ggcctgtgac atactgtctt gtttctgaga atcctccct acttctctag ttaatctcca
                                                                   120
gagacttctg tgactactta atcacaaagg aaattttcag gaatattatc aaatactatt
                                                                   180
ttagaaaaaa aaagagaagg gatttgaatg ttttcagttc agtttagtta tcnnnnnnnn
                                                                   240
nnnnnnnccc caaactccag aatgggggcc ccccttctt taaccccacc taaaaatttt
                                                                   300
tcggaggttc agggttggtt ggcaaattac aaaaacccca aaagaaaatg ggggttaacc
                                                                   360
cccttggaaa agttttctta ctttgggggg tggccctttg acgtnggccc gggttac
                                                                   417
<210> 161
<211> 300
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (1)...(300)
<223> n = A, T, C or G
<400> 161
                                                                    60
ctatatctct ctgcgccctc tccccctctt gtgttttccc ccgcccctct agagatatct
ctctcactcg cgggcgcaca cccccttta caaaataggg ggctctctgt gtgtggtgtt
                                                                   120
                                                                   180
tagacacacc ccccgcgcg tgttttttat aaatatctgt ctctcacaca ccccctactg
                                                                   240
cccctctqtq tqtqqqcqcq ttcccccca cacacacaqa qtqtqtqnnn nnnnnnnnn
                                                                   300
<210> 162
<211> 411
<212> DNA
<213> Homo sapiens
<400> 162
                                                                    60
ggcacgaggg caccgagcct cctgtgggag gtcccgaggc agcttcgcct gctcggcctg
gctgcagccc tcacctgccg cagccttagc tgagcagccg ccgccactgg gcgccccccg
                                                                   120
ctccccactt cgccagcgcc cgctcctcgg ctcggcccgg ggtagtttgt agggacgcag
                                                                   180
ctctccacgt gcgcgactgc gaggctggac gctacgggct cctggaaagg agcagacacc
                                                                   240
agcatttqcc acaatqctqt catccactqa ctttacattt qcttcctqqq aqcttqtqqt
                                                                   300
ccgcgttgac catcccaatg aagagcaggc agaaagacgt ccgcactgag aggattctgg
                                                                   360
agacccttca cgttggaagg agtgatgctc aaggttagta gaacagatca a
                                                                   411
<210> 163
<211> 412
<212> DNA
<213> Homo sapiens
```

agagcctccc acgtgcccgg aggcgagggg gtgtatgcgt cacatgcgtg	tcattcaatt atagcccagg ccttgccctc tggaggaggc gtgtgtacgc gccgcctgtg ctggcgtggc	cctccgtagg aagggttttt cccagcacag gtgtacgcgt gtgtgcacgt	cctcctctg gcttttctcc cctcatctcc gtgtgtacgc gtgctctggg	tgtgagtccc tgtgcacctg atgtgtacac gtgagtacgt ctccgaggct	accaggagcc gctaggctga gtgtgtacgt gctgtgtgta tctccagagc	60 120 180 240 300 360 412
<210> 164 <211> 411 <212> DNA <213> Homo	sapiens					
<220> <221> misc <222> (1) <223> n = F	. (411)					
aagaaatgct aagtaaaatg tgatactttc gctagtacac nnnnnnnnn	gatatggtgc aggagaaagc tggtatgatt agctgtcaca tacttggctc nnnnnnnnn nnnnnnnnn	taaaagctcc ttgagtggtc gaggtcatag agaagtgaac nnnnnnnnn	atactaaaat agcagagtgt aattgggctt aaaattgcag nnnnnnnnn	aatggtccta aagaataatc attgagaagg tttgnnnnnn nnnnnnnnnn	atattaagca tatttgcact aaaggtaaat nnnnnnnnn nnnnnnnnn	60 120 180 240 300 360 411
<210> 165 <211> 415 <212> DNA <213> Homo	sapiens					
<220> <221> misc <222> (1) <223> n = F	. (415)					
aagaaatgct aagtaaaatg tgatactttc gctagtacac nnnnnnnnn	gatatggtgc aggagaaagc tggtatgatt agctgtcaca tacttggctc nnnnnnnnn nnnnnnnnn	taaaagctcc ttgagtggtc gaggtcatag agaagtgaac nnnnnnnnn	atactaaaat agcagagtgt aattgggctt aaaattgcag nnnnnnnnn	aatggtccta aagaataatc attgagaagg tttgnnnnn nnnnnnnnn	atattaagca tatttgcact aaaggtaaat nnnnnnnnn nnnnnnnnn	60 120 180 240 300 360 415
<210> 166 <211> 403 <212> DNA <213> Homo	sapiens					
cgcgaatggg tgtggagcag acctcacacg ttctgaggga ctgttaaaca tctcatcttt	aggtgtcagg cagagcagaa atccgatgga ccatgctgct cagcaatgag ctttcatgtt gaaggatttt	cttctagaag gaggctgagc gaagctcttc accaccgggc gaatatactg	ggaagatgag tgctccagga tcctctcaaa tgtactctct gatattcatt	cacccaggat cttggggtgg tggatgtgac ctctgtgagg taaatttggc	ccctcagatc tatcacggca ggcagctacc gccaaagatt	60 120 180 240 300 360 403
<210> 167						

<210> 167 <211> 407

```
<212> DNA
<213> Homo sapiens
<400> 167
ggcacgaggg gcgacaagct gttggagctg caatgggccg cggctgggga ttcttgtttg
                                                                      60
gcctcctqqq cqccqtqtqq ctqctcaqct cqqqccacqq aqaqqaqcaq ccccqqaqa
                                                                     120
cagcggcaca gaggtgcttc tgccaggtta gtggttactt ggatgattgt acctgtgatg
                                                                     180
ttgaaaccat tgatagattt aataactaca ggcttttccc aagactacaa aaacttcttg
                                                                     240
aaagtgacta ctttaggtat tacaaggtaa acctgaagag gccgtgtcct ttctggaatg
                                                                     300
acatcagcca gtgtggaaga agggactgtg ctgtcaaacc atgtcaatct gatgaagttc
                                                                     360
ctgatggaat taaatctgcg agctacaagt attctgaaga agccaat
                                                                     407
<210> 168
<211> 416
<212> DNA
<213> Homo sapiens
<400> 168
qqcacqaqac acaactttqa qacaccccaa qtqctttctq caqaqqttqt cqttqqaaaa
                                                                      60
                                                                     120
ctgtcacctt acagaagcca attgcaagga ccttgctgct gtgttggttg tcagccqqqa
                                                                     180
gctgacacac ctgtgcttgg ccaagaaccc cattgggaat acaggggtga agtttctgtg
tgagggcttg aggtaccccg agtgtaaact gcagaccttg gtgctttgga actgcgacat
                                                                     240
                                                                     300
aactagcgat ggctgctgcg atctcacaaa gcttctccaa gaaaaatcaa gcctgttgtg
tttggatctg gggctgaatc acataggagt taagggaatg aagttcctgt gtgaggcttt
                                                                     360
qaqqaaacca ctqtqcaact tqaqatqtct qtqqttqtqq qqatqttcca tccctc
                                                                     416
<210> 169
<211> 386
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (1)...(386)
<223> n = A,T,C or G
<400> 169
                                                                      60
ggcacgagga atctcgcctc tgtctggtgt gttacctact gggggcacag gaacaatttc
ctcaaggaga cagtggcatg gagctttgaa agacgagtag gtgttagcaa ggaaataagg
                                                                     120
                                                                     180
aggaacgggg gttacgggca gaggagaaag cacatgccaa gtcagcaaag aaaagtagaa
ticgaaaact tittaaaaat attactaagg attitcacaa tgctgcactg ggctagaaac
                                                                     240
tgaagctaaa acagatacgt ggtccctgct gctatggggc ttccgttcta gaggcaagga
                                                                     300
caggitigtiga tgagggttct gaaggataga gaccaagcag ggagggtgtt gaggaggctt
                                                                     360
ctgcgagacc tgaaggatgg gaagen
                                                                     386
<210> 170
<211> 391
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (1)...(391)
<223> n = A, T, C or G
<400> 170
qqcacqaqaa taqaqqqtcc ctqqtqacaq qqcaqqqcta gatctqqaqc ctqcacttqq
                                                                      60
                                                                     120
cctqtqacat actqtcttqt ttctqaqaat cctcccctac ttctctaqtt aatctccaqa
gacttctgtg actacttaat cacaaaggaa attttcagga atattatcaa atactatttt
                                                                     180
                                                                     240
nnnncccaa aactcaagat tggggccccc ccctcttta accccgctaa aaagtttttt
                                                                     300
qqqqqtttaq qqtqqqttqq caaataacaa aacccccaaa agaaaagggq ggtaaacccc
                                                                     360
                                                                     391
cttggaaaag tttcctaact ttggggggcg c
```

```
<210> 171
<211> 391
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (1)...(391)
<223> n = A, T, C or G
ggcacgagcc tgcatcgacc catttttcct catgacaaac tattggtgca nnnnnnnnn
                                                                      60
120
catctgtcat ggaaccagaa tctaaatcca aataggctgt tgccagtaca gatggtaagt
                                                                     180
acatgtactt ctggcaggaa agcagaataa aagttgactg aacctgaaag tctcggaaat
                                                                     240
ggtcttctca tttctattct gtaaagtgtc acgtcttcta ggcctacctc tgtcaatatt
                                                                     300
gaaatacaaa attaactttt tctgcttttt atttcacaaa tcaacgggaa cagtcttagt
                                                                     360
catttgtgtt ttatgagttt taattaggcc n
                                                                     391
<210> 172
<211> 385
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (1)...(385)
<223> n = A, T, C or G
<400> 172
ggcacgagga cagtggcatg gagctttgaa agacgagtag gtgttagcaa ggaaataagg
                                                                      60
aggaacgggg gttacgggca gaggagaaag cacatgccaa gtcagcaaag aaaagtagaa
                                                                     120
ttcgaaaact ttttaaaaat attactaagg attttcacaa tgctgcactg ggctagaaac
                                                                     180
tgaagetaaa acagatacgt ggtccctgct gctatggggc ttccgttcta gaggcaagga
                                                                     240
caggttgtga tgagggttct gaaggataga gaccaagcag ggagggtgtt gaggaggctt
                                                                     300
                                                                     360
ctgcgagacc tgaaggatgg gaagccagga agtgggaggg gtgggggtnc aggctggagg
ggcccaatgt angtgtaaag ggact
                                                                     385
<210> 173
<211> 392
<212> DNA
<213> Homo sapiens
<400> 173
ggcacgagaa aggctggaag ggaggcagct gcctttgttt gccatggatg ggtaggggct
                                                                      60
                                                                     120
gcactgagca gcaccggtgt tcttcatccg gctgcacccc cgacagagct ctttcttccc
cagatecett ttacagitgg attetecete ttggatetgg etetgeetta gteegaceta
                                                                     180
                                                                     240
gagggatcag cttcgcccac gcccactctc acccggaacc tttcatctct tattgaagcc
ttttaggccc attgggatgt tcattagaac tctgaaaact acagttctcc cctttatgag
                                                                     300
qactqcacca caqctcqccc tctcctqqqt tccqcctqqt tqcaqaqtqa gcccatqqqa
                                                                     360
                                                                     392
cagccctctg aaattatact gcttacaacc at
<210> 174
<211> 394
<212> DNA
<213> Homo sapiens
<400> 174
ggcacgagat ggaatgacag ctttttttag tagcatatcc ttgcgctgtg ttagatggag
                                                                      60
tctttgccct gatttccgtc ttttgaaaat ttatctggga tgtggacatc agtgggccag
                                                                     120
atgtacaaaa aggaccttga actcttaaat tggaccagca aactgctgca gcgcaactct
                                                                     180
catgcagatt tacatttgac tgttggagca atgaaagtaa acgtgtatct cttgttcatt
                                                                     240
tttatagaac ttttgcatac tatattggat ttacctgcgg tgtgactagc tttaaatgtt
                                                                     300
```

tgtgtttata cagataagaa tttttctttg gaaataataa			ctgcagccat	tggaaaaact	360 394
<210> 175 <211> 387 <212> DNA <213> Homo sapiens					
<400> 175 ggcacgaggg cagttagggg gctccccag ggcagtgtggg tggagcatac cacctggtcc attctgcctt cctggagacc aggaacataa ggctgtggct gtccttgagc acccactcac caggctgggg cttgctgacc	tagcacatcc cgttcatgag agtgggatgg agacagcagg ctgtctatgt	cattgtagag tggtggcaaa gtcagtacag ggtctcaggt	atgagggcac gctagcactc cccaccacac tcatacatga	cgaggcttcc tcacttgtcc cattagcccc ggactggctt	60 120 180 240 300 360 387
<210> 176 <211> 395 <212> DNA <213> Homo sapiens					
<pre><400> 176 ggcacgagca gacctccatt agtaagggct ttttttaaaa attcagatga gcggtttctg tggcgagccc cccttggaag ctcgtggtgg gaatgcagag ggacccgctg ggcctttggt gaaggacttt gagcagtggt</pre>	gaataaaatg cattaaccct gttctggtgc ccctttgctt ctgcatcccc	acttggtttg gcctatcacg ttcagctggc tccttcttgc tggccaggtc	cgcttggaag catctcgtgt tcctgcagag cgcctgcttc	caggggaagc cctgtgtggc tccaccccgc ctgttcctgg	60 120 180 240 300 360 395
<210> 177 <211> 388 <212> DNA <213> Homo sapiens					
<pre><400> 177 ggcacgaggg acgctgcgga cccgggtggg ccggcggcgg caacagagag aaattatgcg aggaacacag atcttcttaa atatcattct tttgtgtcat gttgctagga agaggctcaa aattaatcca gactggaaaa</pre>	ccgcgggcgg aatcactcca acaacagcat ctgtttttag tgtttgtgtt	caggaaggag ggctgtcttt tgagaaatcg cctgtttatg	aaccaccagt gttcagagtt ggctggctat tctagaacat	ggtatgtgtg accttgatca ttatccaatt ctatcaatgg	60 120 180 240 300 360 388
<210> 178 <211> 397 <212> DNA <213> Homo sapiens					
<400> 178 ggcacgagca ggatccctca aggacttggg gtggtatcac caaatggatg tgacggcagc ctctctctgt gagggccaaa catttaaatt tggctttaat atcagccttt gattggaagc gaaaagtgga agaaccctcc	ggcaacctca taccttctga gattctgtta gaattctcat gagacaggca	cacgccatgc gggacagcaa aacactttca ctttgaagga ctctgatggt	tgctgaagct tgagaccacc tgttgaatat ttttgtcaag	cttctcctct gggctgtact actggatatt cattttgcaa	60 120 180 240 300 360 397
<210> 179 <211> 397 <212> DNA <213> Homo sapiens					

```
<400> 179
ggcacgaggc gtggggcgac aagctgccgg agctgcaatg ggccgcggct ggggattctt
                                                                        60
gtttggcctc ctgggcgccg tgtggctgct cagctcgggc cacggagagg agcagcccc
                                                                       120
ggagacagcg gcacagaggt gcttctgcca ggttagtggt tacttggatg attgtacctg
                                                                       180
tgatgttgaa accattgata gatttaataa ctacaggctt ttcccaagac tacaaaaact
                                                                       240
tottgaaagt gactacttta ggtattacaa ggtaaacctg aagaggccqt gtcctttctg
                                                                       300
gaatgacatc agccagtgtg gaagaaggga ctgtgctgtc aaaccatgtc aatctgatga
                                                                       360
agttcctgat qgaattaaat ctgcqagcta caagtat
                                                                       397
<210> 180
<211> 399
<212> DNA
<213> Homo sapiens
<220>
<221> misc_feature
<222> (1)...(399)
<223> n = A,T,C or G
<400> 180
                                                                        60
ggcacqaggt caccctttt gcctccatcc tcaaagacct ggtcttcaag tcatccgtca
gctgccaagt gttctgtaag aagatctact tcatctgggt gacgcggacc cagcgtcagt
                                                                       120
ttgagtggct ggctgacatc atccgagagg tggaggagaa tgaccaccag gacctggtgt
                                                                       180
ctgtgcacat ctacatcacc cagctggctg agaagttcga cctcaggacc actatgctgt
                                                                       240
acatetgtga geggeactte cagaaggtte tgaaceggag tetatteaca ggeetgeget
                                                                       300
ccatcaccca ctttggccgt ccccctttg agcccttctt caactccctg caggaggtcc
                                                                       360
                                                                       399
accccacgt ccggaagatc ggagtgttta gctgtggcn
<210> 181
<211> 402
<212> DNA
<213> Homo sapiens
<400> 181
ggcacgaggc tacttcgctc gcaaggatta gtactgcaag gagtatgtgg cagctgtcct
                                                                        60
ggagcatatc gagaacaaga acctcatgcc acctcttcta gtggtgcaga ccctggccca
                                                                       120
catctccaca gccacactct gcgtcatcag ggactacctg gtccaaaaac tacagaaaca
                                                                       180
                                                                       240
gagccagcag attgcacagg atgagctgcg ggtgcggcgg taccgagagg agaccacccg
tatccqccaq qaqatccaaq aqctcaaqqc caqtcctaaq attttccaaa aqaccaaqtq
                                                                       300
caqcatctqt aacagtqcct tggagatgcc ctcagtccac ttcctqtgtg qccactcctt
                                                                       360
ccaccaacac tgctttgaga gttactcgga aagcgaagct ga
                                                                       402
<210> 182
<211> 384
<212> DNA
<213> Homo sapiens
<220>
<221> misc_feature
<222> (1)...(384)
<223> n = A, T, C or G
<400> 182
                                                                        60
ggcacgagag caactcaggc ctgctgggtt aactgcttac accattttcc ttcccctcct
cttccttqcc ttcqacactc ttaacctqqa aaaaqcacta atttqtcctc catatctqtq
                                                                       120
gttttgtcat ttggaaaggt tgtagaaatc ctagagtatg tgacctttta agatgcactt
                                                                       180
                                                                       240
tttagaaaac tcaacatgtt gctcttgtgt taatagtttg ttctttttag tgttcggtat
                                                                       300
tctcttgtgt ggtcatgccc cagtttattt aaccatccca tagatgttta ttttcccttg
taaagttggt tagcatgtan nnnnnnnnn nnnnnnggga aactcattct cnnnnnnnn
                                                                       360
nnnnnnnnn nnnntgccc cttg
                                                                       384
<210> 183
```

<211> 384

1010: 517						
<212> DNA <213> Homo	sapiens					
agcagtacat gactctagac ttggtgacat gaattgacca ctaaaatgta	aaggtgaggg cccttccatt ttgtagaaaa tttgctttta aatgcttatc cctattaaag gtaccagcca	ttgtttaaat gagccatttt tgtgaaatag tacgaggttc ataaatgctt	tgggcttgga agtttcaact tgcacagtat ctagagctct	gaatctattc caaatgtaaa gagttaatct gctgaccctt	tgaaaacatt gcaaggtagt gagcaggtct ggccgaaact	60 120 180 240 300 360 384
<210> 184 <211> 379 <212> DNA <213> Homo	sapiens					
tgacttccag tccaccactg ggacataccc gaccccagga	tcctccagcc gctcccagaa gccaaagaac attgtgctga caccagaact agcaacagcc accaatatt	accccacct atgccagcag tcaacggctg ccgttcaacc	aaccatgggc ctgccccca cccagaacca tggagctgct	caacccagaa tccatcacca gggtcttctc tctcccagca	cacccactc actccatggt caccccagcg acccctgtcc	60 120 180 240 300 360 379
<210> 185 <211> 368 <212> DNA <213> Homo	sapiens					
gttgtcgctg gatcgtgctg ctggctggtg ctatcgccgc	ccggtccagg ctgcgaggac gcggcccaca gcgctggcgc aaggatctct ctgacacctg	gccccggaaa ggtgcggcct ggctgcacgc ggaaggtaac	aacggtggat ccgcccggcc ctggagggcc ctggggatcc	ctgggctctg gtgggctacg ggctgtgccg ctggccaccc	gcgacggcag agctgaaccc gcagcgtctg gctgacagcc	60 120 180 240 300 360 368
<210> 186 <211> 375 <212> DNA <213> Homo	sapiens					
acctctgtga ggatccctca gtggtatcac tgacggcagc	ctcacagagc agggcgcgaa gatctgtgga ggcaacctca taccttctga gattctgtta gaatt	tgggcagagc gcagatccga cacgccatgc gggacagcaa	agaacttcta tggagaggct tgctgaagct tgagaccacc	gaagggaaga gagctgctcc cttctcctct gggctgtact	tgagcaccca aggacttggg caaatggatg ctctctctgt	60 120 180 240 300 360 375
<210> 187 <211> 368 <212> DNA <213> Homo	sapiens		٠			
tcccaggaaa	cgtgcagagc gatgtgcact gcagggccct	gactttgaaa	cctgggactc	ctacagcccc	caaggaaggc	60 120 180

ggcaacagca actgtacatt acgactcaga gccccgtcca ctgcggcagc gtcattgaat ggatccgg	ctgcaggaaa	gatgggtcgg	gatgaaccaa	aacattgagg	240 300 360 368
<210> 188 <211> 436 <212> DNA <213> Homo sapiens					
<pre><400> 188 ggcacgagaa ggggctgggg caggggagg caggggactg cacacccact ctgatgaggc tcttcatttc catcacgttt agtactacta tgggcattac gcctgtcagg cctcggcgc tcctcgccag ccccacggag tcagcctcct catcat</pre>	tgcaggggct tcatggcctc gtgctggatg ttggacgact agcctcaacg	cagggaggcc ctggcaggtc ccgtcaaggg atcacacaaa ccagcctcca	tccccacct gacggaggag cacggttaaa aaggacttca cactgccctc	gcccctgac atcatcgccc atcttctgga tcccttgtca aatgccagct	60 120 180 240 300 360 420 436
<210> 189 <211> 435 <212> DNA <213> Homo sapiens					
<220> <221> misc_feature <222> (1)(435) <223> n = A,T,C or G					
<pre><400> 189 ggcacgagac agaccctttc tgtagtgtgg agcactaacc ggaaacatct agactcactg tcatccagat ttcactcatt ctgaaaccca ccaagagctg atatgggaaa tgctgctgct gcacacttga aacactgcgt aaatagttta cctga</pre>	atggcagggt cattaacaga ctgaccacag catagagcac atacttttag	aatttattcc gcattttgtt ccaggaagct gtttagctag gaatttctga	aggcacagag tctaaagtag gagggtgaag agtaggagtt gtgcaattta	tcataattct acctcttatg ccagaattag tgcagtgctc gaaacatcta	60 120 180 240 300 360 420 435
<210> 190 <211> 437 <212> DNA <213> Homo sapiens					
<220> <221> misc_feature <222> (1)(437) <223> n = A,T,C or G					
<pre><400> 190 ggcacgagat taggaccctt cattatggag ggctggaagg gcgagagatt gagaagagcga aaggcctgga aagaagatga ggctgacacc tgggctgccc aagaactggg tctctgggct aggaagtgag agtcaaggcc gganggaccg gtttgng</pre>	ggctcaaccc gcaggaaaaag cgaggaggag tcaatccca ccctatgcac	cgatttggag aggtcttgga gagagaggga aggccaggga tgcccaaact	agaagtttgg gcctgggact agtggggtgg gggcggngct ggctgagcca	gatggagtgg gatggtggat atgaggagca ggcccctggg ggagtggggc	60 120 180 240 300 360 420 437
<210> 191 <211> 434 <212> DNA					

```
<213> Homo sapiens
<400> 191
ggcacgagaa gaaactgtga agggaaagaa aggtttatac tgagaaatgg aagagataat
                                                                     60
tttagaaact tgtgaaaaat ggcttaatct aaatgagtgt taggggagat acagttgtga
                                                                    120
tgataggttg agetcacatg gtggagagec acagttgegg gtgettgeac tgataatgtg
                                                                    180
agggcatgga gacagacaat aggttgaatg ctctttttt acaaaaggaa gtagaaaggg
                                                                    240
agggggatgt aaatttgata aataggttgg tgaaaactta tattttcttg taaagagaga
                                                                    300
gaactgagca tgttgtaggt ataaggtaaa aaggcgtgaa gaggaatatt tcgttgataa
                                                                    360
tqaaaqtqaq caqctaqqqa aqaaaactcc caqaqqaaqa qqqaqqcaaq qaaatcaaqa
                                                                    420
acacacttaa agtg
                                                                    434
<210> 192
<211> 323
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (1)...(323)
<223> n = A, T, C or G
<400> 192
gggtctctcg ccccctctc tctcttttgt gtgtctctct ctctgtcccg tgtgtgnnnn
                                                                     60
                                                                    120
nnnnnnnnt ctctctatat ctcgcgcgcg cgcactcccg tgtgtgtgtg tgaccccgcc
coctcatgcg ctctctcatt tgtggagaga gagaccgcta tctatctctc tctcccccgc
                                                                    180
cctatacaca tctccctctc tgtgaaagag acgtgtgtgt gtctccacac cccttgggcg
                                                                    240
                                                                    300
cgcgcgccc acccctctc ctgggggggg tgtcctctct gtatatatat atgtgcacac
                                                                    323
acgcgcgcgc gctctgtgtt gtt
<210> 193
<211> 412
<212> DNA
<213> Homo sapiens
<400> 193
                                                                     60
ggcacqagaa ggggccgtga cagccgttgc catctgctgc cggagccggc acctggcgca
                                                                    120
ggcctcccag gagctccagt gacagcccca tcccaggatg ggtgtctggg gagggtcaag
ggctggggct gagctttaaa atggttccga cttgtccctc tctcagccct ccatgqcctg
                                                                    180
240
gcagcctcct tgcctggaac tcactcactc tgggtgcctc ctccccaggt ggaggtgcca
                                                                    300
qqaaqctccc tccctcactq tqqqqcattt caccattcaa acaqqtcqaq ctqtqctcqq
                                                                    360
qtqctqccaq ctqctcccaa tqtqccqatq tccgtgggca qaatqacttt ta
                                                                    412
<210> 194
<211> 405
<212> DNA
<213> Homo sapiens
<220>
<221> misc_feature
<222> (1)...(405)
<223> n = A, T, C or G
<400> 194
                                                                     60
cgttgctgtc ggtcagcaat gaaataaata tcttgtagaa tgttcnnnnn nnnnnnnnn
nngaaccete gggggccett ttttcccgaa acceccactg gaaaaaaacc cttggggggt
                                                                    120
tggcaaaacc ccccaataaa aggggggaa aaaaaggctt tttttggaaa aatggggggg
                                                                    180
                                                                    240
tctttgcttt ttttggaccc ctttaaagcg gggaaaacca ggttaacccc ccccaggggc
nnnnnnnnn gtttcagggc cnnnnnnnn nnnnnnnnt tttttccctn tctcccttct
                                                                    300
atctcgccct gctgcgctgc cgttttctcg ttccactccc cccgtttttg tactccccc
                                                                    360
                                                                    405
qtqccqttqa qcqtccaccc tattctttcq cqccqgtqca ccccc
```

```
<210> 195
<211> 400
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (1)...(400)
<223> n = A, T, C or G
ggcacgagat taggaccett cettggcaca ggggtgagaa agagettggg gaacgettgg
                                                                   60
cattatggag ggctggaagg ggctcaaccc cgatttggag agaagtttgg gatggagtgg
                                                                  120
gcgagagatt gagagagcga gcaggaaaag aggtcttgga gcctgggact gatggtggat
                                                                  180
aaggccttga aagaagatga cgaggaggag gagagaggga agtggggtgg atgaggagca
                                                                  240
ngctgacacc tgggctgccc tcaatcccca aggccaggga gggcggngct ggcccctggg
                                                                  300
aagaactggg tctctgggct ccctaggcac tgcccaaact ggctgagcca ggagtggggc
                                                                  360
aagaaatgag agttcaggcc caacacaagg agggggaggg
                                                                  400
<210> 196
<211> 402
<212> DNA
<213> Homo sapiens
<400> 196
ggcacgagat taggaccett cettggetca ggggtgagaa agagettggg gaacgettgg
                                                                   60
cattatggag ggctggaagg ggctcaaccc cgatttggag agaagtttgg gatggagtgg
                                                                  120
gcgagagatt gatagagcga gcaggaaaag aggtcttgga gcctgggact gatggtggat
                                                                  1.80
aaggcctgga aagaagatac taggaggagg agagagggaa gtggggtgga tgaggagcag
                                                                  240
gctgacacct gggctgccct caatccccaa ggccagggag ggcggggctg gccctggga
                                                                  300
agaactqqqt ctctqqqctc cctagqcact gcccaaactq gctqaaccaq gaqtqqqqca
                                                                  360
agaaqtqaqa qtcaaqgccc aacaaaaqqa qqqqqaqqaq ct
                                                                  402
<210> 197
<211> 401
<212> DNA
<213> Homo sapiens
<400> 197
ggcacqagct ctcaqcggcc ggtttctgcq tccgctgccg caggttccac cgcgctccaq
                                                                   60
gtattttttt ttctgaagga aagctgcttc ctcatatgtt tcaagaatgg ctctccctat
                                                                  120
cattgtaaaa tggggtggac aggagtattc agtgaccaca ctttcagaag atgatactgt
                                                                  180
gctcgatctc aaacagtttc tcaagacct tacaggagtt cttccagaac gccaaaagtt
                                                                  240
acttggactc aaagttaaag gcaaacctgc agaaaatgat gttaagcttg gagctctcaa
                                                                  300
                                                                  360
actgaaacca aatactaaaa tcatgatgat gggaactcgt gaggagagct tggaagatgt
                                                                  401
cttaggtcca cccctgaca atgatgatgt tgttaatgac t
<210> 198
<211> 397
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (1)...(397)
<223> n = A,T,C or G
<400> 198
tgcatattag acattcttaa cagggcggca gtctagtgtt gaaagtttta tttttccatt
                                                                   60
                                                                  120
tttcttttaa gcaaattttt tttaaaaaat tctgattnnn nnnnnnnnn nnnnnnnnn
180
240
ttcttttatt tatcataagg ggtttaattc ctgaagtaaa ggtttgcacc tattaaactt
                                                                  300
```

	attttt gttcttttat ctcaag ctagggcago		gaaatacaaa	gaatggagtg	360 397
<210> 199 <211> 398 <212> DNA <213> Homo sapie	ens .				
aatggcttaa tctaa atggtggaga gccac aataggttga atgct ataaataggt tggtg ggtataaggt aaaaa	ggttta tactgagaaa aatgag tgttagggga cagttg cgggtgcttg cctttt tttacaaaag gaaaac ttatatttto aggcgt gaagaggaat ccaagg aggagggag	gatacagttg cactgataat gaagtagaaa ttgtaaagag atttcgttga	tgatgatagg gtgagggcat gggagggga agagaactga	ttgagctcac ggagacagac tgtaaatttg gcatgttgta	60 120 180 240 300 360 398
<210> 200 <211> 394 <212> DNA <213> Homo sapie	ens				
gtggctgcgc tggga aggtaataaa gaaga cctccgagct gctat tacacaggga ttttg cgtgatcagt tttga	gcagcg gtctaggcga acaaga attccttaac aactac gaaaatgttt gggac ctggaatttc gcagat acctggaaaa acgccc gagctcatcc ccacat ttatcagtca	tttggaggca tggggcccga tcgtatgaat acaattcagt atccagtggg	gtgaaacgac atggagtttg gacttgacca gacttaaagc	taatagcaga ggacagctgg tcatccagac agaaaggcat	60 120 180 240 300 360 394
<210> 201 <211> 391 <212> DNA <213> Homo sapie	ens .				
caaagcacag ggcto tcccactttc cagca agccgtgagg gcaco aacctccaga ggggg ggagcttact ggcto	egtetg ggtaaccatg eagete cagagggaga ageact tggtgecage eaggtt caggecegge gtgage tgggaacttg eaegge tgatgeecea	cgggctgggc agaggctgca atctcagggt tgtgaagggg gacagcctcg	tgtcagtggt ggtgtggcag ggagagccag ctttttccaa	cccaggtgca gagggggccc ggctgtcctg aaggaaaacg	60 120 180 240 300 360 391
<210> 202 <211> 392 <212> DNA <213> Homo sapie	ens				
tatcatgtgg gacad gtatatgtag tgtgg attctggaaa catct ttatgtcatc cagat attagctgaa accca	agtaca ctaaacactt cagacc ctttcttcct gagcac taaccatggo tagact cactgcatta ttcac tcattctgao accaag agctgcatao atgctg ctgctatact	aaaggctttg agggtaattt acagagcatt cacagccagg agcacgttta	tggcatcaga attccaggca ttgtttctaa aagctgaggg	cacataaagg cagagtcata agtagacctc tgaagccaga	60 120 180 240 300 360 392
<210> 203 <211> 392 <212> DNA <213> Homo sapie	ens				

```
<220>
<221> misc feature
<222> (1)...(392)
<223> n = A, T, C or G
<400> 203
ggcacgagga ggaqcccqcc ccggaggctg aggctctqqc cqcaqcccqq gaqcqqaqca
                                                                           60
gccgcttctt gagcggcctg gagctggtga agcagggtgc cgaggcgcgc gtgttccqtq
                                                                          120
gccgcttcca gggccgcgcg gcggtgatca agcaccgctt ccccaagggc taccggcacc
                                                                          180
cggcgctgga ggcgcggctt ggcagacggc ggacggtgca ggaggcccgg gcgctcctcc
                                                                          240
getgtegeeg egetggaata tetgeeecag ttgtettttt tgtggaetat getteeaact
                                                                          300
gcttatatat ggaagaaatt gaaggctcag tgactgttcg agattatatt cagtccacta
                                                                          360
tggagactga aaaaactccc cagggtctct cn
                                                                          392
<210> 204
<211> 386
<212> DNA
<213> Homo sapiens
<400> 204
ggcacgagaa gccttaaacc gggaaatttc catgctatct agaggttttt gatgtcatct
                                                                           60
taagaaacac acttaagagc atcagattta ctgattgcat tttatgcttt aagtacgaaa
                                                                         120
gggtttgtgc caatattcac tacgtattat gcagtattta tatcttttgt atgtaaaact
                                                                          180
ttaactgatt tctgtcattc atcaatgagt agaagtaaat acattatagt tgattttgct
                                                                          240
aaatcttaat ttaaaagcct cattttccta qaaatctaat tattcagtta ttcatgacaa
                                                                          300
tattttttta aaagtaagaa attctgagtt gtcttcttgg agctgtaggt cttgaagcag
                                                                         360
caacgtcttt caggggttgg agacag
                                                                         386
<210> 205
<211> 295
<212> DNA
<213> Homo sapiens
<400> 205
gcgctctctt cacacacaaa agatatatat atagaaaggg agtgtggata tccccctaa
                                                                           60
atatgtgage gtgtetetet egacegtete ecceagagaa aatateteta gagagageae
                                                                          120
aagtgtgttc tctgtgtctt gtgtgtgaga aaaaataagt gcccgcgcac acatagattt
                                                                          180
ttatatcqct ccccccqcq cctttatata tqtttttqqt qtqtatatat attttataca
                                                                         240
aaaacatgtt tctttttgag gccccttaca acaaaaattt tgttcttttt gaacc
                                                                         295
<210> 206
<211> 383
<212> DNA
<213> Homo sapiens
<400> 206
                                                                           60
ggcacgaggt tacccatcag cccttgcaag tcccccactc aggcctctgg aaggtccagg
                                                                          120
gatgggctct gatgagaggg taaaagatgc tcagggaaac acaggcctca gctgcctaga
ggaccetece ectgeettge agtgggeteg ggtagageag tateaggage tagggttgte tgetgeecae acteetgett tttgggatat etaactgeta aggagggagt tgacateece
                                                                          180
                                                                          240
                                                                          300
cttctggctc atgtgtctga caccaacaac atggtctctg tccctctctc tttgactctc
                                                                          360
cctttgtcct ccccatagag ctgggtggg gtggatccct atacctgggg caggcagccc
                                                                          383
caaagtgggg gaggggatg gca
<210> 207
<211> 385
<212> DNA
<213> Homo sapiens
<220>
<221> misc_feature
<222> (1)...(385)
<223> n = A,T,C or G
```

ggaactacac ccatgccagt acattgacaa ggctcccgga cacttcggcc	tcaggataag ccgcttcgat cttccagtcc tgccatgagg attctacaac agaacttatt actcggaaga	gactggtacc ttggaggcct accttcctca attcctcagg gaaagcgcaa	tgtgggttca actggcctgg actactacac gatacacagt	gatgtacaag tcttcagagc tgtatggaag ggagaagcga	gggactgtgt ctcattggag cagtttgggg gagggctacc	60 120 180 240 300 360 385
<210> 208 <211> 374 <212> DNA <213> Homo	sapiens					
cagtatcagg ctaaggaggg ctgtccctct cctatacctg	tcagctgcct agctagggtt agttgacatc ctctttgact gggcaggcag tctggcaagg gagg	gtctgctgcc ccccttctgg ctccctttgt ccccaaagtg	cacactcctg ctcatgtgtc cctcccata ggggaggggg	ctttttggga tgacaccaac gagctggggt atggcagaga	tatctaactg aacatggtct ggggtggatc ctgtaaaggc	60 120 180 240 300 360 374
<210> 209 <211> 425 <212> DNA <213> Homo	sapiens		•			
ccaattgcaa tggccaagaa ccgagtgtaa gcgatctcac atcacatagg	caagtgcttt ggaccttgct ccccattggg actgcagacc aaagcttctc agttaaggga tctgtggttg	gctgtgttgg aatacagggg ttggtgcttt caagaaaaat atgaagttcc	ttgtcagccg tgaagtttct ggaactgcga caagcctgtt tgtgtgaggc	ggagctgaca gtgtgagggc cataactagc gtgtttggat tttgaggaaa	cacctgtgct ttgaggtacc gatggctgct ctggggctga ccactgtgca	60 120 180 240 300 360 420 425
<210> 210 <211> 396 <212> DNA <213> Homo	sapiens					
cggttttctt tgcctgtaaa atgtgaagct tacttatgta tgatcctgtc	gcaaggaagt atctatgaaa cagtgcctgg ttgctctgtg gctatctctg tgtgttccct aaagcatcaa	tgaggctaag catatagctt aggtctgtat aaacttagaa gttcccagca	aataataaaa attattcatc tacaatcaca atgaaatcat taaagcctaa	tagagaatta cagctaagag ttcagttata cgaggaaaaa	aatgagataa gcccttccat gctaattatt ggccatttct	60 120 180 240 300 360 396
<210> 211 <211> 267 <212> DNA <213> Homo	sapiens					
gcacgctctc gatgtagtga ctgtgctggc	cacacagaga tetetetete gagtttgatg cetatettgt tatgtagtge	tctatccctc catatttgtc gtgtatgttt	agaaagatct cgtgtccgcc	tcctttttcc cccacagacc	ctctccctgt ctctacctct	60 120 180 240 267

<210> 212 <211> 396 <212> DNA <213> Homo sapiens					
<400> 212 ggcacgagcc aggaggaccc gagtccatct cagttcgcag ctcaagcagt cacggggaga cgggggagcc tgagtcagga gtaaggttct gggccccagg tagctgcgca gaaggtctcc catcctcctc cacaggcagt	ttctgtgact aggattgtag ggtcagtggg caagaaggca gctggctctc	tgcattgacc atgggccagt ccctggaagg gagtttctcc caagccgggc	tggctccaat gactcacagg gagggggcaa gcaggggtgt	caagctacaa gtcaggcact gcctgggtgg gtgcaagagc	60 120 180 240 300 360 396
<210> 213 <211> 284 <212> DNA <213> Homo sapiens					
<220> <221> misc_feature <222> (1)(284) <223> n = A,T,C or G					
<400> 213 tgggctgtct cgcccctcct gcgtgcgggg cgcgctcttt gagcctccga gcgctctgc ctcnnnnnn nnnnctcttc gtctgtgcag cagaggacta	acttttttt cccctcctct cagagatacg	ctctctcaca ctctctctct ggggcttgtt	catatttata tcacgtgtgt tcctccgctc	tatatagaga gcatcaccca	60 120 180 240 284
<210> 214 <211> 440 <212> DNA <213> Homo sapiens					
<220> <221> misc_feature <222> (1)(440) <223> n = A,T,C or G					
<400> 214 ggcacgaggg attgcagtca tcataccaag gagtggagag tagaaagcgt ttctcttcct ggaagaaaca atacaggatt aagaaattaa tgctggagta ctataaatac ttataaatta ttaaaatcct caggttgcaa ctttgttcac ctatagaaan	ttgaagtttc gagtatttca gcctttaatt tggaggggtg taaacacaat aaccaaaatg	ctcccagtga aaaagatgta aattaagaat ataaccttaa ataattaaaa	ctccagtgac aaagagctgg tgcctcctga agattataaa ttagaacatc	agaccaccc ggagagtatg taaaaggaaa tatttgttgt aggaaaagaa	60 120 180 240 300 360 420 440
<210> 215 <211> 439 <212> DNA <213> Homo sapiens		•			
<400> 215 ggcacgagtg cacaggggac ccaggggtga ggggcaggca gacagccagc accagagcca gagcccggca tatacccagg gctctgggct ggagcgaggg ctcccttcta gcctctgacc	gcagttgtag tcaccactcc gcacccctac ccaggttttg	ttactgccgc ctgggctggc ggctgccgcc ggccgaggct	ggggcactgc tggcaggtat agtctcatgc tccccaggca	tatgtgcagg ggcaccctgg ccaggtgggt atcctgtgag	60 120 180 240 300 360

gaagttcagg tcctggcttt ccacctgaga ctgtcactg	gcctttgcct	gatgtggatg	agcagctcac	atgctcaggg	420 439
<210> 216 <211> 392 <212> DNA <213> Homo sapiens					
<400> 216 ggcacgagga gacagagaag aggaggcaga gaagtttggc atcatggcgt tagtcaggct cagcagggca ggctgggaaa acgaggccgg gaaggaggca ccgggaagga agcagacaaa aggaagcaga gaaacttggc	caggtgggga ggaagggagg gagggagaca gggcagtttg gcggtccaag	aggaggaaga cggggcagtt tagcagttca gccagggagt ggttccacac	cagagtggtc tggccacgac tggtgtccaa tcaccatacc	caaggcctcc attcaccaca cctggggtcc cttgaacagg	60 120 180 240 300 360 392
<210> 217 <211> 394 <212> DNA <213> Homo sapiens					
<400> 217 ggcacgagcc catctggggc cctcgtggtc tttgcggaca cctgtacgag gggacgaagg gaaggagatc ttgaggctac caagaccatc tccaacagcc ccgcatgaaa cagctgcggc gcgggagctg gagcagctta	gtctcattag tggtgtttcg agaatggcct ggaagctgat agctgcgcat	caacatcctc ctatgccttg ggaaatctac gaacatcgcc ggtccaccgg	cttcgggtct gccattttca cagtacctgc ttcaatgaca	gggatgcctt agtacaacga gcttcttcac tgaacccctt	60 120 180 240 300 360 394
<210> 218 <211> 432 <212> DNA <213> Homo sapiens					
<400> 218 acacccactt gtttgaggac acgtgcctta caggagttct caaacctgca gaaaatgatg catgaggatg gcatctcgag tgatgatgtt gttaatgact agaaaaccta ctgaaaattt tcccagggaa gggaaaaagc gtcttgtgca ag	tccagacacg ttaagcttgt aggagagctt ttgatattga ctcgcagagc	ccaaaagtga agctctcaaa ggaagatgtc agatgaagta gaaagagtac	cttggactca ctgaaaccac ttaggtccac gttgaagtag aaagtggaaa	aagttaaagg atactaatat cccctgacaa aaaataggga ttttgaatcc	60 120 180 240 300 360 420 432
<210> 219 <211> 395 <212> DNA <213> Homo sapiens					
<pre><400> 219 ggcacgagcc ctttactcct tatctagctt gcaggatttg gagagaaaag acagacagag tgtattttat caatatgatg aatcgccact ggagatatcc ggctgtgaag cggcagcagg cattgatgag tgccgggccc</pre>	agttgaggaa tcaaatctac taaagtctga cgtttcaagg agccactggg	aacacagact agcatatctc aatatacagc ctgtaattct tgaagactgc	tccatgagtt tcacctcagg tttggaatcg gagaagatcc	tgggaactac aactggaaga tcctctggga gcaagctggt	60 120 180 240 300 360 395
<210> 220 <211> 487 <212> DNA					

```
<213> Homo sapiens
<220>
<221> misc feature
<222> (1)...(487)
<223> n = A,T,C or G
<400> 220
tgctcttttg atgatgccat cgattcgaat tcggcacgag cagctagctc agttcaaggt
                                                                   60
ggaaatggct taacgagagg aacggcaaca gcaggtggct gaggactacg agctcagact
                                                                  120
ggcccgggag caagcgcgag tgtgcgaact gcagagtggg aaccagcagc tggaggagca
                                                                  180
gcgggtggag ctggtggaaa gactgcaggc catgctgcag gcccactggg atgaggccaa
                                                                  240
ccagctgete ageaccacte tecegeegee caacceteca getecteetg etggaccete
                                                                  300
cagccccggg cctcaggagc ccgagaagga ggagaggagg gtctggacta tgcctcccat
                                                                  360
ggccgtggcc ctgaagcctg tattgcagca gagccgggaa gcaagggacg agctacctgg
                                                                  420
agegeeteet ggtttttgea gnteeteete agatettage eteetggtgg geeeetettt
                                                                  480
tcagage
                                                                  487
<210> 221
<211> 365
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (1)...(365)
<223> n = A, T, C or G
<400> 221
ggatgccagt ggtgaggctg taagcgaaac tcttcagttt aaagctcaag atctcttaag
                                                                   60
ggcagtccca agatccagag cagagatgta tgatgacgtc cacagcgatg gcagatactc
                                                                  120
cctcagtgga tctgtagctc actctagaga tgccggaaga gaaggcctga gaagtgacgt
                                                                  180
atttccaggg ccttccttca gatcaagcaa cccttccatc agtgatgaca gctactttcg
                                                                  240
                                                                  300
caaagaatgt ggccgggatc tggaattttc tcactctgat tctcgggacc aggtcattgg
ccaccggaaa ttggggcatt tccgttctca ggactggaaa tttgcgctcc gtggttcttg
                                                                  360
                                                                  365
ggaan
<210> 222
<211> 376
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (1)...(376)
<223> n = A,T,C or G
<400> 222
ggcacgagga gatttcccgg cgggtcccgg cctctgcgtg cacgcgcctg cgtgctcgcg
                                                                   60
120
                                                                  180
240
nnnnnnnnn nnntgatggc agcagtggcc tgcctgaagc agccactgcc aagaatctag
                                                                  300
ctgcagtnnn nnnnnnnnn nnnnnnnnca tgctccacac agccaccgga agccaagaac
                                                                  360
gcaccetect gggtacaget gcaageegee ageegagget geggaeeegg geeteeetgg
                                                                  376
tgctctgggg gttggg
<210> 223
<211> 399
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
```

```
<222> (1)...(399)
 <223> n = A, T, C or G
 <400> 223
 ggcacgaggg gtgacagagc ggctggcgca tgctcagtag agcagcctac ggcaaqcaqc
                                                                       60
 ctccctcagg gaacatcaca ggaagcagct gcaggacctg agtggacagc accagcagga
                                                                      120
 gctggccagt cagctagctc agttcaaggt ggaaatggca gaacgagagg aacggcaaca
                                                                      180
 gcaggtggct gaggactacg agctcagact ggcccggqag caagcgcqag tgtqcqaact
                                                                      240
 gcagagtggg aaccagcagc tggaggagca gcgggtggag ctggtggaaa gactgcaggc
                                                                      300
 catgctgcag gcccactggg atgaggccaa ccagctgctc agcaccactc ttccgccgcc
                                                                      360
 caaaccttca gcttcttctg cttgaccctc cagccccgn
                                                                      399
 <210> 224
 <211> 402
 <212> DNA
 <213> Homo sapiens
 <400> 224
 ggcacgaggg cagttcagta tcgatggaca gatcttccta ctctttgact cagagaagag
                                                                       60
 aatqtqqqca acqqttcatc ctqqaqccaq aaaqatqaaa qaaaaqtqqq aqaatqacaa
                                                                      120
 ggatgtggcc atgtccttcc attacatctc aatgggagac tgcataggat ggcttgagga
                                                                      1.80
                                                                      240
 cttcttgatg ggcatggaca gcacctgga gccaagtgca ggagcaccac tcgccatgtc
                                                                      300
 ctcaggcaca acccaactca gggccacagc caccaccctc atcctttgct gcctcctcat
 catectecee tgetteatee teeetggeat etgaggagaa teetttagag tgacaggtta
                                                                      360
 aagatgatac caaaaagccc ctgtgagcac ggtcttgatc ag
                                                                      402
 <210> 225
 <211> 270
 <212> DNA
 <213> Homo sapiens
 <220>
 <221> misc feature
 <222> (1)...(270)
 <223> n = A,T,C or G
. <400> 225
 ctetetttet ttetecetee eeceeggge gegeteattt atetegtete ttatgtetet
                                                                       60
                                                                      120
 ctctctgtgt ctgtgacaga cacactcttt ttcatatagc gcgctccctt ttctttgctc
                                                                      180
 teggggggg tetetetgta egegtgtgtt eteteteeag tgagtgtgca egeetaggtg
                                                                      240
 agagagagtn nnnnnnnnn nnnnntgtgt gtgaatttta tatatttcta tatctctcac
                                                                      270
 tctctgggtg tcacactctc cgtgtgtggg
 <210> 226
 <211> 404
 <212> DNA
 <213> Homo sapiens
 <220>
 <221> misc_feature
 <222> (1)...(404)
 <223> n = A,T,C or G
 <400> 226
 ggcacgagaa ccctcccagg ctaagcccca atttggggct cgcctgccct gcatcaggga
                                                                       60
 gacatgtcag ctgaggagta attgaccaga tttctgcttt agaaatatgg cagtggaggc
                                                                      120
 aggagatggc atctgaggcc caggctgggg agaagggtgc tgggatgaga acctggagtt
                                                                      180
                                                                      240
 caqaccaqqq aaqqqatqaq aqcctaaqaa qaqqaqctct caccctqaga caqqctggtg
                                                                      300
 caggagtetg etegatecag geetgggtee etggtteeet etgagettgg gaggaetatg
 tgagacagaa caggaccagg ggcctgcatt cccccttgta ttattcatct tcnnnnnnn
                                                                      360
                                                                      404
```

<210> 227

```
<211> 389
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (1)...(389)
<223> n = A,T,C or G
<400> 227
ggcacgagaa gtcactcaac ctctctgagc cttttcttca cctataaagt ggggatagta
                                                                      60
actacctacc ttatggaagc atatgaggat tgtgtgaaat catccatgta gcccttccac
                                                                     120
cgccacgtgg agtttggcat ggagcagttt ctaaatggaa gtcatcttga tcaggtgggc
                                                                     180
tgccaacctc tctgagcctc agtttgctct tctagggaat ggggacaatg caatgggaat
                                                                     240
ctgaggattg tgtgaaattg tgcaaatgca tgaatgtggg ctgggatagt aaaagggagg
                                                                     300
gccccggagc agcccacctg gggtcctatc tagtggacgc gcccggtgcc cacccattgc
                                                                     360
tgtgatgcca gcagcccact gcaagcatn
                                                                     389
<210> 228
<211> 384
<212> DNA ·
<213> Homo sapiens
<220>
<221> misc_feature
<222> (1)...(384)
<223> n = A, T, C or G
<400> 228
ggcacgagct gccacctcta gaaagctgct ttcttctatc accgcttgcc cttgaattat
                                                                      60
tccctgaatg aagccaagaa ccctcccagg ctaagcccca atttggggct cgcctgccct
                                                                     120
gcatcaggga gacatgtcag ctgaggagta attgaccaga tttctgcttt agaaatatgg
                                                                     180
cagtggaggc aggagatggc atctgaggcc caggctgggg agaagggtgc tgggatgaga
                                                                     240
acctggagtt cagaccaggg aagggatgag agcctaagaa gaggagctct caccctgaga
                                                                     300
                                                                     360
caggctggtg caggagtetg ctcgatccag gcctgggtcc ctggttccct ctgagettgg
gaggactatg tgagacagaa cagn
                                                                     384
<210> 229
<211> 292
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (1)...(292)
\langle 223 \rangle n = A,T,C or G
<400> 229
ggtgtetete tetegggggg geececete tetetatttt tttttgegeg cacacteaet
                                                                      60
ctctctctt tttttccccc gcgcgcgcc acgcgctttt tttttctttt ttctnnnnn
                                                                     120
180
totcacccac agacactete tetgtgtgcg cacetetete tetegggggg ceggatetet
                                                                     240
ctccccctc tctatctctg ttattttggg ggtcccctcc gcgctctcct ca
                                                                     292
<210> 230
<211> 400
<212> DNA
<213> Homo sapiens
<400> 230
                                                                      60
ggcacgaggt gggacagaag tagaagaggg tgaatggccc tggcaggcta gcctgcagtg
ggatgggagt catcgctgtg gagcaacctt aattaatgcc acatggcttg tgagtgctgc
                                                                     120
tcactgtttt acaacatata agaaccctgc cagatggact gcttcctttg gagtaacaat
                                                                     180
```

```
gtggagcaac cttaattaat gccacatggc ttgtgagtgc tgctcactgt tttacaacat
                                                                     120
ataagaaccc tgccagatgg actgcttcct ttggagtaac aataaaacct tcgaaaatga
                                                                     180
aacggggtct ccggagaata attgtccatg aaaaatacaa acacccatca catqactatq
                                                                     240
ataltitctct tgcagagctt tctagccctg ttccctacac aaatgcagta catagagttt
                                                                     300
gtctccctga tgcatcctat gagtttcaac caggtgatgt gatgtttgtg acaggatttg
                                                                     360
gagcactgaa aaatgatggt
                                                                     380
<210> 235
<211> 410
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (1)...(410)
<223> n = A,T,C or G
<400> 235
ggcacqaqct qaqcaqqact taqaqqaact ccqqctacqt ttqctqtccc aacaaataqa
                                                                      60
ccagggttcc ctaagtgtcg cttcctccaa gaagccctcc ctgatgagtt gagccacttt
                                                                     120
agtttgtgct caggctcacc ctgcacgtct tggttgctct catcactgta atgatctaaa
                                                                     180
acacacgtct gctcatgaga cccqcatccc acccccqatg ctggggccgc tcttggattt
                                                                     240
teatgeetge tgeeageace cagggggage teeggaaatg tetgetgggg geteggaata
                                                                     300
cccacctttc tggtaatgca gcccagcggg tcccagcctc gttntccagc cctcactcan
                                                                     360
aatggagtcg ctctggttcg aacgcctctg acaagtgtgt acctacgtgt
                                                                     410
<210> 236
<211> 394
<212> DNA
<213> Homo sapiens
<400> 236
ggcacgagac tccggctacg tttgctgtcc caacaaatag accagggttc cctaagtgtc
                                                                      60
gcttcctcca agaagccctc cctgatgagt tgagccactt tagttttgtgc tcaggctcac
                                                                     120
cctgcacgtc ttggttgctc tcatcactgt aatgatctaa aacacacgtc tgctcatgag
                                                                     180
                                                                     240
accogcatoc caccoccgat gotggggccg ctottggatt ttoatgcctg ctgccagcac
ccagggggag ctccggaaat gtctgctggg ggctcggaat acccaccttt ctggtaatgc
                                                                     300
agcccagcgg gtcccagcct cgttttccag ccctcactca aaatggagtc gctctggttc
                                                                     360
gaacqcctct gacaagtgtg tacctacgtg tcag
                                                                     394
<210> 237
<211> 428
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (1)...(428)
<223> n = A,T,C or G
<400> 237
ttcggcacga nnnaagaaga ggccctcaga gatctgacag cctatgagtg cgtggacacc
                                                                      60
                                                                     120
acctcagccc actgagcagg agtcacagca cgaagaccaa gcgcaaagcg acccctgccc
                                                                     180
tecatectga etgetectee taagagagat ggeaceggee agageaggat tetgeceeet
tctgctgctt ctgctgctgg ggctgtgggt ggcagagatc ccagtcagtg ccaagcccaa
                                                                     240
300
caactcagcc atgaaaaaca ttaacaagca cacaaaacgg tgcaaagacc tcaacacctt
                                                                     360
cctqcacqaq cctttctcca qtqtqqccqc cacctqccaq acccccaaaa taqcctqcaa
                                                                     420
                                                                     428
gaatggcc
<210> 238
<211> 432
```

<212> DNA

<213> Homo	sapiens					
tttaatacat agcctgcggc ccagcctgac aacgcaatgc ttgccaaata	gaacccatcc ttactggagc tgtagatgtg tcacaaggag atatgggggc tgccactacc tttccagcgc	cagaaaccta gaactcacag atagcgaagg ttctcttcta gcctacgtgc	ggccatcatc catatgcatt ccactagcat ctcacgatac catctgagga	gaacgccagc gttggcccag ataggcttgg tgtagttgct gatcaacctg	ccttggtctg cttaccaagc ttggccaagc gtacaagctc gttgtaaaat	60 120 180 240 300 360 420 432
<210> 239 <211> 373 <212> DNA <213> Homo	sapiens					,
atgaccaacc ggcatgtcag cgcgacgaga ttacagcagc	aggacetect teteceacaa agegggageg teegegeeaa ageagacaeg eecaggggaa age	ggatgtcaac acaggtgatg ggacagggag gctgatgaag	ttctcagagg aacaagctga ctgggcctga atcaaccatg	aggagttcca aggaggtggt aaaatgagga accttcggca	gaagcatgaa ggacaaacaa cgttgaggct ccgggtcacg	60 120 180 240 . 300 360 373
<210> 240 <211> 392 <212> DNA <213> Homo	sapiens					
cgagcgggtc gcgcgtgctg cgatctgcgc gcagctcatg gcatgaaggc	ctgaccgaga attgaccagc gagatcttgg ctggagcagg accaacctct atgtcagagc gacgagatcc	acgggtgtta aggtgctggt acctcctctc cccacaagga gggagcgaca	ggccatcgcg cagtcgcctc ccagatcgcc tgtcaacttc ggtgatgaag	cgcctcatgc cacgtcgcgc cagctgctgg tcagaggagg	ccaaggtcgt ccgagctgga aggagaacaa agttccagaa	60 120 180 240 300 360 392
<210> 241 <211> 434 <212> DNA <213> Homo	sapiens					
gctgacccaa gtcactgagg ggtgggacag gaaaatgggg aatggccaag	attcgaattc gtaggaagcc aagagatcaa atcagcagta ctgcggccct acctaaagaa tgtctctgag aagg	ggacgagctg tcttaccaga tgtctccaac ggatgggcgg cctgctgcac	taaaacatga gggccctcag gacagtggca ctccaggagg caggatgctg	acggaagagt ggctgggctt tctacgtcag gtgataagat tagacctctt	ggattatttg caacatcgtc ccgcatcaaa cctttcggta tcgtaatgca	60 120 180 240 300 360 420 434
<210> 242 <211> 385 <212> DNA <213> Homo	sapiens	١				
	gagcgcggac gcgacccctg					60 120

gccaaaacag gattatgccc atcccactca gtgccaaacc atgcagccca gccctcaagc cggtgcaaag acctcaacac cagaccccca aaatagcctg	caagggcatg atgcaactca cttcctgcac	acctcatcac gccatgaaaa	agtggtttag acattaacaa	aattcagcac gcacacaaaa	180 240 300 360 385
<210> 243 <211> 388 <212> DNA <213> Homo sapiens					
<400> 243 ggcacgagag aaggcctgcg atccccgatg gcactcccaa ggtgcgtctc aggaagctgc tggctacgaa aacttgctgg cttcagttag aggaggaacg gcaggactgc agaatggctc caaattagcg aatacaaatt	tggtgatgtc tcaggtcttg agagaaggaa acagaaatgc agacttgcag	agtcatgaac gagtcaccag gaactactgt tccatgactg	cagtggctgg gagaagggcc cacagattac atggcacagt	agccatcact attacatgtt aaaactgaag gggtgacctg	60 120 180 240 300 360 388
<210> 244 <211> 388 <212> DNA <213> Homo sapiens					
<220> <221> misc_feature <222> (1)(388) <223> n = A,T,C or G					
<pre><400> 244 ggcacgaggt cactgttgaa acatcgccgg tgggacagat gcatcaaaga aaatggggct tttcggtaaa tggccaagac gtaatgcagg ctatgctgtg ctataggaca tcgaggtgaa cgnggctggc ctctccctgg</pre>	taccagtatg gcggccctgg ctaaagaacc tctctgagag ggggacccaa	tctccaacga atgggcggct tgctgcacca tgcagcacag	cagtggcatc ccaggagggg ggatgctgaa gttacaggcg	tacgtcagcc gataagatcc cacctctttc cagaatgtac	60 120 180 240 300 360 388
<210> 245 <211> 390 <212> DNA <213> Homo sapiens					
<400> 245 ggcacgaggc tgtgtgtctc cctgttccct tacccctaca ctccagctcg gtgcaccgcc ctacagcccc tactccatcc cctgccctcc atggcggcgg cagcccggcc tcggtggcag ctcctccagc tccatgtcct	cgtacatggc accccttcct cggtgccggt ccgcggggcc aggactcggg	cgcagcggcg caatctgaac cccggacggc cctggacggc	gccgcctcct accatgcgcc agcagtctgc aaagtcgccg	ctgcggcagc cgcggctgcg tcaccaccgc ccctggccgc	60 120 180 240 300 360 390
<210> 246 <211> 397 <212> DNA <213> Homo sapiens					
<400> 246 ggcacgagac cactgggacc tgggctgcct tggatccatg cttagtggag gagcgtgtgg gacgcggctg acctcgctgg	ccgcctaccc agaacggaca	ccactccccg catctatgac	ctgcacgtgc acgattgtga	gagccctggc acgtgaagga	60 120 180 240

```
ggtcccgctt cagtggatcc ccaagcccgt gctctatggc ctcttcctct acatcgcgct
                                                              300
cacctccctc gatggcaacc agctcgtcca gcgcgtggcc ctggtggttc aggaaccaaa
                                                              360
ctggggaacc ccccgacaca ctacatcccg gaggggg
                                                              397
<210> 247
<211> 471
<212> DNA
<213> Homo sapiens
<220>
<221> misc_feature
<222> (1)...(471)
<223> n = A,T,C or G
ttacggcgcg tttgttaggg gacccaccg attcgaattc ggcacgagct ctttttattt
                                                               60
tegetgatat etttettta etaaatgeea eeateettae etgttegggt gtetgegtge
                                                              120
                                                              180
ctaatttttc ctggctgtta cacaagaacc cggattttag ttgaactctg gagcaaaaat
cctgcatcat ttgtaggtgg gtgtcattgt gactggctgc tacctcccca tgagtcttct
                                                              240
aaaataaaac ctgcaaattc acatcttccc catgcttcca gagaatgcat attcttcctt
                                                              300
360
420
471
<210> 248
<211> 403
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (1) ... (403)
<223> n = A,T,C or G
<400> 248
                                                               60
ggcacgaggt acagacatct agttggcagg agccaaagat gttgccaaac atgtagtann
                                                              120
nnnnnnnga gtagaggatg cctggtatga ggcaatattt gggataggga agggaagctt
                                                              180
gggattttag ctacgtagag acacttgaaa attggaggga ggaaaggagt gggtggcttt
                                                              240
qqaqatqttc tqqaatatqt qaatqaqqqq aqtqqaqqqq ncctqnnnqc tctqnqqaaq
                                                              300
gccangcccg gtttcctgtc tttcancctc ttccaggaaa attacgggca gaaagaggct
                                                              360
                                                              403
qaqaaaqtqg tcccggggaa ggcgctttat gaagagcttg gtg
<210> 249
<211> 316
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (1)...(316)
<223> n = A,T,C or G
<400> 249
                                                               60
ccgcttaaag gcgccttctt ttaatgcaat cattttgaac atgtgcgaca gtcgagaata
ctaattggat caatcttgat atactctacc taaagacagt ctagaaacct gggggagaaa
                                                              120
gaactcacgg cacaaaacat tgggccgaga acggaattct ctgtaagcct agttgctgaa
                                                              180
acttectget gtaaccagaa gecagtttta tetategget actgaaacac ceactgtqtq
                                                              240
ttgctcactc cctcactcac cgaacanaac ctgctacctc cgcatgaatc tactagtgcc
                                                              300
                                                              316
gataaactat atcaga
<210> 250
<211> 419
```

<212> DNA <213> Homo	sapiens					
ctgcctcca ggtagggagg cagcaagagg tcgatggctc ctgcatgatc	atcagtcaag ctgggtccca acactattc gcacctgtga ccaccttact tgatccatcc gacactctgg	tggccaccac cctcaactac acacctgagt tgcagtaaat cttacctacc	cttgaccttg ttctagtaaa cacagcgcat gctgaggtcc ctcatctctc	gaaagctctg aagctcagtt tcctcctctg ttcctgtggc cactggcctc	ttatatggaa ctctccccag cttagaacat ccccggggcc cccacacttg	60 120 180 240 300 360 419
<210> 251 <211> 434 <212> DNA <213> Homo	sapiens					
<220> <221> misc <222> (1). <223> n = 1	(434)					
ctgcggcgca acgtcctggc acacgtacat gccacccctt tcccggtgcc	ggcctccacc gggactgtcc ctctcagggc ggacgcagcg cctcaatctg ggtcccggac gcccctggac	ggggcgtccg ctggccatgt gcggccgcct aacaccatgc ggcagcagac	cggacaccct cccctttcgg cctctgcggc gcccgcggct tgctcaccac	gcccttccac aagcctgttc agcctccagc gcgctacagc cgccctgccc	ctccagcagc ccttacccct tcggtgcacc ccctactcca tccatggcgg	60 120 180 240 300 360 420 434
<210> 252 <211> 425 <212> DNA <213> Homo	sapiens					
actccccgca ccttggagga gggacgggac gcgggcaccc acagtacccc	agcactcagc gagagttctt ggtgcccttt ggaggtggcc tgctagccca ggcatagccc gcggccctgc	gaagaggagc gccgctgcct gtgaagatcc gagaagtgac agagcattca	tcggcaggga caattgggca aggtgagagg tcccaccttc gagcgatgtc	ctggcaggcc ggtgcaccag ggaggctggg tctccctccc cagaacctgc	aaggtggcct ggcctgctga cagggtaggg ttctcccttt tggcggtact	60 120 180 240 300 360 420 425
<210> 253 <211> 395 <212> DNA <213> Homo	sapiens					
<220> <221> misc <222> (1). <223> n = 1	(395)					
nnnnnnnnn nnnngagta attttagcta	gacatctagt nnnnnnnnn gaggatgcct cgtagagaca aatatgtgaa	nnnnnnnnn ggtatgaggc cttgaaaatt	nnnnnnnnn aatatttggg ggagggagga	nnnnnnnnn atagggaagg aaggagtggg	nnnnnnnnn gaagcttggg tggctttgga	60 120 180 240 300

aagcccgttt tcctgtcttt aaagtggccc gggtgaatgc			acgggcagaa	ggaggctgag	360 395
<210> 254 <211> 307 <212> DNA <213> Homo sapiens					
<220> <221> misc_feature <222> (1)(307) <223> n = A,T,C or G					
<400> 254 agtcgtcttc ttttaatgta atcaatcttg aaatactcaa ggcacaaaat attggtctga ctgtaaccag aagccagttt tccctcactc accgatcaaa ttctcan	ccaaaagaca gaatggaatt tatctaacgg	gtcgagaagc ctctgtaagc ctactgaaac	cagggggaga ctagttgctg acccactgtg	aagaactcag aaatttcctg ttttgctcac	60 120 180 240 300 307
<210> 255 <211> 312 <212> DNA <213> Homo sapiens					
<pre><400> 255 agtcgtcttc ttttaatgta atcaatcttg aaatactcaa ggcacaaaat attggtctga ctgtaaccag aagccagttt tccctcactc accgatcaaa ttctcaaaga gc</pre>	ccaaaagaca gaatggaatt tatctaacgg	gtcgagaagc ctctgtaagc ctactgaaac	caggggaga ctagttgctg acccactgtg	aagaactcag aaatttcctg ttttgctcac	60 120 180 240 300 312
<210> 256 <211> 415 <212> DNA <213> Homo sapiens					
<220> <221> misc_feature <222> (1)(415) <223> n = A,T,C or G					
<400> 256 ggcacgagca ggagcagctg tggaaaaggc agcgcgtgcc ccccggggag gcaggaccgg gctgggctgg gagccccagg ctaacgaggg cttcagccca aagcgagtgt ctgatcccc tagccagtgc tccagccct	tggcgccaaa gagaggcaga ggaggcagag cccggcccac tgctggccca	gcagggcggg gctgggcgga ctgggcggag cacccaccct ggtcctcact	aggagtcgag gtcgtcaagc gtagtgggga tctggggttc ttgcacctgt	ctgccgggag tgctgggagc cagagacttc ccttgctggg gtgggccct	60 120 180 240 300 360 415
<210> 257 <211> 396 <212> DNA <213> Homo sapiens					
<400> 257 agaaagggtg agtgaggtgc ggtttgaagc tgaagtgggc ggaaggcatt tggatatcca cccccaccca tacctgtctg	ctgggggaat gccctttctc	gggttgaagg tgtggccttg	cagaagcaac gccctgggtc	cagtttggag tgtcctgtta	60 120 180 240

```
tttaaagttg gcaaggggag gttaataagc acctaggtgg ctgagtgtct ctgtcttctg
                                                                       300
gcttgttcac aggacttcga gtaagaaggt gatttacagc cagcctagtg cccgaagtga
                                                                       360
aggagaattc aaacagacct cgtcattcct ggtgtg
                                                                       396
<210> 258
<211> 431
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (1)...(431)
<223> n = A,T,C or G
<400> 258
gnnggagggc ctgcggcaaa gagatgagct tattgagaaa catggcttag ttataatccc
                                                                        60
                                                                       120
cgatggcact cccaatggtg atgtcagtca tgaaccagtg gctggagcca tcactgttgt
                                                                       180
gtctcaggaa gctgctcagg tcttggagtc agcaggagaa gggccattag atgtaaggct
acgaaaactt gctggagaga aggaagaact actgtcacag attagaaaac tgaagcttca
                                                                       240
                                                                       300
gttagaggag gaacgacaga aatgctccag gaatgatggc acagtgggtg acctggcagg
actgcagaat ggctcagact tgcagttcat cgaaatgcag agagatgcca atagacaaat
                                                                       360
                                                                       420
tagcqaatac aaatttaaqc tttcaaaaqc agaacaggat ataactacct tggagcaaag
tattagccgg c
                                                                       431
<210> 259
<211> 404
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (1)...(404)
<223> n = A,T,C or G
<400> 259
                                                                        60
ggcacgagca ggagcagctg gcaagggaga aggacacggt gaagaagctg caggaacagc
                                                                       120
tqqaaaaqqc aqcqcqtqcc tqqcqccaaa qcaqqqcqgq aqqaqtcqaq ctqccqqqaq
ccccggggag gcaggaccgg gagaggcaga gctgggcgga gtcgtcaagc tgctgggagc
                                                                       180
                                                                       240
gctqqqctqq qaqccccaqq qqaqqcaqaq ctqqqcqqaq gtaqtqqqqa caqaqacttc
ctaacgaggg cttcagccca cccggcccac caccaccct tctggggttc ccttgctggg
                                                                       300
aagcgagtgt ctgatccccc tgctggccca ggtcctcact ttgcacctgt gtgggcccct
                                                                       360
tagccagtgc tccagcccct gccctgcagg atgatggttt cccn
                                                                       404
<210> 260
<211> 402
<212> DNA
<213> Homo sapiens
<400> 260
                                                                        60
ggcacgagat ctccctgcct tgtgagcagc tggccggcgg ctctgggaca ggcggggatg
ggagggagte tacegggeea etgtagaget ggtagetggg agetggaget gtagagttee
                                                                       120
                                                                       180
aggetgggag etggagagee etgggtgaga gggaggeeta taggggeece gggggacaca
ccaggettga gggtagtagg tgetggagge agageetgge etgtecaggg tgggaeetea
                                                                       240
                                                                       300
cgacccaccc tgtccggccc ccagctcgga ggagcttcta cgtgtatgcg ggcatcctgg
                                                                       360
cactgctcaa cctactgcag gggctgggga gtgagctgct gtgcttcgac atcatcgagg
ggctctggtg cgtgggggcc gcagggagtc tgcctcgtgg gg
                                                                       402
<210> 261
<211> 402
<212> DNA
<213> Homo sapiens
<400> 261
```

ggcacgagat ctccctgcct ggagggagtc taccgggcca aggctgggag ctggagagcc ccaggcttga gggtagtagg cgacccaccc tgtccggccc cactgctcaa cctactgcag ggctctggtg cgtgggggcc	ctgtagagct ctgggtgaga tgctggaggc ccagctcgga gggctgggga	ggtagctggg gggaggccta agagcctggc ggagcttcta gtgtgctgct	agctggagct gaggggcccc ctgtccaggg cgtgtatgcg gtgcttcgac	gtagagttcc gggggacaca tgggacctca ggcatcctgg	60 120 180 240 300 360 402
<210> 262 <211> 151 <212> DNA <213> Homo sapiens					,
<400> 262 gccgaatatg aagctacgtc tacttagatt tgattaccta gattttgggc ggtctcaaaa	tggaccacat	tggtagaact			60 120 151
<210> 263 <211> 404 <212> DNA <213> Homo sapiens					
<220> <221> misc_feature <222> (1)(404) <223> n = A,T,C or G					
<400> 263 ggcacgaggg aacgtggaag nnnnnnnnn nnnnnnnnn ggacctaccc cccgagtggt tgcattatca gctttcctac acttgcagat ggcctgttgt acccctccca gggatgatgg gcacattgaa ccagatagtc	nnnnnnnn ttgccagggg ttttgaggtt gggacctcac aaggttaagg	nnnnnnnn ctctcaggcc ttgggacttt cttgtgatca tcctaacacc	nnnnnnnn ttcggctaca actggctttc tgtacatgag tcctgcacat	nnnnnnntt gactgagggc ttgctcctca ggaaatacac	60 120 180 240 300 360 404
<210> 264 <211> 380 <212> DNA <213> Homo sapiens					
<400> 264 ggcacgaggg gaacgggaag gggtgtacga agccccgggc ctgtgcggga gatgaacgac tgaagtacca ccactgtgtg agttcgtaga acgaattatc ttgatgacaa ggacacagct tcacctgctg ccacaatcgg	tttttcctgg ctaccggaca ggtgagaagt ctgacaaggg	acctggagcc cgcaggtctt accgctgggt acaagacggt	catcccggga catctgcacc ggagcagcac ggtcttgggg	gccttggacg agccccctgc ctggggcccc gacctgctca	60 120 180 240 300 360 380
<210> 265 <211> 440 <212> DNA <213> Homo sapiens					
<220> <221> misc_feature <222> (1)(440) <223> n = A,T,C or G					
<400> 265 ggcagaggcg tggacaccac	ctcagcccac	tgagcaggag	tcacagcacg	aagaccaagc	60

agcaggattc agtcagtgcc gcccagccct caaagacctc ccccaaaata	ccctgccctc tgcccccttc aagcccaagg caagcatgca aacaccttcc gcctgcaaga tgaagctccn	tgctgcttct gcatgacctc actcagccat tgcacgagcc	gctgctgggg atcacagtgg gaaaaacatt tttctccagt	ctgtgggtgg tttaaaattc aacaagcaca gtggccgcca	cagagatccc agcacatgca caaaacggtg	120 180 240 300 360 420 440
<210> 266 <211> 396 <212> DNA <213> Homo	sapiens					
<220> <221> misc <222> (1) <223> n = A	. (396)					
nnnnnnnnn tggacctacc ctgcattatc aacttgcaga cacccctccc	gaacgtggaa nnnnnnnn ccccgagtgg agctttccta tggcctgttg agggatgatg accagatagt	nnnnnnnn tttgccaggg cttttgaggt tgggacctca gaagggtaag	nnnnnnnnn gctctcaggc tttgggactt ccttgtgatc gtcctaacac	nnnnnnnn cttcggctac tactggcttt atgtacatga	nnnnnnnnt agactgaggg cttgctcctc gggaaataca	60 120 180 240 300 360 396
<210> 267 <211> 429 <212> DNA <213> Homo	sapiens					
tcacagcacg agagagatgg ctgtgggtgg tttaaaattc aacaagcaca	tctgacagcc aagaccaagc caccggccag cagagatccc agcacatgca caaaacggtg cctgccagac	gcaaagcgac agcaggattc agtcagtgcc gcccagccct caaagacctc	ccctgccctc tgcccccttc aagcccaagg caagcatgca aacaccttcc	catcctgact tgctgcttct gcatgacctc actcagccat tgcacgagcc	gctcctccta gctgctgggg atcacagtgg gaaaaacatt tttctccagt	60 120 180 240 300 360 420 429
<210> 268 <211> 405 <212> DNA <213> Homo	sapiens					
taaagtggcc agccttggac cagccccctg cctggggccc ggacctgctc	ggcttcctgg agtgtgtacg gctgtgcggg ctgaagtacc cagttcgtag attgatgaca ttcacctgct	aagccccggg agatgaacga accactgtgt aacgaattat aggacacagt	ctttttcctg cctaccggac gggtgagaag cctgacaagg tcgaggccag	gacctggagc acgcaggtct taccgctggg gacaagacgg gaggagaccc	ccatcccggg tcatctgcac tggagcagca tggtcttggg	60 120 180 240 300 360 405
<210> 269 <211> 372 <212> DNA <213> Homo	sapiens					
<400> 269 ggcacgagaa	ccctgaggcc	tggctatggt	accaccgggt	ggtaggtgcc	cagcgctgcc	60

ccatcgtgga caccttctgg caaacagaga caggtggcca catgtt gtgccacacc catgaaaccc ggttctgcta ctttcccatt ctttgg tcctgaatga gtccggggaa gagttggaag gcgaagctga aggtta ggaccaggat ggctattact ggatcactgg caggattgat gacatg acacctgctg agtacagcag aggtggagtc agcacttgtg gaacat ggcacctgtg gg	rtgta gctcctgcaa 180 atctg gctgccagcg 240 gctca atgtatctgg 300
<210> 270 <211> 411 <212> DNA <213> Homo sapiens	
<220> <221> misc_feature <222> (1)(411) <223> n = A,T,C or G	
<pre><400> 270 ggcacgagag ctctcggcgc acggcccagc ttccttcaaa atgtct cctgtgcaag ctcagcttgg agggtgattg tccaggaagt tattcc acnnnnnnn nnnnnnnnn nnnnnnnnn nnnnnnnnn nnnn</pre>	ragat gaagacttat 120 nnnnn nnnnnnnnnn 180 nnnnn nnnnnnnnnnn 240 nnnnn nnnnnnnnnnn 300 nnnnn nnnnnnnnnnnn 360
<210> 271 <211> 302 <212> DNA <213> Homo sapiens	
<220> <221> misc_feature <222> (1)(302) <223> n = A,T,C or G	
<400> 271 ctgagtgtga cactcagaga gtgtgttata tagacagaga gagagg cccccttgt gtgtgcccca ctccagtgcg cccagatccg tgcccc tgctccctnn nnnnnnnag tgtgcacacc cccctcccc tctcat atattcctgt gtgacccctc ccccccctg ccagtcagtg tccccg actgttttat tttttctcgc ccccaagaag ggatagcgat gtgtct ca	ecccc cggagegeeg 120 egagt geceacatat 180 geegg agegegagte 240
<210> 272 <211> 429 <212> DNA <213> Homo sapiens	
<220> <221> misc_feature <222> (1)(429) <223> n = A,T,C or G	
<pre><400> 272 ggcacgagat gtggtacaga catctagttg gcaggagcca aagatg gtannnnnn nnnnnnnnn nnnnnnnnn nnnnnnnnn nnnn</pre>	nnnn nnnnnnnnn 120 gggat agggaaggga 180 ggaaa ggagtgggtg 240 gcctg gaggctctgg 300 attac gggcagaagg 360

```
<210> 273
<211> 471
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (1)...(471)
\langle 223 \rangle n = A,T,C or G
<400> 273
tgttgtgcat ttgggcatcc caccgattcg aattcggcac gagaaagcat tgaagagacc
                                                                         60
tcaaggcttt aagaaatgag taggccaaaa tctaagtcaa aggagaatct gtactggggc
                                                                        120
ccccqtqcc ctqaqqtcat tqqccaaqcc aaqccqaacc tqaqctttqa tcctqatqqt
                                                                        180
ttggggagtg aggaagacag aagtggaagc ccagttctca ccccaagagg ggacacaaat
                                                                        240
ggatgaccct cccatgatgc tgagacccca aaaggctaca cactcaagct aaaagccaga
                                                                        300
ggaaatccca tcctgccacc cacaagactt caaggaaagt tgttttggtg ctgagcagag
                                                                        360
caggggaaga aggaaaacag cccttaagga gctccagcca ctggccagcc ttcatgtgac
                                                                        420
tctagcccaa attcattccc atcacctggg gtggaagggc cagaaatctc n
                                                                        471
<210> 274
<211> 391
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (1)...(391)
<223> n = A, T, C or G
<400> 274
ggcacgaggt aaacteteta taagtgttea gtgttgacat agcetttgtg catagnnnnn
                                                                         60
nnnnnnnnn nnnnnnnnn nnnnnnnttt tttgccccac ctggaaaaaa ggggatgcnn
                                                                        120
nnnnnnngg ggggaaaaac aattettaag ggeeetttgg ecataaaett tttteeggge
                                                                        180
cacctttgtt acttttggtc ctggaagggg ttttttttggg gggcccacgg ggaggggcc
                                                                        240
cataggtaaa ctcggaaaac tttttctaac ccgggttagt gttttaaatt aaaaccaaaa
                                                                        300
annnnnnnn nnttggaatc cttttcttta aaaaaattaa tctctcaaag gaaaacaaag
                                                                        360
nnnnnnnn nggggggcc ctttcgttta g
                                                                        391
<210> 275
<211> 339
<212> DNA
<213> Homo sapiens
<400> 275
cacteegggg getetatiting total terms acceant the transaction caegoriting
                                                                         60
atataacate tagegecacg gtgeetatgt gtacacacee tetetetata tatagatace
                                                                        120
tctgtgcgca catatagagg ggaaaagaga gatatatcta ttatatatac atttctacac
                                                                        180
aactgtctct ggggggtcag agaacgcgcg cacccctctc ttttgagaga aggagactct
                                                                        240
gtcccccctc tctggggcgc agggaggccc catggcatga agaaaaatac tcacttatat
                                                                        300
                                                                        339
ctctctctc cactctctgt ttgcgaaaaa acacacagg
<210> 276
<211> 434
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (1)...(434)
<223> n = A, T, C or G
<400> 276
```

ccctagctac ttgctctttg accccgaggt gcctgaccag tcttgcactg cctggtgtcc tggcaggctg gcaccgcata ccagtgccat cttcctgcca tcctggcctg cctcttcgtg ggattgacaa cttn	ttctaccgcc atctgcttcc gccatcatct taccgagcag gagctcttcc	tgtggctatc agatgactgt acctgctgag aggtgggtcc agagctggca	cctcttcctg cctgcgggac tggtgtcacc tgctggctcc gatcctggcg	cacgccggga ctggagaagc ggcaacctgg cagttcggca cggccctggc	60 120 180 240 300 360 420 434
<210> 277 <211> 378 <212> DNA <213> Homo sapiens					
<220> <221> misc_feature <222> (1)(378) <223> n = A,T,C or G					
<400> 277 ggcacgagaa aaagtaccgc ctgagtctga gttgcggcca aaagatgaat ggagccctcc cctgcccagt cgtggtcctg gaagacatcg tttggaatgt cctggggctg gcctatgcca gngccatgcg cttctgcc	cttcaggagc cttcggatgc ctcctgggag cagtgttcaa	tgagaggagc tgtgggctac caagccggtc cctcagcaac	aggatggaac aggcaagaac cagttcatgg gccatcatgg	tgcaggatcc gtgagggctt atttcgaggg gcagcggcat	60 120 180 240 300 360 378
<210> 278 <211> 302 <212> DNA <213> Homo sapiens					
<220> <221> misc_feature <222> (1)(302) <223> n = A,T,C or G					
<400> 278 cccccnctct cgccnnnnn cggatccggg ttctttcttt catgggggc tggggagttc acacatgagc ccctccttcc aggggtcttt gtttgtatga cg	cccgtggtgc cccagaaccc ggtggcgggg	cgcgggttgg ccagggggaa acctgtctct	agtgttttat accccctcc ctaagaccct	cttttcttca tatgaaaatg tttctgggaa	60 120 180 240 300 302
<210> 279 <211> 405 <212> DNA <213> Homo sapiens					
<pre><400> 279 ggcacgaggc ctcattggag tgtatggaag cagtttgggg ggagaagcga gagggctacc ccgtgccacg ggggatccca aaaaatcacc aaggtggagt ggacaaccgc atggagtcgt tgacccaacc aacttcatcc</pre>	ggctcccgga cacttcggcc ccctcctaga gcggatttgc tcttcctggc	attctacaac agaacttatt actcggaaga aacaatcaaa cgagactgtg	attcctcagg gaaagcgcaa gatgctgtgg gatctgcgag aaatacctct	gatacacage tgtaceteta aatecattga accacacget	60 120 180 240 300 360 405
<210> 280 <211> 415 <212> DNA					

```
<213> Homo sapiens
<220>
<221> misc_feature
<222> (1)...(415)
<223> n = A,T,C or G
<400> 280
ggcacgaggg tcacctgtgc tgcccctcct taatctcgta tgatggtcac agtccggtgg
                                                                        60
ccgtggggt gctctgcctt ccctggtccc cactgcccat atctgtggac tgccccttcc
                                                                       120
aaagacccct ggggggggtt ggananattc aatcttacca aactcaacga tccatccatt
                                                                       180
tcatqttact gatattacat gcggacaccc ctggatcata ttattcaaat ccagtcatct
                                                                       240
attetgeatt catgacettt tgataactee ateatgacet acttgacggt cactgaceat
                                                                       300
gcttactgga ttccgccttg taacaataaa atctatttaa actnnnnnnn nnnnnnnnn
                                                                       360
nnnaccagcc cacataaaat atgattgaat caatttctta taccttcact agaat
                                                                       415
<210> 281
<211> 389
<212> DNA
<213> Homo sapiens
<400> 281
ggcacgaggt agactggggg ctcactgatt gcattgacac ttttcatcat gggtccccgg
                                                                        60
gggctcacgt ggagtctgac acatgaatac atggctatca tgtctgtcac cttcaatggg
                                                                       120
qaaaacaaac tttgtaatgg taggaaacac aacaggtaca ataatttaca aaaatatgtt
                                                                       180
tgccacattt cagggcaagg caaaatgcag aggagacata tgttaaaatc ttatcattca
                                                                       240
catttqttct ttttatcttt aagatgaagc tcttacacca agtqtcacga gtctggagaa
                                                                       300
cagatgggtt gaagagctgt tcttataaaa taagatctgg ggaacacaat cctttatata
                                                                       360
tcaacatcac agtggatttt tggattggg
                                                                       389
<210> 282
<211> 371
<212> DNA
<213> Homo sapiens
<400> 282
                                                                        60
ggcacgagat agaatccgag gcattgatat cattaaatgg atggagcgct accttaggga
taagaccgtg atgataatcg tagcaatcag ccccaaatac aaacaggacg tggaaggcgc
                                                                       120
tgagtcgcag ctggacgagg atgagcatgg cttacatact aagtacattc atcgaatgat
                                                                       180
                                                                       240
gcagattgag ttcataaaac aaggaagcat gaatttcaga ttcatccctg tgctcttccc
aaatgctaag aaggagcatg tgcccacctg gcttcagaac actcatgtct acagctggcc
                                                                       300
                                                                      . 360
caagaataaa aaaaacatcc tgctgcggct gctgagagag gaagagtatg tggctcctcc
                                                                       371
acgggggcct c
<210> 283
<211> 413
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (1)...(413)
<223> n = A,T,C or G
<400> 283
ggcacgaggt gggagacacc acttgtcttt atgtgggtct caaagatgat gtagaatttc
                                                                        60
ctttaatttc tcgcagtctt cctggaaaat attttccttt gagcagcaaa tcttgtaggg
                                                                       120
atatcagtga aggtctctcc ctccctcctc tcctgnnnnn nnnnnnngga aacaaagttt
                                                                       180
                                                                       240
tgcttttgtt ccccagcctg aaggggaagg gctcaatttt ggttaaccaa aaccttggcc
tccggggtta aagcaattct ccggcctaac cctttggaga acctgggtta ataggcgcag
                                                                       300
qcccccaggc cgggttaatt ttgggtttta agaaaaaaca gggtttctca atgtggggca
                                                                       360
qqcqtqqcca aaacccccac cctaagggga tcqqccctcc ttqqcctccc aan
                                                                       413
```

```
<210> 284
<211> 409
<212> DNA
<213> Homo sapiens
<400> 284
ggcacgaggc ctggggatgc tccctgctaa gtgggcctgc tcccaccctt gccataaagc
                                                                        60
tetgaggeag cetgageetg eegtggggge eecactgtga eeetgeegea gtetteetgg
                                                                       120
gtecetgegt cetettaagg ggeagtgaca cetgeetege tggeeetgtg tgggtggeag
                                                                       180
                                                                       240
gccccactgt ttgggatatc acatggccag gcacgtggtg agcctgctca gggcggacgc
                                                                       300
ctgcaggcgc gtgctcggtc acacactgcc ttgtgtggcc ctcctgtccg gtgcagcctg
gacctggacg cctggatcaa tgagccactc tcggacagcg agtcagagga cgagaggccc
                                                                       360
                                                                       409
agggeegtet tecaegagga ggageagegg egteeeaage aeeggeegt
<210> 285
<211> 404
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (1)...(404)
<223> n = A, T, C or G
<400> 285
ggcacgagec acttcacece ettggggget gettatteac tetgggggatt egecatggae
                                                                        60
acqtctcaac tqcqcaaqct qctqcccatq tttccctqcc cctccaqatt qcctqqaqat
                                                                       120
                                                                       180
ctattttgtt tccttttgtg tttctttttc tgttttgagt gtctttcttt gcaggtttct
gtageeggaa gateteegtt eegeteeeag eggeteeagt gtaaatteee etteeeeetg
                                                                       240
                                                                       300
gggaaatgca ctaccttgtt ttggggggtt taggggtgtt tttgtttttc agnngntttg
nttttttggn nnnnnnnnn gntttgactt ttttnncttt tattttggag ggtaatggaa
                                                                       360
                                                                       404
agaataggaa aatcaggcag gggggagaat ggttgtttat tctt
<210> 286
<211> 441
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (1)...(441)
<223> n = A, T, C or G
<400> 286
ggcacgaggg aagcgggtgg tgtgtgtccc ctgtttactt ttagctgagc tggggttggg
                                                                        60
                                                                       120
tgtacgggtt ctgttcctct gagccctgcg gcccacctga tgtttacgtg tgtgtgtgag
ggggggcggc gctncncnnn cacccccan nggcctctat ccttgtgaag ctctcctcaa
                                                                       180
tctaatactt attgcccctg actccaaatc ttccaccttt tgcctcttat tatatctatg
                                                                       240
ttcattacct taggtcagct gttctctatt atgacactga ttcatacttt tgttttttga
                                                                       300
taagtactta tttcctctct cattgttgct aatatcctct tccttttttc ctttgtctac
                                                                       360
totoacttoa totataaaac tottacatat ototocacta atttotttga actaacaatt
                                                                       420
                                                                       441
tttatataga atttaagcct g
<210> 287
<211> 387
<212> DNA
<213> Homo sapiens
<400> 287
                                                                        60
qqcacqaqca qccctqqaat tccqcaaqca cccqqaqqcc qqqqqtctc cqcqqqcgtc
ccatgcggag gacatggtgc gccgtgtact cttccccacg acctcaggga ccggtccccc
                                                                       120
                                                                       180
eqeeqquaet getteetace tggteeggte eeggeagetg aatetggeea geceaacete
coggtogeta togcacceae aggeetaaca ttcgcgagte cacettccgc cgtccgcgag
                                                                       240
```

gaaaacctga ttggcgccct aacctccaga agtactgcca aaagaccaaa actggtggct	catccgcctg				300 360 387
<210> 288 <211> 439 <212> DNA <213> Homo sapiens					
<220> <221> misc_feature <222> (1)(439) <223> n = A,T,C or G					
<400> 288 ggcacgaggg aggctggaag ggttgggtgt acgggttctg gtgtgagggg gggcggcggn taattaatcc aatcttttt atttactttt actcatcctc ctctttcgca attttccttt agttgtttcc tctttattta gtttgtggag tttttctt	ttcctctgag nncannnnn cttcttctct ctttcttcat attgttgtca	ccctgcggcc nnnnnnngan tctttctact ttactctgtc ctcttttggg	cacctgatgt tctttttcca ctttttcctc ttttgtatta aataacgtac	ttacgtgtgt ataacaatat ctttttttt ctagcttctt tcttatgaga	60 120 180 240 300 360 420 439
<210> 289 <211> 170 <212> DNA <213> Homo sapiens					
<400> 289 atgagtggtc ttttaattag cacaggattg tgagctgggc taatgggggg gcctgctgta	agagccttca	tgaaggcttg	ccaccttggg		60 120 170
<210> 290 <211> 393 <212> DNA <213> Homo sapiens					
<pre><400> 290 ggcacgaggt agactgggg gttctcacgt ggagtctgac gaaaacaaac tttgtaatgg tgccacattt cagggcaagg catttgatct ttttatcttt cagatggggt gagtagttgt tcaacatcac agtggatttc</pre>	acatgaatac taggaaacac caaaatgcag aggatgaagc tcttataaat	atggctatca aacaggtaca tggagacata tcttacacca tagtatctgt	tgtctgtcac ataatttaca tgttaaattc agtgtcacga	cttcaatggg aaaatatgtt ttatcattca gtctggagaa	60 120 180 240 300 360 393
<210> 291 <211> 430 <212> DNA <213> Homo sapiens					
<pre><400> 291 ggcacgaggg atagaatccg gataagaccg tgatgataat gctgagtcgc agctggacga atgcagattg agttcataaa ccaaatgcta agaaggagca cccaagaata aaaaaaacat tcacgggggc ctcttgccac cactgaggcc</pre>	cgtagcaatc ggatgagcat acaaggaagc tgtgcccacc cctgctgcgg	agccccaaat ggcttacata atgaatttca tggcttcaga ctgctgagaa	acaaacagga ctaagtacat gattcatccc acactcatgt aagaaaaaga	cgtggaaggc tcatcgaatg tgtgctcttc ctacagctgg tgtggctcct	60 120 180 240 300 360 420 430

```
<210> 292
<211> 423
<212> DNA
<213> Homo sapiens
<400> 292
atcccatcga ttcgaattcg gcacgaggga agcaagggca cccgccttat ggatggaatt
                                                                   60
gaggggaagg cacceggggc tectgeateg agetteecte etatatteaa tqaqqaaatq
                                                                   120
accetgeaga aggetggetg cagatgeece tgeeteeegg etttgeetge ttggagtttg
                                                                  180
atggacacgt ggtcctgtca gggctacagc aggtctatgg tctttggtaa cggaaagcgc
                                                                  240
tggtgaaaca gtgagctttc ccgtgggtgc ttttccctga cgccaacaac cagggcaagc
                                                                  300
tgcctgtcct gctgcttggc cgctcctcag agctgcggcc gggagagttc gtggtcgcca
                                                                  360
teggaageee gtttteeett caaaacacag teaceacegg gategtgage accaeceage
                                                                  420
                                                                  423
<210> 293
<211> 409
<212> DNA
<213> Homo sapiens
<400> 293
ggcacgaggc taggagtact ggcctagatg gttatagaag tccatgccag gaggtcgtct
                                                                   60
qcagtcagaq qqtqqttctq qqctqqactc caqccccttc ctqtcqqaqq ccaatqccqa
                                                                  120
acquattata cagacettat gtacagtteg aggggeegee etcaaggttg gecagatget
                                                                  180
cagcatccag gacaacaget teatcageee teagetgeag egeatetttg agegggteeg
                                                                  240
ccagagcgcc gacttcatgc cccgctggca gatgctgaga gttcttgaaq aggagctcgq
                                                                  300
cagggactgg caggccaagg tggcctcctt ggaggaggtg ccctttgccg ctgcctcaat
                                                                  360
tgggcaggtg caccagggcc tgctgaggga cgggacggat gtgggcgtg
                                                                  409
<210> 294
<211> 369
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (1)...(369)
<223 n = A, T, C or G
<400> 294
ggcacgaggc cagctgctgg tggagcggca ctggggactg gaggctggaa gcgggtggtg
                                                                   60
tgtgtcccct gtttactttt agctgagctg gggttgggtg tacgggttct gttcctctga
                                                                   120
qccctqcqqc ccacctqatq tttacqtqtq tqtqtqaqqq gqqqcqqnqn nnnnnnnnn
                                                                  180
240
nnnnnnnnn ntnaatatat ttttttgttt aatgggtnnn nnnnnnnnn nnnnnnnnn
                                                                  300
360
attaaattt
                                                                  369
<210> 295
<211> 403
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (1)...(403)
<223> n = A, T, C or G
<400> 295
ggcacgagtg cttctctagc tctctaggcc tctccagttt gcacctgtcc ccacctcca
                                                                   60
ctcagctgtc ctgcagcaaa cactccaccc tccaccttcc attttccccc actactgcag
                                                                   120
cacctccagg cctgttgcta tagagcctac ctgtatgtca ataaacaaca gctgaagcnn
                                                                   180
                                                                  240
nnnnnnnnn nnnnccccg cccttaaaa acaatggggg gccgtttacc gaaaacccaa
```

actggaaaaa acccttggtg gagttggacc accccccacc taaagggcgg ggaaaaaaag gctttattgg aaaaattggg gaggctttgg tttaattgga acccataaaa gccggcaaaa aacaggtaac caccaccatt ggctttcttt ttaggttcag ggg	300 360 403
<210> 296 <211> 384 <212> DNA <213> Homo sapiens	
<pre><400> 296 ggcacgagga gaacttctgg atcgggccca gctcggaggc cctcatccac ctgggcgcca agttttcgcc ctgcatgcgc caggacccgc aggtgcacag cttcattcgc tcggcgcgcg agcgcgagaa gcactccgcc tgctgcgtgc gcaacgacag gtcgggctgc gtgcagacct cggaggagga gtgctcgcta acaggaatta tgccgtcaaa ctcctttcca cgctggcagt gtgggtgaag tggcccatcc atcccagcgc cccagagctt gcgggccaca agagacagtt tggctctgtc tgccaccagg atcccagggt gtgtgatgag ccctcctccg aagaccctca tgagtggcca gaagacatca ccaa</pre>	60 120 180 ¹ 240 300 360 384
<210> 297 <211> 401 <212> DNA <213> Homo sapiens	
<pre><400> 297 ggcacgagat taagtgaatt gcgttatatt tatgacctta aggaccagat acaggaggta gaagggagat acatgcaggg gcttaaagaa ctaaaggaat ctttgtctga agtggaagaa aaatacaaga aagccatggt ttccaatgca cagttagaca atgagaagaa caatttgatc taccatgtag acacactcaa ggatgttatt gaagagcagg aggaacagat ggcagaattt tatagagaaa atgaagaaa atcaaaggag ttagaaaggc agaaccatat gtgtagtgc ctgcagcata agatggaaga acttaaagaa ggcctgcggc aaagagatga gcttattgag aaacatggct taagtataat ccccgatggc actcccaatg g</pre>	60 120 180 240 300 360 401
<210> 298 <211> 430 <212> DNA <213> Homo sapiens	
<220> <221> misc_feature <222> (1)(430) <223> n = A,T,C or G	
<400> 298 aaatggaga actctgaggt ncccaacgat tcgcattcgg cacgaggcca gctgctgggg gagcggctct ggggactgga ggctggaagc gggtggtgtg tgtccctgt ttacttttag ctgagctggg gttgggtgta cgggttctgt tcctctgagc cctgcggccc acctgatgtt tacgtgtgtg tgtgaggggg ggcgggnnac gntatanacc catcttatta tcaaattaca aaatcccant aataggtatc tccatcaagc tgcangagga ggagagagaa atgagagaca attatgttcc tgtggtctca gccttggatc aggagattat tgaagatgat tcttgcccta aggagatgct gaagcttttg gactttgggg gtctgttcaa ccttcatggt acttcaactt cagctgggaa	60 120 180 240 300 360 420 430
<210> 299 <211> 387 <212> DNA <213> Homo sapiens	
<pre><400> 299 ggcacgaggt ttcatacctt ctcagaattg gtatatcaag acacatttaa atataagccc tctggaaatg gatttatata cagtcatcat aattaccccc ttagaaattg gtaatatttt atagccaggt ttaggtttag tgtcaagtat agtgattgct ggtctatcac tactcatgaa gtggaacccc ctctactcat aaaaacccca atcagacata tagatgaata gaaccttgat aacattagaa tgccttgttc tctgaaggct tacaagacta tacgtcagga tatattaagg</pre>	60 120 180 240 300

agaagctgag gaacgaaaga actgaagaat aaaatacagg		agagaatgga	aatgtacatg	ctatagcata	360 387
<210> 300 <211> 373 <212> DNA <213> Homo sapiens					
<400> 300 ggcacgagac tagtccgact tgttactatg gtaacacttt tttaaggttg ccatggtaac tctcctttct gtgcattcat tgggggagag gggcgagaag gtatgtatca tcagttggct ttgataaaag agt	gctttctgaa cagccacagt gcaagagttt gggaaaaatg	ttggaaggga acatatgtaa cttgtaagcc ggaaatagtc	aaaaaatgta ttctttccat atcagaagtt tgattttaat	acgacagcat caccccaacc acttttagga gaaatcaaat	60 120 180 240 300 360 373
<210> 301 <211> 369 <212> DNA <213> Homo sapiens					
<400> 301 ggcacgagac tagtccgact tgttactatg gtaacacttt tttaaggttg ccatggtaac tctcctttct gtgcattcat tgggggagag gggcgagaag gtatgtatca tcagttggct ttgataaaa	gctttctgaa cagccacagt gcaagagttt gggaaaaatg	ttggaaggga acatatgtaa cttgtaagcc ggaaatagtc	aaaaaatgta ttctttccat atcagaagtt tgattttaat	gcgacagcat caccccaacc acttttagga gaaatcaaat	60 120 180 240 300 360 369
<210> 302 <211> 399 <212> DNA <213> Homo sapiens					
<400> 302 ggcacgaggc agcagacacg gtggtggagg cccaggggaa cagaccaagg agcacaggca ctgcaggggg agcacagcca gagagcatct ccgacgcaga ttcaccctgc aggaggtggg ttcttgctgc aggaggagct	agccctgatc gggcagcctg gaatggggag gaaggtggcc ggacgtgctg	gaacagaagg cgagcagagc gaggagcctg atggatctca cacgagagga	tggagctgga tggggaagtt agacggagcc aggaccccaa	ggcagacctg gcgagagag ggtgggagag ccgccccgg	60 120 180 240 300 360 399
<210> 303 <211> 391 <212> DNA <213> Homo sapiens					
<220> <221> misc_feature <222> (1)(391) <223> n = A,T,C or G					
<400> 303 ggcacgagca cagcccctga ccccacgcca gcgcccagcc acaaggagaa tgccatcgac acaagtgcaa gcaggtggag aggacgagct ggataaatat cggagaagaa ggcctccgac tcgttgagga ggagttggac	atggaggcca cgcgcggagc gaggagctga tccgaggacc gctgaaggtg	tcaagnnnnn aggcggaggc cgcacctcca tgaaggacgc atgtggccgc	nnnnnnnnn ggataagaaa gaagaaacta gcaggagaag	nnnnnnngg gccgctgagg aaagggacag ctggagctca	60 120 180 240 300 360 391

```
<210> 304
<211> 418
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (1)...(418)
<223> n = A, T, C or G
<400> 304
ggcacgagtg ccgcagccc cacagagccc gccgcgcacc ccacqtccc cacqccaqcq
                                                                        60
cccaqccatq qaqqccatca aqnnnnnnn nnnnnnnnn nnnnnqqaca aqqaqaatqc
                                                                       120
categacege geggageagg eggaggegga taaqaaaqee getgaggaca aqtgcaaqea
                                                                       180
ggtggaggag gagctgacgc acctccagaa gaaactaaaa gggacagagg acqaqctqqa
                                                                       240
taaatattcc gaggacctga aggacgcgca ggagaagctg gagctcacgg agaagaaggc
                                                                       300
ctccgacgct gaaggtgatg tggccgccct caaccgacgc atccaqctcq ttgaggagga
                                                                       360
                                                                       418
gttggacagg gctcangaac gactggccac ggccctgcag aagctggagg aggcagaa
<210> 305
<211> 420
<212> DNA
<213> Homo sapiens
<400> 305
ggcacgagga tttcggcaac aatttacaca gctggctgga ccaqacatgg aggtgggtgc
                                                                        60
cactgatctg atgaatattc tcaacaaagt cctttctaag cacaaagatc ttaagactga
                                                                       120
cggttttagt cttgacacct gccggagcat tgtgtctgtc atggacagtg acacgactgg
                                                                       180
taagctgggc tttgaagaat ttaagtatct gtggaacaac atcaagaaat ggcagtgtgt
                                                                       240
ttataagcag tatgacaggg accattctgg gtctctggga agttctcagc tgcggggagc
                                                                       300
tctgcaggcc gcaggcttcc agctaaatga acaactttac caaatgattg tccgccggta
                                                                       360
tgctaatgaa gatggagata tggattttaa caatttcatc agctgcttgg tccgcctgga
                                                                       420
<210> 306
<211> 399
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (1)...(399)
<223> n = A,T,C or G
<400> 306
                                                                        60
ggcacgagcc acgtccccca cgccagcgcc cagccatgga ggccatcaag nnnnnnnnn
nnnnnnnnn nnnggacaag gagaatgcca tcgaccgcgc ggagcaggcg gaggcggata
                                                                       120
agaaagccgc tgaggacaag tgcaagcagg tggaggagga gctgacgcac ctccagaaga
                                                                       180
aactaaaagg gacagaggac gagctggata aatattccga ggacctgaag gacgcgcagg
                                                                       240
                                                                       300
agaagctgga gctcacggag aagaaggcct ccgacgctga aggtgatgtg gccgcctca
accgacgcat ccagctcgtt gaggaggagt tggacagggc tcaggaacga ctggccacgg
                                                                       360
ccctgcagaa gctggaggag gcagaanaag ctgcagatg
                                                                       399
<210> 307
<211> 438
<212> DNA
<213> Homo sapiens
<220>
<221> misc feature
<222> (1)...(438)
<223> n = A, T, C or G
<400> 307
```

ccacgccagc aaggagaatg aagtgcaagc gacgagctgg gagaagaagg	ttcgaattcg gcccagccat ccatcgaccg aggtggagga ataaatattc cctccgacgc agttggacag aaagctgc	ggaggccatc cgcggagcag ggagctgacg cgaggacctg tgaaggtgat	aagnnnnnn gcggaggcgg cacctccaga aaggacgcgc gtggccgccc	nnnnnnnn ataagaaagc agaaactaaa aggagaagct tcaaccgacg	nnnnnggac cgctgaggac agggacagag ggagctcacg catccagctc	60 120 180 240 300 360 420 438
<210> 308 <211> 419 <212> DNA <213> Homo	sapiens					
cggggcccgc ggtgggcacc gctggtagcc gggtggcagt ggccagctgg	ttggcctgcc gtcaatgcct caacagctgg agctactgcc gtacccgtca ggtgcagaca gtgctgctcc	gggcctactg gggagttcca cacaggtggt ttatcagcac ggtcctactg	ccacgtgcta gtgctggtca ggaggacggc atcgcgtgtg gaaggagttc	cccactgggg ctagaggagg gtggcagacc agtgcaccac ctggtgatgt	acctgctgct gcttccagca aaacagatga ctggtggcaa gcacgctctt	60 120 180 240 300 360 419
<210> 309 <211> 415 <212> DNA <213> Homo	sapiens					
ctcccgatgc cttcttggcc ggtcaagctg aagggcatcg aagggcaacc	tgagccagag gctgcccgcc ggaggcatcg ctgctgccgt tggactgcat ttgccaacgt acatgcagat	ctgccaccat tcgccgtcat ccagcacgcc tgtccgcatc caatcgctac	gacggaacag cttcaagacg agcaagcaga cccaaagagc ttccccactc	gccatctcct gacgtggctc tcgccgccga atggagtgct aagccctcaa	tcgacaaaga ctatcgagcg ctagcagtac gtccttctgg cttcgtcttc	60 120 180 240 300 360 415
<210> 310 <211> 396 <212> DNA <213> Homo	sapiens					
atggacggct gagtcctgca tgggtgctgg tgcagcgctg tccagctgtg	ggtcctgccg acttcagctc agacgtgctc acgaggcgc cgcagttctg tgggctgcac agcacggaca	gctccggaac gggcctgacc ctgtgtggat taagaacgcc aggggaaggc	gagacccaca aacagagact gtggacgagt aacggctcct ccaggaaact	gcatctgcac gcggcgagtg gtgcggccga acacgtgcga	agcctgtgac tgaagtgggc gccgcctccc agagtgtgac	60 120 180 240 300 360 396
<210> 311 <211> 394 <212> DNA <213> Homo	sapiens					.•
catgcacgtg tgccccgtcc gctgagcctc ctacaaggat	ctctgggccc gcctaccgcg ctgtacgaca atcttcaagg tatgacatgc tacatctccc	aggaacgcga acctgagcaa ccgccgtgga cccgcgtggt	gcgcaagcac gaagcggggc tgctggcttc ggcctgctcc	cacctgaaac ggactgtggt ctctatatct gtggagcctt	acgggcccaa ggacgtactt tccaccgcct gcccccacac	60 120 180 240 300 360

cacagctgca	tggagatctt	cggccccagg	cacc			394
<210> 312 <211> 384 <212> DNA <213> Homo	sapiens					a
cctgtacgac catcttcaag ttatgacatg ttacatctcc catctgcatc	gaggaacgcg aacctgagca gccgccgtgg ccccgcgtgg cggcccacgg ctgctcaacc cccaggcacc	agaagcgggg atgctggctt tggcctgctc agaagaaggt tcagtgaagt	cggactgtgg cctctatatc cgtggagcct cttcacctac	tggacgtact ttccaccgcc tgccccaca ttcatggtga	tgctgagcct tctacaagga ctgtggactg ccacagctgc	60 120 180 240 300 360 384
<210> 313 <211> 430 <212> DNA <213> Homo	sapiens					
<220> <221> misc <222> (1) <223> n = 1	. (430)					
cgtgccagca gcgggcttgg ttgcagtcag ggacaggacg gagctggccg	ggctcgtaag gcaacctgca tgcacggcta tgtgcgtgtt ccgcggcccg cccttgcaga ttttgcactg	ccgcggtccg ccgggtagca ccgcgagcgg gctgctgcgc ccccacgct	ggcggggcgc ggcatgtggg accgcgcggc ctctaccggc cagctgctac	tggtctttct acaagtataa gcgtcctgga gccacgagcc agcgccgcct	ggacaatgag cgagccgctg gctgcaccgc tcgcttcccc cgacttcctc	60 120 180 240 300 360 420 430
<210> 314 <211> 408 <212> DNA <213> Homo	sapiens					
ctatgacgag cacgtgcccc gcaccacctg gggcggactg cttcctctat	cagaaggact ttcttccccg tcactgctcg aaacacgggc tggtggacgt atcttccacc ccttgccccc	tgtcccacgt tggtcatgca ccaatgcccc acttgctgag gcctctacaa	gcgcctctgg cgtggcctac gtccctgtac cctcatcttc ggattatgac	gccctacagc cgcgaggaac gacaacctga aaggccgccg atgccccgcg	tcatcctggt gcgagcgcaa gcaagaagcg tggatgctgg	60 120 180 240 300 360 408
<210> 315 <211> 412 <212> DNA <213> homo	sapiens					
gccgaggtac gcttcgggct ttgccgacgc agcgagaggg caagaaactt	tgcgcagcgg ctttgacagg gcggcacatg catggcgag aagcatcgag tgatggctac tggcttcccg	agcgtgaccc tcctccatgg tcacctagcc actctgagta cgatctccgc	tgctggaggt agcacacgga gggacgtcgt acagctcagg tgcccaccaa	gtgcgggagc ggagggcctc gggatccgga ctccaccagc tgagagccag	tggcctgagg cgggagcgac acagaacttc ggcagcatac cccctcagcc	60 120 180 240 300 360 412

```
<210> 316
<211> 300
<212> DNA
<213> homo sapiens
<400> 316
gccagcccct cagcctcttc ccgactggct tcccgtaggt accagcaacc tgcttctgac
                                                                        60
tggccagccc cctcccctgc tggaggaggg gagaagcccc gctctggtcc tacccttcag
                                                                       120
tetetgetet teetteatea accaeettee ceaagettag tgacageage egeceateet
                                                                       180
acctggatgg agaagagacc cttctccaag cacctcagcg cacttgccct ctgccacacc
                                                                       240
tgtcggtgga ggctgtggcc aggagagact gtagaagctc ggtccctgtg tatgtttgca
                                                                       300
<210> 317
<211> 2064
<212> DNA
<213> homo sapiens
<400> 317
acctcagcca gattcggcac gaggggcgta ggaccctccg agccaggtgt gggatatagt
                                                                        60
ctcgtggtgc gccgtttttt aagccggtct gaaaagcgca atattcgggt gggagtgacc
                                                                       120
cgattttcca ggctgctatc catgtccagg gccaaacatg aatcctattg ctcttgggga
                                                                       180
gccgctggct tgcttatgca gaaaacaagt tgattcgatg tcatcagtcc cgtggtggag
                                                                       240
cctgtggaga caacattcag tcttatactg ccacagtcat tagtgctgct aaaacattga
                                                                       300
aaagtggcct gacaatggta gggaaagtgg tgactcagct gacaggcaca ctgccttcag
                                                                       360
gtgtgacaga agatgatgtt gccatccaca gtaattcacg gcggagtcct ttggtcccag
                                                                       420
gcatcatcac agttattgac accgaaaccg ttggagaggg ccaggtgctt gtgagtgagg
                                                                       480
                                                                       540
attctgacag tgatggcatt gtggcccact tccctgccca tgagaagcca gtgtgctgca
tggcttttaa tacaagtgga atgcttctag tcacaacaga cacccttggc catgactttc
                                                                       600
atgtcttcca aattctgact catccttggt cctcatcaca atgtgctgtc caccatctgt
                                                                       660
atactettea caggggagaa aetgaageea aagtacagga catetgette ageeatgaet
                                                                       720
gtcgctgggt tgtggtcagt actctccggg gtacttccca cgttttcccc atcaaccctt
                                                                       780
atggtggcca gccttgtgtt cgtacacata tgtcaccacg agtagtgaat cgcatgagcc
                                                                       840
                                                                       900
gtttccagaa aagtgctgga ctggaagaga ttgaacaaga actgacgtct aagcaaggag
                                                                       960
gtcgctgtag ccctgttcca ggtctatcaa gcagcccttc tgggtcaccc ttgcatggga
aactgaacag ccaagactcc tataacaatt ttaccaacaa caaccctggc aaccctcggc
                                                                      1020
tctctcctct tcccagcttg atggtagtga tgcctcttgc acaaatcaag cagccaatga
                                                                      1080
cattggggac catcaccaaa cgaaccggca aagttaaacc tcctccacaa atttcaccca
                                                                      1140
gcaaatcgat gggcggagaa ttttgtgtgg ctgctatctt cggaacatcc aggtcatggt
                                                                      1200
ttgcaaataa tgcaggtctg aaaagagaaa aagatcagtc caaacaagtt gtagttgagt
                                                                      1260
                                                                      1320
ccctgtacat tatcagttgc tatggcacct tagtggaaca catgatggag ccgcgacccc
tcagcactgc acccaagatt agtgacgaca caccactgga aatgatgaca tcgcctcgag
                                                                      1380
                                                                      1440
ccagctggac tctggttaga acccctcaat ggaatgaatt gcagccaccg tttaatgcaa
accaccetet geteeteget geagatgeag taeagtatta teagtteetg ettgetggee
                                                                      1500
tggttccccc tggaagtcct gggcccatta ctcgacatgg gtcttacgac agtttagctt
                                                                      1560
ctgaccatag tggacaggaa gatgaagaat ggctttccca ggttgaaatt gtaacacaca
                                                                      1620
ctggacccca tagacgictg tggatgggtc cacagttcca gitcaaaacc atccatccct
                                                                      1680
caggecaaac cacagttate teatecagtt catetgtgtt geagteteat ggteegagtg
                                                                      1740
acacgccaca gcctcttttg gattttgata cagatgatct tgatctcaac agtctcagga
                                                                      1800
tccagccagt ccgctctgac cccgtcagca tgccagggtc atcccgtcca gtctctgatc
                                                                      1860
                                                                      1920
gaaggggagt ttccacagtg attgatgctg cctcaggtac ctttgacagg agcgtgaccc
tgctggaggt gtgcgggagc tggcctgagg gcttcgggct gcggcacatg tcctccatgg
                                                                      1980
                                                                      2040
agcacacgga ggagggcctc cgggagcgac ttgccgacgc catggccgag tcacctagcc
                                                                      2064
gggacgtcgt gggatccgga acag
<210> 318
<211> 1365
<212> DNA
<213> homo sapiens
<400> 318
cgagaactct gagtaacagc tcaggctcca ccagcggcag cataccaaga aactttgatg
                                                                        60
gctaccgate teegetgeee accaatgaga gecageeet cageetette eegactgget
                                                                       120
tecegtaggt accageaace tgettetgae tggecagece ecteecetge tggaggaggg
                                                                       180
```

gagaagcccc gctctggtcc taccettcag tetetgetet teetteatea accacettee ccaagettag tgacagcage egecatect acctggatgg agaagagace etteteeaag cacetcageg cacttgeet etgecaeace tgteggtgga ggctgtggee aggaggaget gtagaagcte ggteeetgtg tatgtttgea tatgacatee tgeattggat eegectttgt attitttaac catacecaeg gtggggeggg tgggggggge etggaacagt gaccagatet gggggeetga gtgggggedga agttgategt ecacetggee attittgaee tgagtggaea gteacageet eageteatgt etgeetgtga eacagateet etgeetggaeagee eaceteete etteeteett etteeteett etteeteett etteetee	240 300 360 420 480 540 660 720 780 840 900 960 1020 1140 1200 1320 1365					
<211> 22 <212> DNA <213> Artificial Sequence						
<220> <223> synthesized primer						
<400> 319 tgggatatag tctcgtggtg cg	22					
<210> 320 <211> 22 <212> DNA <213> Artificial Sequence						
<220> <223> synthesized primer						
<400> 320 tgattcgatg tcatcagtcc cg						
<210> 321 <211> 22 <212> DNA <213> Artificial Sequence						
<220> <223> synthesized primer						
<400> 321 tgtgtcacag ccagacatga gc						
<210> 322 <211> 21 <212> DNA <213> Artificial Sequence						
<220> <223> synthesized primer						
<400> 322						

tgcaaacata cacagggacc g	21
<210> 323 <211> 24 <212> DNA <213> Artificial Sequence	
<220> <223> synthesized primer	
<400> 323 tttagcagca ctaatgactg tggc	24
<210> 324 <211> 22 <212> DNA <213> Artificial Sequence	
<220> <223> synthesized primer	
<400> 324 cgccgtgaat tactgtggat gg	22

WO 01/72781

PCT/US01/09952